,ticker,content
0,ABT,major index trade session lows tuesday afternoon couple major technology stock namely apple aapl microsoft msft drag sector lower nasdaq composite fall computer hardware solar energy software industry group show larger loss most other other technology share be well today trading apple slide fall buy point monday nomura downgrade stock neutral buy lower target price argue stock gain iphone supercycle be late innings analyst jeffrey kvaal say email ibd other news organization morning believe unit growth be well anticipate consensus historically full multiple consider now time downgrade supply demand balance portend component anxiety microsoft big component nasdaq also dow component fall more be now buy point flat base have just clear friday fall dow jone industrial average lose less russell be market volume be lower same time monday decline share lead advancer ratio nyse nasdaq interest rate sensitive industry group be broadly weaker most stock ibd property reit industry group be lower utility industry group ibd track be benchmark yield year treasury note have be trend higher federal reserve raise interest rate wednesday yield be oct high dozen stock fall busy trading none be more alarm factset research fds stock plunge day move average time normal volume be serious break support factset have maintain solid uptrend oct gain more have be wipe cause sell signal market research datum provider miss sale estimate revenue quarter be estimate adjust earning be share view broad weakness few high rate stock break tuesday transportation stock be positive area navistar nav climb past buy point cup handle base tremendous volume truck manufacturer sped past expectation october end quarter navistar earn share adjust restructure cost revenue rise year company post loss ibd take liberty interactive qvc look solid company uneven earning contribute mediocre composite rating liberty interactive qvc group qvca clear week consolidation rise past buy point heavy trading abbott laboratory rise past buy point flat base volume be only average maker medication nutrition product diagnostic equipment other medical product announce earning jan market open related apple stock downgrade neutral iphone lift garden parent darden beat navistar crush profit viewsliberty interactive qvc get closer key technical measure
1,ABT,boston scientific bsx dip wednesday announce delay heart valve replacement product call lotus edge potential competitor product medtronic mdt abbott laboratory close bell stock market today boston fall finish abbott lose close medtronic dip end day earlier year boston voluntarily recall lotus lotus edge aortic valve system cite issue locking mechanism have plan relaunch lotus edge europe first quarter file application food drug administration january late tuesday boston say again delay plan be disappoint delay timeline be work carefully analyze implement necessary modification pass rigorous internal quality standard chief executive mike mahoney say prepared statement didn provide timeline plan relaunch europe file boston say doesn expect delay have material impact fourth quarter guidance provide update fourth quarter earning conference call feb boston lotus edge be system replace diseased heart value used open heart surgery abbott medtronic also make device call transcatheter aortic heart valve replacement tavr ibd take boston have ibd composite rating meaning outperform more stock term key growth metric still lag top leader best possible crs get name leader visit ibd stock checkup canaccord analyst jason mill lower worldwide transcatheter aortic heart valve replacement sale model boston respectively also cut price target keep buy rating needham analyst mike matson estimate transcatheter aortic heart valve replacement market grow third quarter prior quarter expect market have grow worldwide year year next year matson call market grow worldwide boston be expect be third market lotus edge say think be still possible note abbott portico tavr pivotal trial enrollment be complete think be launch late matson keep buy rating price target boston stock related medtronic surge top quarterly earning view rival take chunk medtronic heart unit electricity replace opioid treat chronic pain
2,ABT,medtronic mdt overcome hurricane marium impact fiscal maker medical device be expect face grow competition abbott laboratory boston scientific bsx heart implant analyst say thursday xin september abbott catch medtronic boston gain approval implantable cardioverter defibrillator icd allow patient undergo mri scan need device be implanted help control abnormal heart rhythm still rbc analyst glenn novarro say lower end medtronic full year forecast august sale growth constant basis remain realistic increase view fiscal sale adjust income share impact mr compliant icds abbott boston be topic interest relate second half fiscal fiscal say medtronic fiscal novarro forecast firm manage constant currency growth competitive concern also extend heart valve replacement novarro say early see boston re enter european market lotus edge product boston recall device not approve due problem locking mechanism ibd take medtronic have ibd composite rating meaning perform top half stock term key growth metric still fall medical product industry group term ranking head ibd stock checkup look better rate medtech player mount competition cardiac vascular group novarro see medtronic capable pull full year guidance expect management reaffirm guidance constant currency revenue growth refine guidance further fiscal third quarter call say only possible change fiscal earning share guidance be impact hurricane marium tuesday medtronic be slate report fiscal second quarter earning consensus expect medtronic report adjust income cent share sale sale view be medtronic pre announcement nov hurricane marium batter puerto rico september be expect have impact medtronic second quarter sale trim adjust profit cent majority impact be company minimally invasive restorative therapy group reason novarro shift segment view medtronic second quarter see diabetes group diving minimally invasive therapy lose expect flat sale restorative therapy partly offset growth cardiac vascular internationally novarro expect cardiac vascular diabetes group grow apiece see minimally invasive restorative therapy group grow respective only pain therapy group be expect decline medtronic diabetes group have be plague recently shortage glucose sensor growth latter half fiscal come back new product medtronic have say close bell stock market today medtronic gain close related electricity replace opioid treat chronic painedward lifescience crash heart valve sale miss lofty viewsdow component pop top view pharma strength
3,ABT,stock arrive proper buy point investor buy same stock bring different expectation investor be gun gain intention take profit move next second regard gain something
4,ABT,boston scientific bsx fall thursday medtech player top wall street sale expectation decline pacemaker sale reflect new competition abbott laboratory analyst say xby close bell stock market today boston fall close abbott remain flat boston share break cup base buy point september be now extend point third quarter boston report adjust income cent share sale respective vs year earlier period sale beat consensus view adjust profit be line worldwide rhythm management sale post yearly gain miss rbc analyst glenn novarro estimate neuromodulation method used electrical pulse pain management grow boston cardiovascular unit sale cardiac rhythm movement product decline vs last year be due year year dip sale pacemaker new rivalry abbott novarro say note client ibd take boston have ibd composite rating best possible meaning perform top stock term key growth metric head ibd stock checkup look other top performer industry group boston lift sale guidance earlier view be year year top analyst expectation adjust profit guidance be tighten penny low end share analyst have modeled share related biotech firm top third quarter view only popsedward lifescience crash heart valve sale miss lofty glaxosmithkline scoop pfizer counter unit
5,ABT,abbott laboratory deliver sale beat third quarter help strength pharmaceutical medical device unit analyst say wednesday xby close bell stock market today abbott have gain finish share break flat base buy point early september have climb mark third quarter end abbott report adjust earning cent share revenue sale grow comparable basis exclude impact st jude medical acquisition earning grow metric top consensus analyst poll zack investment research adjust profit cent share sale rbc analyst glenn novarro credit sale beat strong sale abbott establish pharmaceutical diabetes care cardiovascular neuromodulation product keep outperform rating abbott stock ibd take washington base expert recently suggest president donald trump sign executive order bring drug price day now prod biotech stock collective monday head ibd industry theme more executive order mean biotech drug stock quarter establish pharmaceutical post year year growth group doesn sell key emerge market deliver growth comparable year year basis help quick recovery india novarro say worldwide medical device sale grow vs year earlier period comparable basis follow dow stock johnson johnson jnj report tuesday see medical device grow lag view neuromodulation sale grow globally neuromodulator be implantable device use electricity deliver pain relief test study electrical activity heart rise comparable basis structural heart sale grow same medical device business global diabetes care jump drive growth internationally help offset decline rhythm management sale decline vs year earlier period diagnostic sale grow globally core laboratory product sale growth slow compare double digit growth first half novarro write note client international sale growth improve again abbott also narrow adjust profit growth share earlier view novarro say new guidance bracket consensus year analyst see abbott pull sale related dow component pop top view pharma strengthibd rating upgrade johnson johnson show improve relative price strengthfda chief gottlieb address opioid cancer new therapeutic
6,ABT,medical related exchange trade fund have rac healthy gain year ongoing quest longer healthier life outperformer be ishare medical device ihi gain year date well ahead gain period fund boast year average annual return vs benchmark index accord morningstar inc ihi launch track dow jone select medical equipment index top holding etf include medtronic mdt abbott laboratory thermo fisher scientific tmo abbott developer generic drug disease screening system other product be buy range clear flat base entry thursday xihi be etf pick featured ibd last month oscar pursche chief executive bruderman brother bruderman asset management opposed take broad view health care sector do overall see great opportunity medical device space investor get exposure ishare medical device etf say also note fund top holding account nearly portfolio increase risk profile ihi be extend past buy point clear april ibd take find biotechs stand benefit most president trump propose tax reform recent tech column spdr health care equipment xhe return ytd year average year old fund track health care equipment select industry index have gather asset top holding include align technology algn intuitive surgical isrg edward lifescience ew account portfolio xhe be trading record high be extend recent bounce day line spdr biotech xbi year have average annual gain past year fund launch january be form flat base buy point entry still july peak vertex pharmaceutical vrtx regeneron pharmaceutical regn abbvie abbv be top name hold xbi top holding make asset related be best health care etf gop move replace etf ride industry recovery
7,ABT,alere alr stock rocket month high monday trading day abbott laboratory agree drop pair lawsuit set new merger price agree share be higher close price alere stock last thursday previously company agree share december begin wrangling price value stock market today alere stock rise share abbott lift company push merger timeline september agree shelve legal proceedings other canaccord analyst mark massaro call settlement good outcome alere write dec alere be say still believe alere have win case alere acknowledge anything have happened court most shareholder be willing take risk table ibd take abbott stock have ibd composite rating meaning outperform stock term key growth metric biotech industry group be stronger player celgene have lead cr visit ibd stock checkup list hefty competitor massaro lower price target alere stock reflect new merger price say shareholder likely have approve anything north share share price bridge expectation share settlement rbc analyst glenn novarro say alere likely have take earning expectation merger be announce february alere view cent accretive more cent accretive accretion estimate appear high base alere recent result write note client last month analyst have broadly cut earning view alere sale expectation novarro keep outperform rating price target alere stock related mylan topple big med player divest shareswhich medtech stock buy ahead
8,ABT,abbott laboratory divest more stake mylan myl stock accord filing security exchange commission prompt mylan share dip friday abbott sell share apiece document file late thursday show divest portion represent abbott share mylan stock now abbott own share mylan total outstanding share mylan stock trade stock market today share be form latter portion cup handle begin august stock fall just day move average friday try hold support day line abbott stock other hand dip ibd take mylan announce generic version epipen several month face competition impax laboratory kaleo head ibd technology page prediction rivalry share close fraction thursday mylan confirm recall epipen country outside device fail emergency situation case patient be able use alternate epipen related mylan stock dip recall epipen outside trumpcare have momentum health stock be scramblingthese pharma stock be big loser trump drug pricing tweet
9,ABT,abbott laboratory file suit wednesday terminate purchase alere alr cite setback deal be sign january say have significantly erode value medical test maker acquisition be trouble almost start february alere disclose delay filing financial result security regulator revenue recognition problem china africa marked begin drumbeat bad news company say receive subpoena regard bribery investigation bill practice restate earning pull product market have diabetes division exclude medicare health insurance program bill patient have already die alere share halter trading day end session abbott be fractionally file delaware chancery court complaint claim abbott base suburban chicago have right terminate transaction cumulative effect setback constitute material change alere prospect alere be longer company abbott agree buy month abbott spokesman scott stoffel say statement numerous negative development be unprecedented be not isolate incident bring chance abbott suit seek scuttle merger be likely be hear delaware chancery court judge sam glasscock iii have oversee earlier litigation concern deal june glasscock conclude energy transfer equity ete back merger rival pipeline operator william wmb tax problem tie combination tulsa base william be now sue dalla base energy transfer more damage response energy transfer be seek force william pay fee tie deal failure alere acknowledge challenge year waltham mass base company say setback didn constitute material change insist deal close originally agree august sue compel abbott pursue antitrust clearance close transaction claim abbott be intentionally drag foot derail deal focus pending acquisition st jude medical stj side be work mediator settle dispute abbott file own suit november claim alere violate term agreement hiding information relate bribery investigation overseas operation bill practice side agree settle suit alere provide document none have yet be provide stoffel say have attempt secure detail information assess issue month alere have block attempt say damage alere business only be result systemic failure internal control combine lack transparency lead filing complaint
10,ABT,st jude medical stj stock dip fraction early wednesday medical device maker report earning narrowly miss view ongoing security tussle short seller muddy water meanwhile share abbott laboratory be process acquire st jude topple breezy beat quarterly growth medical device sale more offset decline abbott nutrition unit ibd take medical stock be suffering volatile election season wednesday worst perform stock group total track be tie medical sector check ibd industry theme keep eye mover shaker st jude report sale cent earning share ex item respectively vs year earlier quarter sale be line consensus analyst poll thomson reuter ep miss cent abbott lab post board beat sale cent ep item respective vs last year consensus have modeled cent abbott also narrow ep ex item outlook be neither firm offer guidance st jude cite sale abbott lack guide stock market today st jude stock fall nearly abbott stock fall share be wrack august accusation short seller muddy water st jude pacemaker be hackable muddy water allegation be base research security startup medsec typically security researcher turn potential vulnerability affected company case public disclosure prompt st jude stock fall aug abbott stock dip fraction st jude address allegation earning call muddy water tweet series video purport show security backdoor st jude implantable cardioverter defibrillator icd pacemaker muddy water be now short st jude stock video haven be verify st jude say statement ibd st jude be now work form cyber security medical advisory board vet security firm medical device st jude again denounce muddy water method disclosure behavior continue circumvent form responsible disclosure related cybersecurity patient safety continue demonstrate total patient physician regulatory agency govern industry company say muddy water renew pressure come st jude abbott work close merger year end tuesday pair agree sell product terumo medical device maker transaction be subject abbott successful acquisition st jude
11,ABT,st jude medical stj be warning patient battery thousand implantable defibrillator quickly unexpectedly deplete rare case leave vulnerable need shock device restart falter heart premature battery depletion have be see less device company say letter send doctor patient person die device fail work correctly drain battery other report dizziness fainting warning apply device make be use person worldwide company share drop early trading be recommend patient utilize remote monitoring enable physician monitor device performance time chief medical officer mark carlson say telephone interview physician patient take specific measure mitigate risk small impact health warning come sensitive time st paul minn base medical device manufacturer be midst be purchase abbott laboratory august short seller carson block investment firm muddy water capital llc issue report say st jude heart device be uniquely vulnerable cybersecurity attack include depletion battery issue hand have nothing do wireless communication be essential doctor closely monitor patient carlson say problem stem lithium power battery run device st jude share fall nearly premarket action end trading day device fall st jude cardiac rhythm unit have company sale last year ibd take st jude share have be trading tightly range due pending acquisition abbott company have decent rating only rank st ibd medical product group top list be abiom hold highest possible composite rating check abiom leaderboard chart here be safety measure alert doctor patient battery be lose power company say vibrate patient chest twice second much restaurant paging device buzze customer table be ready then repeat notification several time hour increment addition remote home monitoring network inform doctor patient battery be low rapid drain battery happen day carlson say device be replace immediately st jude say provide replacement device cost issue doesn affect pacemaker doesn lead inappropriate shock other complication say st jude recommend only replace device battery have fail risk surgery outweighed risk device be still work fine device charge lithium cluster form move cluster connect positive negative electrode battery create short circuit drain battery sap power carlson say company identify issue base analysis device sell worldwide be link premature depletion return lithium cluster visible electrical shorting be see device number be low not case be recognize report affected device include fortify fortify assura quadra assura quadra assura mp unify unify assura unify quadra company set www sjm com batteryadvisory allow patient determine device be affected battery depletion
12,ABT,boston scientific bsx have agree buy endochoice holding gi expand endoscopy business move send endochoice share soar early trade tuesday purchase price share be almost double endochoice close price monday endochoice share finished day gain deal be expect close fourth quarter boston scientific say tuesday prepared statement company be base just outside boston marlborough mass share boston scientific be slightly recent trade endochoice base atlanta suburb alpharetta ga develop product service used treatment condition include resection retrieval device needle grasper infection control kit company have sale month end june accord statement annual sale boston scientific be major medical device maker compete like medtronic mdt st jude medical stj medtronic st jude be trading time high st jude be schedule be purchase abbott laboratory end year ibd take boston scientific have be climb back reach low mid stock have be flat base july now be trading day line still hold composite rating ibd highest possible score
13,ABT,ishare medical device etf ihi find high most holding participate hottest segment medical sector year most stock fund fall ibd industry group medical product medical system equipment have be top ibd group many week have best year date performance group make medical sector medical system equipment be group medical product group have climb market low june however biotechs generic drug stock have make much stronger gain still medical equipment subset be period product group be better nearly other health care group win find pharmaceutical company ishare medical device rather company provide tool develop drug help patient deal medical problem indeed company product offering span syringe heart valf robotic surgical system etf be more be try break past buy point flat base hold day move average better chance rise past entry share have best run february early august etf chart closely resemble largest hold medtronic mdt stock have be form shallow base be new high many product medtronic make insulin pump ear infection treatment coronary stent brain stimulus device treat nervous system disorder thermo fischer scientific tmo fund second largest hold rally most september also be near new high company be research equipment service industry group make medical research instrument complete acquisition fei maker high performance microscope acquisition have be part story medical device industry not always result stock gain dhr have be drag portfolio stock be base nicely high august start tumble announcement be acquire cepheid cphd make system fast genetic testing abbott laboratory nearly weighting etf also hasn be much contributor share remain lock month old consolidation ishare medical device have average annual return year year ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list related buy cepheid expand diagnostic business
14,ABT,diagnostic company cepheid cphd be soar early trading tuesday life science instrument giant dhr announce agreement acquire company cash share cepheid genexpert system provide rapid automate genetic testing expect generate revenue year add annual revenue base expect cent share earning accretion first year rise cent year cepheid share rise nearly stock market today highest september evercore isi analyst ross muken write deal fit larger acquisition strategy ceo thomas joyce cepheid be growth centric acquisition add basis point organic growth high consumable flow cement tom bias technology forward ceo muken write research note asset compliment company exist diagnostic platform accelerate entry molecular market needham analyst mike matson write acquisition have be baked thesis cepheid abbott laboratory be other likely acquirer say abbott be too tie legal battle acquisition alere alr make counter bid so downgrade cepheid stock neutral stock be fall tuesday ibd take strong composite rating be longtime resident ibd big cap list large cap solid growth profile related ge buy european printing firm lift system stratasys
15,ABT,be time life medical device company single food drug administration ruling have pivotal impact future edward lifescience recently get such decision ruling come thursday regard sapien edward ew transcatheter aortic valve replacement tavr artificial valve implanted patient aortic stenosis disease bring real valve start malfunction due calcification fda decision mean instantly increase potential market lead product half make sapien different other valf be transcatheter part traditionally aortic valf have be replace medical vernacular crack chest not surprisingly pretty traumatic patient especially risky re talk elderly population suffering heart disease tavr be deliver catheter small hole groin make much less shock less decade first commercial tavr case be perform europe technology have prove not only be invaluable option patient too sick frail undergo open heart surgery also superior treatment strategy large swath traditional surgical population write guggenheim analyst chris pasquale june initiation report edward however fda heart surgeon be naturally cautious new technology give don mess vital organ lightly so first generation sapien be approve be only patient highest risk death surgery expand other patient edward have have conduct large clinical trial segment population prove sapien benefit outweigh risk april edward demonstrated exactly person study patient intermediate risk complication surgery day procedure patient treat tavr die compare patient receive surgical valve replacement year death rate be tavr group surgery group similar contrast appear prevalence stroke investor know meant edward stock leap almost day news hit clinical datum presentation represent best case scenario sapien broader tavr market write rbc capital market analyst glenn novarro research note time key debate be fda accelerate approval timeline intermediate risk label turn fda approve indication past thursday line management recent guidance come sometime third quarter statement edward call major milestone share rise thursday early friday trading timing be significant not only help edward term financial also competitive position only other tavr player market be medtronic mdt acquisition corevalve corevalve sapien hit european market medtronic have lag bit edward timeline get corevalve approve january be more year sapien medtronic also be conduct trial intermediate risk patient result aren due next year expect label use corevalve intermediate risk patient once sapien label be expand penetration population be likely accrue edward medtronic surtavi trial read analyst pasquale write report stake be big be aortic stenosis sufferer alone sapien corevalve have grow analyst have be see not just displace surgery increase demand aortic replacement general quarterly report estimate overall tavr market size go ibd take edward lifescience be top rate stock ibd leaderboard check here find buy range better expect growth now quarters row ramp competition europe signify tavr market be clearly grow seemingly sustainably faster expect now expect exceed time frame edward sapien be best class particularly now datum demonstrate overwhelming superiority vs surgery intermediate risk patient leerink analyst danielle antalffy write research note edward second quarter report july quarterly report push stock new high revenue earning growth accelerate last quarters earning rise year earlier quarter cent share sale be strong financial stock performance have keep edward constant presence ibd big cap last few month tavr line be growth driver now account more half revenue edward be continue work other heart related device aug rolled new intuity elite valve system number product make traditional surgical valve replacement believe surgery continue have vital role patient even tavr expand edward spokeswoman heather chamber tell investor business daily email be patient include younger patient patient complex need continue be well serve surgery chamber add be lot other structural heart defect surgery be best option other defect be also ripe minimally invasive approach transcatheter mitral valve replacement tmvr have lately become hot area cardiac device field medtronic boston scientific bsx abbott laboratory work device edward have be develop house tmvr call fortis last year add program acquire privately hold cardiaq valve technology tmvr turn be even bigger opportunity tavr give higher prevalence mitral regurgitation population challenge treat many patient surgically pasquale write report add many question remain unanswered however include treatment strategy be optimal repair replacement disease morphology benefit most transcatheter approach degenerative functional prospective clinical study be design evaluate new technology
16,ABT,drugmaker thursday dividend leader have plenty go re not screamer mean be grow nicely compelling pipeline solid dividend yield pfizer pfe look poise clear long consolidation last month share slump nearly week end aug report second straight quarter double digit earning
17,ABT,abbott laboratory say second quarter profit top analyst estimate rise demand business segment medical device recent underperformer lead way earning exclude time item be cent share beating cent average analyst estimate survey bloomberg profit continue operation fall cent share cent year abbott park ill base company say statement abbott lab sit merger frenzy health care industry last year have make time agree buy alere alr february deal have turn contentious striking deal st jude medical stj april st jude base st paul minn also report earning thursday second quarter adjust profit exclude item share match average estimate analyst compile bloomberg revenue gain year earlier report revenue increase percent abbott medical device unit lead sale performance help settlement issue surround royalty revenue previous year demand mitraclip device used repair damage mitral valf heart company endovascular business also post strong result lead sale stent used treat block blood vessel leg device used close puncture wound ibd take abbott hasn prove be particularly resilient stock composite rating stock ibd medical diversify group have be carry most part sole companion group dow stock johnson johnson more information jnj check ibd stock checkup abbott maintain adjust earning forecast share share end trading more close wednesday
18,ABT,diagnostic test maker alere alr be sharply friday trading analyst see better chance acquisition abbott laboratory go issue preliminary financial result abbott first announce deal feb month later alere say not file annual report time be look timing revenue recognition africa china abbott ask alere terminate merger agreement alere board refuse still wall street remain uncertain deal close late thursday alere say indeed have revise earning do not expect change be material still hasn file issue preliminary result year well year be somewhat analyst consensus canaccord genuity analyst mark massaro be reassure enough give stock upgrade buy hold alere update confirm scope audit square revenue recognition cutoff scope have expand alere have be require disclose today interim update massaro write upgrade note give further disclosure alere expectation immaterial revision update confirm alere have review thousand individual revenue transaction suggest be likely week away filing not month have markedly increase confidence transaction close deal price share ibd take alere most recent report show decline revenue continue trend early ibd see important negative sale growth margin return equity be incorporate smr rating smartselect rating ibd offer help identify quality stock leerink analyst dan leonard write preliminary result be not strictly comparable consensus estimate new sec guideline gaap report issue alere preliminary gaap adjust ebitda figure include noncore item cost related propose acquisition abbott financial statement review alere have historically backed leonard write research note company expect provide color noncore item report operate result alere stock close stock market today share have fall more abbott buyout be announce bad news have keep come abbott stock dip
19,ABT,many medical stock have be have tough year maker medical device system have be popular lately especially large cap name offer stability uncertain time week biggest name show performance justify investor trust report late tuesday robotic surgery specialist intuitive surgical isrg be expect continue recent growth rebound slower pace year year comparison have be make tougher strong analyst currently expect earning sale grow year earlier quarter grow respectively july preview second half year leerink analyst richard newitter write ll be watch continue uptake da vinci xi surgical system launch help intuitive surgical turn rough couple year importantly see intuitive surgical turn point transition next leg growth general surgery outside expansion stabilization urology gynecology franchise increasingly begin benefit xi new product cycle newitter write intuitive surgical stock hit time high july move flat base june intuitive rise fractionally stock market today wednesday morning medical device titan abbott laboratory company process acquire st jude medical stj be due report earning company have struggle growth department recent quarters st jude top line have be accelerate estimate abbott do not grow previous quarters be expect report single digit percentage growth top bottom line global footprint company hit foreign exchange headwind rbc capital market analyst glenn novarro expect continue report give stronger dollar especially several emerge market currency be lower sale forecast abbott report constant currency novarro write july preview note greater fx headwind expect management reaffirm revenue guidance low single digit report mid single digit constant currency ep guidance range abbott have also say buy diagnostic company alere alr close have be doubt company have admit accounting problem last week alere report preliminary financial leave analyst believe deal go doubt be interested abbott management have say conference call abbott share shave penny close day st jude share inched cent alere slip ibd take medical device stock have lately be mainstay ibd big cap stock choose strong potential gain volatility smaller growth stock see else be big cap list finally late thursday orthopedic giant stryker syk be set report modest accelerate growth estimate sale rise be highest stryker be have gangbuster stock more ibd composite rating putt top stock stryker have be grow top line range last couple year see momentum continue next several year reconstructive volume be stable hospital capital spending be stable recent tuck acquisition drive faster sale growth corporate average analyst novarro write preview note friday raise estimate price target stryker furthermore company be gain share core segment orthopedic medsurg neurotechnology spine styker stock end trading
20,ABT,struggle stock cardiac device maker heartware international htwr nearly double monday medtronic mdt say buy company medtronic agree pay share cash heartware close friday soar monday heartware make world smallest ventricular assist device heart failure hvad stock have take beating last year due fail attempt acquire company last year well trial problem next generation mvad device give issue heartware be currently lose market share say evercore isi analyst vijay kumar email client be say believe acquisition make sense medtronic medium term add growth driver round company cardiovascular offer broadest industry heartware ceo doug godshall say statement believe have medtronic infrastructure help accelerate development introduction innovative pipeline product expand access therapy offering sizable heart failure population medtronic expect deal have significant impact term financial heartware month sale be just compare medtronic deal continue trend consolidation cardiac device industry last year st jude medical stj acquire thoratec heartware competitor now st jude be be acquire abbott laboratory medtronic close stock market today share have be trading new high lately sell rest market friday medtronic boast strong overall composite rating
21,ABT,drugmaker be lag term industry group performance handful boast solid earning track record abbvie abbv share second best earning share rating other ibd ethical drug group also pay big dividend shareholder last week chicago base company key product include immunology drug humira cancer drug imbruvica
22,ABT,share pharma major abbvie abbv be slide wednesday morgan stanley downgrade concern increase competition analyst david risinger downgrade abbvie stock equal weight lower price target note nature abbvie pipeline have become clearer day june presentation cancer drug weekend include negatively receive report rova meantime abbvie still depend immunology drug humira analyst say sale humira be world best selling drug generate abbvie total sale estimate vast majority profit risinger write humira not only face challenge several biosimilar player include amgen amgn novartis nvs sandoz pfizer pfe also novel brand injectable oral abbvie score string patent litigation victory allay investor concern be unable make call risinger write humira market exclusivity already suffer setback last month patent board agree review challenge humira patent bring biosimilar developer coherus bioscience chrs likely take year resolve risinger write newer class drug treat same condition humira do include novartis cosentyx eli lilly lly taltz baricitinib slow humira growth term threat gain support wednesday novartis say presentation european league rheumatism conference run wednesday saturday be new long term analysis suggest cosentyx lead higher response humira improve sign symptom person live ankylose spondylitis psoriatic arthritis psa week novartis say initiate head head trial confirm say abbvie own novel autoimmune disease product help offset moderation include jak il risankizumab risinger write expect launch abbvie stock fall close stock market today share touch month high friday
23,ABT,giant cardiac device agree merge thursday abbott laboratory announce agreement acquire st jude medical stj deal worth abbott agree pay abbott share st jude share base abbott day average share price deal value st jude share apiece st jude stock be more morning trading stock market today abbott stock be more abbott say deal add cent ep next year cent follow year expect save cost combination abbott also assume refinance st jude debt move greatly enlarge abbott cardiovascular device business now represent revenue st jude medical strong position heart failure device atrial fibrillation cardiac rhythm management complement abbott lead position coronary intervention transcatheter mitral repair say abbott press release together company compete nearly area cardiovascular market hold position large high growth cardiovascular device market leerink analyst danielle antalffy agree st jude flat negative sale growth last few year picked write research note set continue abbott look be grow only low single digit antalffy also write compete bid be unlikely most logical buyer abbott view be johnson johnson jnj antalffy write meeting mid management emphasize company be not interested deem value market medtech specifically call cardiac rhythm management nearly st jude total sale drug eluting stent deal announcement come busy day medical field biotech medivation mdvn confirm have receive unsolicited bid big pharma sanofi sny abbvie abbv used be abbott biopharma division be spun agree buy cancer focuse biotech stemcentrx
24,ABT,big money be move medical field thursday giant company announce attempt multibillion dollar buyout abbott laboratory announce agreement acquire fellow cardiac device maker st jude medical stj deal worth meanwhile abbvie abbv used be abbott biopharma division be spun agree buy biotech stemcentrx upfront milestone payment cancer focuse biotech medivation mdvn confirm have receive unsolicited bid big pharma sanofi sny week rumor abbott agree pay abbott share st jude share base abbott day average share price deal value st jude stock apiece abbott say deal add cent ep next year cent follow year expect save cost combination abbott also assume refinance st jude debt move greatly enlarge abbott cardiovascular device business now represent revenue st jude medical strong position heart failure device atrial fibrillation cardiac rhythm management complement abbott lead position coronary intervention transcatheter mitral repair abbott say press release together company compete nearly area cardiovascular market hold position large high growth cardiovascular device market leerink analyst danielle antalffy agree st jude flat negative sale growth last few year picked write research note set continue abbott look be grow only low single digit nonetheless abbott share fall close st jude rise ibd take healthy be abbott lab stock find ibd stock checkupabbvie sanofi meanwhile be big pharmas look fill pipeline innovative drug lead product face slowdown abbvie immunology drug humira be best selling drug world patent start expire year sanofi have have scale back expectation diabetes franchise increasingly competitive space have push price stemcentrx lead late stage asset be call rovalpituzumab tesirine rova already registrational trial small cell lung cancer abbvie say pay purchase price cash rest stock stemcentrx also receive cash milestone payment drug successfully clear regulatory development hurdle meantime however be financial drain abbvie expect transaction be approximately cent dilutive ongoing earning share accretion begin company say announcement lower ep guidance meanwhile abbvie early thursday report earning beat wall street estimate fall tad short revenue abbvie say earn share item cent better analyst expect sale analyst poll thomson reuter have expect global humira sale rise exclude foreign exchange impact abbvie say thursday research note investor evercore isi analyst mark schoenebaum cite approximately beat humira sale largely offset miss global viekira revenue primarily drive miss possibly due competition merck mrk well abbvie put total humira sale sale viekira treat hepatitis be abbvie drug generate globally total sale abbvie say abbvie stock end higher stock market today sanofi unsolicited offer be share cash medivation make deal worth medivation have be subject takeover rumor recent week astrazeneca azn sanofi rumore suitor medivation sole commercial product be prostate cancer drug xtandi market japan astella xtandi success launch have help drive medivation stock excellent composite rating propose purchase price represent premium medivation month volume weight average price buyout talk begin sanofi say medivation stock rise thursday suggest investor think bid go higher sanofi stock finished image provide shutterstock
25,ABT,share medical product maker baxter international bax hit time high tuesday company beat estimate raise guidance baxter earning exclude time item rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter sale decline beating wall street number exclude foreign exchange impact sale rise baxter add cent full year ep guidance now last year company say constant currency sale growth be have previously guide second quarter baxter forecast earning cent share top analyst average estimate cent say sale grow even include fx impact street have expect slight decline baxter stock hit new high early trading stock market today afternoon trading share be less baxter product include iv system dialysis machine surgical equipment be sell mainly hospital market have be look strong earning season accord leerink analyst danielle antalffy now third consecutive growth quarter consecutive quarters low single digit decline serve encourage datum point addition johnson johnson jnj st jude medical stj abbott laboratory report last week support potential trend improve procedure volume overall antalffy write research note fortune hospital stock support view medical hospital group have be fastest rise ibd industry group leap week present
26,ABT,abbott laboratory agree buy st jude medical stj deal value maker heart device make biggest ever acquisition industry consolidate gain bargaining power hospital st jude medical shareholder receive cash share abbott common stock represent total approximately share accord statement thursday medical device maker be merge get access new technology hospital push lower price st jude last year acquire thoratec add left ventricular pump device take fail heart combine abbott st jude medical company have pipeline new medical device product cardiovascular diabetes vision neuromodulation patient care accord statement abbott say statement have financing st jude medical plan acquisition alere alr send alere share higher early trading stock market today abbott chief executive officer mile white decline reiterate commitment alere deal last week company earning call alere hasn yet file report regulator have be subpoena justice department st jude medical close wednesday give company market value stock jump market open new york abbott drop percent early trading alere rise percent acquisition further reshape abbott split brand name pharmaceutical business abbvie abbv then company have shy away major acquisition pursue many smaller deal even ceo talk often desire larger purchase abbott have cash hand obtain selling generic drug business medicine market europe develop world mylan myl
27,ABT,stock close mixed yesterday spending day just kiss index unable muster strength push thru weak earning think technology weak macro datum think housing start build permit weaker dollar help commodity sector think oil keep index check nasdaq end day lower dow manage squeak small gain now poor earning work way right goldman sachs gs net income fall demand spectrum business line tank yet investor trader take stock sh big blue think ibm ibm report worst qtr yr investor trader kick gutter take pt be tech stock manage gain ground big revenue miss drop income more datum scream difficult time recession more desperate fed become clearer become rate remain right here yesterday see dollar move lower help send oil once again line gold surge oz close oz well support earning be disaster yet be pay attention factset remind earning be due decline earning be lower remember say yesterday mkt be discounting mechanism so have already price negative datum be look month time frame fact set tell be midst turnaround look earning growth skyrocket christmas see adjustment far number way see complete turn number remember early january forecast earning be positive only be adjust well negative territory short week be headwind cause adjustment longer present doubtful gdp well bit absurd well early consensus forecast call growth yr be originally forecast atlanta fed gdpnow model be suggest scant slew disappointing macro datum point be even wonder qtr turn slightly negative yet mkt march higher think lower rate longer fed struggle do end not surprise see total annual growth range be consider remember consumer be exhaust retail sale be slow wage real avg weekly earning be stagnant have be meaningful uptick business inventory keep rise sale slow so expect see day sale everything almost daily basis mean many time month do macy throw private sale private mean belong person group usually cause everyone want be group cache be private do see be go financial debt rise faster gdp last year financial debt be consider total household debt business debt federal state local gov debt doesn sound good dr lacy hunt hoisington investment management tell total debt increase last year be more gain nominal gdp ratio total debt gdp close year well level academic study suggest debt begin slow economic activity digest datum find big corporation continue default debt usa today report so far year company have defaulted debt highest level company have defaulted week dc keep tell don worry good beg differ economy be not grow take real drastic step think structural reform be stick quagmire whole generation millenial want elect bernie sander really do country owe something remember word president john kennedy ask not country do ask do country latest macro datum yes folk even dow tease march housing start fall bed fall single family fall multus family unit drop housing permit not much better here northeast permit decline midwest south west news flash build permit be lead economic indicator so march datum be warning sign future build activity just sayin here ny yesterday voter layer trump clinton notch take step closer nomination california be next eco datum today mortgage apps exist home sale exp future be now slightly positive early trading late yesterday find crude oil inventory rise mil barrel vs exp mil barrel today hear eia energy information agency have say look earning abbott laboratory dish network dish textron txt coca cola ko bancorp usb st jude medical stj host other
28,ABT,be key today find strength push thru remember be rd attempt first back november rd second yesterday so rd time be charm do feel so pierce then look swift move high ish plot thicken europe german ppi british labor market report miss expectation cause profit take continent early weakness mkt have re-cover be now slightly positive territory ftse flat cac dax eurostoxx spain italy take good care
29,ABT,kpfollow kenny polcari twitter kenny polcari comkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
30,ABT,be busy week business economic investing news stock market come more pressure apple aapl report first sale decline facebook fb amazon amzn turn gas federal reserve signale rush raise rate economy crawl market rally come more pressure slew earning report big economic news nasdaq tumble week fall day line thursday day average friday loser such apple twitter twtr first solar fslr trump big gain facebook amazon dow be well support level also tumble loss come thursday friday oil price continue march higher help weaker dollar further decline production year treasury yield give much recent gain healthy be share amazon facebook do compare rival find ibd stock tech titan certainly wasn growth company fiscal second quarter report first revenue decline iphone unit sale tumble earning share fall expect apple give weak guidance current quarter apple hasn have huge product big screen iphone smartphone sale generally be stagnate point apple be so huge be hard new product really move needle sign shift rapid growth more mature model apple add additional shareholder return program more buyback higher dividend meanwhile activist investor carl icahn decide cash apple stock so do other apple stock fall week nearly settle worst close mid apple chip supplier generally fared relatively well part due diversify away apple smartphone generally apple investor worry glory day be federal reserve expect vote leave interest rate unchanged latest policy meeting give hint tighten fall earliest fed note labor market have strengthen even economic growth slow true now economy rise annual rate first quarter weakest year meanwhile jobless claim be year lows economy be barely grow hard see continue add job month analyst be expect friday april employment report fed go slow approach couple bank japan unexpected decision not increase stimulus effort push dollar big loss boost multinational profit give further lift dollar price oil other commodity commerce giant see sale largely wall st view gain midpoint mark slowdown pop highest nearly year still be faster be typical past year earning also crushed estimate cloud unit amazon web service remain hot china version amazon alibaba baba report thursday alphabet googl unit google ford motor uber lyft volvo announce tuesday formation coalition advocate self drive car lobbying effort come automaker race develop autonomous technology alphabet be late stage talk fiat chrysler fcau partnership regard autonomous car accord multiple report meanwhile tesla motor tsla already have self drive feature electric car have not unveil plan join coalition tesla report earning wednesday autonomous tech firm mobileye mbly thursday social networking king facebook linkedin have good week post earning top estimate send stock higher facebook report third straight quarter accelerate earning revenue growth concern slow user engagement advertiser be definitely used facebook mobile advertising account facebook ad revenue facebook stock spiked thursday record high pull back close week modestly buy point linkedin renew investor confidence harrowing see stock plunge linkedin turn solid earning investor applaud global economy grow tepid pace company be stress cost cut prop earning revenue flatline fall latest week defense contractor lockheed martin snack giant mondelez international mdlz procter gamble pg announce recent new effort curb expense restructure sell asset join like coca cola ko banking giant jpmorgan chase jpm bank america bac cut help company short run need stronger top line growth fuel earning longer term shift priority medium company come play last week handful megamerger capture spotlight serve attempt keep grow simply cling survival cable content titan comcast cmcsa seek grow foreign market deal buy dreamwork animation dwa studio responsible shrek kung fu panda meanwhile look comcast rival charter communication chtr be able keep bid buy time warner cable twc win regulatory approval survival struggle newspaper industry be mind usa today parent gannett gci bid buy tribune publish tpub owner los angele time chicago tribune crude oil future continue rise hit high big oil be still adjust lower price saudi arabia aim reduce oil dependence float less saudi ipo value world largest oil company excess meanwhile conocophillip cop slash capital spending even further bp bp say be consider further cut baker hughe bhi warn american rig count still have room fall count stabilize later year chevron cvx swung loss production fall overall output most major rise even investment fall exxon xom lose aaa rating still keep commitment dividend raise cent cent quarterly result shale player continental resource clr eog eog carrizo crzo be week medical merger activity take thursday abbott laboratory inked buyout deal cardiac device giant st jude medical stj abbott former biopharma arm abbvie abbv agree buy biotech startup stemcentrx possible milestone payment big french pharma sanofi sny make unsolicited cash bid smaller drugmaker medivation mdvn medivation reject sanofi offer sanofi vow press medivation stock trade investor be expect sanofi perhaps bidder go higher stemcentrx medivation be focuse cancer treatment field have provide biggest drug launch recent year chipotle grill cmg recovery be slow go april same store sale date surprising many burrito king logged first ever quarterly loss cent share wall street expect revenue decline miss view comp plummet fast casual chain panera bread pnra report strong result stock be set short consolidation go back march burger king parent restaurant brand international qsr turn mixed result domino pizza dpz miss completely dunkin brand dnkn edge past forecast
31,ABT,major average end sharply lower thursday market mild distribution show more least nasdaq dow jone industrial average nasdaq lose give preliminary datum show nyse nasdaq volume come higher wednesday level stock market today stock be pressured early bank japan surprisingly hold monetary policy unchanged send yen soar euro dollar also send tokyo nikkei loss home front labor department estimate gdp growth sharply growth consensus view amazon amzn headline thursday hour session big beat share surge amazon be member leaderboard portfolio investor com other hour mover include linkedin lnkd baidu bidu regular session facebook fb easily lead nasdaq advance facebook earning report late wednesday trigger handful analyst price target increase thursday morning nasdaq chip stock lag include xilinx xlnx nxp nxpi lam research lrcx analog device adi earning report also lift share paypal pypl zimmer biomet zbh stock end session lows early strength news abbott lab announce plan buy st jude medical stj cash stock deal share st jude soar abbott lose sanofi sny meanwhile strike deal acquire cancer drugmaker medivation mdvn medivation recently release positive early stage trial datum talazoparib shrink tumor ovarian cancer patient share medivation soar sanofi give medivation have be show relative strength lately biotech group several other name see leader be ibd stock checkup downside luster wear longtime leader domino dpz share crash disappointing earning
32,ABT,stock tumble mixed trade thursday morning earn report economic news overseas factor have say early action nasdaq hold gain buoy primarily facebook fb dow jone industrial average drop dip volume rise mildly nyse higher nasdaq vs action same time wednesday stock market today feel early pressure overseas market trade generally lower bank japan hold monetary policy unchanged send yen soar tokyo nikkei loss thursday economic news increase weight labor department estimate gdp growth sharply growth consensus view nearly dow stock decline open unitedhealth group unh lead few advance issue dupont dd shoulder heaviest loss more possibly affected investor response result pending merger mate dow chemical dow dow result top expectation economic outlook appear wobbly dow share slip facebook easily lead nasdaq advance facebook earning report late wednesday trigger handful analyst price target increase thursday morning gain send share past buy point cup handle base weak end nasdaq chipmaker xilinx xlnx tank company report late wednesday earning revenue narrowly top consensus view management guide ep line view guidance flat revenue disappoint expectation acquisition news power healthy piece early trade st jude medical stj open higher fellow heart device maker abbot lab agree buy company deal abbott share fall more facebook technical fundamental vital sign be avaible used ibd stock checkup featurebiom medivation mdvn scribe early advance ignited takeover proposal france sanofi sny sanofi share shed chicago base drugmaker abbvie abbv slump almost announce plan acquire privately hold cancer treatment biom stemcentrix deal value outside medical territory comcast cmcsa seal deal ingest dreamwork animation dwa dreamwork trade flat thursday spiking news wednesday session comcast trade fraction lower thursday be week haynesbrand hbi jockeyed higher announce pay acquire lead australian undergarment maker pacific brand company schedule report today close include amazon com amzn baidu bidu netsuite linkedin lknd western digital wdc many other
33,ABT,major average be mixed early thursday pressure overseas market supplement reaction earning report weak gdp estimate dow jone industrial average lose give nasdaq edge higher federal reserve decision wednesday hold interest rate unchanged appear be mild positive stock stock market today receive mixed early nudge labor department estimate gdp growth be sharp drop growth just consensus projection gain gdp price index gauge inflation rise view increase labor department also say unemployment claim climb week end april prior week estimate claim week move average tick lower lowest level oil trade flat early thursday rise wednesday leave west texas intermediate just barrel gold gain almost ounce bond rise send year yield basis point dollar trade lower particularly yen spiked sharply bank japan surprisingly announce change current stimulus program decision send tokyo nikkei china market close narrowly mixed loss japan spun trading europe eurozone market trade more afternoon trading london ftse be unitedhealth unh buck trend dow rise early laggard include dupont dd goldman sachs gs intel intc medical deal news make early headline st jude medical stj spiked abbott lab agree buy st paul minn base heart device maker deal value abbott share slip san francisco base biom medivation mdvn jump news report say france sanofi sny offer buy company deal dow jone report sanofi opted take news public medivation management decline unsolicited offer sanofi trade medivation be ibd stock check medivation technical fundamental vital sign used ibd stock checkup feature st jude lead follow facebook fb facebook result easily clear analyst forecast revenue gain advance adjust earning facebook gap buy point early thursday loss be equally dramatic cybersecurity outfit symantec symc lose early action mountain view calif company lower fiscal sale earning guidance announce resignation ceo michael brown continue act chief executive successor be find company say paypal pypl add nearly positive report late wednesday stock have be fight get lift alternate entry reilly automotive orly fall furthest nearly auto part chain report late wednesday sale earning top consensus forecast management guide earn expectation nutritional supplement chain gnc gnc dive deliver miss earning revenue slip slightly less expect full year ep guidance be prior guidance far consensus view management cite challenge company vitamin line say challenge continue remainder year gnc have manage climb january low wednesday remain well august high
34,ABT,share biotech medivation mdvn tumble tuesday day congress attack pricing lead drug company hire new cfo late monday press picked letter representative senator include democratic presidential candidate bernard sander head national institutes health nih urge agency exercise march right lower price medivation prostate cancer drug xtandi bayh dole act give federal agency include nih authority license patent action be necessary alleviate health safety need be not reasonably satisfied invention be not available public reasonable term letter note price be clear barrier access consumer law be place year nih have never used broad powerful authority protect consumer excessive prescription drug price letter go say xtandi be sell medivation partner astella cost less third japan sweden canada letter urge nih hold public hearing xtandi pricing similar hearing lead abbott laboratory lower price aids drug norvir medicaid aids drug assistance program say nih do not actually use march authority however send letter advocate explain thought such move be inappropriate ub analyst matthew roden point only minority xtandi prescription be cover medicaid worst case dual eligible medicare medicaid be impact roden estimate xtandi sale be paid medicare perhaps be dual eligible letter represent latest salvo politician recent war high drug price something change focus recent attack valeant pharmaceutical vrx turing pharmaceutical focuse steep price increase old neglected generic drug xtandi be innovative product just launch price be not exceptionally high new cancer drug instance bristol myer squibb bmy opdivo merck mrk similar drug keytruda launch late be go year meanwhile medivation also say late monday have hire citigroup manager jennifer jarrett new cfo replace rick bierly retire july analyst roden write jarrett bring buyout expertise company turn dampen speculation medivation be buy morning trading stock market today medivation stock be growth xtandi have give company healthy ibd ep rank stock have be recover hit year low feb have weak relative strength rating just so stock have perform lowest stock past month
35,ABT,generic drug giant mylan myl announce buyout swedish counterpart meda late wednesday also report earning miss estimate stock tumble hour trading mylan say acquisition be immediately accretive earning add cent ep next year allow company hit previously state
36,ABT,medical product giant abbott laboratory agree pay diagnostic company alere alr monday send latter stock sharply early trading abbott agree pay share cash represent premium alere friday close price assume refinance alere debt abbott say arrangement add cent ep cent earning alere hold strong ibd ep rank revenue stock price have suffer last few quarters miss estimate last month warn also be lower expect weak flu season be partly blame leerink analyst dan leonard note malaria cd testing also be underperform cut price target stock early november cut create buy opportunity abbott ceo say company conference call last week be hunting buyout target valuation be look high abbott stock suffer report guidance year disappoint wall street morning trading stock market today alere stock be month high abbott stock be nearly touch time high july
37,ABT,stock future be steady premarket action monday bland read december consumer spending income dow future hung fair market value future nasdaq future slip respectively stock market today appear poise continue recent back forth action strong session friday end
38,ABT,new week trading monday follow old script major average follow oil market lower good new be stock be well session lows little more hour remain session dow jone industrial average give nasdaq ease volume nyse
39,ABT,go get tough tough build monitor etf watch list most investor be feel skittish sharp stock market sell wise focus inevitable upside smart investor also consider overall direction market make buy sell decision ibd market direction recently shift correction status again so time active etf investor be cautious even several last year etf winner have sunk day move average key support level cautious doesn mean idle several sector equity etfs track ibd be buy point buy etfs stock break buy point price chart base formation increase chance nail big gain here be etfs worth get know wait stock market trend turn bullish again spdr semiconductor xsd hold equal weight stock behemoth intel intc have roughly same stake portfolio asset smaller top notch player such monolithic power system mpwr etf have average daily trading volume roughly share ibd rs rating mean price performance have surpass most stock ibd database past month xsd be buy point cup handle base consolidated hit week high june have rally significantly interim september low last year xsd peg gain global social medium socl hold stock include linkedin lnkd facebook fb tencent holding tcehy etf have average daily volume share have rs rating socl be buy point cup handle base rally day line first second quarters then fall long consolidation full course socl jump ishare medical device ihi target niche medical device manufacturer distributor hold stock biggest position medtronic mdt abbott laboratory thermo fisher scientific tmo etf trade roughly share day average have rs rating ihi be buy point slice key day day support level broad loss stock market monday ihi bag gain
40,ABT,diagnostic system firm hologic holx be much bad day market friday stifel upgrade buy hold analyst block write hologic be overcome problem lead growth flatten last couple year diligence lead believe hologic transformation
41,ABT,action camera maker gopro gpro get price target cut monday embattled restaurant chain chipotle grill cmg suffer series downgrade price target cut own
42,ABT,analyst also make call biotech startup bluebird bio blue teva pharmaceutical teva new issue ferrari race
43,ABT,jpmorgan trim gopro target friday robert baird downgrade gopro neutral outperform slash price target share be hit last week chip supplier ambarella amba give weak guidance due part soft sale action camera
44,ABT,gopro share lose stock market today ambarella give
45,ABT,cowen co guggenheim security downgrade chipotle former market perform latter neutral maxim group lower price target stock
46,ABT,report say friday coli outbreak chipotle have expand state outbreak have sicken dozen customer force closure restaurant
47,ABT,chipotle share sank year low early monday recover later session stock close
48,ABT,bluebird bio stock price tumble be downgrade neutral buy roth capital have price target chopped nearly half weekend bluebird present disappointing gene therapy datum american society hematology annual meeting
49,ABT,teva stock price rise be initiate buy rating mizuho security last week reuter report generic drugmaker be divest worth asset address antitrust concern deal buy allergan agn generic drug business
50,ABT,share home depot hd fall even price target be raise telsey advisory group have outperform rating stock
51,ABT,sport luxury car manufacturer ferrari have initial public offer october be initiate overweight give price target morgan stanley ferrari share rise monday be still more close price first day trading
52,ABT,abbott laboratory climb be upgrade buy jeffery give price target
53,ABT,share big pharma firm eli lilly lly lose score upgrade buy deutsche bank follow upgrade overweight barclay last week
54,ABT,follow vance cariaga twitter ibd_vcariaga action camera maker gopro gpro get price target cut monday embattled restaurant chain chipotle grill cmg suffer series downgrade price target cut own analyst also make call biotech startup bluebird bio blue teva pharmaceutical teva new issue ferrari race jpmorgan trim gopro target friday robert baird downgrade gopro neutral outperform slash price target share be hit last week chip supplier ambarella amba give weak guidance due part soft sale action camera gopro share lose stock market today ambarella give cowen co guggenheim security downgrade chipotle former market perform latter neutral maxim group lower price target stock report say friday coli outbreak chipotle have expand state outbreak have sicken dozen customer force closure restaurant chipotle share sank year low early monday recover later session stock close bluebird bio stock price tumble be downgrade neutral buy roth capital have price target chopped nearly half weekend bluebird present disappointing gene therapy datum american society hematology annual meeting teva stock price rise be initiate buy rating mizuho security last week reuter report generic drugmaker be divest worth asset address antitrust concern deal buy allergan agn generic drug business share home depot hd fall even price target be raise telsey advisory group have outperform rating stock sport luxury car manufacturer ferrari have initial public offer october be initiate overweight give price target morgan stanley ferrari share rise monday be still more close price first day trading abbott laboratory climb be upgrade buy jeffery give price target share big pharma firm eli lilly lly lose score upgrade buy deutsche bank follow upgrade overweight barclay last week follow vance cariaga twitter ibd_vcariaga
55,ABT,medical device maker boston scientific bsx beat analyst estimate raise guidance wednesday send stock sharply boston scientific make cent share quarter exclude time item year earlier quarter beating analyst consensus penny accord thomson reuter revenue rise wall street estimate exclude foreign exchange impact sale grow boston scientific raise full year sale guidance now vs last year raise low end ep guidance now cent cent last year be line consensus boston scientific guide sale earning cent share street estimate cent analyst focuse organic sale growth come significantly higher be look part boost contribution recently close am acquisition well solid pipeline execution write leerink analyst danielle antalffy research note regardless again represent boston scientific strongest ex fx sale growth quarters recent memory rbc capital market analyst glenn novarro write cardiovascular sale largely drive beat believe cardiovascular result be lead strong stent sale owing continue share gain promus premier strong peripheral sale novarro write boston scientific chief rival stent be abbott laboratory medtronic mdt novarro add sale implantable cardioverter defibrillator icds be tad expectation believe medtronic continue take share tri chamber segment icd market say boston scientific stock be nearly early afternoon trading stock market today just shy year high share touch follow amy reeve twitter ibd_areeve facebook
56,ABT,amazon com amzn reportedly be be sue several driver prime now delivery business courier file lawsuit los angele superior court be demand amazon pay back wage compensation expense such fuel amazon allegedly isn pay tip receive delivery worker accord medium report worker also claim
57,ABT,fda say thursday require warning liver damage be put label abbvie abbv hepatitis treatment viekira pak technivie send abbvie share plunge month low gilead science gild sharply review adverse event report fda adverse event report system faer database
58,ABT,sophia loren michelangelo benvenuto cellini leonardo da vinci guglielmo marconi fibonacci leonardo bonacci federico fellini luciano pavarottus be just handful famous italian have contribute immensely italian world history today most famous sexually charge italian come nyse today welcome ferrari ticker symbol race nyse family company
59,ABT,ferrari be italian luxury sport car manufacturer founder enzo ferrari originally build race car ferrari moved production street legal luxury car fiat acquire company take control more take total stake
60,ABT,fiat chrysler announce sell company public today be day expect street be awash testosterone excitement build
61,ABT,broad street now know experience square have dozen ferrari display only look touch allow only serve drive man frenzy ipo be price last night share high end range be way oversubscribed so instead raise ipo price cool demand decide remain range create desire aftermarket feel excitement build tingle spine rapid breathe toe curling excitement rush blood heart beat faster faster explode fury open bell ring great way start day exhaust already
62,ABT,stock chopped yesterday healthcare stock get whack more political wrangling investor trader grow concern ibm ibm earning mount concern marissa meyer option yahoo yhoo choppy trading wall street suggest trader be uncertain term direction equity follow recent volatility continue disappointment earning report forward guidance
63,ABT,ibm share drop company report lower quarterly revenue straight quarter also lower guidance fiscal year
64,ABT,so investor trader react far mark ibm stock price be fundamental stronger dollar case do hurt stock have be downtrend july investor begin re price company base concern breaking support level have only find support level late august churn build new base be only last month investor trader thought maybe market have adjust punish enough cause go bargain hunting spree well didn work too well yesterday news send stock right back lows question now be find support here share
65,ABT,yhoo also disappoint warn future hold putt mayer turnaround plan jeopardy cause announce new plan reset sort top executive fly coop say change be result careful plan ask plan be
66,ABT,more broadly company so far have beat bottom line only company have beat top revenue line be become more problem cause disconnect fundamental stock price rhetoric washington economy be do just fine
67,ABT,recession hit continue hammer earning stock price eventually fall hard be gear fall technically be still struggle bull bear be lock battle major index be still downtrend dma be trend dma have find resistance have recently approach longer term technical indicator so remain lock tight range
68,ABT,next oil energy stock say current state economy sense be stock stay sideway channel long oil price remain range oil break then look stock come renew pressure breaking reason oil pierce unlikely short term then see renew excitement stock take longer term resistance now overnight oil fall be now trading barrel only cause remain laser focuse today eia report energy information admin
69,ABT,look report ba ko bhi biogen nt gm emc stj itw today well fed governor jerome powell be speaking pm give clue rate do october money say rate hike
70,ABT,take good care
71,ABT,kp
72,ABT,follow kenny twitter kennypolcari kennypolcari com
73,ABT,kenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate sophia loren michelangelo benvenuto cellini leonardo da vinci guglielmo marconi fibonacci leonardo bonacci federico fellini luciano pavarottus be just handful famous italian have contribute immensely italian world history today most famous sexually charge italian come nyse today welcome ferrari ticker symbol race nyse family company ferrari be italian luxury sport car manufacturer founder enzo ferrari originally build race car ferrari moved production street legal luxury car fiat acquire company take control more take total stake fiat chrysler announce sell company public today be day expect street be awash testosterone excitement build broad street now know experience square have dozen ferrari display only look touch allow only serve drive man frenzy ipo be price last night share high end range be way oversubscribed so instead raise ipo price cool demand decide remain range create desire aftermarket feel excitement build tingle spine rapid breathe toe curling excitement rush blood heart beat faster faster explode fury open bell ring great way start day exhaust already stock chopped yesterday healthcare stock get whack more political wrangling investor trader grow concern ibm ibm earning mount concern marissa meyer option yahoo yhoo choppy trading wall street suggest trader be uncertain term direction equity follow recent volatility continue disappointment earning report forward guidance ibm share drop company report lower quarterly revenue straight quarter also lower guidance fiscal year so investor trader react far mark ibm stock price be fundamental stronger dollar case do hurt stock have be downtrend july investor begin re price company base concern breaking support level have only find support level late august churn build new base be only last month investor trader thought maybe market have adjust punish enough cause go bargain hunting spree well didn work too well yesterday news send stock right back lows question now be find support here share yhoo also disappoint warn future hold putt mayer turnaround plan jeopardy cause announce new plan reset sort top executive fly coop say change be result careful plan ask plan be more broadly company so far have beat bottom line only company have beat top revenue line be become more problem cause disconnect fundamental stock price rhetoric washington economy be do just fine recession hit continue hammer earning stock price eventually fall hard be gear fall technically be still struggle bull bear be lock battle major index be still downtrend dma be trend dma have find resistance have recently approach longer term technical indicator so remain lock tight range next oil energy stock say current state economy sense be stock stay sideway channel long oil price remain range oil break then look stock come renew pressure breaking reason oil pierce unlikely short term then see renew excitement stock take longer term resistance now overnight oil fall be now trading barrel only cause remain laser focuse today eia report energy information admin look report ba ko bhi biogen nt gm emc stj itw today well fed governor jerome powell be speaking pm give clue rate do october money say rate hike take good care kpfollow kenny twitter kennypolcari kennypolcari comkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
74,ABT,medical product giant abbott laboratory agree friday buy chilean drugmaker cfr pharmaceutical abbott stock dip fraction heavy trading stock market today
75,ABT,deal also involve abbott assumption debt add abbott revenue make top pharmaceutical company latin america accord press release announce deal abbott get business develop new drug spun abbvie abbv last year outside already have strong presence brand generic drug company say cfr buyout double brand generic presence latin america
76,ABT,abbott also say cfr portfolio include more product be well align abbott current pharmaceutical therapeutic area focus woman health central nervous system cardiovascular respiratory disease
77,ABT,abbott say expect double digit sale growth business useful boost company sale have be flat last couple quarters company management have be say time now re look emerge market growth develop market have be subject pricing pressure general market saturation
78,ABT,follow amy reeve twitter product giant abbott laboratory agree friday buy chilean drugmaker cfr pharmaceutical abbott stock dip fraction heavy trading stock market today deal also involve abbott assumption debt add abbott revenue make top pharmaceutical company latin america accord press release announce deal abbott get business develop new drug spun abbvie abbv last year outside already have strong presence brand generic drug company say cfr buyout double brand generic presence latin america abbott also say cfr portfolio include more product be well align abbott current pharmaceutical therapeutic area focus woman health central nervous system cardiovascular respiratory disease abbott say expect double digit sale growth business useful boost company sale have be flat last couple quarters company management have be say time now re look emerge market growth develop market have be subject pricing pressure general market saturation follow amy reeve twitter ibd_areeve
79,ABT,medtronic buyout fellow medical device giant covidien get mostly friendly reception wall street monday analyst foresee further round mega merger change industry landscape late sunday medtronic mdt announce have agree buy covidien cov cash stock deal give covidien shareholder ownership new company
80,ABT,share medical device maker covidien cov jump stock market today medtronic mdt announce late sunday be buy company medtronic cash stock payment amount share base medtronic close price friday create industry heavyweight annual revenue covidien
81,ABT,business don have weather kick anymore have lead analyst expect improve not spectacular profit revenue growth second quarter earning season kick week first quarter abysmal gross domestic product decline be blame largely polar vortex blizzard profit growth turn better
82,ABT,much century ask person most exciting technology future be robot probably have be right fly car decade ve appear movie tv show essentially slave often superhuman ability offensive moral implication wasn way robot have
83,ABT,stock future hold early gain wednesday boost positive action overseas disappointing housing market datum march
84,ABT,dow future stand solid point fair market value nasdaq future trade healthy point future be point
85,ABT,stock market today find test see build tuesday positive action jump back recent habit early gain fading weak volume loss session end
86,ABT,global market receive boost china official gdp growth estimate be slower country gain economy weakest performance month just consensus expectation chinese regulator have target growth vicinity year
87,ABT,china market post mild gain tokyo nikkei leap give extra boost comment country finance minister europe major index be positive foot midday
88,ABT,economic news housing start jump annualize rate march be nearly commerce department upwardly revise start february consensus projection build permit cue future activity decrease annualize pace pace february undercut view
89,ABT,stock busy session hour earning report tuesday left railroad csx csx chip maker intel intc fraction wednesday open
90,ABT,yahoo yhoo whoop gain flat first quarter earning performance beat expectation penny decline display ad sale advanced surprising analyst alibaba china base online retailer yahoo hold stake turn quarters decline sale gain
91,ABT,yahoo share have be correct early january high work retake week move average past week
92,ABT,wednesday early earning action send abbott lab pnc financial service pnc more apiece real firework start busy report schedule today close
93,ABT,dutch chip manufacturing equipment maker asml hold asml slump report healthy first quarter sale earning growth guide only moderate growth next quarters management cite order weakness link industry timing uncertainty next generation device design
94,ABT,currency yen tumble vs euro dollar euro gain buck crude oil be focal point commodity action claw nearly just barrel
95,ABT,industrial production capacity number march be expect federal reserve et fed april beige book report be due stock future hold early gain wednesday boost positive action overseas disappointing housing market datum march dow future stand solid point fair market value nasdaq future trade healthy point future be point stock market today find test see build tuesday positive action jump back recent habit early gain fading weak volume loss session end global market receive boost china official gdp growth estimate be slower country gain economy weakest performance month just consensus expectation chinese regulator have target growth vicinity year china market post mild gain tokyo nikkei leap give extra boost comment country finance minister europe major index be positive foot midday economic news housing start jump annualize rate march be nearly commerce department upwardly revise start february consensus projection build permit cue future activity decrease annualize pace pace february undercut view stock busy session hour earning report tuesday left railroad csx csx chip maker intel intc fraction wednesday open yahoo yhoo whoop gain flat first quarter earning performance beat expectation penny decline display ad sale advanced surprising analyst alibaba china base online retailer yahoo hold stake turn quarters decline sale gain yahoo share have be correct early january high work retake week move average past week wednesday early earning action send abbott lab pnc financial service pnc more apiece real firework start busy report schedule today close dutch chip manufacturing equipment maker asml hold asml slump report healthy first quarter sale earning growth guide only moderate growth next quarters management cite order weakness link industry timing uncertainty next generation device design currency yen tumble vs euro dollar euro gain buck crude oil be focal point commodity action claw nearly just barrel industrial production capacity number march be expect federal reserve et fed april beige book report be due
96,ABT,nowadays amgen be gray eminence biotechs more sale last year kingpin industry turn america biggest innovation machine highest return stock group last few year
97,ABT,hard believe now back biotech be still largely unproven business model amgen amgn founder public be first show be do
98,ABT,think forefather biotech think amgen genentech say funtleyder author healthcare investing profit new world pharma biotech health care service be able go public early able show lot success early
99,ABT,industry watcher give much credit amgen first chief executive george rathmann rathmann work research chemist old school giant mmm abbott laboratory be recruit venture capitalist new biotech startup
100,ABT,rathmann die speak ibd leader success profile emphasize importance investing good science key business success
101,ABT,person lead good scientific team have have tremendous respect science have be able differentiate good science bad then mostly support function rathmann say time get guy money get facility get resource make possible sustain effort way marketplace
102,ABT,rathmann be particularly interested genetic engineering be then cut edge science pharmaceutical technology then dominant platform drug development be base chemistry biotechnology be base manipulate biological process rathmann eventually zero goal clon erythropoietin gene stimulate production red blood cell see potentially huge market treat severe anemia bring kidney failure chemotherapy
103,ABT,eventual result be epogen launch become biotech first blockbuster not surprisingly also launch big stock run july january stock be already sharply level several year earlier increase more fold
104,ABT,amgen share have stage other big run then last month hit time high low gain put amgen top greatest stock past year
105,ABT,amgen wasn only company interested erythropoietin early day fact be something race get viable product first rathmann be so conscious time pressure reportedly threaten shut research eventually successful scientist isolate gene
106,ABT,be resolute determination be first market epogen say michael king biotech analyst jmp security be salesperson time used call try convince stock be explode new high sell stock diversify answer be constantly be right build great fortune family maintain vision focus amgen be
107,ABT,commitment rathmann decide hand rein cfo gordon binder shepherd amgen greatest period financial growth leave binder oversaw launch blood cell stimulating blockbuster neupogen rheumatoid arthritis treatment enbrel drug together pegylate version neupogen launch still provide more third revenue
108,ABT,be go biotechs start breaking measles market funtleyder say amgen not only help prove science biotechnology also business model company lose money nearly decade most time publicly trade bring product market eventually earn investor handsome return
109,ABT,amgen send clear message be pure biotechnology company succeed say king way also set expectation bit too high lot early biotech company picked low hang fruit
110,ABT,nonetheless era produce number winner go become big cap such alexion pharmaceutical alxn biogen idec biib gilead science gild be acquire big pharmas get ground floor young biotech be still risky king say model work much better now due long year experience
111,ABT,interview ibd former ceo binder point innovation research technology have also help speed biotech innovation
112,ABT,early day amgen want make piece dna base pair be major project now robot make thousand year human be do anything set turn binder say year make dna faster easier cheaper continuous improvement knowledge grow build nowadays amgen be gray eminence biotechs more sale last year kingpin industry turn america biggest innovation machine highest return stock group last few year hard believe now back biotech be still largely unproven business model amgen amgn founder public be first show be do think forefather biotech think amgen genentech say funtleyder author healthcare investing profit new world pharma biotech health care service be able go public early able show lot success early industry watcher give much credit amgen first chief executive george rathmann rathmann work research chemist old school giant mmm abbott laboratory be recruit venture capitalist new biotech startup rathmann die speak ibd leader success profile emphasize importance investing good science key business success person lead good scientific team have have tremendous respect science have be able differentiate good science bad then mostly support function rathmann say time get guy money get facility get resource make possible sustain effort way marketplace rathmann be particularly interested genetic engineering be then cut edge science pharmaceutical technology then dominant platform drug development be base chemistry biotechnology be base manipulate biological process rathmann eventually zero goal clon erythropoietin gene stimulate production red blood cell see potentially huge market treat severe anemia bring kidney failure chemotherapy eventual result be epogen launch become biotech first blockbuster not surprisingly also launch big stock run july january stock be already sharply level several year earlier increase more fold amgen share have stage other big run then last month hit time high low gain put amgen top greatest stock past year amgen wasn only company interested erythropoietin early day fact be something race get viable product first rathmann be so conscious time pressure reportedly threaten shut research eventually successful scientist isolate gene be resolute determination be first market epogen say michael king biotech analyst jmp security be salesperson time used call try convince stock be explode new high sell stock diversify answer be constantly be right build great fortune family maintain vision focus amgen be commitment rathmann decide hand rein cfo gordon binder shepherd amgen greatest period financial growth leave binder oversaw launch blood cell stimulating blockbuster neupogen rheumatoid arthritis treatment enbrel drug together pegylate version neupogen launch still provide more third revenue be go biotechs start breaking measles market funtleyder say amgen not only help prove science biotechnology also business model company lose money nearly decade most time publicly trade bring product market eventually earn investor handsome return amgen send clear message be pure biotechnology company succeed say king way also set expectation bit too high lot early biotech company picked low hang fruit nonetheless era produce number winner go become big cap such alexion pharmaceutical alxn biogen idec biib gilead science gild be acquire big pharmas get ground floor young biotech be still risky king say model work much better now due long year experience interview ibd former ceo binder point innovation research technology have also help speed biotech innovation early day amgen want make piece dna base pair be major project now robot make thousand year human be do anything set turn binder say year make dna faster easier cheaper continuous improvement knowledge grow build
113,ABT,baxter international bax announce thursday split biopharma medical product business separate company mid jump start lag stock move seem surprise wall street many investor have always view separation attractive prospect have mostly discount idea term give management
114,ABT,israeli drug giant teva pharmaceutical industry teva report positive result recently acquire drug tuesday teva stock be fraction however company also face new roadblock effort take mylan myl
115,ABT,teva say sd drug have gain buyout auspex pharmaceutical last month hit primary endpoint pivotal trial dyskinesia movement disorder sometimes afflict person take psychotic medication news follow successful trial sd huntington disease teva say dyskinesia be larger market potentially pass year peak sale
116,ABT,importantly study also show favorable safety tolerability profile include low rate depression somnolence insomnia akathisia movement disorder be differentiate factor competitive landscape maxim group analyst jason kolbert write research note tuesday
117,ABT,evercore isi analyst umer raffat note efficacy seem broadly similar neurocrine bioscience nbix candidate nbi agree email safety tolerability continue look excellent teva drug be very important commercial differentiator
118,ABT,also tuesday abbott laboratory own stake mylan say vote support mylan attempt acquire perrigo prgo mylan have be pursue april support acquisition be problem teva pursuit mylan teva offer company late april same time make clear not interested perrigo business
119,ABT,neither perrigo mylan want be buy investor not care company want perrigo stock be nearly afternoon trading stock market today mylan stock be
120,ABT,follow amy reeve twitter ibd_areeve israeli drug giant teva pharmaceutical industry teva report positive result recently acquire drug tuesday teva stock be fraction however company also face new roadblock effort take mylan myl teva say sd drug have gain buyout auspex pharmaceutical last month hit primary endpoint pivotal trial dyskinesia movement disorder sometimes afflict person take psychotic medication news follow successful trial sd huntington disease teva say dyskinesia be larger market potentially pass year peak sale importantly study also show favorable safety tolerability profile include low rate depression somnolence insomnia akathisia movement disorder be differentiate factor competitive landscape maxim group analyst jason kolbert write research note tuesday evercore isi analyst umer raffat note efficacy seem broadly similar neurocrine bioscience nbix candidate nbi agree email safety tolerability continue look excellent teva drug be very important commercial differentiator also tuesday abbott laboratory own stake mylan say vote support mylan attempt acquire perrigo prgo mylan have be pursue april support acquisition be problem teva pursuit mylan teva offer company late april same time make clear not interested perrigo business neither perrigo mylan want be buy investor not care company want perrigo stock be nearly afternoon trading stock market today mylan stock be follow amy reeve twitter ibd_areeve
121,ABT,stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge
122,ABT,volume nasdaq nyse be tracking tuesday level
123,ABT,fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis
124,ABT,stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast
125,ABT,stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation
126,ABT,solar stock be day best performer lead first solar fslr jump new high heavy volume
127,ABT,maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar
128,ABT,downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy
129,ABT,meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise stock pare gain midday wednesday expectation federal reserve raise interest rate later day nasdaq be dow jone industrial average edge volume nasdaq nyse be tracking tuesday level fed policymaker be expect raise interest rate basis point mark first increase central bank drop rate financial crisis stock market today drugmaker valeant pharmaceutical vrx jump heavy volume issue weaker expect earning forecast stock jump tuesday announce distribution agreement walgreen boot alliance wba canada base drugmaker say help rebuild business cut ty philidor rx service allegation wrongdoing however valeant forecast jump profit fall short analyst expectation solar stock be day best performer lead first solar fslr jump new high heavy volume maker solar panel component have get lift negotiator nearly other country reach deal last weekend cut greenhouse gas emission agreement lead greater investment energy efficient solar technology solar downside global payment gpn plunge heavy volume slice day line credit card payment processor say buy rival heartland payment system hpy meanwhile homebuider rise housing start build permit rise much more expect november accord datum commerce department send homebuilder pulte group phm toll bro tol horton dhi lennar len rise
130,ABT,top rate drugmaker akorn akrx be morning trading monday analyst weigh friday evening news again restate earning early monday company also announce series new executive appointment
131,ABT,street have assume accounting problem first reveal company file extension report march have be resolve akorn issue modest downward revision march friday statement reveal investigation have reveal further problem have result overstatement pretax income tune also firm say result not be issue timely manner
132,ABT,piper jaffray analyst david amsellem run patience downgrade stock neutral
133,ABT,management do not believe accounting issue impact result be sticking guidance be view far too large credibility gap simply take statement face value write research note sunday believe significant management change be need restore akorn credibility further find difficult envision misstep not result change cfo position
134,ABT,monday however bring news hire new corporate controller randall pollard former accounting chief novartis nvs generic unit sandoz
135,ABT,akorn also announce newly create position former allergan vice president kafer be now executive vice president sale marketing former abbott laboratory executive steve lichter be executive vice president pharmaceutical operation former baxter bax quality controller jaspreet gill be evp global quality compliance
136,ABT,leerink analyst jason gerberry writing new management announcement be bit more trusting amsellem still lower price target
137,ABT,view business isn break re encourage management isn change guidance recommend investor take profit strong year date write note sunday
138,ABT,late morning stock market today akorn stock be kill cup base have form late february
139,ABT,follow amy reeve twitter ibd_areeve top rate drugmaker akorn akrx be morning trading monday analyst weigh friday evening news again restate earning early monday company also announce series new executive appointment street have assume accounting problem first reveal company file extension report march have be resolve akorn issue modest downward revision march friday statement reveal investigation have reveal further problem have result overstatement pretax income tune also firm say result not be issue timely manner piper jaffray analyst david amsellem run patience downgrade stock neutral management do not believe accounting issue impact result be sticking guidance be view far too large credibility gap simply take statement face value write research note sunday believe significant management change be need restore akorn credibility further find difficult envision misstep not result change cfo position monday however bring news hire new corporate controller randall pollard former accounting chief novartis nvs generic unit sandoz akorn also announce newly create position former allergan vice president kafer be now executive vice president sale marketing former abbott laboratory executive steve lichter be executive vice president pharmaceutical operation former baxter bax quality controller jaspreet gill be evp global quality compliance leerink analyst jason gerberry writing new management announcement be bit more trusting amsellem still lower price target view business isn break re encourage management isn change guidance recommend investor take profit strong year date write note sunday late morning stock market today akorn stock be kill cup base have form late february follow amy reeve twitter ibd_areeve
140,ABT,be set be big year specialty drugmaker depome year lumpy quarters drive licensing deal other drugmaker depome depo be come own independent commercial pharma develop acquire approve product most recently regular extend release version pain medicine nucynta deal johnson
141,ABT,medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more
142,ABT,company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect
143,ABT,sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth
144,ABT,st jude say currency adjust sale growth continue rest year
145,ABT,stock break flat base surge past buy point volume be heavy
146,ABT,st jude composite rating be middling mainly company ep rating be unimpressive
147,ABT,st jude be ibd medical product industry group rank group wednesday edition have be top group many week
148,ABT,meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate
149,ABT,abbott affirm previous full year profit guidance share vs last year
150,ABT,continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january
151,ABT,abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance
152,ABT,abbott be diversify medical industry group rank have be trend lower
153,ABT,ibd staff contribute report medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth st jude say currency adjust sale growth continue rest year stock break flat base surge past buy point volume be heavy st jude composite rating be middling mainly company ep rating be unimpressive st jude be ibd medical product industry group rank group wednesday edition have be top group many week meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate abbott affirm previous full year profit guidance share vs last year continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance abbott be diversify medical industry group rank have be trend lower ibd staff contribute report
154,ABT,share abbott laboratory dip early wednesday broad first quarter beat pharmaceutical sale lag wall street expectation nearly stock market today abbott stock fall sharply recoup loss finish regular session share be form cup handle buy point revenue establish pharmaceutical sell outside fall short rbc analyst glenn novarro write note client evercore analyst vijay kumar note sale unit miss consensus broadly quarter be success rbc novarro say keep outperform rating abbott follow first quarter earning report get newsletter deliver inbox more info product service privacy policy term use sale exceed forecast broad base strength say re buyer pullback quarter abbott report adjust income cent share sale grow respectively abbott say organic sale grow include internationally medical device sale have best organic growth rise beat consensus evercore kumar say diagnostic also post big beat rise organically sale top consensus further nutrition segment performance continue improve rbc novarro say worldwide nutrition sale be organically top guidance low single digit growth adult pediatric segment perform well grow respective organic basis novarro say year abbott reaffirm adjust profit target share analyst modeled adjust earning share sale abbott also see second quarter adjust income come cent share related chart read basic buy point mark time real opportunitynew option strategy limit risk earningsstill rule stock investor always cut loss short
155,ABT,question abbvie abbv have prove be pharmaceutical leader extremely healthy dividend boot company debut nyse january then stock have climb much same period have rally much abbvie therefore be live proof savvy dividend investor also seek capital appreciation achieve be key chicago base medical giant long term success first company focus important therapeutic area provide opportunity abbvie aim product tackle disease immunology cancer virology neuroscience company have produce medicine gain traction friday abbvie announce fda grant approval venclexta treatment combination rituximab treat patient chronic lymphocytic leukemia cll small lymphocytic lymphoma sll have receive least prior therapy phase iii clinical trial find combine regimen cut risk disease progression death vs standard abbvie total revenue grow top line be abbvie spinoff abbott lab earn share last year second solid dividend generator tend show stable increase earning abbvie excel year earning stability factor show tremendous stability scale accord william neil co datum wall street expect profit rise year abbvie paid cent share cash holder record april dividend translate vs year abbvie paid cent share feb third income investor gain advantage more fund be pile stock abbvie end march mutual fund hedge fund own abbvie share totale fund end second quarter total share ownership also grow same time frame rise share top rate fidelity contrafund ticker symbol fcntx boost ownership share share end year abbvie share be base mode be still trading time high stock be try hold support day move average aug last year abbvie rally week flat base heavy volume stock surpass proper entry rally go current base action related top growth stock today peek ibd best large cap stock today big cap investor corner find right buy point most stock
156,ABT,share boston scientific bsx surge monday report wall street journal have be approach stryker syk deal medical device maker unclear boston scientific be open takeover journal say cite source didn identify boston scientific share soar much end regular trading session stryker share fall close trading stock be halter just monday neither company comment merger rumor deal company be latest series large acquisition industry have be consolidate market share package sale hospital doctor health clinic boston scientific make heart device such pacemaker stent other product be worth estimate market value nearly value stryker make orthopedic product artificial hip knee get newsletter deliver inbox more info product service privacy policy term usecombine company let wring cost effort sell product similar set customer also give combine firm more market power merger large health insurer have increase pressure hospital lower expense movement come ongoing debate cost medical care matter company policy do not comment potential stryker jon zimmer say email representative boston scientific didn immediately respond request comment many largest competitor have already execute large takeover recent year abbott laboratory last year buy st jude medical make heart device then month later complete takeover medical testing diagnostic supplier alere medtronic mdt buy covidien make surgical product
157,ABT,dow jone component johnson johnson jnj engage bidding war sweep boston scientific bsx stryker syk analyst say tuesday follow rumor latter merge report emerge monday stryker approach boston takeover bid boston share spiked rumor stryker topple canaccord analyst say stryker be far only medical device maker interest boston headline be substantiated stryker be fact make bid boston scientific see high likelihood emerge potential bidder say note client have be banter potential boston scientific acquirer year bidding war emerge place high likelihood be involved stock market today boston stock dip close stryker share plunge even stock look somewhat dim ease fraction get newsletter deliver inbox more info product service privacy policy term deal have analyst somewhat split tuesday regard materiality report do not find potential such marriage be shocking canaccord analyst say indeed see merit such combination standpoint product line synergy stryker acquisition help add product sector higher potential growth bigger market also help stryker differentiate portfolio technology compete large company medtronic mdt boston case deal cap year turnaround allow end high note canaccord analyst say sum definitively think boston scientific be game do fair deal here say rbc analyst glenn novarro view deal unfavorably acknowledge strategic rationale make sense also likely boston win deal less share combine premier growth company medical device space be limit product overlap say however bar value creation be set high give potential valuation company combine stryker boston scientific have revenue stand grow sustainable higher compound annual growth rate medium term novarro say have enterprise value canaccord analyst call potential deal merger equal stryker be only third larger boston also lead further med tech consolidation consummate create behemoth medical device stryker boston scientific join abbott medtronic say think edward lifescience ew be next potential major acquisition target also highlight nephew snn be last remain pure play total joint operation market related chart read basic buy point mark time real trade stock most penny stock fail make investor basic analyze stock cup handle
158,ABT,food drug administration approve world smallest heart valve tuesday several year seattle surgeon used dime size device abbott laboratory save tiny baby name sadie leaky heart valve sadie rutenberg be first patient abbott halo trial begin month age sadie struggle breathe stop gain weight wasn eating well due congenital heart defect sadie need surgery right away smallest replacement valf time be still too big pound body so parent lee wendy rutenberg enrolled sadie abbott trial be first receive millimeter device month age doctor come surgery tell surgery be success parent moment ll never forget lee rutenberg say written statement provide abbott valve save sadie life tuesday fda approve abbott master hp rotatable mechanical heart valve be implanted baby toddler born congenital heart defect baby born year have congenital heart defect use ibd marketsmith free march
159,ABT,see stock buy point get chart pattern recognition run custom screen start nowbefore approval surgeon only choose array too large heart valf replace pediatric heart valf be repair abbott say news release mechanical valve mimic valve healthy heart open close beat master hp valve be primarily approve base result clinical trial sadie be first patient trial enrolled patient age younger have diseased damage malfunctioning heart valf sadie receive new valve seattle child hospital heart center today be thrive year old love color red think giraffes be funny creature wendy rutenberg outlined gratitude statement place dr chen save sadie life say be very real possibility have die need heart transplant come here have such positive outcome just amazing stock market today abbott rise close related chart read basic buy point mark time real opportunitylong term retirement investing strategy basic analyze stock cup handle
160,ABT,medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more
161,ABT,company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect
162,ABT,sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth
163,ABT,st jude say currency adjust sale growth continue rest year
164,ABT,stock break flat base surge past buy point volume be heavy
165,ABT,st jude composite rating be middling mainly company ep rating be unimpressive
166,ABT,st jude be ibd medical product industry group rank group wednesday edition have be top group many week
167,ABT,meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate
168,ABT,abbott affirm previous full year profit guidance share vs last year
169,ABT,continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january
170,ABT,abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance
171,ABT,abbott be diversify medical industry group rank have be trend lower
172,ABT,ibd staff contribute report medical product giant break basis wednesday beating first quarter expectation st jude medical stj jump new high report earning cent share year earlier quarter line analyst consensus revenue shrank beat consensus more company guide earning high side consensus cent share shave few cent previous full year guidance now lower be due foreign exchange headwind analyst say be generally expect sale beat be encouragingly broad base notable outperformance cardiac rhythm management crm atrial fibrillation af write leerink analyst danielle antalffy research note wednesday constant currency sale growth quarter point ahead midpoint guidance range stj appear be set stage deliver promise drive accelerate sale growth st jude say currency adjust sale growth continue rest year stock break flat base surge past buy point volume be heavy st jude composite rating be middling mainly company ep rating be unimpressive st jude be ibd medical product industry group rank group wednesday edition have be top group many week meanwhile abbott laboratory report earning cent share year earlier quarter beating consensus nickel sale rise street estimate abbott affirm previous full year profit guidance share vs last year continue track deliver consistently improve operational result year company meaningfully reshape portfolio shedding slower growth lower margin business acquire high growth business focuse key emerge market antalffy write notably constant currency sale growth come year year strongest operational sale growth quarter spin pharmaceutical business abbvie abbv january abbott share break base base pattern buy point volume be average stock have mediocre relative price strength rating owing moderate long term price performance abbott be diversify medical industry group rank have be trend lower ibd staff contribute report
173,ABT,market have be relatively quiet late let take quick look story day get file be someone kid headline not be clearer flash crash charge be file wsj mystery trader arm algorithms rewrite flash crash history bloomberg fed endanger space time continuum arrest future trader
174,ABT,seek avoid be takeover mylan myl raise offer perrigo prgo promptly reject bid say proposal be generic drugmaker mylan bid cash mylan share share perrigo be worth friday close higher informal offer unspecified cash
175,ABT,handful big cap stock be hover buy point regeneron pharmaceutical regn be try clear buy point cup handle base pattern be late stage make risky
176,ABT,profit revenue growth have picked straight quarters earning latest quarter climb jump sale
177,ABT,eylea treatment macular degeneration be drive company growth
178,ABT,well regard fidelity contrafund add holding latest quarter columbia marsico st century fund open new position
179,ABT,nike nke be approach buy point base base pattern stock accumulation distribution rating indicate rise demand share
180,ABT,also stock relative strength line be hit new high bullish indicator
181,ABT,president obama visit athletic apparel maker oregon headquarters friday promote tran pacific partnership trade deal country
182,ABT,most nike sale currently come north america europe nike make most apparel overseas say pact create job
183,ABT,abbvie abbv drugmaker have shape cup handle base buy point
184,ABT,company be spun abbott laboratory be top stock highly rate prescription drug industry group
185,ABT,profit year be expect rise share follow increase
186,ABT,abbvie make drug treat rheumatoid arthritis psoriasis other ailment
187,ABT,present new datum oncology drug pipeline meeting american society clinical oncology june
188,ABT,anthem antm provider manage health care service be flat base buy point
189,ABT,company have benefit growth enrollment business customer government program such medicaid
190,ABT,anthem announce last month profit jump share easily beating wall street estimate revenue climb
191,ABT,stock have triple past year late base be third stage pattern
192,ABT,april oppenheimer raise price target anthem number other manage care stock cite continue improvement economy prospect federal reserve interest rate hike boost return investment portfolio
193,ABT,manage care industry be rank ninth group track ibd monday handful big cap stock be hover buy point regeneron pharmaceutical regn be try clear buy point cup handle base pattern be late stage make risky profit revenue growth have picked straight quarters earning latest quarter climb jump sale eylea treatment macular degeneration be drive company growth well regard fidelity contrafund add holding latest quarter columbia marsico st century fund open new position nike nke be approach buy point base base pattern stock accumulation distribution rating indicate rise demand share also stock relative strength line be hit new high bullish indicator president obama visit athletic apparel maker oregon headquarters friday promote tran pacific partnership trade deal country most nike sale currently come north america europe nike make most apparel overseas say pact create job abbvie abbv drugmaker have shape cup handle base buy point company be spun abbott laboratory be top stock highly rate prescription drug industry group profit year be expect rise share follow increase abbvie make drug treat rheumatoid arthritis psoriasis other ailment present new datum oncology drug pipeline meeting american society clinical oncology june anthem antm provider manage health care service be flat base buy point company have benefit growth enrollment business customer government program such medicaid anthem announce last month profit jump share easily beating wall street estimate revenue climb stock have triple past year late base be third stage pattern april oppenheimer raise price target anthem number other manage care stock cite continue improvement economy prospect federal reserve interest rate hike boost return investment portfolio manage care industry be rank ninth group track ibd monday
194,ABT,mylan lab myl gap lower monday morning announce abbott laboratory sell third recently acquire stake generic drug maker mylan share bounce key support level mylan offer share behalf abbott abbott stake mylan underwriter also have right buy
195,ABT,generic drug giant mylan announce wednesday have bid share cash stock sizable peer perrigo send stock soar perrigo prgo hadn agree deal mylan myl indicated have be talk proposal be culmination number prior discussion mylan perrigo compelling strategic
196,ABT,startup key rite passage come founder hand rein ceo take next stage life sucampo pharmaceutical take year happen judge wall street reaction not moment soon sucampo scmp be founder married japanese
197,ABT,generic drug giant mylan myl late monday report earning guidance line wall street expectation shortly close major buyout mylan profit rise year earlier quarter share exactly analyst expect accord thomson reuter revenue gain slightly consensus still mylan stock be nearly hour trading monday company release december quarter result year profit rise share revenue friday mylan close stock swap deal acquire abbott laboratory business selling generic drug develop market add annual revenue officially relocate company lower tax netherlands be reflect mylan guidance sale ep guidance range bracket consensus be great start recent completion acquisition abbott develop market specialty brand generic business announcement propose acquisition famy care woman health care business expect mylan deliver revenue growth adjust diluted ep growth constant currency basis mylan ceo heather bresch say statement addition exciting activity have previously state continue expect aggressively pursue additional acquisition opportunity make financial strategic sense company mylan hold excellent ibd composite rating be likely improve growth ramp stock have be form possible flat base hit new high nov regular trading stock market today mylan stock rise close follow amy reeve twitter ibd_areeve
198,ABT,mylan myl stock break wednesday rumor circulate twitter generic brand drugmaker be sale possibly teva announce drug launch mylan stock rise wednesday briefly pass buy point ease teva pharmaceutical industry teva gain analyst be divide logic
199,ABT,stock continue hold best level session late monday rally hope stimulus china number buyout nasdaq be respectively be pace biggest gain march meanwhile dow jone industrial average lead jump only intel intc be lower blue chip index lead stock madison square garden msg cool record high be still friday announcement split company focus sport entertainment other medium fading madison square garden be still past buy point flat base clear early february ambarella amba rally time high canaccord genuity bump price target stock be now past buy point break late stage base signet jeweler limit sig rise time high nomura raise price target share be nearly past buy point flat base retailer deliver better expect earning last week downside mylan myl pare loss more half earlier stock market today drugmaker announce offer share be be sell subsidiary abbott laboratory mylan test buy point flat base
200,ABT,larry wood liken aortic stenosis cancer heart aortic stenosis be most common serious valve disease problem restrict blood flow left ventricle aorta cause fatigue pain occur birth defect elderly patient edward lifescience ew medtronic ticker
201,ABT,abbott laboratory pop friday medical giant announce raise dividend cent mark consecutive quarterly dividend be paid abbott cash dividend be payable shareholder record close business april abbott say news release abbott have increase dividend payout consecutive year month dividend yield be firm have year dividend growth spokesperson tell investor business daily comparison average month yield health care company be stock market today abbott rise close related biogen seek merger wake alzheimer worriesabbvie stock rise increase dividend biotech stock need anesthesia collapse nearly
202,ABT,abbott laboratory pop record high wednesday beating fourth quarter sale earning forecast quelling worry share plateau follow big run close bell stock market today abbott have jump finish share break flat base buy point mid december have trade buy zone cowen analyst joshua jenning expect abbott operational momentum drive stock higher next month reiterate outperform rating price target believe company impressive sale result be sufficient quell investor doubt abbott stock plateau follow big run say note client share remain top pick fourth quarter abbott report adjust profit cent share rise sale grow year earlier period metric beat consensus adjust income cent share sale fourth quarter represent return growth rbc analyst glenn novarro write note client revenue increase operationally be significant improvement growth third quarter ibd take biotechs biogen celgene be slate report fourth quarter earning early thursday keep tab stock look likely surprise upside visit ibd industry theme diagnostic medical device sale benefit abbott acquisition alere st jude medical respectively total diagnostic revenue rise operationally medical device sale grow operational basis alere sale be higher novarro estimate acquisition close early october medical device sale cardiovascular neuromodulation diabetes care unit top novarro expectation grow structural heart product sale rise neuromodulation revenue be sale diabetes care jump abbott guide adjust profit share be midpoint analyst poll zack investment research have call share sale related biotech merger spigot turn juno bioverativ biotech stock outperform peer electricity replace opioid treat chronic pain
203,ABT,long costly process big pharma biotech stock abbvie abbv vertex pharmaceutical vrtx abbot laboratory get food drug administration approval new drug lead clinical research organization cro pra health science prah help drugmaker get new treatment market conduct clinical trial base
204,ABT,key stock index fund rise thursday fang stock other big cap techs power big gain tech heavy powershare qqq trust powershare qqq trust qqq lead upside gain spdr spy spdr dow jone industrial average dium add respective small cap lag slightly ishare russell iwm ishare core small cap ijr climb respectively fang stock boost techs facebook fb gap soar almost retake day move average first time week close wednesday social network report result top view top bottom line amazon netflix pop stock regain day line alphabet googl advanced reclaim day line intel intc microsoft msft rise more dow stock be time high apple aapl add be tough week so far iphone maker share trade day line analyst expect apple earn share revenue report tuesday chip technology biotechs be biggest sector fund gainer stock market today vaneck vector semiconductor smh gap rise retake day line advanced micro device amd surge regain day line earning sale beat late wednesday well higher revenue outlook real estate homebuilder financial underperform stock fund be ailing volatility market health care play hold medtronic mdt abbott laboratory be find healthy support ishare medical device ihi continue consolidate mark record high late january tumble day move average stock market slump early february etf find support have be trading day line then climb back high market environment improve potential buy point be fund track dow jone select medical equipment index turn year old next month health care equipment represent biggest sector weighting tuesday nearly asset life science tool service make health care service rest top holding include medtronic abbott lab thermo fisher scientific tmo becton dickinson bdx dhr account stock portfolio get free access ibd digital april
205,ABT,get premium stock list pass fail stock rating more start herethermo fisher have produce gain wednesday close becton dickinson abbott be medtronic be medtronic have have rough start year share weaken mid february medical device maker suggest first use human hugo surgical robot be delay previously plan start operate patient end fiscal end month fund return year date tuesday accord morningstar inc far ahead loss average annual return past year have also outperformed broader index gain same period be ihi carry expense ratio wednesday pick spdr bank kbe spdr regional bank kre see mixed finish continue work right side respective shallow basis also be interested stock rise boee soar ge sink bitcoin pare lossesai robotic blockchain hot new etf industry trendshere way invest fang stock etf
206,ABT,here investing action plan wednesday need know investor come day earning season continue roll result asml hold asml alcoa aa steel dynamic stld american express axp unite rental uri other federal reserve release beige book economic survey alcoa aluminum giant used unofficially
207,ABT,index dow jone industrial average nasdaq composite rise strongly early week then erased most gain friday close netflix nflx soar subscriber growth guidance energy stock bust higher crude oil price keep rise alcoa aa american express axp unitedhealth unh jump report offset weak outlook taiwan semiconductor manufacturing tsm chip gear giant lam research lrcx asml asml broader chip sector apple aapl come pressure index dow jone nasdaq composite be more thursday friday close be major average rally wednesday netflix nflx earning oil fuel energy stock stock pull back taiwan semiconductor manufacturing tsm warn rest cite weak smartphone demand already pressured weak asml asml lam research lrcx guidance chip stock sell apple aapl also come heavy pressure thursday friday iphone demand concern year treasury yield jump year high internet television network netflix nflx add stream subscriber first quarter beating target end march quarter subscriber worldwide netflix expect add subscriber top wall street target netflix also top ep sale figure guide higher metric subscriber number benefit new original content such science fiction series alter carbon fresh season comic book series marvel jessica jone comedy grace frankie share shot record high taiwan semiconductor manufacturing tsm cut sale outlook rest year largely softer smartphone demand slam chip stock apple aapl taiwan semi be world largest contract chipmaker count apple nvidia nvda qualcomm qcom customer meanwhile chip gear maker lam research lrcx asml hold asml pressured semiconductor stock day earlier weak outlook lam equipment shipment view rest year come light asml forecast lower gross profit margin current quarter get newsletter deliver inbox more info product service privacy policy term useu oil future rise barrel hit fresh multiyear high opec russia likely stay course output cut meeting jeddah saudi arabia friday president trump blast opec crude hold domestic crude stockpile fall barrel last week energy information administration say defy view small gain oil production climb fresh high barrel day schlumberger slb meet view energy stock be big winner yet again more oil play breaking set charle schwab schw interactive broker ibkr trade financial etfc report better expect quarterly earning schwab share reclaim day move average build right side flat base interactive broker moved buy zone just earning then pull back slightly trade moved buy range late thursday report bank america bac first quarter earning top expectation rebound trading lead estimate beating result goldman sachs gs morgan stanley ms extra client activity goldman reversed lower say say likely pause buyback second quarter meanwhile comerica cma sank other super regional bank weak loan growth treasury yield soar financial stock rise weekly lows southwest airline luv flight head dalla new york make emergency landing philadelphia jet left engine explode burst window kill female passenger result passenger jennifer riordan be pronounce dead hospital unite airline ual say inspect engine boee ba type plane experience engine failure follow recent faa bulletin unite share jump carrier narrow expansion plan year ahead stay upbeat sale trend bristol myer squibb bmy plunge report drug combination opdivo yervoy reduce risk lung cancer progression death be lower merck regimen keytruda chemotherapy cut risk death similar group lung cancer patient merck mrk stock climb nearly commerce department ban domestic firm selling component chinese telecom gear maker zte spark sell optical device maker acacia communication acia oclaro oclr lumentum holding lite government determine zte violate term settlement involve illegally ship networking gear iran acacia garner sale zte oclaro analyst say ciena cien compete zte optical system get lift year ban be not lift unitedhealth group unh cruised past wall street first quarter earning estimate net share cent view revenue grow manage care enrollment gain come medicare advantage medicaid meanwhile unitedhealth fast grow optumhealth service unit grow revenue deliver care related service person share rise week approach buy point alcoa aa stock break past buy point record alumina price strong earning blowout profit guidance aluminum giant earning rise revenue grow alcoa expect full year adjust ebitda range offer january expect industry supply shortage year trump administration sanction unite co rusal impose month bar ban entity do business russian aluminum giant top steel maker steel dynamic stld nucor nue edge past first quarter earning estimate issue moderately positive comment outlook nucor expect sustainable strength steel market not quite bullish steel investor have expect late february president trump initially call tariff steel import exemption then more half steel import have be exempt general electric ge report smaller expect adjust ep decline revenue rise more expect aviation health care be solid ge power remain drag ge reaffirm full year ep guidance say have plan cut dividend again ge stock rise friday atlassian team report adjust fiscal profit cent share revenue jump top estimate maker project management collaborative software guide low current quarter ep share tumble friday amazon com amzn ceo jeff bezos disclose amazon prime have more member worldwide first time online sale leader have give specific membership figure be higher expect intuitive surgical isrg break wednesday robot surgical system maker report adjust ep gain sale grow beating view textron txt sell tool test business segment emerson electric cash maker cessna jet bell helicopter also report jump ep cent share rise revenue beating analyst view announce share buyback program textron soar gapping past buy point ibm ibm beat first quarter estimate stock tumble weak margin slower growth key area ebay ebay shot morgan stanley upgrade stock boost price target more cite recent partnership payment processor adyen move away paypal pypl abbott laboratory beat expectation wednesday adjust income cent share sale share dip pharmaceutical sale come expectation johnson johnson jnj top estimate share edge lower share fall wednesday news kentucky be sue allegation run deceptive marketing scheme related painkiller consumer electronic retailer best buy bby amazon com amzn announce partnership best buy use amazon fire tv operate system insignia brand television replace roku roku software best buy also sell tvs amazon american express axp jump thursday report better expect earning wednesday ep rise revenue climb nearly rail giant csx csx gap wednesday beating earning day report ep cent revenue operate income increase skecher skx crash friday give weak earning sale outlook athleisure shoe maker meet ep estimate rise modestly beat sale view gain be interested look best stock buy watch start invest stock market start simple routine
208,ABT,market knock healthy early gain monday broad range stock rebound last week slump dow jone industrial average grab gain nasdaq climb volume stock market today open mixed trade rise nyse possibly good sign rebound day move average volume dip nasdaq index retook day line
209,ABT,stock precision castpart pcp lead soar news acquisition berkshire hathaway brka
210,ABT,dow issue moved higher start trade apple aapl boee ba lead nearly chip stock drugmaker stake high ground nasdaq issue texas instrument txn kla tencor klac rise so do alexion alxn mylan myl
211,ABT,ibd list cyberark software cybr investment wetf swat better gain
212,ABT,cyberark move lift share back stock day move average attempt begin right side month consolidation
213,ABT,be climb day move average trading past cup base buy point
214,ABT,june quarter earning season be slow today hour session be nevertheless busy big name such hertz global htz kraft heinz khc report smaller name shake shack shak vipshop vip schedule report market knock healthy early gain monday broad range stock rebound last week slump dow jone industrial average grab gain nasdaq climb volume stock market today open mixed trade rise nyse possibly good sign rebound day move average volume dip nasdaq index retook day line stock precision castpart pcp lead soar news acquisition berkshire hathaway brka dow issue moved higher start trade apple aapl boee ba lead nearly chip stock drugmaker stake high ground nasdaq issue texas instrument txn kla tencor klac rise so do alexion alxn mylan myl ibd list cyberark software cybr investment wetf swat better gain cyberark move lift share back stock day move average attempt begin right side month consolidation be climb day move average trading past cup base buy point june quarter earning season be slow today hour session be nevertheless busy big name such hertz global htz kraft heinz khc report smaller name shake shack shak vipshop vip schedule report
215,ABT,last week space several big cap stock show healthy earning sale increase be discuss week column ask question big cap name be make most sale growth other word much profit be generate dollar sale profit margin tell well
216,ABT,several stock clear buy point en route new high thursday market rebound sharply citrix system ctxs soar very heavy trading software developer report profit jump share biggest increase more year well ahead wall street estimate sale
217,ABT,lead medical equipment stock be thursday report strong result guidance continue season theme foreign exchange headwind life science toolmaker thermo fisher scientific tmo report earning time item share year earlier quarter beating analyst consensus cent sale rise top estimate more
218,ABT,generic drug giant mylan myl announce monday buy asset india base woman health company mylan also buy lung disease drug candidate mylan agree pay upfront contingent payment certain female health care business famy care mylan have have partnership
219,ABT,stock market index fund extend gain monday key dow jone industrial average etf reclaim couldn hold day move average spdr dow jone industrial average dium rally nearly inch day line then retreat gain spdr spy powershare qqq trust qqq also add stock market today foreign market trail ishare msci eafe efa ishare msci emerge market eem edge higher dow stock advanced top blue chip winner include unh merck mrk apple aapl add mark third straight advance iphone maker be work right side shallow base potential buy point raymond james warn apple get hit sell news reaction report expectation be already baked share price utility consumer staple homebuilder be top sector fund gainer spdr homebuilder xhb advanced continue trade day day line aerospace defense also show strength ishare aerospace ita lift build flat base potential buy point defense contractor include raytheon rtn northrop grumman noc dow component unite technology utx rally heel coordinate strike syrium britain france friday raytheon lift clear flat base entry average volume telecom biotech gold miner underperform most biotech health care fund get hurt past month heighten volatility broader market top performer accompany table see healthy year date gain vs wednesday accord morningstar direct first trust nyse arca biotechnology index fund fbt place first year date return even drop past month fund regain day move average thursday be form double bottom base buy point top holding thursday include avexis avxs intrexon xon nektar therapeutic nktr agio pharmaceutical agio intercept pharmaceutical icpt avexis share soar april news novartis nvs buy biotech get newsletter deliver inbox more info product service privacy policy term useark genomic revolution multus sector arkg come second year date return fund invest company involved genomic related field such gene therapy target therapeutic next generation oncology top holding intellium therapeutic ntla edita medicine edit illumina ilmn invitae nvta bluebird bio blue account third stock portfolio fund lose past month have be trading day line late march share be march intraday high third place go ishare medical device ihi gain wednesday fund track dow jone select medical equipment index sit high top holding make stock portfolio be medtronic mdt abbott laboratory thermo fisher scientific tmo becton dickinson bdx dhr alp medical breakthrough sbio spdr biotech xbi round top etfs respective year date gain also be interested stock lower big bank weigh dow apple buck declinestock market rally intel apple boost dow bitcoin biotechs drugmaker fare senate tax bill
220,ABT,build list stock watch market correction be sure see stock best mutual fund have be buy adobe adbe zebra technology zbra link show stock fit bill term dollar amount invest adobe top list new buy best mutual fund last month lead fund invest estimate total maker adobe analytic creative software tool photoshop illustrator top portfolio manager also invest least other company include abbot laboratory deere co constellation brand stz micron technology mu abiom abmd lam research lrcx zebra technology provide bar code other tracking technology amazon amzn wide range other company see total investment approximately market correction best avoid make new buy perfect time build list stock watch focus form basis launch new breakout next market rally pay particular attention stock best mutual fund have be buy get newsletter deliver inbox more info product service privacy policy term uselead apparel stock pvh pvh own tommy hilfiger calvin klein brand be get set unveil new move first stage flat base market cooperate last month best mutual fund invest approximately new york base company pvh be recently featured ibd stock analysis recently clear entry pvh be now trading buy point luxury apparel accessory stock loui vuitton owner lvmh moet hennessy lvmuy also make list lvmh have manage keep climb market turbulence be now extend entry best mutual fund scoop estimate share gentex gntx make automatic dim rearview mirror garage door opener gentex be trading just buy point early stage flat base beer wine spirit distributor constellation brand be stock watch list corona modelo distributor have be testing entry first stage flat base find support day move average generic pharmaceutical maker abbott laboratory have now make list new buy best mutual fund straight month be work cup handle note stock be still try retake day move average line fall nearly friday zebra technology be now buy point clear double bottom january payment processor total system service tss top list stock be sell net seller fund selling buy ibd stock pull back clear buy point last month now try rebound retake day move average newmont mining nem best buy bby idex iex also have fair amount net seller also best mutual fund manager see silver line weak stock performancebest mutual fund award quickly find track best mutual fundstop mutual fund ab large cap growth performance excel idiosyncratic opportunity
221,ABT,here weekly investing action plan need know investor come week earning season pick momentum result due netflix nflx goldman sachs gs general electric ge ibm ibm score other airline stock get rattle further unite airline ual report give update expansion plan
222,ABT,small cap medical stock quidel qdel grow earning last year street expect earning jump year revenue leap gain far year growth rate account huge surge sale apart rise demand be additional cause
223,ABT,bank america bac cigna ci texas instrument txn once again earn spot latest list new buy top perform mutual fund most noteworthy name be didn return apple aapl apple have make list consecutive month stock continue climb bottom reach january report top fund invest total nearly tech giant analyst see slowdown iphone sale institutional investor fear explosive growth past be come back earth company settle new headquarters nickname apple spaceship cupertino calif december quarter apple beat estimate sale earning come short iphone sale guide lower current quarter apple stock have now fall sharply week line heavy volume sign institutional selling apple be currently testing support week line stock list receive estimate investment top fund past month bank america medical sector stock unitedhealth unh abbott semiconductor pioneer texas instrument bofa be more september have show resilience support day line face increase volatility selling pressure general market abbott have give back much gain make buy point clear december maker generic pharmaceutical diagnostic system be now trading entry unitedhealth break earlier month have pull back be now buy point texas instrument have also be retreat remain entry clear september nasdaq show increase selling pressure volatility many stock list such orbotech orbk dmc global boom have see recent breakout fail other such new york time nyt have manage keep climb paper record break double bottom jan be now more buy point jump today earning beat pull back recent day defense stock hexcel hxl be testing support entry clear jan louisiana pacific lpx provide engineer wood product home construction have splintered recently be now back buy point first clear jan modine mod have be hold better many other name list have share wild price swing currently still trading just buy zone modine make thermal management system build industrial refrigeration market initially sank recent earning report bounce back buy range heavy volume last week jpmorgan chase jpm top list stock be sell net seller fund selling buy just banking rival bofa jpmorgan have continue climb higher sell side be aetna aet have net seller fund selling buy last year cvs health cvs announce be buy manage care provider also quickly find best mutual fundsis time get stock market
224,ABT,last month top perform mutual fund have be heavily buy share big name industry leader include bank america bac intel intc boee ba abbott laboratory charle schwab schw investing well period bofa lead group top fund manager scoop more financial giant share boost demand stock be now buy point clear september semiconductor equipment maker apply material amat software analytic leader adobe adbe come just shy mark get investment approximately respectively ibd screen identify top growth stock be strongly display key trait typically share biggest stock market winner name month list new buy top fund be also currently ibd include apply material adobe abiom abmd lam research lrcx global spgi get newsletter deliver inbox more info product service privacy policy term usein addition bofa other bank stock make list joined financial sector company include charle schwab be name best online stock broker lead portfolio manager also continue pick share semiconductor stock include aforementioned intel apply material lam research well microsemi mscc kla tencor klac portfolio manager also show healthy interest medical stock company sector join abiom abbot laboratory list include express script esrx cantel medical cmd just mutual fund manager have be buy stock doesn mean time individual investor pick share especially give overall market have come selling pressure recently be sure run stock idea buy checklist do additional research make investment decision tuesday apply material clear buy point later stage therefore riskier double bottom relative strength line have be trend sharply higher be just shy new high ground lam research be also work late stage double bottom have now climb entry scanning tracking solution leader zebra technology zbra leap past buy point january pull back stock market fall sharply early february feb zebra soar earning report be now initial entry adobe also launch successful january have now climb buy point ibd member svb financial sivb own silicon valley bank be just featured ibd stock analysis break past entry tuesday be now testing support buy point resignation donald trump top economic advisor gary cohn rattle market be top new buy month boee top list stock be sell net seller fund selling buy american express axp be second net seller fund selling buy manage care provider humana hum motorola solution msi also see significant number net seller also be today fastest grow company find track best mutual fundsvideo quickly find top perform mutual fund
225,ABT,wednesday abbott laboratory clear key performance benchmark see relative strength rs rating jump percentile improvement day ibd unique rating measure share price action worst best score grade show stock price performance trail week compare other stock database history show top perform stock tend have rs rating least begin biggest run see ibd help make more money stocksabbott laboratory be build flat base entry see stock clear price volume least higher normal company bottom line growth drop company most recent performance report sale rise previous report abbott laboratory hold rank peer medical diversify industry group johnson johnson jnj ibd be also group highest rate stock related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
226,ABT,big pharma abbvie deal acquire hot biotech pharmacyclic be meet widespread skepticism abbvie investor thursday send abbvie stock fall thursday abbvie abbv announce cash stock acquisition late wednesday rumor have be swirl afternoon novartis nvs johnson johnson jnj be engage bidding war pharmacyclic pcyc surprised wall street abbvie turn be buyer especially already have partnership pharmacyclic market blood cancer drug imbruvica doesn really make sense be abbvie prevailing pcyc partner natural buyer jnj secure pcyc pay price do asset bernstein analyst geoffrey porge write research note thursday believe jnj be only buyer able secure operational advantage full control buy partner jnj more other buyer have be able maximize synergy reduce product support single commercial organization cash stock deal value pharmacyclic share stock rise thursday stock trade start year conference call analyst early thursday abbvie ceo richard gonzalez affirm bidding war have come contestant didn name justified price cite enormous market potential imbruvica launch late bring pharmacyclic last year abbvie reckon imbruvica bring firm year peak change exist deal split profit evercore isi say assume total worldwide sale make imbruvica biggest selling cancer drug history say analyst mark schoenebaum analyst consensus sale estimate be bullish not bullish latest year available average estimate be call gonzalez break assumption number growth come expansion imbruvica currently approve used second line treatment chronic lymphocytic leukemia cll mantle cell lymphoma well anytime treatment less common condition cll deletion macroglobulemia additional come expansion first line treatment cll lymphoma gonzalez say have very high probability success give clinical trial datum rest come unspecified amount accounting approval other cancer cell more speculative assumption product also work solid tumor do see datum solid tumor be impressed gonzalez say many analyst view abbvie late stage blood cancer candidate potential competitor imbruvica chief scientific officer michael severino say drug potentially work combination expect launch clinical trial prove general executive say acquisition boost abbvie entire cancer business much be change focus abbvie make fortune immunology blockbuster drug humira however humira likely get biosimilar competition amgen amgn pfizer pfe other patent expire call gonzalez affirm abbvie commitment humira defend patent court develop new improve version drug say have nothing do price paid pharmacyclic analyst porge however say premium here be explain abbvie desperation
227,ABT,rapidly consolidate industry re hunter prey mylan be former mylan myl make generic brand drug treat illness cardiovascular central nervous system other disorder operate segment generic specialty generic unit make generic brand generic product tablet capsule injectable transdermal patch form active
228,ABT,drug industry recent spate deal get shot arm monday bristol myer squibb announce plan acquire privately hold drugmaker day valeant pharmaceutical international vrx say buy salix pharmaceutical bristol myer squibb bmy early monday agree buy flexus bioscience san carlos
229,ABT,diversify dutch giant royal philips phg agree acquire san diego base medical imaging company volcano cash wednesday send latter stock morning trading stock market today
230,ABT,philips say volcano volc catheter base imaging technology used heart surgery add portfolio image guide surgery product be build past few year
231,ABT,volcano impressive unique product portfolio be highly complementary strong offer live image guidance solution create opportunity accelerate revenue growth image guide therapy business high single digit rate philips ceo fran van houten say statement
232,ABT,leerink analyst danielle antalffy write note share valuation premium tuesday close price seem fair wednesday move volcano stock have fall nearly half start year due slow market miss quarterly expectation
233,ABT,be other logical acquirer volc namely abbott laboratory medtronic mdt don expect other bidder enter fray re incline think large cap medtech company be likely remain focuse higher growth market scale antalffy write do however view acquisition beacon thing come medtech
234,ABT,philips stock be nearly morning trading wednesday
235,ABT,follow amy reeve twitter ibd_areeve diversify dutch giant royal philips phg agree acquire san diego base medical imaging company volcano cash wednesday send latter stock morning trading stock market today philips say volcano volc catheter base imaging technology used heart surgery add portfolio image guide surgery product be build past few year volcano impressive unique product portfolio be highly complementary strong offer live image guidance solution create opportunity accelerate revenue growth image guide therapy business high single digit rate philips ceo fran van houten say statement leerink analyst danielle antalffy write note share valuation premium tuesday close price seem fair wednesday move volcano stock have fall nearly half start year due slow market miss quarterly expectation be other logical acquirer volc namely abbott laboratory medtronic mdt don expect other bidder enter fray re incline think large cap medtech company be likely remain focuse higher growth market scale antalffy write do however view acquisition beacon thing come medtech philips stock be nearly morning trading wednesday follow amy reeve twitter ibd_areeve
236,ABT,animal health giant zoetis zts offer guidance street consensus longer term financial goal analyst day tuesday brief halt trading early afternoon announcement stock be more afternoon trading stock market today zoetis say expect ep next year
237,ABT,mylan myl be early trading stock market today drugmaker beat estimate late thursday earlier stock be more nearly month high
238,ABT,earning come high end raise guidance range mylan offer oct share be year earlier quarter cent higher analyst consensus accord thomson reuter sale rise ahead street consensus
239,ABT,mylan also raise narrow full year ep guidance give oct now lower revenue guidance however range
240,ABT,leerink analyst jason gerberry write beat be drive sale epipen adrenaline self injection device treat anaphylaxis help push specialty pharma revenue larger generic drug business be line expectation bit light europe
241,ABT,many question conference call analyst be mylan pending deal buy develop market segment abbott laboratory establish product business be base netherlands mylan say go ahead deal treasury department propose new rule limit ability company lower taxe buy overseas firm
242,ABT,company reiterate pro tax rate low cfo expect tax rate step high teen next few year gerberry say research note thursday abbvie abbv board walk away shire shpg transaction concern relate treasury notice generally agree myl management notice remain recommendation ultimately not pass law
243,ABT,mylan be largest highest rate company ibd generic drug group composite rating have be consolidation pattern hit time high march
244,ABT,follow amy reeve twitter ibd_areeve mylan myl be early trading stock market today drugmaker beat estimate late thursday earlier stock be more nearly month high earning come high end raise guidance range mylan offer oct share be year earlier quarter cent higher analyst consensus accord thomson reuter sale rise ahead street consensus mylan also raise narrow full year ep guidance give oct now lower revenue guidance however range leerink analyst jason gerberry write beat be drive sale epipen adrenaline self injection device treat anaphylaxis help push specialty pharma revenue larger generic drug business be line expectation bit light europe many question conference call analyst be mylan pending deal buy develop market segment abbott laboratory establish product business be base netherlands mylan say go ahead deal treasury department propose new rule limit ability company lower taxe buy overseas firm company reiterate pro tax rate low cfo expect tax rate step high teen next few year gerberry say research note thursday abbvie abbv board walk away shire shpg transaction concern relate treasury notice generally agree myl management notice remain recommendation ultimately not pass law mylan be largest highest rate company ibd generic drug group composite rating have be consolidation pattern hit time high march follow amy reeve twitter ibd_areeve
245,ABT,big cap biotech amgen amgn beat wall street third quarter estimate guide full year earning bit consensus monday send recently hot stock hour trading amgen earning exclude time item rise year quarter share beating analyst consensus cent accord thomson reuter sale increase ahead estimate conference call discuss result ceo robert bradway note last year include order anemia drug neupogen government inflate quarter sale back sale growth be consistent first half year sale neulasta drug stimulating white blood cell beat consensus more be last year third quarter be drive price increase more volume accord amgen story be virtually identical anemia drug epogen sale rise last year also price reason total analyst have expect rheumatoid arthritis drug enbrel miss estimate dip sale unit grow year year call cfo david meline remind analyst have see inventory build be burn mask strength demand nonetheless enbrel help drive overall profit growth be longer profit sharing agreement pfizer pfe research development spending be more lower analyst consensus sale general administrative spending be also street estimate company add full year revenue guidance now slightly street forecast last year guide full year ep previous range analyst target however imply ep be short street average last year company make share full year fourth quarter conference call meline say amgen be lift tax rate estimate percentage point due uncertainty extension federal tax credit however cowen analyst eric schmidt comment even accounting increase operate expense be imply guidance meline answer expense usually increase end year so be nothing unusual however bradway add company be prepare product launch next year also increase spending most anticipate street be evolocumab first new class cholesterol drug call pcsk analyst expect sale run forecast remain uncertain regeneron pharmaceutical regn be see launch compete product shortly thereafter management keep call short plan hold business review meeting tuesday re expect give longer term outlook company business strategy re also expect address shareholder pressure split part get extra publicity last week daniel loeb hedge fund manager third point capital loeb take idea propose sanford bernstein analyst geoffrey porge june argue make abbott laboratory pfizer splitting establish legacy drug such enbrel newer more innovative product unlock hide value chatter general recovery biotech stock have help drive amgen stock last week regular trading monday hit new high eventually close
246,ABT,big cap medical firm biogen idec abbott laboratory thermo fisher scientific underwhelm investor third quarter earning guidance wednesday biogen stock especially punish company say patient have die take lead drug biogen biib earning rise year earlier quarter share beating analyst estimate cent
247,ABT,biotech company enanta pharmaceutical have be year fiscal year enter now be surely most important life dec food drug administration be expect approve abbvie abbv viekirax hepatitis treatment combine enanta enta drug paritaprevir abbvie develop drug enanta partnership
248,ABT,go flow be well good rise head shoulder crowd be sign solid stock
249,ABT,today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index
250,ABT,china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item
251,ABT,security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year
252,ABT,fellow chinese tailer jumei international jmei report wednesday
253,ABT,chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week
254,ABT,veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release
255,ABT,small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis
256,ABT,idexx laboratory idxx pet livestock health care company recently clear stock buy point
257,ABT,company report result late october share earning rise share top cent sale grow beating analyst forecast
258,ABT,related
259,ABT,invest relative strength line confirm power go flow be well good rise head shoulder crowd be sign solid stock today screen day feature company have bolt relative strength line rs line track stock be do incline instance mean company be outperform index china base flash sale site vipshop holding vip report earning tuesday be expect report round triple digit earning revenue gain analyst poll thomson reuter see revenue surge ep bump cent share item security research firm capital say monday company seem be benefit current chilly weather china share have almost triple start calendar year fellow chinese tailer jumei international jmei report wednesday chinese search engine baidu bidu recently joined force beij base commerce company lightinthebox litb sell latter product apps lightinthebox retail bargain clothe home good electronic other product online mostly consumer outside china partnership give baidu leg try match pace heavyweight recent ipo alibaba group baba have team costco wholesale cost alibaba conduct wildly successful single day tail holiday last week veterinary drugmaker zoetis zts say monday acquire abbott laboratory animal health asset deal worth abbott animal health boost zoetis companion animal product portfolio expand diagnostic business say zoetis release small cap stock be spun pfizer pfe be mutual fund manager favorite bill ackman persh square last week disclose stake zoetis idexx laboratory idxx pet livestock health care company recently clear stock buy point company report result late october share earning rise share top cent sale grow beating analyst forecast related invest relative strength line confirm power
260,ABT,medical equipment maker becton dickinson bdx carefusion hit new high stock market today buyout deal be announce sunday evening
261,ABT,conference call analyst monday morning company leader say firm complement other technologically geographically carefusion cfn sell mostly bd sell mostly outside combine portfolio product service offer full suite medication management industry say
262,ABT,also fielded question bd be make such large buyout do not fit recent history tuck deal response cite consolidation customer base need cut cost necessity global presence most growth industry be come emerge market
263,ABT,such factor have be drive consolidation medtech market medtronic mdt buyout covidien cov zimmer zmh acquisition biomet already work
264,ABT,third big medtech deal be announce year transaction likely be view yet indication scale be take increase level importance management team plan future position company write leerink analyst richard newitter research note add pressure company strong balance sheet often talk likely acquirer stryker syk abbott put capital work sooner rather later potentially larger size transaction
265,ABT,rbc capital market analyst glenn novarro echo point note add acquisition smaller cap medtech company continue be push large cap medtech company digest recent sizeable acquisition
266,ABT,becton dickinson stock hit new high monday late morning be just carefusion also hit new high late morning be
267,ABT,follow amy reeve twitter ibd_areeve medical equipment maker becton dickinson bdx carefusion hit new high stock market today buyout deal be announce sunday evening conference call analyst monday morning company leader say firm complement other technologically geographically carefusion cfn sell mostly bd sell mostly outside combine portfolio product service offer full suite medication management industry say also fielded question bd be make such large buyout do not fit recent history tuck deal response cite consolidation customer base need cut cost necessity global presence most growth industry be come emerge market such factor have be drive consolidation medtech market medtronic mdt buyout covidien cov zimmer zmh acquisition biomet already work third big medtech deal be announce year transaction likely be view yet indication scale be take increase level importance management team plan future position company write leerink analyst richard newitter research note add pressure company strong balance sheet often talk likely acquirer stryker syk abbott put capital work sooner rather later potentially larger size transaction rbc capital market analyst glenn novarro echo point note add acquisition smaller cap medtech company continue be push large cap medtech company digest recent sizeable acquisition becton dickinson stock hit new high monday late morning be just carefusion also hit new high late morning be follow amy reeve twitter ibd_areeve
268,ABT,share drug giant merck mrk fall tuesday federal judge tossed record verdict have win gilead science gild hepatitis treatment federal jury have say gilead owe merck sale sovaldi harvoni hepatitis drug district court judge leonard stark wilmington del agree friday gilead argument merck patent be invalid patent issue be compound merck idenix unit contend be basis major treatment hepatitis include one make gilead merck claim be first synthesize compound gilead say didn cover new idea patent owner be require describe invention enough detail allow other replicate unnecessary time effort case stark say merck patent cover so many potential compound take excessive experimentation narrow base only reasonable find be patent be invalid stark say decision merck share lose close foster city calif base gilead add merck base kenilworth pledge appeal judge finding say do not reflect fact case patent issue case facilitate significant advance treatment patient hcv infection achieve advancement require many year research significant investment subsidiary partner company say written statement believe strong patent protection be essential innovation merck add give guarantee firm period return investment patent protection provide research base pharmaceutical biotechnology industry incentive invest research development sovaldi be approve food drug administration harvoni get regulatory go ahead year later merck drug zepatier be approve gilead have concede infringement patent common legal tactic allow focus validity issue trial reject gilead argument patent jury say gilead owe royalty total sale drug separate part ruling stark reject gilead argument damage amount be unfair issue become important only patent be later revive appeal verdict be largest patent infringement verdict history dwarf next biggest verdict win johnson johnson jnj abbott laboratory be later throw appeal accord datum compile bloomberg
269,ABT,mile white be name ceo abbott laboratory be youngest head major health care company today longest serve chief health care have make reputation master strategist know make bold move abbott none be more dramatic spun research base pharmaceutical half firm abbvie abbv abbott have market capitalization half industry leader pfizer pfe merck mrk seem crazy many white perceive develop new drug have completely different business rhythm new abbott now focus device diagnostic nutritional product brand generic drug result abbott stock have rise share share give market cap abbvie share increase share share give value approach creation combine be now worth far more pfizer merck white have be rank barron world best ceo straight year keep company current relevant white tell ibd continually shape business ensure re need opportunity be future instance recent acquisition st jude medical make leader range grow medical device category new technology make huge difference patient investor white grow la vegas earn bachelor science mechanical engineering stanford mba year later joined mckinsey co chicago consultant feel work be fascinating project client come go white say want something feel connect longer term be more fulfill white be hire abbott base north chicago suburb abbott park ill director sale diagnostic year later be offer chance head division grow asia pacific region prestigious position year old turn meant move japan wife want open child bookstore white say be big believer work life balance be confident other opportunity advancement come way indeed year later be choose be new ceo follow year add title chairman board wife run bookstore year selling abbott have rarely do acquisition divestiture founding whirlwind change follow white take helm include be dramatic traumatic abbott acquire kos pharmaceutical maker cardiovascular drug cash deal sell core laboratory point care diagnostic division general electric ge fall white decide revive challenged division instead investing research development streamline operation reorganize product service new diagnostic division august begin launch family next generation instrument informatic service common software hardware platform design be easy use more efficient white call game changer industry other acquisition abbott paid pharmaceutical unit belgium base solvay expand presence emerge market same year plan be announce purchase unit piramal healthcare make abbott biggest pharmaceutical company india success company acquisition largely depend ability anticipate consumer medical need understand practice medicine be head aggressively position company benefit internal external investment not just acquire company white say do do more business make better improve exist operation ve develop very discipline integration process learn best bring new asset abbott help expand reach potential faster better have more be just preliminary spin half company abbott take third quarter charge abbvie be officially list new york stock exchange jan make white such savvy deal maker ask jim cramer mad money show cnbc november have real talent anticipate consumer future medical need then aggressively position company benefit year become ceo abbott release humira go treat form arthritis plaque psoriasis crohn disease other ailment now part abbvie make sale make best selling drug world white have foresight spin part company ahead explosion debate drug price guide global enterprise massive change result mistake abbott biggest occur midst drama lead split october abbott be fine marketing depakote brand valproic acid world most widely prescribe epileptic drug condition not approve food drug administration part settlement cost total company agree strengthen internal control separate abbvie january new abbott emerge focus not only diagnostic product service medical device nutritional line brand generic medicine latter be establish pharmaceutical division sell develop market brand name be trust more unknown due high quality efficacy standard doesn have high cost base pharma division now offer more product development acquire cfr pharmaceutical more double latin american brand generic pharmaceutical presence abbott be also world leader adult nutritional product include ensure zoneperfect well leader baby nutrition similac other line special dietary need glucerna juven company be also leader diabetes care introduce revolutionary continuous glucose monitoring device freestylelibre september company purchase st jude medical cash stock establish abbott leader medical device arena also close alere make leader point care diagnostic market ve reinvent company multiple time past year white say continuous process shape company future work very deliberately ensure remain relevant current person serve change take place environment re several different business today be decade be choose specifically relevance science be go demographic socioeconomic factor be go customer be go re still grow strong stock be time high today abbott employ worker country revenue be net income be ceo chairman abbott laboratory global leader medical device diagnostic nutritional product brand generic medicine overcome fail sale challenged diagnostic business turn investing innovation become highly profitable consistent grower company lesson envision long term big goal work detailed step get even mean defy industry consensus need continually ask be better way answer be always yes even exactly not yet be apparent more leader success pam nicholson drife global growth enterprise holdingstaco bell founder change america fast food menumeet man hire take amazonphil knight clear hurdle make nike merchandising champion
270,ABT,stock get rivet start new year particularly tech sector apple aapl behaved way expect lead stock be testing support key technical juncture apple global consumer electronic digital service play rise more bounce rise day move average day line graph stock average close price trail trading session have be rise ever stock edge slowly key early stage base jan gain solid cup handle reach nearly more recently apple oct clear new second stage cup handle volume be brisk stock day average turnover apple fellow nasdaq tech giant alphabet googl now extend past recent flat base entry help lead nasdaq composite day end nasdaq soar best annual gain year nasdaq rally nearly index tracking powershare qqq trust qqq also almost be now cent time high rally more investor also scoop share infrastructure build material firm please see prior stock market today column more detail top chinese company adrs be highly profitable grow strong revenue steel automaker generic drug group steel producer group be shape tuesday top performer group track day ibd see entire list go datum table stock list section investor com strength apple chevron cvx extend december past base base walt disney form new base help dow jone industrial average edge higher overcome sell insurance titan traveler trv meanwhile bitcoin investment trust gbtc get great start rise point intraday high dull trading end even deep session plunge take bitcoin tracking etf high low bitcoin investment still finished year return likely interest bitcoin be set only rise give grow acceptance commerce digital transaction concern unusual gain other equity relative newness alternative currency fact cme group cboe now conduct future trading bitcoin be currency greatest accomplishment past few month watch see bitcoin investment act day day move average latter have be catch now well day move average usually act excellent defense oriented sell signal growth stock torpedo huge volume have not be effective timing indicator ultrahot etf go back apple speculation iphone marketer be go go huge shopping spree investor continue simply monitor price volume action daily weekly basis so far action remain healthy big reason be possibility further double digit top bottom line growth earning growth accelerate street see earning rise current fiscal year end september share jump fy end september year service revenue be big part picture new product new edition iphone macbook apple watch form big part apple rating stock checkup remain good include composite rating decent grade accumulation distribution hint fund manager be net buyer past week trading accumulation grade go rating be neutral medical sector heart pump innovator abiom abmd abbott laboratory continue show leadership former rise more retake day move average quiet yet rise turnover watch potential new flat base form possibly present entry abbott diversify pharmaceutical medical product diagnostic system giant rally more new high steep turnover share be still buy range clear narrow shallow flat base buy point buy zone abbott have score quarters row double digit top bottom line growth ep revenue be go abiom be member ibd sector leader growth stock screen investor dump utility stock interest rate rise dow utility average fall nearly yield benchmark treasury year note jump sharply yield be last month peak dec federal reserve hike fed fund rate overnight bank loan fifth time december new target rate be now related tech break today stock buy invest do better resultshot growth stock today peek ibd spot next major stock market top yes here easy way
271,ABT,boston scientific bsx issue better expect outlook thursday help part stronger sale medsurg unit top consensus nearly fourth quarter boston scientific now see revenue street model guidance adjust profit share be just line analyst view march quarter guidance sale beat consensus boston scientific say expect adjust earning cent share line consensus cent close bell stock market today boston scientific lose close same time rival abbott laboratory tick cent fourth quarter boston scientific bring sale grow top analyst estimate sale adjust profit cent share grow meet expectation ibd take boston scientific have ibd composite rating meaning outperform more stock term key growth metric head ibd stock checkup look stronger medtech stock lion share sale growth be drive boston scientific medsurg unit increase analyst have expect medsurg unit bring sale evercore analyst vijay kumar say note client organically unit grow rbc analyst glenn novarro say report medsurg sale include endoscopy pelvic health neuromodulation revenue sale grow double digit percentage quarter cardiovascular unit sale be also bright spot quarter evercore analyst kumar say sale grow beat view rhythm management sale defibrillator grow pacemaker sale decline defibrillator sale be help introduction device be used mri machine novarro say pacemaker be face competition abbott related lilly issue beat raise dife other drug stockssage therapeutic just pop record high here biopharma merger activity become abbvie story
272,ABT,stock be quiet ahead long weekend nike nke weigh bitcoin continue volatile week trade apple aapl be flat spdr dow jone industrial average dium powershare qqq trust qqq fall spdr spy give emerge market extend gain third straight session ishare msci emerge market eem rise stock market today nike provide biggest drag dow tumble apple meanwhile be flat enter positive territory less flat base buy point initially crossed monday telecom bank health care lead downside sector fund gold miner energy real estate be biggest gainer gold future leap ounce west texas intermediate crude price be flat barrel bitcoin crash pare loss accord coindesk earlier jump nearly level cryptocurrency have top sunday bitcoin investment trust gbtc have make double digit move past session reversed upward gain track snap session slide pare steep early loss gbtc be now tuesday intraday high look set drop week be tumultuous week cryptocurrency string decline be spark coinbase announce support bitcoin offshoot bitcoin cash subsequent probe possible insider trading grow number global central bank have issue warning potential risk bitcoin other digital currency medical stock be often consider defensive play name such abbott laboratory have also proven growth potential ishare medical device ihi have be testing support day move average month solid advance line mark opportunity buy share rise late september rebound day nov intraday high fund marked anniversary have amassed asset track dow jone select medical equipment index be make maker distributor medical device include magnetic resonance imaging scanner prosthetic pacemaker health care equipment represent lion share asset life science tool service contribute health care supply technology service make rest top holding dec include medtronic mdt abbott lab thermo fisher scientific tmo dhr stryker syk top account asset abbott share have rally year thermo fisher have rise stryker be have advanced ibd take make money catch etf uptrend require knowledge read chart learn ibd university etf ytd gain dec outpace return ihi have deliver healthy performance longer haul average annual return past year respectively have return same period ihi bear expense ratio related apple bank boost dow record bitcoin stop slump apple set sight buy point bitcoin dife nvidia gear here apple be weigh dow techs bitcoin high
273,ABT,be nearly year lori swearingen change life forever fall job take decade be be relatively pain free again reno nev firefighter time swearingen be help guide rig back icy hill new year eve slip land backside be only woman crew get right back shake keep go recall swearingen soon begin experience pelvic pain radiate lower back affected daily decade thought check tailbone turn have be fracture number surgery drug fail relieve mind numbing pain discover answer implantable device call neuromodulator xsuch implant be now part big business well someday do job opioid other medication treat pain tell estimate be total addressable market year needham analyst mike matson write recent note client matson expect neuromodulation market grow upper single digit range next few year leader space be medtronic mdt market abbott laboratory boston scientific bsx be heel matson say competition be mount matson estimate medtronic neuromodulation sale be fiscal first quarter report august short original forecast medtronic doesn break neuromodulation sale meanwhile company nevro nvro livanova livn be swipe share neuromodulation also call have be decade only be recent year technique have become less crude say dr mark malone founder advanced pain care austin texas malone used device patient see neuromodulation become mainstream come year last month so new generation have come include abbott burst dorsal root ganglion malone tell investor business daily technique be far more effective really amazing revolution first time ever ve be able say thing cure chronic pain neuromodulation essentially trick brain think region body be longer pain say dr allen burton abbott medical director neuromodulation movement disorder pain modern iteration be result better understand nervous system be application electrical energy nervous system quiet pain impulse tell ibd more language re speaking nervous system language nervous system tell brain pain be longer important burton explain difference old vs new technology term hammer hammer nail miss hit thumb rub thumb dull pain introduce new sensory signal thereby block pain signal call tonic stimulation new technology neuromodulation have adopt electrical signal nervous system abbott used call burstdr dorsal root ganglion stimulation latter treat mysterious pain condition call complex regional pain syndrome boston precision spectra system precision novi precision montage mri product use software call illumina treat chronic pain include complex regional pain syndrome fail back surgery syndrome patient swearingen not specific device maker matter do lot research settle device boston scientific pain relief swearingen have tailbone remove several year incident appendectomy partial hysterectomy back surgery effort ease pain pelvis none help work few year staving pain cocktail opioid antidepressant epidural radio frequency ablation acupuncture sometimes swearingen work emergency medical other time go back fire line pain permit year swearingen finally take medical retirement ibd take company medical product industry group be now rank group track lead align technology have best possible composite rating meaning perform top stock head ibd stock checkup look other strong medtech player meet psychologist learn cope skill technique family not focus pain tell ibd be pretty depress be gain weight have very physical job very physical lifestyle be kind circle depression drain year later discover neuromodulator retire firefighting swearingen moved seattle begin see pain management doctor doctor office featured poster neuromodulation swearingen say didn know anything device first see poster thought maybe be delivery system drug say then realize be lead go spinal cord thought heck spend year look poster physician be look neuromodulation first step treat form chronic pain often back replace doctor penchant prescribe addictive course opioid opioid be huge drug market project reach alone opioid be also tie major unintended consequence include addiction dependence often lead overdose also major black market opioid have create somewhat stigma patient seek pain treatment malone say doctor question motive say mess top current opioid crisis news day so really amazing gift suddenly have treatment so effective even worst pain patient completely drug free malone have have own neuromodulator more month implant be disability year have work part time several year follow back injury see success own patient have medical practice partner implant abbott device difference be night day malone get choke talk relief be tell patient ve be very real say even own wife be wonder have give doesn want work anymore be just layer bed day day pain be real trial period temporary device be implanted sedation attach external battery tape skin patient use remote control flick different signal setting strength malone say abbott burton estimate opt permanent implant neuromodulator differ opioid be completely drug free reversible be implanted patient learn potential risk benefit patient have unique chance try device go permanent still reversible route burton say big problem opioid be person be often initiate much talk risk benefit say first prescription come pain pill short low dose pain become chronic doesn turn heal suddenly patient become resistant start traumatic injury often lead chronic pain problem need sleeping med antidepressant say now patient never need medication be interact electricity isn addictive burton say euphoric side effect still neuromodulation isn end answer type pain have limitation most notable used be chronic back pain include complex regional pain syndrome fail back surgery syndrome wouldn work widespread pain fibromyalgia lion share malone patient be ve go ahead back surgery attain relief needham matson say also market neuromodulation parkinson disease essential tremor incontinence epilepsy depression migraine obesity still neuromodulation remain best accidental secret pain community interventional pain management be new specialty malone say most neurosurgeon orthopedist aren aware swearingen be finally persuade give neuromodulation shot attend patient seminar do exhaustive research own part recommendation give anyone consider implant indeed day trial implant be ready permanent device today back gym strengthen core have lose weight gain due immobility ride bicycle horse lift hay bale property seattle walking mailbox be longer daunting prospect say last couple year husband say have lor back say be back meanwhile swearingen be left wonder have stay firehouse never know be possibility now retire medical point don care return work say instead focuse positive be life change family everyone say related abbott zero year high top sale drug bellwether sale miss actually bode well sectormedtronic sink sale lag earning beat view
274,ABT,specialty drugmaker salix pharmaceutical announce oct be do something unusual back merger close back july salix slxp have agree acquire cosmo technology irish subsidiary italian drugmaker cosmo pharmaceutical stock swap value deal have allow salix so many
275,ABT,share specialty drugmaker shire plummet stock market today word get late tuesday big pharma abbvie be reconsider buyout company shire shpg confirm report wednesday morning statement say abbvie abbv board intend consider withdraw modify recommendation light
276,ABT,medical product giant st jude medical stj abbott laboratory beat analyst expectation raise guidance wednesday share didn move much stock market today st jude smaller specialize mainly cardiovascular device say earning rise year earlier quarter share beating analyst consensus cent sale climb
277,ABT,just few year drug generate small slice revenue jazz pharmaceutical drug xyrem target small patient population narcolepsy sufferer person prone fall suddenly asleep middle day high price make sale effort worthwhile jazz pharmaceutical jazz keep raise price
278,ABT,dow industrial rally strongly thank ibm ibm turnaround johnson johnson jnj several other blue chip earning general electric ge be big miss adobe system adbe also be big winner bullish outlook netflix nflx hit new high boom subscriber growth ipos be hot dow industrial rise week fuel ibm predict return revenue growth johnson johnson unitedhealth unh be also notable blue chip contributor general electric crash big ep miss have little impact price weight dow rise nasdaq help senate first step big tax cut adobe system soar outlook paypal pypl beat netflix pull back record high high subscriber gain unite airline ual crash carrier have few answer question few new ipos impressed internet television network netflix cheer investor third quarter subscriber addition trounce expectation earning growth miss view sign net new stream subscriber third quarter beating wall street target december quarter netflix expect add new subscriber edge consensus view end september quarter stream subscriber worldwide netflix share hit record high tuesday morning sank week remain buy range related netflix stock fall third quarter subscriber beatadobe system share surge record high maker digital medium marketing software announce upbeat sale earning target fiscal san jose calif base adobe be target adjust earning share year year sale wall street be modele related adobe system rocket outlookibm share soar tech icon report quarterly earning beat estimate indicated sale growth return first time more year ibm do not provide formal quarterly guidance management indicated revenue snap quarter string revenue decline related ibm get price target hike earning report outlookgeneral electric earn just cent share far cent expect revenue rise more expect organic industrial revenue dip industrial operate margin shrank ge power business be big drag industrial cash flow operate activity plunge adjust due weakness power business ge slash full year earning cash flow guidance raise concern dividend cut ge share fall soon friday open close related ge earning miss badly cash flow dive add dividend fearsunited airline tumble more management carrier third quarter earning call be unable provide detail longer term plan drive profit lack clarity lead analyst believe carrier be walking back target outlined last year grow earning higher expect cost be also concern drop fare compete ultra low cost carrier morgan stanley ms top estimate help strong stable wealth management business rival investment bank goldman sachs gs also beat analyst raise concern result be help more volatile capital intensive line business goldman trading result continue struggle morgan outperformed other big bank morgan stanley rise retake buy point goldman sachs climb dow component johnson johnson top wall street view report adjust earning share sale pharmaceutical sale jump worldwide medical device revenue rise miss estimate abbott laboratory narrowly beat expectation early wednesday lion share beat come abbott establish pharmaceutical diabetes care cardiovascular neuromodulation product share rise clear buy point hit record high abbott advanced also time best related dow component pop top view pharma strengthqudian qd china base online credit firm backed alibaba baba rise debut raise pricing expect range singapore base online gaming company sea backed chinese internet giant tencent tcehy edge higher debut raise upsized ipo mongodb mdb provide open source database software platform business pop ipo top just raise price range qudian be profitable sea be poise start make money related sea upsized ipo raise millionmongodb price high qudian strong debut play new ipostop semiconductor industry player deliver generally upbeat report september quarter past week taiwan semiconductor manufacturing tsm beat target third quarter sale earning guide higher current quarter sale maxim integrate product mxim beat wall street target earning sale be tad short however maxim guide earning sale december quarter be well view chip gear vendor lam research lrcx beat view guide higher current quarter rival asml asml beat sale earning target third quarter revenue guidance be light unitedhealth group unh share vault record high tuesday then keep climb insurer report earning growth cent ahead estimate show enviable strategic position have exit obamacare exchange unitedhealth say benefit president trump executive order make low cost plan more widely available amazon com amzn want enter retail prescription business analyst say unitedhealth be ideal partner company signale willing meanwhile anthem antm insurer follow example unitedhealth announce broaden offer include pharmacy benefit management anthem share near buy point news dump express script esrx utilize cvs health cvs process retail distribution start related anthem jump prescription business amazon speculation signal openness amazon partnership earning beatpaypal report september quarter profit revenue top view forecast current quarter sale estimate send share commerce payment processor paypal say adjust earning be cent share year revenue rise current quarter paypal forecast revenue growth midpoint guidance gaap profit cent vs consensus estimate cent paypal jump friday new record high related paypal earning revenue top expectation share slb say friday investment demand north america be moderate baker hughe bhge warn challenge year end customer remain cautious spending due volatile oil price suggest shale other operator be rein production growth plan schlumberger meet ep view gain baker hughe report first quarter merger general electric oil gas unit july crude price hold barrel inventory fall yet again production plunge due gulf shutdown hurricane nate charle schwab schw trade etfc beat wall street consensus third quarter earning schwab miss revenue trade meet expectation schwab report ep cent revenue trade post earning cent share revenue schwab undercut buy point report sharp fall trading revenue share rebound friday trade share fall be still buy range past entry ebay ebay meet third quarter earning estimate revenue be slightly forecast online marketplace fourth quarter ep outlook fall short estimate share sank close day move average recent buy point undercut intraday thursday related ebay meet earning view share tumble weak outlooksap sap report quarterly earning top estimate german enterprise software giant raise guidance year base cloud compute strength bombardier bdrbf agree sell stake struggle series jet airbus eadsy commerce department call tariff narrow body jet deliver boee ba accuse canadian company receive unfair government subsidy gilead science gild win fda approval car drug dub yescarta treat aggressive form hodgkin lymphoma yescarta come gilead recent kite pharma deal gilead rise thursday be little change weekcelgene celg scrap trial crohn disease drug win start third cite internal futility review celgene fall friday intuitive surgical isrg top expectation late thursday report sale adjust profit share share rise friday atlassian team surge maker project management software report fiscal first quarter sale profit handily top estimate atlassian up full year revenue guidance midpoint guidance earlier forecast share surge nearly verizon communication vz add more postpaid wireless phone subscriber expect revenue also top estimate proofpoint pfpt report earning revenue top estimate fiscal outlook disappoint share rise friday video game publisher electronic art ea disappoint news be delay star war action adventure game have be set release fiscal run april march do not give new release time frame ea share be so far week rv maker winnebago wgo exceed forecast profit growth cent share revenue increase company also approve share buyback share close american express axp exceed earning estimate longtime ceo kenneth chenault retire stephen squeri set take place feb unite rental uri steamrolled estimate cent share ep rise revenue boost hurricane rebuild be reason nation largest equipment rental company boost guidance capital spending plan procter gamble pg profit grow share top view cent organic sale rise just result follow narrow proxy fight trian fund management nelzon peltz share fall friday unilever report weak sale thursday european consumer food product giant fall week related stock buy watch top ipos big small cap growth stockslooking best stock buy watch start here
279,ABT,first run food drug administration gene cell therapy be early stage theoretical concept fda commissioner scott gottlieb say tuesday last month fda approve first cellular therapy drug call kymriah novartis nvs treat form acute lymphoblastic leukemia patient age younger kite pharma kite soon be acquire gilead science gild be expect grab similar approval november gene cell therapy drug biologically copy exist product know biosimilar didn exist gottlieb tell medtech conference san jose calif now have product re review approve say gottlieb be nearly month stint fda commissioner be first appointment president donald trump take office first serve fda deputy commissioner gottlieb background have uniquely prepared head be now much bigger fda say scott whitaker chief executive advame world largest medical technology association gottlieb be diagnosed type lymphoma be younger be kind tumor only hypochondriac doctor have find gottlieb tell audience san jose mcenery convention center doctor gottlieb research type treatment want know have very good chance survival ibd take medtech stock have be ride drug pricing fear have hurt pharma biotech sector analyst say head industry snapshot closer look winner loser political discourse acknowledge not patient fit bucket be very different patient patient be tell have chance survival say re look something experimental something not be approve yet lot different cancer patient part challenge gottlieb say be ensure fda have policy help patient difficult simultaneously serve type patient serve patient potentially impact patient say today fda have hand number area gottlieb say most person be surprised find spend most time work tobacco side win surprise public be fda be work closely ameliorate opioid crisis last month trump declare opioid crisis national emergency cope company boston scientific bsx abbott laboratory medtronic mdt be work therapy call neuromodulation use electricity conceal pain brain gottlieb note medical product step alternative addictive opioid medical device deliver localize therapy patch treat localize pain vs drug have systemic approach be very addictive say fda be also work framework quicker review certification software program rather go longer product review software program be review less information apple appl fitbit fit johnson johnson jnj pear therapeutic phosphorus roche rhhby samsung tidepool verily be involved pilot program seek identify information company need provide quicker review process gottlieb say need modernize regulatory framework so match kind innovation re be ask evaluate foster beneficial technology ensure consumer have access high quality safe effective digital health device say related biotech crater late stage alzheimer drug failure
280,ABT,here weekly investing action plan need know investor come week xearning season really get go start netflix nflx kick thing tech sector end general electric ge be grow pressure turn stock investor
281,ABT,hurricane harvey irma marium didn just devastate texas florida puerto rico medtech player medtronic mdt group medical group wmgi be flail headwind monday xin afternoon trading stock market today ibd company medical product industry group medtronic lead market cap fall collective medtronic acknowledge impact hurricane have quarterly metric win be alone rbc analyst glenn novarro write note client news report indicate puerto rico hospital be not operational end third quarter be operational not have be run full capacity say assume lose week procedure end third quarter puerto rico device manufacturer say also conservatively estimate elective procedure be perform puerto rico fourth quarter friday medtronic say expect impact revenue earning fiscal second quarter firm say too early determine be impact latter half year least analyst cut price target stock follow medtronic monday pre announce negative result sustain least price target haircut quarter expect report sale vs year earlier period analyst view firm also trim sale outlook grow share be hardest hit medical product group plunge close monday nuvasive nuva globus medical gmed make medical implant dove respective novarro say be opportunity investor nuvasive nuvasive be capable accelerate organic revenue growth fourth quarter have strong product portfolio operate margin expansion opportunity say expect management team cut guidance due hurricane related revenue shortfall sell past several week be already discounting say nuvasive be deal specific short term issue setup look attractive separate report pre announcement novarro note investor sentiment spine stock remain negative cut price target keep outperform rating say be buyer pullback stock worst be already price argue needham analyst mike matson be more bearish still spine player outside hurricane be impact weaker degenerative deformity procedure growth august september matson write note client likely globus nuvasive miss estimate third quarter matson lower view now see earlier expectation also trim price target keep strong buy rating medtronic topple month low monday series price target cut announce hurricane marium damage puerto rico hit earning revenue also last week zimmer biomet zbh say hurricane be headwind third quarter earning novarro expect abbott laboratory boston scientific bsx chip away sale medtronic implantable heart device several newly launch product be back order status have lower inventory level hurricane firm say press release ibd take medtronic have ibd composite rating best possible meaning underperform more half stock term key growth metric head ibd stock checkup look stronger performer competitor be able take advantage such supply shortage be hard quantify stage novarro say therefore see downside risk revenue earning guidance second half second fiscal quarter novarro trim model sale cent earning share novarro also slash view fiscal model sale earning share forecast ep sale fiscal result price target cut novarro keep outperform rating least other analyst cut price target medtronic stock well fargo downgrade medtronic market perform outperform medtronic topple finish dow component johnson johnson jnj appear sustain minimal damage janssen unit gurabo facility make remicade xarelto prezista number other drug accord ub analyst carter view satellite image facility base utilization most lot site appear activity be return facility write note client fellow drugmaker amgen amgn have visible damage roof building flood access road manufacturing site puerto rico oct roof appear have be fix parking lot be capacity say amgen confirm used diesel generator site contract fuel provider have be make shipment meantime first shipment inventory puerto rico have already fly island say unlikely food drug administration require inspection allow amgen restart production ultimately expect accounting charge related be incrementally less concern potential disruption product supply say related medtronic sink sale lag earning beat robotic player near then topple here drug bellwether sale miss actually bode well sector
282,ABT,trump administration push tax reform package include relief foreign profit bring goldman sachs have new way look biggest potential gainer propose change repatriate overseas cash be part bigger trump tax reform package company currently most overseas cash be apple aapl microsoft msft cisco system csco alphabet googl google oracle orcl many wall street analyst have speculate cash bring back be used stock buyback acquisition goldman sachs report focus stock highest overseas cash equity cap ratio top company goldman sachs say be cisco netapp ntap qualcomm qcom apple amgen amgn oracle microsoft bit further be western digital wdc citrix system ctxs general electric ge abbott laboratory goldman sachs forecast firm repatriate overseas cash tax reform package be approve ibd take try premium ibd feature free oct popular feature include exclusive stock list ibd stock checkup rank leader industry group base earning sale margin stock performance big picture daily update underlie market trend cash rich tech company apple microsoft cisco currently pay tax so call repatriate earning rather take tax hit ve keep money overseas president trump have propose time tax offshore earning republican controlled house have propose lower rate company have more overseas cash be need continue funding foreign operation related trump tax cut plan be still unbelievably hugeoverseas tax holiday tech titan come catch
283,ABT,here weekly investing action plan need know investor come week xwhat see last chance repeal replace obamacare next year midterm election be come odd success just take sharp dive meanwhile handful notable earning due
284,ABT,johnson johnson jnj have relative strength rs rating upgrade thursday welcome improvement still higher score prefer see exclusive rating investor business daily measure market leadership worst best score score show stock price movement trail week compare other stock database history show top perform stock tend have higher rs rating begin biggest run see johnson johnson continue rebound clear threshold stock be not proper entry right now see manage form break proper consolidation johnson johnson show ep growth last quarter sale rise company hold rank peer medical diversify industry group abbott laboratory be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
285,ABT,thank gilead kite merger biotechs have big week ve also rally year longer haul top health sector etfs rank year date return aug be biotech focuse accord morningstar direct top performer spdr biotech xbi post gain well ahead advance etf featured monday etf leader column break past flat base entry thursday remain buy range share run june flat base start just clear pattern fund launch january have asset bear expense ratio come second be first trust nyse arca biotech fbt ytd gain etf be buy zone past flat base entry year old fund track nyse arca biotechnology index have attract asset carry expense ratio count top holding aug kite pharma kite juno therapeutic juno illumina ilmn kite gap soar aug gilead science gild announce buy kite xbi mentioned also get boost kite ishare medical device ihi take third place ytd return etf recently regain day move average line shape flat base potential buy point fund marked anniversary track dow jone select medical equipment index ibd take gilead science have be news lately due kite pharma acquisition do rank biotechs find now ibd stock checkup top holding aug include medtronic mdt abbott laboratory thermo fisher scientific tmo ihi expense ratio be ishare nasdaq biotechnology ibb round top ytd gain price action be similar other biotech etfs buy range follow thursday flat base buy point case be etf sport expense ratio ibb oldest biotechs year have amassed asset top holding aug be gilead biogen biib celgene celg kite account position portfolio fund have beaten past year return vs gain fund have outperformed past year related gilead science buy kite pharma sector boost stock breakout put apple amazon focusretail lead broad stock sell biotechs find support celgene flirt giant soon join
286,ABT,year euro area be expect grow third slower unite state china project growth rate be still impressive country lowest growth rate quarter century xthese datum point seem dismal investor shouldn be scared foreign market many country young economy more mature one be poise long term growth key be invest right one establish company significant presence right market general motor gm be example latter group company introduce vehicle model chinese driver today company attribute car sale china colgate palmolive cl story be similar consumer product company report organic growth emerge market time experience develop market dell continue capitalize india rapidly grow technology sector last year computer company announce india revenue surpass anticipate revenue reach few year now consider health care sector be often lead indicator foreign market be right one many foreign country especially emerge one be early stage investing billion dollar update health care infrastructure million person be graduate middle class re demand cut edge medication facility service progress economic ladder china instance spend billion improve disease diagnosis chinese have hypertension abnormally high blood pressure only quarter affected know more lung cancer patient suffer pulmonary disease emphysema bronchitis less half case be diagnosed india also struggle satisfy citizen demand health care indian lack access basic medication less hospital bed person prevalence chronic disease be increase country city boom unsurprisingly country health care expenditure be expect grow exclude currency annually colombia meanwhile have quadruple share citizen access health care colombian overall health have improve nation capita health spending lag develop nation change country economy grow other emerge market include indonesia philippine vietnam be also expand health coverage develop nation be expect account estimate health spending growth company country benefit investment so establish european company abbott laboratory derive more revenue faster grow economy company have build health care infrastructure develop nation have capacity know do so again emerge world same time health care infrastructure much develop world also need attention investment germany population instance be age german be age consequently health spending be expect increase annually next few year rate outpace country overall economic growth japanese citizen be older japan also face grow obesity diabetes crisis country have historically spend less health care other develop nation consequence age rise incidence chronic disease soon change be person society have better health live better life work longer help save health care system course volatility be certainty foreign investment number factor include political uncertainty change business cycle hamstring foreign market short term growth diversify company be not overreliant business segment country be best position mitigate short term risk also have most opportunity generate sustainable reliable growth long term trajectory foreign market be head fact sign revival capital spending investment global scale be already move positive direction smart investor benefit investing growth opportunity
287,ABT,abbott laboratory stock near time high thursday medical giant report second quarter profit revenue narrowly top wall street view xin early trading stock market today abbott surge time high reach july johnson johnson jnj closest competitor lift reach time close high second quarter end june abbott report adjust income cent share sale grow respective vs year earlier period consensus have call adjust profit cent share sale major sale growth include acquisition st jude medical be complete january comparable year year basis exclude acquisition sale grow abbott say news release rbc analyst glenn novarro credit slight revenue beat higher expect sale abbott medical device unit offset light sale nutrition segment revenue medical device grow comparable basis nutrition sale rise less ibd take abbott belong medical related exchange trade fund have rac healthy gain year visit ibd etfs page closer look other top holding perform first half year adult nutrition sale fall hardest globe comparable basis sale segment topple competitive market dynamic abbott say first half year adult nutrition revenue decline solid quarter abbott diagnostic unit help offset diagnostic sale inched comparable basis sale growth easily outperform international sale meanwhile drug sale climb exclude impact acquisition key emerge market lead drug unit grow worldwide sale other drug be flat abbott also boost adjust profit outlook share analyst be broadly call earning share novarro write keep outperform rating abbott stock related philips rival stage coup spectranetic biotechs benefit most trump tax reform vision
288,ABT,wall street analyst friday raise price target share software giant microsoft msft chipmaker skywork solution swks credit card company visa drugmaker abbott laboratory robotic surgery leader intuitive surgical isrg report quarterly earning thursday xmicrosoft crushed wall street target fiscal fourth quarter end june redmond wash base company earn cent share exclude item year year sale analyst be expect ep cent sale microsoft give cautious revenue guidance current quarter least analyst raise price target microsoft stock earning news piper jaffray be most bullish analyst alex zukin reiterate overweight rating microsoft up price target microsoft report very strong end fiscal year beating segment metric punctuate commercial cloud booking growth accelerate azure growth improve gross margin zukin say report other firm raise price target microsoft include bmo capital market canaccord genuity cfra research cowen deutsche bank jeffery keybanc capital market raymond james stifel ub microsoft stock close stock market today apple aapl chip supplier skywork solution earn share revenue fiscal third quarter analyst be expect ep sale skywork result marked third straight quarter accelerate earning growth skywork receive price target increase least investment bank cowen mizuho security needham mizuho analyst vijay rakesh be most optimistic stock maintain buy rating skywork increase price target skywork share close hit morning action cowen analyst george mihalos raise price target visa maintain outperform rating visa report third consecutive quarter outperformance drive solid global volume trend sustainable line item lower tax rate additional buyback mihalos say report san francisco base visa earn cent share sale fiscal third quarter analyst be look ep cent sale share be hit record intraday visa be still buy range buy point north chicago ill base abbott earn cent share sale second quarter analyst be modele cent rbc capital market analyst glenn novarro reiterate outperform rating abbott raise price target abbott stock dip cent sunnyvale calif base intuitive surgical earn share sale second quarter analyst have expect least investment bank up price target company barclay cantor fitzgerald rbc barclay keep overweight rating intuitive surgical up price target cantor stick hold rating raise price target rbc stay sector perform bump price target intuitive surgical share fall
289,ABT,number high profile medical technology firm include like boston scientific bsx abbott laboratory medtronic mdt be unlikely stand way dutch firm philips bid heart device maker spectranetic spnc analyst say wednesday xon stock market today spectranetic stock rocket record close high philips announce plan acquire spectranetic cash share deal value spectranetic euro needham analyst mike matson say bidding likely stop boston scientific abbott medtronic aren expect bid company spectranetic make drug coat balloon call stellarex treatment disease artery leg stomach arm head narrow rival bard bcr boston scientific medtronic already make drug coat balloon matson write note client further becton dickinson bdx be acquire bard leave major firm sector lack drug coat balloon abbott cardinal health cah terumo suspect abbott be too preoccupy st jude medical alere alr acquisition pursue large deal say similarly cardinal be process acquire medtronic medical supply business ibd take heart valve sector heated last year boston scientific make acquisition bring closer compete medtronic edward lifescience head sector leader look battle be shape matson be unsure terumo acquisition strategy similarly doesn expect philips acquisition get catch regulatory issue philips spectranetic only overlap atherectomy process harden narrow artery be remove body philips get area earlier acquisition believe market share be very low think regulatory issue be unlikely say philips say wednesday expect deal close third quarter dutch firm expect see revenue growth profit accretion matson keep buy rating spectranetic stock boost price target reflect acquisition cost related medtronic edward rivale unit outgrow broader market boston heart valve win face trial rival medtronicedward rocket month high strong heart valve sale
290,ABT,here weekly investing action plan need know investor come day xearning season really take come week report netflix nflx microsoft msft general electric ge lockheed martin lmt johnson johnson jnj remain bank giant also come well
291,ABT,wag mull use loophole tax law save million dollar move headquarters europe former treasury official argue white house close loophole congressional approval article publish monday tax note journal accountant tax lawyer stephen shay former treasury
292,ABT,biotech pharmacyclic pcyc get price target cut nomura monday investment bank maintain buy rating pharmacyclic stock say company competitive position remain strong
293,ABT,pharmacyclic stock be flat midday trading stock market today
294,ABT,nomura analyst ian somaiya write research note meeting management be raise forecast company expense due higher spending international launch blood cancer drug imbruvica clinical trial other product higher tax rate thus lower price target
295,ABT,somaiya however say survey competition find still potential upside imbruvica go im health im weekly prescription tracker launch gilead science gild rival zydelig be go slower imbruvica launch write citi analyst last month also be negative zydelig
296,ABT,somaiya add abbvie abbv succeed shortening development time potential rival just half year still give imbruvica time get establish note however abbvie new partnership infinity pharmaceutical infi put lead develop combination novel drug infinity duvelisib be expect be test together
297,ABT,follow amy reeve twitter ibd_areeve biotech pharmacyclic pcyc get price target cut nomura monday investment bank maintain buy rating pharmacyclic stock say company competitive position remain strong pharmacyclic stock be flat midday trading stock market today nomura analyst ian somaiya write research note meeting management be raise forecast company expense due higher spending international launch blood cancer drug imbruvica clinical trial other product higher tax rate thus lower price target somaiya however say survey competition find still potential upside imbruvica go im health im weekly prescription tracker launch gilead science gild rival zydelig be go slower imbruvica launch write citi analyst last month also be negative zydelig somaiya add abbvie abbv succeed shortening development time potential rival just half year still give imbruvica time get establish note however abbvie new partnership infinity pharmaceutical infi put lead develop combination novel drug infinity duvelisib be expect be test together follow amy reeve twitter ibd_areeve
298,ABT,abbott laboratory first quarter revenue earning dip earning still top analyst estimate send share slightly higher wednesday medical product giant report fall earning cent share still top cent share analyst poll thomson reuter be expect revenue dip slightly less view
299,ABT,push company move overseas keep investor busy monday mylan agree buy part abbott laboratory generic drug business relocate netherlands mean abbott former proprietary drug unit abbvie close deal anglo irish shire pharmaceutical fifth offer abbott keep brand generic business emerge market
300,ABT,push company move overseas keep investor busy monday mylan agree buy part abbott laboratory generic drug business relocate netherlands mean abbott former proprietary drug unit abbvie close deal anglo irish shire pharmaceutical fifth offer abbott keep brand generic business emerge market
301,ABT,doesn appreciate company not only pay dividend have history consistently raise payout year be type stock tuesday etf pick aim invest xvanguard dividend appreciation vig track nasdaq dividend achiever select index count holding highly profitable company have increase dividend least year row top holding include microsoft msft pepsico pep johnson johnson jnj mmm accord morningstar inc microsoft didn start pay dividend have boost payout year other company be member dividend aristocrat company have increase dividend payout least straight year dividend stock be often thought slow gainer have outpaced year date return microsoft be july pepsico have rally vig be testing day move average line set buy opportunity solid rebound offer annualize yield nearly slightly ahead average payout fund have year average annual return line expense ratio be proshare dividend aristocrat nobl be show similar action vig too seek support day line name imply fund track dividend aristocrat index johnson johnson be top name other big ytd winner top include mcdonald mcd abbott laboratory nobl carry expense ratio pay yield fund launch october have return nearly year july accord morningstar lag gain nobl have year average annual return vs go back june pick spdr growth spyg ishare russell iwf be still trading respective day line solid bounce still put play related income play buy point own big dividend stockmarket sell tough offer opportunity
302,ABT,week row recent base just week april past buy point week lose mere respectively see such action stock chart time sit pay attention have just find
303,ABT,regeneron pharmaceutical regn gilead science gild biogen biib benefit most biotechs president trump propose tax reform measure cut corporate tax rate trump proposal business size fortune mom pop shop freelancer live job job pay more business income taxe make corporate inversion unnecessary corporate tax rate be currently mean regeneron gilead biogen have guide adjust tax rate see serious boost cash trump proposal pass analyst say compromise beltway so rate be still air trump approval rating jump april gain ibd tipp presidential leadership index unveil tax reform proposal be first month month increase trump become president doesn mean big pharma biotech be totally sell trump proposal page document release april share biotechs drugmaker collectively lift less day generic drug stock pop gilead chief executive john milligan note uncertainty washington be norm so think ve kind learn filter focus thing be right company say gilead first quarter earning conference call be tax reform be repatriation count trump plan slash corporate tax rate benefit company consolidated tax rate remain well level consolidate taxe allow firm treat group wholly majority own company single entity tax purpose domicile drugmaker typically pay consolidated taxe canaccord analyst dewey steadman tell investor business daily company acquire foreign firm move tax domicile outside acquire company often lower tax homeland mylan myl acquire generic manufacturer abbott laboratory keep operational headquarters pennsylvania reincorporate netherlands march mylan say expect pay tax rate similarly allergan agn guide february adjust tax rate allergan corporate headquarters be ireland april pfizer pfe scrap attempt acquire allergan day treasury unveil new rule curb inversion former president barack obama call global tax avoidance huge problem urge congress close loophole good trump other hand say tax reform proposal make inversion unnecessary make america tax rate best world regeneron gilead biogen be biggest winner cut evercore analyst umer raffat say april report regeneron have guide effective tax rate gilead see first quarter biogen paid adjust taxe drugmaker pfizer eli lilly lly merck mrk bristol myer squibb bmy guide effective tax rate canaccord steadman mizuho analyst salim sy tell ibd everything politic be subject negotiation smaller biotechs say obviously positive future everyone be take see approach steadman say rate be probably go happen re not change capital expenditure organizational structure meantime ibd take look latest biotech drug news be sure bookmark ibd biotech pharma industry stock news page second facet trump plan allow time repatriation corporate cash park overseas discount tax rate be follow end deferral taxe corporate income earn abroad evercore raffat say amgen amgn benefit most drugmaker provision amgen have cash stash overseas money amgen use help boost war chest generic rivalry battle regeneron sanofi sny cholesterol front same be say gilead overseas cash be face dwindle sale hepatitis drug franchise gilead have be pressure month analyst chatter buy something bolster sale incyte incy be likely candidate analyst say accord raffat merck pfizer have respective cash outside lilly bristol celgene celg biogen abbvie abbv have park overseas cash be repatriate research development used fuel pfizer chief executive ian read offer similar view gilead milligan company first quarter earning conference call expect industry consolidation continue time political atmosphere remain major deterrent believe be simply too much redundancy fragmentation globally sector continually efficiently deliver medicine society say however be lack clarity potential tax reform health care policy uncertainty european market canaccord steadman doesn expect wave even trump tax reform pass muster congress need attempt pfizer allergan merger inversion purpose say appetite biotechs look healthy see decline big inversion type merger be not necessarily strategic see appetite biotech asset just tax picture look better say net result be actually decrease large merger maybe increase valuation biotech don think drife much more much still murky trump tax proposal analyst say general theme be tax reform be good thing biotech mizuho sy tell ibd don exactly know tax reform be go be be still lot piece move repatriation border tax don have component border tax be extreme drawback company manufacturing less expensive country such adjustment exempt export taxation tax import pwc analyst doug strang kathy michael write feb report january speech chamber commerce house way mean committee chairman kevin brady say tax eliminate tax incentive company move manufacturing overseas couple new lower gop tax rate local business end double taxation earning overseas establish america st century magnet new job technology breakthrough headquarters say gop tax plan be already drive company ask soon bring supplier back most company relocate operation back be paperwork nightmare canaccord steadman say current plan doesn include border tax provision nothing incentivize company bring operation back be enough keep newer smaller company re domicile overseas say probably entice future company not leave think core goal re try do say be domicile lower rate wouldn have leave cash foreign subsidiary cash be base encourage investment related do gilead just provide incyte potential deal dow pfizer top earning view sale come lilly new drug spark deeper rivalry pfizer novartis
304,ABT,fast food restaurant operator yum brand yum be upgrade buy drug giant pfizer pfe be downgrade sell wall street analyst tuesday goldman sachs initiate coverage host medical pharmaceutical company rating baxter international bax intuitive surgical isrg buy abbott laboratory hold argus research upgrade yum brand stock buy hold yum operate franchise kfc pizza hut taco bell restaurant yum stock rise stock market today break cup base buy point remain buy zone hit record regular session trading high louisville ky base yum report better expect revenue earning first quarter thank strong sale taco bell citigroup downgrade share pfizer sell stock be tuesday pfizer stock have form saucer handle chart pattern buy point past week new york base pfizer report mixed first quarter result earning top view sale come short goldman initiate coverage baxter buy rating price target start surgical robot maker intuitive surgical buy price target begin coverage abbott lab hold rating price target baxter rise hit fresh time high intuitive surgical rise climb also set record high abbott lab fall related baxter raise guidance hospital market rebound stock hit highpfizer follow baxter get slam subpoena related saline shortagerobotic surgeon maker launch record high strong
305,ABT,abbott laboratory stock be flat wednesday even firm top wall street first quarter sale profit expectation follow acquisition st jude medical abbott share have climb fall ultimately close stock market today have be form flat base march buy point first quarter abbott report sale grow vs year earlier period beating consensus analyst poll yahoo yhoo abbott report adjust earning cent share top view cent first quarter result reflect strong start year chief executive mile white say news release integration st jude be go well recently launch product be contribute double digit sale growth several area medical device business rbc analyst glenn novarro note seem be massive sale beat be mislead unclear consensus estimate include sale abbott medical optic sell johnson johnson jnj february unit sell period ibd take tuesday johnson johnson result highlighted multiple issue medtech pharma space issue likely trickle sector analyst say head ibd technology page closer look total nutrition sale decline quarter pediatric sale take biggest hit core laboratory sale grow vs year earlier quarter top novarro view slow venezuelan operation weigh diagnostic sale note research report establish pharmaceutical be outside only grow first quarter sale key emerge market include brazil russia india china emerge pharma sale grow medical sale double quarter drive growth sale cardiovascular device tool stimulate nervous system abbott also reaffirm guidance adjust earning share be line analyst view related abbott alere make altar new merger deal medtech stock buy ahead dow johnson johnson set lackluster result sector
306,ABT,stock open higher monday weak read new york manufacturing activity april dow jone industrial average nasdaq climb be bank financial remain big piece week report news quarterly result due week bank america bac goldman sachs gs morgan stanley ms visa other bank mtb rolled monday early earning report rise more result easily top analyst first quarter expectation company repurchase share quarter raise annual dividend cent cent mcdonald mcd rise apple aapl dow well fargo upgrade mcdonald outperform market perform apple gain rbc capital raise price target maintain outperform rating pacific crest security raise concern difficulty fingerprint sensor apple upcoming iphone pfizer pfe gilead science gild abbvie abbv rise incyte incy drop more early action wilmingon del base biotech report friday food drug administration deny application incyte eli lilly lly rheumatoid arthritis treatment baricitinib estimate have put annual value drug incyte share plunge day move average heavy volume trigger sell signal eli lilly share drop also break day line remain buy point gilead gain abbvie jump pfizer be flat pfizer gilead abbvie compete market rheumatoid arthritic treatment
307,ABT,china alibaba group hold baba climb open financial unit ant financial raise offer global payment service moneygram international mgi ant initial offer be top euronet worldwide eeft place offer march moneygram share rise open euronet share rise ibd leaderboard stock alibaba be buy range alternative handle buy point medical diagnostic product maker alere alr open waltham mass base company announce friday abbott laboratory have mutually dismiss compete lawsuit abbott have reduce takeover offer share deal now value alere be expect close third quarter abbott drop open manufacturing slow sharply new york region april send new york federal reserve empire state manufacturing survey read read be still positive march far economist expectation well level post nearly new order retreat unfilled order slow delivery time lengthen shipment edge gauge employment hour work remain firm national association home builder release builder confidence survey et gauge be april internationally readout global stock market today be spotty due holiday schedule japan tokyo nikkei post gain monday hold back dollar weaken yen concern north korea china shanghai composite end top regulator pledge resolute crackdown risky market action hong kong stock exchange remain close holiday europe exchange london paris frankfurt remain close holiday related big week dow stock earning investing action planinvestor unfazed north korea netflix unite continental earning tap
308,ABT,johnson johnson jnj zimmer biomet zbh be medtech stock own go earning season several other be put buy list pullback analyst say rbc analyst glenn novarro say wednesday large cap medtech stock johnson zimmer offer best risk reward first quarter earning season zimmer be cheapest arena johnson have lag group investor sentiment have turn more favorable johnson recent week anticipate further multiple expansion back strong first quarter result consensus estimate move higher year write research report consensus analyst poll yahoo yhoo broadly expect johnson report sale year year share adjust earning dip johnson be also cusp close acquisition actelion pharmaceutical second quarter sanofi sny be lock battle late last year take swiss biotech johnson bid win company zimmer company just have hit consensus estimate stock move higher novarro say consensus model year year sale growth adjust earning share novarro however say abbott laboratory boston scientific bsx edward lifescience ew stryker syk be attractive pullback see deliver solid result reaffirm guidance investor likely track ongoing litigation abbott alere alr heart valve replacement sale edward boston likely comment voluntary recall lotus heart valve replacement company recall lotus device discover malfunction result premature release pin implantation medtronic mdt onyx stent launch represent term challenge boston still want own boston novarro say small midsize cap world novarro recommend nuvasive nuva medical group wmgi group potential takeout be likely baked stock price nuvasive say ibd take isn first time edward have be list best stock own head ibd technology page deeper dive edward be hold strong remain top pick small midsize medtech group expect play catch group investor focus shift company impressive new product lineup improve international sale growth company experience distributor issue write novarro needham analyst mike matson also prefer zimmer also have strong buy rating share inogen ingn mimedx mdxg see cardiovascular orthopedic market slow diagnostic market improve quarter matson model cardiovascular market growth decelerate fourth quarter orthopedic market advance vs growth prior quarter diagnostic sale likely grow say be standout matson say model transcatheter aortic valve replacement market boston edward medtronic operate have grow orthopedic matson model growth extremity market related medtronic do heart valve study rival reap benefitsboston scientific make acquisition battle medtronic edward
309,ABT,american company such abbvie abbv mylan myl edge closer merger firm base overseas obama administration be push end inversion practice company reincorporate abroad reduce taxe letter member house way mean committee treasury secretary jacob lew urge lawmaker immediately
310,ABT,development stage biotech infinity pharmaceutical infi land key deal develop blood cancer drug duvelisib partnership big pharma abbvie abbv send infinity stock month high stock market today abbvie infinity collaboration include upfront payment milestone payment duvelisib pass
311,ABT,medical product giant st jude medical abbott laboratory beat analyst expectation raise guidance wednesday share have bumpy ride market fresh attack drug industry merger abbott report first sale beat quarters revenue rise consensus earning climb cent share beating estimate cent company add few penny full year ep guidance now analyst average be conference call analyst discuss result abbott cfo thomas freyman say revenue rise low mid single digit be high side analyst expectation growth freyman also guide sale growth similar range say earning be cent cent year be line street estimate have be bit show story last few quarters company work headwind establish product generic drug nutritional business leerink analyst danielle antalffy write research note wednesday now sale ep beat hand prompt ep guidance raise recent transaction execute optimize portfolio include acquisition cfr pharmaceutical chilean base brand generic company divestiture develop market establish product business be near potential sale growth inflection point monday abbott announce be selling develop market establish product business mylan myl plan take opportunity re incorporate netherlands follow virtual stampede drugmaker lower tax country wednesday however treasury secretary jack lew issue letter congress urge moratorium such arrangement comprehensive tax reform be enact lew want ban be retroactive view be caution be certainly warrant concern pending recently announce deal such mylan announce acquisition abbott establish product business bmo capital market analyst david maris write research note wednesday perhaps abbott stock seesaw trading wednesday open then drop midday eventually close fraction analyst be impressed abbott cost control result improvement gross profit margin rbc capital market analyst glenn novarro say make quality beat morgan stanley analyst david lewis project basis point improvement operate margin second half year st jude stj have plan tax inversion say earning rise year earlier quarter share beating analyst consensus cent sale climb vs street company guide ep cent cent bracketing consensus sale guidance miss analyst year st jude guide ep sale slightly higher previous guidance line expectation st jude see share gainson conference call discuss result st jude ceo daniel stark say growth start accelerate second half year due mainly new product launch say ramp continue next year revenue growth mid high single digit vs year expect range stark also say st jude be still gain share implantable cardioverter defibrillator icd market sale division rise st jude say overall market continue shrink stark admit however first quarter firm didn know exactly icd market be do rival boston scientific bsx medtronic mdt have report quarters later earning medtronic boston scientific be still road result however have indicated st jude gain basis point market share still analyst antalffy write st jude guidance be disappointing give beat also point stock be richly value hit time high july trading wednesday do almost reverse abbott drop nearly early recover somewhat close nearly
312,ABT,stock ease intraday high monday afternoon be still higher bounce back last week weakness
313,ABT,nasdaq be rise much respectively monday high dow jone industrial average outperformed gain volume be tracking higher major exchange stock market today
314,ABT,trade be run only touch higher nyse
315,ABT,kandi technology kndi gap bolt month high huge trade chinese automaker announce kandi electric vehicle group joint venture shanghai maple guorun automobile sell electric vehicle first quarter kandi lose money past quarters sale growth accelerate straight period
316,ABT,mylan myl be session high still active trading share be nearly news agree acquire piece abbott laboratory generic drug business mylan also move netherlands lower tax bill
317,ABT,facebook fb rise fast trade extend rebound day move average stock regain buy point cup handle facebook fall nearly trigger rebound
318,ABT,oppenheimer co project strong result base channel check investment boutique stay outperform rating share facebook report result close july
319,ABT,downside william lyon home wlh erased early gain fall pace sixth straight loss potential cup handle base take shape last month newport beach calif base homebuilder agree buy residential homebuilding business polygon northwest company cash buyout mark expansion pacific northwest stock ease intraday high monday afternoon be still higher bounce back last week weakness nasdaq be rise much respectively monday high dow jone industrial average outperformed gain volume be tracking higher major exchange stock market today trade be run only touch higher nyse kandi technology kndi gap bolt month high huge trade chinese automaker announce kandi electric vehicle group joint venture shanghai maple guorun automobile sell electric vehicle first quarter kandi lose money past quarters sale growth accelerate straight period mylan myl be session high still active trading share be nearly news agree acquire piece abbott laboratory generic drug business mylan also move netherlands lower tax bill facebook fb rise fast trade extend rebound day move average stock regain buy point cup handle facebook fall nearly trigger rebound oppenheimer co project strong result base channel check investment boutique stay outperform rating share facebook report result close july downside william lyon home wlh erased early gain fall pace sixth straight loss potential cup handle base take shape last month newport beach calif base homebuilder agree buy residential homebuilding business polygon northwest company cash buyout mark expansion pacific northwest
320,ABT,dow jone industrial average rally midweek wo president trump top aide signale tax cut other key agenda item be track dow credit card giant visa american express axp charge higher ibm ibm goldman sachs gs netflix nflx subscriber growth underwhelm even internet tv giant be hit user facebook fb tout augment reality developer conference dow jone industrial average fall month low wednesday follow weaker expect result ibm goldman sachs johnson johnson jnj blue chip index rebound thursday leave dow modestly higher week still day line index retook day line thursday return support friday nasdaq rally fuel chip gear stock facebook netflix predict reach milestone stream video subscriber worldwide weekend netflix miss forecast first quarter subscriber growth guide analyst higher customer addition current period internet television network expect end subscriber worldwide netflix fall tuesday close week virtually unchanged related ibm stock plunge big blue report straight quarter year year decline ibm revenue fall miss consensus time tech icon continue struggle multiyear transition ep rise share modestly beating related goldman sachs gs show surprise weakness first quarter trading bank chalk estimate miss result more re-serve market trump agenda stutter european election approach ultimately didn navigate market well deputy cfo martin chavez say quarter define franchise compound goldman wo rival morgan stanley ms beat goldman fix income trading revenue analyst estimate overall meanwhile bank america bac beat higher rate fed kick say fall treasury yield hurt result further related facebook ceo mark zuckerberg make augment reality centerpiece keynote presentation company annual facebook developer conference be also see strike snapchat snap operator snap be also push augment reality zuckerberg say mainstream augment reality platform future be not headset glass smartphone related strong result semiconductor equipment maker lam research lrcx spark rally already hot chip gear sector rival asml asml beat first quarter sale earning target disappoint guidance wireless chip maker qualcomm qcom post better expect fiscal second quarter sale earning guide analyst lower current quarter qualcomm warn potential revenue earning shortfall ongoing legal clash major customer apple aapl related crude future week barrel concern shale production offset opec effort rein global supply saudi arabia say several top oil producer have agree extend output cut help reduce global inventory energy information administration say inventory drop barrel smaller drop expect gasoline inventory rise barrel crude output continue rise schlumberger slb meet ep view drop revenue rise first increase revenue year fall short wall street view oilfield service giant say deploy more idled north american equipment see difficult year international business related unite airline ual turn strong first quarter share initially sell close slightly higher management defend plan expand flight reclaim call natural market share executive unite earning call repeatedly expressed need improve security forcibly remove passenger be tell give seat sell flight refuse additional policy change related incident management say present result review april meanwhile hawaiian airline parent hawaiian holding also report result top estimate send share soar friday related verizon report first quarter profit revenue fall even more lower expectation dow component lose surprising postpaid subscriber intense price competition verizon say buy least optical fiber wiring corning glw deploy wireless service installation firm dycom dy surge news fiber optic stock fall china demand concern verizon be set june takeover close yahoo yhoo report better expect earning revenue growth verizon ceo lowell mcadam say open strategic talk wide range company include comcast cmcsa fellow dow component walt disney cbs cbs related steel stock show sign life boost thursday executive order president trump lead new protectionist measure positive earning guidance nucor nue steel dynamic stld trump order launch promise be quick investigation import steel be hurt national security order potentially pave way trade restriction trade expansion act meanwhile nucor steel dynamic expect preannounce march report strong first quarter earning signale be also shape be good help stronger steel consumption nonresidential construction improve energy sector demand related trump turbocharge thursday top perform stock groupgeneral electric ge report flat earning share cent revenue less vs year earlier be better expect ge aviation power segment lead way dow stock sank friday undercut day line organic revenue climb organic order climb honeywell earning rise exclude divestiture sale edge lower honeywell hon rise friday hit record high intraday briefly top buy point related ge beat view lead aviation power honeywell topsebay stock tumble thursday keep fall friday even commerce giant receive several price target hike wake first quarter result meet revenue forecast beat bottom line revenue rise ep rise cent value good sell site quarter reach ebay guidance be light related dow component unitedhealth unh earn share first quarter year cent ahead expectation revenue grow top estimate unitedhealth also raise full year guidance be be help pullback obamacare exchange meanwhile large fast grow optum health service unit set unitedhealth apart other insurer expand reach acquisition surgical care affiliate related unitedhealth rise blowout surgical isrg stock launch record high wednesday report procedure growth first quarter sale rise year year top consensus adjust earning share rise beating dime related charle schwab schw logged most quarterly account opening year top forecast ep revenue growth ongoing online broker war have take trading fee major player schwab report growth retail brokerage account march end quarter meanwhile rival trade etfc handily beat cent ep sale td ameritrade amtd post mixed result visa result beat estimate cent ep revenue full year revenue guidance growth also top visa share initially soar record high friday close flat be still week american express axp also top forecast softer expect earning sale decline share leap thursday american express lose card partnership costco cost last year be midst premium credit card war jpmorgan chase jpm csx report first quarter earning revenue well wall street estimate operate metric also strong show csx be improve even ceo president hunter harrison take helm march csx also raise dividend cent share say buy back stock csx share surge thursday then add close buy point canadian pacific railway cp harrison previously be ceo also top view late wednesday rise thursday pare gain friday kansa city southern ksu narrowly top view friday morning fall sharply more then offset thursday advance union pacific unp gain thursday tick higher friday related drug medical product giant johnson johnson jnj abbott laboratory diverged first quarter earning sale be light drug revenue advance just adjust ep do top view abbott crushed view dow component fall week abbott lab rise related horton dhi report better expect quarterly earning revenue order cancellation rise share initially retook buy point quickly reversed fall thursday several other builder also reversed exist home sale rise year high march national association realtor report friday earlier week housing start fall more expect march homebuilder sentiment sank be still longtime high related
321,ABT,stock open mainly higher help wave positive earning news counter heavy undertow ibm ibm tumble earning report late tuesday dow jone industrial average be flat rise nasdaq climb american express axp rise dow industrial ahead first quarter result close coca cola ko climb open credit suisse upgrade stock outperform neutral apple aapl run higher be just buy point week tight pattern earning drive bulk early action ibm dive first quarter revenue fall more expect earning rise expectation revenue company target core strategic imperative rise ibm share have be consolidate early march morgan stanley ms muscle report earning gain rise revenue number be analyst projection stock be work new base adtran adtn marched higher early trade optical network system maker report late tuesday sale earning easily beat expectation share rise day move average remain correction intuitive surgical isrg add early trade maker da vinci robotic surgical system report tuesday close earning rise revenue climb number analyst target stock gap find support week move average chip equipment maker lam research lrcx surge fiscal earning revenue gain top analyst target raise guidance view ibd stock be extend more buy point abbott laboratory climb open solidly beating analyst first quarter revenue earning target stock rebound find support week move average monday work first weekly gain week consolidation oil price bob trade essentially flat west texas intermediate hold just barrel ahead energy information administration weekly inventory report due et boston federal reserve bank president eric rosengren be schedule speak et federal reserve release april beige book report et related dow face point drag commerce giant be buy range stock basis ahead earning investing action plan
322,ABT,dow component johnson johnson jnj set potentially lackluster first quarter sector orthopedic sale medtech bellwether lag surgical unit be merely line cardiovascular sale grow double digit stock close stock market today last month share break flat base begin july hit buy point stock have retreat point first quarter report sale growth view drug sale advanced just adjust earning rise share beating consensus cent revenue miss light pharma sale rbc analyst glenn novarro remain bullish stock keep outperform rating share note underlie pharma trend remain solid first quarter miss have call stock own head earning drug make unit bring first quarter miss novarro model immunology biggest pharma unit come line novarro view remicade sale top oncology sale be novarro estimate cardiovascular drug sale miss xarelto invokana invokamet decline respectively year year basis underlie demand drug look strong novarro say company note pharmaceutical segment sale growth be negatively impact lower adjustment rebate accrual first quarter compare adjustment first quarter novarro write note client medical device pull grow vs year earlier period cardiovascular unit grow diabetes sale dip surgical sale grow evercore analyst vijay kumar note result be positive general cardio utilization orthopedic sale fall meaning trend seem be decelerate hint softer utilization trend first quarter kumar doesn cover johnson say result major medtech company be read entire sector include estimate impact actelion purchase first time johnson johnson now see full year ep revenue have project reach sale adjust earning expect top share ibd take johnson johnson stock have ibd composite rating meaning outperform stock term key growth metric head ibd stock checkup list top leader johnson johnson be stock medical diversify industry group abbott laboratory abbott be set report own first quarter earning open wednesday related medtech stock buy ahead biotech survive activist investor get take
323,ABT,drug sector have be upswing recent week result addition dividend leader list abbvie abbv have dividend yield annualize basis be week winning streak indicate ethical drug company be do fall try brother
324,ABT,world largest restaurant chain mcdonald mcd be close decide do real estate holding call spinoff asset real estate investment trust board member mile white be chairman ceo diversify medical product maker abbott laboratory tell wall street journal interview fast food giant have do lot due diligence hasn yet make final decision mcdonald share change little extend hour trading thursday rise regular session stock market today customer have shift away mcdonald fast casual chain such chipotle grill cmg investor analyst have push reit fact mcdonald have be mull take action real estate part broad restructure undertake new ceo steve easterbrook take rein march easterbrook say mcdonald examine opportunity look spin real estate asset create reit structure other company have face similar call spin real estate mgm resort international mgm have be pressure shareholder land building investment sell real estate sear shld spun property seritage growth property srg several hedge fund ask macy consider option real estate follow james detar twitter ibd_jdetar facebook
325,ABT,abbott laboratory largest maker heart stent adult nutritional beverage say second quarter profit climb percent sale increase emerge market profit continue operation rise cent share cent year earlier abbott park illinois base company say statement today earning exclude time item
326,ABT,smattering stock hit new high thursday holiday shorten session send dow jone industrial average record high nasdaq year high cognex cgnx go new high increase day move long consolidation stock have rise
327,ABT,medical product giant abbott laboratory miss sale estimate meeting profit expectation wednesday send abbott stock morning trading stock market today earlier have be much
328,ABT,abbott say revenue totale quarter year earlier quarter short analyst consensus earning rise cent share match estimate company say ep be bracketing consensus vs last year
329,ABT,leerink analyst danielle antalffy write email client abbott operate leverage allow meet profit goal have miss sale estimate quarters row
330,ABT,trend top line miss highlight continue head wind key business primarily nutritional establish product brand generic drug write business be key accelerate long term sale growth profile think investor likely look sign stable improve fundamental here share move meaningfully higher current level
331,ABT,bright spot establish product business be key emerge market segment include sale china brazil russia
332,ABT,abbott quarter be weaker fellow diversify medical giant johnson johnson jnj report tuesday beat estimate drive strong performance proprietary drug abbott longer have proprietary drug business spun abbvie abbv start last year ep guidance nonetheless miss consensus drive stock tuesday several analyst rise company defense however point early guidance be usually conservative midmorning wednesday jnj stock be flat
333,ABT,follow amy reeve twitter ibd_areeve medical product giant abbott laboratory miss sale estimate meeting profit expectation wednesday send abbott stock morning trading stock market today earlier have be much abbott say revenue totale quarter year earlier quarter short analyst consensus earning rise cent share match estimate company say ep be bracketing consensus vs last year leerink analyst danielle antalffy write email client abbott operate leverage allow meet profit goal have miss sale estimate quarters row trend top line miss highlight continue head wind key business primarily nutritional establish product brand generic drug write business be key accelerate long term sale growth profile think investor likely look sign stable improve fundamental here share move meaningfully higher current level bright spot establish product business be key emerge market segment include sale china brazil russia abbott quarter be weaker fellow diversify medical giant johnson johnson jnj report tuesday beat estimate drive strong performance proprietary drug abbott longer have proprietary drug business spun abbvie abbv start last year ep guidance nonetheless miss consensus drive stock tuesday several analyst rise company defense however point early guidance be usually conservative midmorning wednesday jnj stock be flat follow amy reeve twitter ibd_areeve
334,ABT,johnson johnson jnj be quintessential income play company offer slow steady profit growth pay rise dividend be defensive nature root date back late century johnson johnson be titan health care field new brunswick base firm make everything wound care woman health product
335,ABT,big pharma abbvie abbv beat estimate friday get street talk company executive imply win discount new hepatitis regimen stock be morning trading stock market today
336,ABT,abbvie earning rise year earlier quarter cent share beating analyst consensus cent sale rise estimate
337,ABT,company do not raise full year guidance however still expect ep vs last year sale fraction exclude impact company new hepatitis regimen await fda approval
338,ABT,analyst have many question regimen hepatitis particularly abbvie pricing strategy compete gilead science gild recently launch blockbuster sovaldi pharmacy benefit manager express script esrx have be say hope reduce sovaldi price play competitor other ask abbvie plan compete price ceo richard gonzalez say not strategy go forward
339,ABT,sound abbvie wouldn engage significant price war gain share hep morningstar analyst damien conover write email ibd abbvie hold very strong treatment hep think compete efficacy relatively good side effect profile treatment
340,ABT,research note friday rbc capital market analyst michael yee agree abbvie executive sound very bullish competitive potential
341,ABT,consistently comment allude drug be competitive stand nicely market profile be strong convenience be lower totem pole patient need think long large market never suggest pricing be key lever share write further support gild long term view hcv market be billlion global market gild earn share least mean gild stock be reasonably cheap
342,ABT,gilead investor didn seem entirely assuage gilead stock be flat late morning trading
343,ABT,yee also note abbvie candidate chronic lymphocytic leukemia cll be move nicely late stage testing potentially create more competition pharmacyclic pcyc recently launch imbruvica however model be likely best sicker patient probably not optimal community docs want less aggressive tolerable pcyc regimen
344,ABT,pharmacyclic stock be nearly morning trading
345,ABT,follow amy reeve twitter ibd_areeve
346,ABT,related gilead illumina earning wall street lovebig pharma abbvie abbv beat estimate friday get street talk company executive imply win discount new hepatitis regimen stock be morning trading stock market today abbvie earning rise year earlier quarter cent share beating analyst consensus cent sale rise estimate company do not raise full year guidance however still expect ep vs last year sale fraction exclude impact company new hepatitis regimen await fda approval analyst have many question regimen hepatitis particularly abbvie pricing strategy compete gilead science gild recently launch blockbuster sovaldi pharmacy benefit manager express script esrx have be say hope reduce sovaldi price play competitor other ask abbvie plan compete price ceo richard gonzalez say not strategy go forward sound abbvie wouldn engage significant price war gain share hep morningstar analyst damien conover write email ibd abbvie hold very strong treatment hep think compete efficacy relatively good side effect profile treatment research note friday rbc capital market analyst michael yee agree abbvie executive sound very bullish competitive potential consistently comment allude drug be competitive stand nicely market profile be strong convenience be lower totem pole patient need think long large market never suggest pricing be key lever share write further support gild long term view hcv market be billlion global market gild earn share least mean gild stock be reasonably cheap gilead investor didn seem entirely assuage gilead stock be flat late morning trading yee also note abbvie candidate chronic lymphocytic leukemia cll be move nicely late stage testing potentially create more competition pharmacyclic pcyc recently launch imbruvica however model be likely best sicker patient probably not optimal community docs want less aggressive tolerable pcyc regimen pharmacyclic stock be nearly morning trading follow amy reeve twitter gilead illumina earning wall street love
347,ABT,maker medical device be come increase pressure owing fundamental power shift american medicine favore insurance company hospital patient change accord moty avisar president medical system maker surgical theater be base patient be force soar medical cost take control health care let say patient be
348,ABT,abbott laboratory show many classic trait want see high quality income stock broad array enviable nich industry solid unspectacular stock uptrend history rise dividend big cap abbott lab produce generic drug research base drug diagnostic system nutrient abbott pay annualize dividend share
349,ABT,big pharma abbvie abbv release first set result phase trial new hepatitis regimen monday send abbvie stock stock market today study find week treatment abbvie drug candidate standard oral drug ribavirin patient show sustain viral
350,ABT,big pharma abbvie abbv beat analyst expectation friday send share highest point stock market spinoff abbott laboratory start year company sale rise beating analyst consensus profit be cent share best estimate cent
351,ABT,big pharma abbvie abbv say friday advance rheumatoid arthritis drug successful midstage clinical trial also bail similar drug be develop belgian biotech galapago glpg send latter stock tumble abbvie conduct trial testing various dose placebo study patient respond inadequately methotrexate
352,ABT,stock future be have pull back early high ahead thursday open surprise jump mid atlantic region manufacturing
353,ABT,dow future trade point fair market value point gain hour earlier nasdaq future hold point gain sticking close earlier high future pull back point gain
354,ABT,stock market today carry bit less weight shoulder decisively punch past day move average nasdaq gain more altitude important line support wednesday
355,ABT,investor draw confidence minute fed oct meeting show majority federal open market committee favor rate hike december apple aapl also factor day gain gapping better gain upgrade goldman sachs
356,ABT,current uptrend still bear heavy load distribution day nasdaq be good cause keep cautious stance new purchase stock flash sell signal
357,ABT,relatively light economic calendar open labor department report weekly jobless claim ease week end nov prior week economist consensus have forecast pullback claim week move average continue higher mark third straight advance
358,ABT,philadelphia federal reserve regional manufacturing survey firm november rise beat consensus expectation flat outcome index fall read october follow tally september
359,ABT,conference board be set release lead economic indicator index october et
360,ABT,dow unitedhealth unh drop premarket action minnetonka minn base manage care provider trim full year ep guidance consensus view company say claim activity deteriorate individual participation insurance exchange lag
361,ABT,seller keep pressure retail apparel maker send best buy bby perry ellis pery loss mixed quarterly report buckle bke ton store bont report earning miss stock remain unchanged premarket trade
362,ABT,keurig green mountain gmcr ahead top premarket action owner cup coffee franchise trounce analyst earning expectation revenue fall less forecast management boost quarterly dividend cent keurig share end wednesday november high
363,ABT,salesforce com crm jab bell ep leap gain revenue narrowly clear analyst consensus projection revenue earning projection be line analyst view management hoist full year ep guidance just consensus software service leader end wednesday buy range bit more cup base buy point
364,ABT,china base play chalk strong premarket move
365,ABT,ctrip com international ctrp soar higher deliver result online travel site end wednesday buy point double bottom base
366,ABT,china base micro blog site weibo wb shot premarket trade report ep cent cent share loss year view cent revenue surge better forecast stock finished wednesday deep cup base stock future be have pull back early high ahead thursday open surprise jump mid atlantic region manufacturing dow future trade point fair market value point gain hour earlier nasdaq future hold point gain sticking close earlier high future pull back point gain stock market today carry bit less weight shoulder decisively punch past day move average nasdaq gain more altitude important line support wednesday investor draw confidence minute fed oct meeting show majority federal open market committee favor rate hike december apple aapl also factor day gain gapping better gain upgrade goldman sachs current uptrend still bear heavy load distribution day nasdaq be good cause keep cautious stance new purchase stock flash sell signal relatively light economic calendar open labor department report weekly jobless claim ease week end nov prior week economist consensus have forecast pullback claim week move average continue higher mark third straight advance philadelphia federal reserve regional manufacturing survey firm november rise beat consensus expectation flat outcome index fall read october follow tally september conference board be set release lead economic indicator index october et dow unitedhealth unh drop premarket action minnetonka minn base manage care provider trim full year ep guidance consensus view company say claim activity deteriorate individual participation insurance exchange lag seller keep pressure retail apparel maker send best buy bby perry ellis pery loss mixed quarterly report buckle bke ton store bont report earning miss stock remain unchanged premarket trade keurig green mountain gmcr ahead top premarket action owner cup coffee franchise trounce analyst earning expectation revenue fall less forecast management boost quarterly dividend cent keurig share end wednesday november high salesforce com crm jab bell ep leap gain revenue narrowly clear analyst consensus projection revenue earning projection be line analyst view management hoist full year ep guidance just consensus software service leader end wednesday buy range bit more cup base buy point china base play chalk strong premarket move ctrip com international ctrp soar higher deliver result online travel site end wednesday buy point double bottom base china base micro blog site weibo wb shot premarket trade report ep cent cent share loss year view cent revenue surge better forecast stock finished wednesday deep cup base
367,ABT,last couple week market have be punish formerly highflying drug device stock common side effect lower valuation be more buyout fan fair bit wall street chatter speculation week here be get most attention most likely be true friday afternoon bloomberg
368,ABT,stock jump solid open thursday aid slowdown job cut well accommodative comment central banker europe
369,ABT,step dow jone industrial average take gain nasdaq climb early trade
370,ABT,volume be soft nasdaq lower nyse vs action same time wednesday
371,ABT,europe market help buoy trade upshifting sharply afternoon trade european central bank lower economic growth inflation forecast say be prepared expand stimulus need dax frankfurt paris cac jump gain more afternoon trade london ftse climb
372,ABT,china hong kong stock exchange be shut thursday shanghai exchange thursday friday country celebration anniversary end wwii
373,ABT,economic news start year year increase layoff employer august number be july year high large piece bad news be link bankruptcy grocery chain
374,ABT,researcher markit report purchasing manager index gauge service sector rise august july far better read expect economist
375,ABT,datum institute supply management be less rosy ism index dip view
376,ABT,stock market today open higher heavy loss due problem second quarter result dollar store tumble fiber optic gear maker ciena cien drop verint system vrnt developer security software tumble mining equipment joy global joy trench lowest mark march
377,ABT,be also nonearning related stumble netflix nflx pull back putt loss week caterpillar cat picked bad vibe fall worst loss dow
378,ABT,third dow stock post open gain more almost nasdaq rise start bell
379,ABT,lannett lci stab higher announce acquisition kremer urban pharmaceutical late wednesday gain send share back converge week move average month consolidation
380,ABT,packaging container maker greif gef bolt ahead fiscal result earning clobber analyst expectation revenue fall line consensus target gain put long suffering stock back week move average
381,ABT,blackhawk network hawk rattle gain strong trade lead ibd list provider gift promotional card be rebound day move average stock jump solid open thursday aid slowdown job cut well accommodative comment central banker europe step dow jone industrial average take gain nasdaq climb early trade volume be soft nasdaq lower nyse vs action same time wednesday europe market help buoy trade upshifting sharply afternoon trade european central bank lower economic growth inflation forecast say be prepared expand stimulus need dax frankfurt paris cac jump gain more afternoon trade london ftse climb china hong kong stock exchange be shut thursday shanghai exchange thursday friday country celebration anniversary end wwii economic news start year year increase layoff employer august number be july year high large piece bad news be link bankruptcy grocery chain researcher markit report purchasing manager index gauge service sector rise august july far better read expect economist datum institute supply management be less rosy ism index dip view stock market today open higher heavy loss due problem second quarter result dollar store tumble fiber optic gear maker ciena cien drop verint system vrnt developer security software tumble mining equipment joy global joy trench lowest mark march be also nonearning related stumble netflix nflx pull back putt loss week caterpillar cat picked bad vibe fall worst loss dow third dow stock post open gain more almost nasdaq rise start bell lannett lci stab higher announce acquisition kremer urban pharmaceutical late wednesday gain send share back converge week move average month consolidation packaging container maker greif gef bolt ahead fiscal result earning clobber analyst expectation revenue fall line consensus target gain put long suffering stock back week move average blackhawk network hawk rattle gain strong trade lead ibd list provider gift promotional card be rebound day move average
382,ABT,hot new technology widespread deadly disease whole lot money change hand be story last wednesday st jude medical stj agree pay cash thoratec thor developer implant call left ventricular assist device lvad help heart failure patient keep blood move lately be
383,ABT,top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis
384,ABT,share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move
385,ABT,allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition
386,ABT,also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average
387,ABT,biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july
388,ABT,regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break
389,ABT,alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring
390,ABT,ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open
391,ABT,abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target
392,ABT,analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early top industry group medical sector show nice price action monday group have be long time market leader number stock group be shape late stage basis share generic drug giant allergan agn formerly know actavis clear cup handle entry monday volume be modestly average allergan latest base correct mild be late stage stock relative strength line touch new high break add confirmation move allergan report earning open aug analyst be look share earning climb sale sale estimate be boost recent allergan acquisition also generic drug camp mallinckrodt mnk be tracking sideway consolidation date back march stock clear short handle buy point reversed lower trigger loss sell signal few week later handle only be see daily chart now mallinckrodt face test resistance day move average biotech group celgene celg briefly clear handle buy point intraday retreat close volume be light flaw latest base pattern be majority base be form week move average line base also show week net distribution celgene report earning result market open july regeneron pharmaceutical regn be approach buy point late stage flat base stock be find support week line have already make huge run make riskier buy stock break alexion pharmaceutical alxn jump monday be try sixth straight weekly advance climb right side consolidation pattern stock be back time high set december month sideway action sharp drop spring ethical drug group valeant pharmaceutical vrx be climb right side new late stage flat base pattern share hit peak have largely find support week move average latest pullback stock have highest possible composite rating valeant report second quarter result july open abbvie abbv remain buy range cup handle monday jeffery raise earning estimate stock reiterate buy rating price target analyst expect abbvie july open report ep growth second straight quarter double digit growth sale be expect climb be second quarter acceleration best quarterly revenue growth year abbvie be spun abbott laboratory early
393,ABT,abbott laboratory early wednesday report result meet wall street estimate affirm outlook prospect be bit hazy medical giant plan split company abbott report sale hair short thomson reuter consensus figure year earlier quarter exclude
394,ABT,lot be go specialty drugmaker horizon pharma so much almost different company be month last july horizon hznp learn express script esrx cvs cvs caremark be knock flagship drug vimovo duexis prefer formulary list ground drug
395,ABT,biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis
396,ABT,tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock
397,ABT,juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money
398,ABT,celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating
399,ABT,stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share
400,ABT,celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma
401,ABT,gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group
402,ABT,gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi
403,ABT,gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic
404,ABT,enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually
405,ABT,enanta have composite go public march have be profitable
406,ABT,intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be
407,ABT,other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week biotechs have not only show resilience bout volatility past few month also remain top group many lead stock set basis tuesday biotech startupjuno therapeutic juno soar heavy trading follow late monday announcement deal celgene celg celgene pay upfront buy juno share option license juno chimeric antigen receptor car cell cancer therapy year deal also include option buy juno stock juno go public dec share be high still more offer price seattle base company car therapy be still early stage have yet make money celgene other hand be steady earning producer have year earning growth rate earning stability factor scale most stable least stable biotech be group best possible composite rating stock be shape handle cup base potential buy point volume ratio neutral level positive accumulation distribution rating indicate demand share celgene develop therapy treat cancer immune inflammatory related disease best seller revlimid account revenue last year treat multiple myeloma gilead science gild also earn composite have pull back just buy point clear june earning share rating be highest biotech group gilead drug treat hiv hepatitis other disease hepatitis drug harvoni sovaldi account more half sale drug have come fire high price tag harvoni cost week treatment sovaldi gilead share take hit december rival abbvie abbv hep drug win fda approval then gilead have acquire danish drugmaker epitherapeutic enanta pharmaceutical enta maker hepatitis drug antibiotic be build cup handle buy point fact biotech develop antiviral agent find abbvie hep drug cocktail analyst forecast agent generate annually enanta have composite go public march have be profitable intrexon xon have dip cup handle buy point synthetic biology firm hold ipo august design build regulate gene cellular system have yet turn annual profit year sale growth rate be other top rate biotechs shape basis include biogen biib composite unite therapeutic uthr composite biotech group rank third wednesday issue vs week
408,ABT,biotechnology industry group remain year hottest have couple stock ipo leader screen be intrexon xon be trading buy point cup handle base
409,ABT,company many new biotechs have be post loss be expect lose money again year next do earn profit past quarters sale growth be be most impressive
410,ABT,revenue surge first quarter follow increase previous period part be payment various partner
411,ABT,company also have operation food production energy such process convert natural gas fuel chemical lubricant
412,ABT,germantown md base intrexon be lead company new field synthetic biology intrexon design build regulate gene cellular system
413,ABT,partly acquisition intrexon have create suite technology handle drug development process engineering production
414,ABT,enanta pharmaceutical enta be form right side cup shape base potential buy point be base be unusually deep chart reader tend frown
415,ABT,company make hepatitis drug antibiotic bacterium resistant current treatment
416,ABT,enanta develop antiviral agent abbvie abbv cocktail potential drug hepatitis virus analyst believe be advanced trial generate year mean milestone payment royalty enanta
417,ABT,most development stage biotechs enanta have be profitable march end quarter earn share vs loss cent share year period
418,ABT,revenue soar more be just year enanta result have be uneven be ep rating be just
419,ABT,enanta recently get payment abbvie viekirax drug certain type hepatitis have win regulatory approval europe biotechnology industry group remain year hottest have couple stock ipo leader screen be intrexon xon be trading buy point cup handle base company many new biotechs have be post loss be expect lose money again year next do earn profit past quarters sale growth be be most impressive revenue surge first quarter follow increase previous period part be payment various partner company also have operation food production energy such process convert natural gas fuel chemical lubricant germantown md base intrexon be lead company new field synthetic biology intrexon design build regulate gene cellular system partly acquisition intrexon have create suite technology handle drug development process engineering production enanta pharmaceutical enta be form right side cup shape base potential buy point be base be unusually deep chart reader tend frown company make hepatitis drug antibiotic bacterium resistant current treatment enanta develop antiviral agent abbvie abbv cocktail potential drug hepatitis virus analyst believe be advanced trial generate year mean milestone payment royalty enanta most development stage biotechs enanta have be profitable march end quarter earn share vs loss cent share year period revenue soar more be just year enanta result have be uneven be ep rating be just enanta recently get payment abbvie viekirax drug certain type hepatitis have win regulatory approval europe
420,ABT,medical stock have be market top performer year drugmaker abbvie abbv be try add sector gain chicago base firm be leader ethical drug industry group also include valeant pharmaceutical vrx horizon pharma hznp jazz pharmaceutical jazz establish leadership position rapidly growth hematological oncology market
421,ABT,stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today
422,ABT,volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange
423,ABT,ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high
424,ABT,integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday
425,ABT,worst performer ibd be regeneron pharmaceutical regn more
426,ABT,energy name be day best perform industry group push oil price be higher
427,ABT,chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base
428,ABT,sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs stock be trading moderately lower lows day head noon hour monday nasdaq drop dow jone industrial average fall stock market today volume finish well level friday abbreviated post thanksgiving level be tracking average nyse nasdaq exchange ibd stock be higher be lower top performer be cambrex cbm volume well average last week developer active pharmaceutical ingredient break cup handle base buy point stock be trading time high integrate device technology idti ibd stock be nearly also trading time high company management present credit suisse global technology conference tuesday worst performer ibd be regeneron pharmaceutical regn more energy name be day best perform industry group push oil price be higher chinese social medium platform weibo wb rise nearly volume run nearly triple usual pace attempt build right side deep base sohu com sohu chinese internet stock gap be trading lower be several chinese name downgrade goldman sachs
429,ABT,health care company abbott laboratory plead guilty agree pay monday settle federal state allegation promote seizure drug depakote used weren approve food drug administration settlement abbott agree plead guilty misdemeanor violation food drug cosmetic act misbrand
430,ABT,diversify medical giant abbott laboratory thursday say cut deal buy experimental kidney treatment separately also announce open first nutrition center india abbott agree pay cash action pharmaceutical ap currently late stage trial prevent acute kidney injury associate major cardiac surgery
431,ABT,abbott laboratory prepare give birth new pharma giant year announce choose name abbott say new company be call abbvie derive combination abbott vie reference latin root vi meaning life accord company press release spinoff plan first announce
432,ABT,diversify medical giant abbott laboratory report fourth quarter result outlook roughly expect wednesday morning do better bottom line top
433,ABT,profit checked share year earlier period penny analyst consensus sale increase shy analyst have expect average
434,ABT,full result follow similar pattern sale rise vs view profit gain share cent estimate
435,ABT,company note be fifth straight year double digit profit growth break streak year abbott guide profit range share line street expectation mean growth upper single digit
436,ABT,share be fractionally premarket trading diversify medical giant abbott laboratory report fourth quarter result outlook roughly expect wednesday morning do better bottom line top profit checked share year earlier period penny analyst consensus sale increase shy analyst have expect average full result follow similar pattern sale rise vs view profit gain share cent estimate company note be fifth straight year double digit profit growth break streak year abbott guide profit range share line street expectation mean growth upper single digit share be fractionally premarket trading
437,ABT,major stock index bounce back friday early loss more close higher first time session
438,ABT,want hear ibd analysis today market emerge stock
439,ABT,click here watch latest market wrap video
440,ABT,nyse composite rally boost steel related group bank be also strong thursday passage sweeping overhaul regulation senate jpmorgan chase jpm morgan stanley ms jump well fargo wfc gain
441,ABT,meanwhile nasdaq climb respectively undercut flash crash low intraday dow rise have yet breach low turnover end mixed option expiration rise nyse ease nasdaq
442,ABT,european worry continue keep market edge early friday house germany parliament approve country contribution bailout plan
443,ABT,friday rebound equity still finished lower week nasdaq drop nyse composite dow
444,ABT,leader stage nice comeback
445,ABT,overstock com ostk erased open loss bolt more twice average trade analyst see internet retailer earn cent share year quarter share
446,ABT,salesforce com crm bounce back loss more climb monster trade regain day move average late thursday cloud compute firm give weak earning outlook early friday equity upgrade stock hold sell
447,ABT,volterra semiconductor vltr turn higher bounce day move average advanced double average volume
448,ABT,treehouse food th rise rebound day line
449,ABT,datum exist home sale earning phillip van heusen pvh be monday
450,ABT,stock snap lose streak volatile session
451,ABT,vincent mao
452,ABT,stock close higher wild session friday halter session slide
453,ABT,nyse composite climb dow nasdaq volume rise exchange accord preliminary datum
454,ABT,economically sensitive group such steel energy be best performer travel service provider be also strong thank big comeback ctrip com international ctrp priceline pcln
455,ABT,stock pare gain late session action
456,ABT,jonah keri
457,ABT,major index give back much early gain late friday market fought stay positive territory
458,ABT,nyse composite climb nasdaq dow volume continue track sharply higher board option expiration
459,ABT,overstock com ostk extend earlier gain surge more twice normal trade discount online retailer own composite rating relative price strength rating
460,ABT,volterra semiconductor vltr marvell technology mrvl jump heavy volume chip stock continue friday rally
461,ABT,decker outdoor deck rise rapid turnover maker ugg boot teva sandal have see accumulation distribution rating dip poor broad market correction
462,ABT,stock retain gain option expiration volume
463,ABT,major stock index bounce back friday early loss more close higher first time session want hear ibd analysis today market emerge stock
464,ABT,click here watch latest market wrap video
465,ABT,nyse composite rally boost steel related group bank be also strong thursday passage sweeping overhaul regulation senate jpmorgan chase jpm morgan stanley ms jump well fargo wfc gain meanwhile nasdaq climb respectively undercut flash crash low intraday dow rise have yet breach low turnover end mixed option expiration rise nyse ease nasdaq european worry continue keep market edge early friday house germany parliament approve country contribution bailout plan friday rebound equity still finished lower week nasdaq drop nyse composite dow leader stage nice comeback overstock com ostk erased open loss bolt more twice average trade analyst see internet retailer earn cent share year quarter share salesforce com crm bounce back loss more climb monster trade regain day move average late thursday cloud compute firm give weak earning outlook early friday equity upgrade stock hold sell volterra semiconductor vltr turn higher bounce day move average advanced double average volume treehouse food th rise rebound day line datum exist home sale earning phillip van heusen pvh be monday stock snap lose streak volatile sessionby vincent maostock close higher wild session friday halter session slide nyse composite climb dow nasdaq volume rise exchange accord preliminary datum economically sensitive group such steel energy be best performer travel service provider be also strong thank big comeback ctrip com international ctrp priceline pcln stock pare gain late session actionby jonah major index give back much early gain late friday market fought stay positive territory nyse composite climb nasdaq dow volume continue track sharply higher board option expiration overstock com ostk extend earlier gain surge more twice normal trade discount online retailer own composite rating relative price strength rating volterra semiconductor vltr marvell technology mrvl jump heavy volume chip stock continue friday rally decker outdoor deck rise rapid turnover maker ugg boot teva sandal have see accumulation distribution rating dip poor broad market correction stock retain gain option expiration volume
466,ABT,abbott free report report first quarter adjust earning continue operation cent share beating zack consensus estimate penny bottom line also improve year year meet high end company guide range cent moreover report earning quarter come cent share compare year figure cent first quarter worldwide sale come year year report basis top line also exceed zack consensus estimate organic basis adjust impact foreign exchange certain divestment sale increase year year report quarter quarter detailabbott operate segment namely establish pharmaceutical division epd medical device nutrition diagnostic epd sale rise report basis organic basis include positive impact currency fluctuation sale key emerge market increase drive double digit growth india china brazil medical device business sale increase report basis organic basis sale grow cardiovascular neuromodulation sale reportedly organic basis rise double digit growth neuromodulation vascular product sale however decline report basis rhythm management company see sale increase report basis decline abbott laboratory price consensus ep surprise abbott laboratory price consensus ep surprise abbott laboratory quote diabetes care sale improve buoy double digit international sale growth lead consistent consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis organic basis foreign exchange drive sale pediatric nutrition sale increase organic basis adult nutrition sale be organically diagnostic sale soar year year report basis comparable operational basis core laboratory point care diagnostic sale grow respectively organic basis molecular diagnostic sale be nominal strong growth infectious disease testing business be partially offset plan scale other testing area primarily unite state rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing full year guidanceabbott have reiterate earning share guidance adjust certain net specify item full year adjust earning continue operation be still expect band zack consensus estimate remain project range company have also provide second quarter adjust earning share outlook expect report adjust earning continue operation range cent consensus mark cent fall lower end predict range takeabbott have steer past zack consensus estimate earning revenue be optimistic company strong consistent epd medical device performance also solid contribution company other business encourage company continue benefit strong integration synergy st jude medical offer industry lead pipeline cardiovascular neuromodulation diabetes vision care be also impressed abbott alere buyout synergy consolidation form revenue rapid diagnostic have be drive company growth meanwhile company emerge market performance have be extremely promising several strategic development zack rank key picksabbott carry zack rank hold few better rank stock broader medical sector be abaxis inc abax free report bio rad laboratory inc bio free report align technology inc algn free report abaxis bio rad sport zack rank strong buy align carry zack rank buy see complete list today zack rank stock here abaxis be expect release fourth quarter fiscal result apr zack consensus estimate quarter adjust ep be peg cent revenue stand bio rad be expect release first quarter result zack consensus estimate period adjust ep be cent revenue align technology be slate release first quarter result apr zack consensus estimate adjust bottom line be report quarter be cent top line hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
467,ABT,triple digit gain regular day tuesday trading dow nasdaq be bolster number different thing strong housing start lack relative geopolitical tension early week nothing so influential very strong earning season be still early stage so far only week have pass delta air line beat estimate top bottom line overall result have be notably better expect bell earning report yesterday be better expect board company perform more impressively other intuitive surgical isrg free report post robust earning beat ibm ibm free report eke positive surprise new corporate tax benefit alone ibm watson enterprise have thus far fail inspire fresh investment big blue result ibm have shed more today pre market isrg share be morning new earning report be follow suit start morgan stanley ms free report left estimate dust morning investment banking major post share quarterly revenue outpace zack consensus estimate respectively net income grow sale trading rise more ms earning click here fellow financial institution bank usb free report beat earning estimate penny cent share miss revenue expectation bring opposed analyst be look still represent good year year growth pre market trading show usb share slip half percentage point hour more usb earning click here base chicago north shore abbott lab free report also top earning consensus penny cent share revenue also slightly surpass expectation report sale guidance full year have be post share zack consensus be roughly midpoint share be ahead today open bell more earning click here defense component major textron txt free report however perform much better morning cent share blow away expectation cent more double cent share year sale also impressed estimate year figure industrial sale perked company see gain arctic cat acquisition share be today pre market more txt earning click here
468,ABT,wednesday april triple digit gain regular day tuesday trading dow nasdaq be bolster number different thing strong housing start lack relative geopolitical tension early week nothing so influential very strong earning season be still early stage so far only week have pass delta air line beat estimate top bottom line overall result have be notably better expect bell earning report yesterday be better expect board company perform more impressively other intuitive surgical isrg free report post robust earning beat ibm ibm free report eke positive surprise new corporate tax benefit alone ibm watson enterprise have thus far fail inspire fresh investment big blue result ibm have shed more today pre market isrg share be morning new earning report be follow suit start morgan stanley ms free report left estimate dust morning investment banking major post share quarterly revenue outpace zack consensus estimate respectively net income grow sale trading rise more ms earning click here fellow financial institution bank usb free report beat earning estimate penny cent share miss revenue expectation bring opposed analyst be look still represent good year year growth pre market trading show usb share slip half percentage point hour more usb earning click here base chicago north shore abbott lab free report also top earning consensus penny cent share revenue also slightly surpass expectation report sale guidance full year have be post share zack consensus be roughly midpoint share be ahead today open bell more earning click here defense component major textron txt free report however perform much better morning cent share blow away expectation cent more double cent share year sale also impressed estimate year figure industrial sale perked company see gain arctic cat acquisition share be today pre market more txt earning click here mark vickerysenior editorquestion comment article author click here https www zack com bio mark vickery medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
469,ABT,abbott laboratory free report be illinois base company focuse bring diverse line healthcare product market abbott report diversify business segment namely establish pharmaceutical division epd medical device diagnostic nutrition company have reshape portfolio strategic acquisition divestiture recent time feb abbott complete sale brand generic pharmaceutical business develop market realignment epd division acquisition latin america russia business divestiture develop market have position company well come quarters abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory company ride strong epd business strategic buyout abbott complete acquisition alere be expect enhance company stance healthcare however foreign currency headwind raise major concern company considerable percentage abbott revenue come outside unite state abbott have impressive track record company beat estimate last trail quarters average positive earning surprise currently abbott have zack rank hold definitely change follow company first quarter earning report be just release see complete list today zack rank strong buy stock here have highlighted key stat just reveal announcement earning abbott first quarter adjust earning share continue operation cent outpaced zack consensus estimate penny revenue abbott post first quarter worldwide revenue beating zack consensus estimate revenue key stat worldwide revenue increase organic basis year year basis revenue nutrition segment come year year diagnostic segment report sale worth year year basis establish pharmaceutical revenue be year quarter medical device revenue come year quarter major factor company expect full year earning share be range reflect growth midpoint several new product launch company have contribute strong growth furthermore january abbott announce fda approval magnetic resonance mr conditional labele quadra assura quadra assura mp device stock price follow earning release share price decrease pre market trading session hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
470,ABT,be first big week earning season mean ll get lot big cap company report include several dow component re also hearing company not pay much attention run gamut industry drug manufacturer equipment play paint coating high end tool provider pool product company have something else common great earning surprise track record not easy beat quarter year be just couple dozen company have perfect record even miss however be impressive track record hard maintain be best earning chart company report week amazing earning chart weekabbott lab free report have perfect record share have finally break new high have be little dicey earning beat help share regain momentum unite rental uri free report have miss just once last year share have rally hope congress pass big infrastructure plan boost big equipment lender ppg industry ppg free report hasn miss year share have be stick narrow trading range last year take new height snap sna free report hasn miss year share be also stall narrow trading range look break start year instead have sunk low end range corporate tax cut help stock regain momentum pool corporation pool free report specialize pool pool product have miss only once last year share be year high consumer feel good look leisure experience pool be perfectly position benefit author article own share uri personal portfolio
471,ABT,varian medical system inc var free report be schedule report second quarter fiscal earning apr market close favorable revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence be likely drive company second quarter fiscal earning last quarter company deliver adjust earning share beat zack consensus estimate cent adjust earning also improve year year basis revenue totale beat zack consensus estimate second quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate adjust earning be peg share indicate increase year year varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quote let delve factor be likely impact varian medical upcoming quarterly result factor playoncology drive growth be upbeat varian medical oncology business account company total revenue last quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have be winning international contract oncology space bid overhaul oncology system segment varian medical recently acquire montreal base privately hold evinance innovation inc clinical decision support cds software company deal be initiate september company have state utilize evinance patented technology offer better service client mar varian medical announce st petersburg center nuclear medicine successfully complete first pediatric patient treatment varian probeam proton therapy system product launch successful launch halcyon therapy system deserve mention regard varian medical have be undertaking initiative attract customer broad spectrum product recently company unveil halcyon radiotherapy treatment system recently first quarter fiscal halcyon platform witness order inception reflect solid demand platform quarters ahead jan varian medical announce halcyon system have receive taiwan fda approval allow company market new cancer treatment system country feb varian medical announce halcyon cancer treatment platform receive atomic energy regulatory board aerb certificate import supply india company expect revenue range adjust earning share be expect band cash flow operation be project range cut throat competition varian medical compete large electronic company such siemens philips well smaller more specialize radiation therapy equipment manufacturer elekta accuray emerge proton therapy market company face competition hitachi ion beam application mevion medical system sumitomo intense competition be anticipate increase expenditure nascent proton therapy market dent margin moreover pricing pressure traditional radiotherapy be major concern earning whispersour proven model do not show earning beat varian medical quarter be stock need have positive earning zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here cardinal heath cah free report have earning esp zack rank abbott laboratory free report have earning esp zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
472,ABT,baxter international inc bax free report be schedule report first quarter earning apr market open positive tiding regulatory front expand product portfolio strategic collaboration strong presence international market be key positive moment expect company witness steady growth hospital product sale major revenue component be project drive first quarter earning expect improvement revenue other sub segment generate impressive result last quarter baxter post adjust earning share cent beat zack consensus estimate cent improve year quarter figure cent current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate adjust earning share be peg cent indicate increase year year baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotelet delve other factor be likely impact baxter first quarter result hospital product drive resultsbaxter have impressive product portfolio improve exist product new product development recently company announce distribution agreement launch arisure close system transfer device last quarter hospital sale be drive solid demand injectable pharmaceutical hospital pharmacy compound service sale segment benefit solid demand company advanced surgery product cytotoxic contract manufacturing service overall zack consensus estimate hospital product revenue be peg reflect increase year quarter here take sneak peek major sub segment hospital product be poise gain be report quarter surgical care surgical care include anesthesia biosurgery sale record year year sale growth last quarter low double digit growth anesthesia critical care product drive grow demand inhaled anesthetic internationally well increase sale brevibloc fast act iv beta blocker mar baxter complete acquisition hemostat sealant product mallinckrodt plc expand exist surgical portfolio hemostat sealant especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter surgical portfolio include product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other portfolio be compose hemostasis address bleed tissue sealing hard tissue regeneration well soft tissue repair microsurgery product available nearly country company consistently strive improve advanced surgery business company expect advanced surgery business increase constant currency cc basis baxter announce plan focus launch advanced surgery product japan come day zack consensus estimate segment sale be peg reflect rise year quarter fluid system hospital product sale fluid system be expect be solid robust iv solution sale unite state expect fluid system maintain trend first quarter be evident zack consensus estimate fluid system first quarter reflect rise year quarter integrate pharmacy solution ip global sale ip sub segment hospital product increase formidable margin last quarter partly back increase sale premixed injectable drug however baxter performance last year have lack luster majorly lower sale threat integrate pharmacy solution franchise business baxter expect sale be approximately reflect decline upcoming quarterly result lower sale be expect impact top line low single digit first quarter zack consensus estimate ip be peg show increase year number other factor playguidance baxter expect first quarter adjust earning range cent however net sale first quarter be expect be affected approximately due disruption puerto rico facility baxter estimate sale growth approximately cc adjust earning be expect band regulatory approval baxter have be witness positive tiding regulatory front recently baxter announce approval bivalirudin percent sodium chloride injection bivalirudin management confirm fda have grant new approval temporary importation certain drug facility canada mexico development baxter now have operational site approve address demand market dull projection pharmaceutical unit pharmaceutical business include baxter broad generic injectable portfolio anesthesia critical care product well hospital pharmacy compound service conduct outside unite state be expect be flat year year basis lackluster performance be primarily drive increase competition select product segment further other business segment primarily include baxter contract manufacturing service management expect low single digit decline management sale segment benefit customer order baxter expect lower manufacturing revenue shire acquire year model predictsour quantitative model do not predict earning beat baxter quarter be stock need have positive earning zack rank strong buy buy hold be able beat estimate zack esp earning esp baxter be uncover best stock buy sell re report earning esp filter zack rank baxter carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here cardinal heath cah free report have earning esp zack rank abbott laboratory free report have earning esp zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
473,ABT,stock open higher monday investor seem think lead air strike syrium win lead much larger conflict strike also coincide real start first quarter earning season investor use way fight volatility have plague market recently earning season kick gear last friday banking giant jpmorgan chase jmp free report citigroup free report pnc financial pnc free report report financial result go forward investor use highly anticipate period try recoup loss have suffer extend bearish run say investor still need be selective earning season hunt stock look poise top quarterly earning estimate conversely investor stay away company disappoint report lower expect earning result luckily zack premium customer utilize earning esp screener order search stock be expect surprise way other be do generally speaking analyst post estimate right earning release mean have fresh information potentially be more accurate analyst thought company month positive earning esp pair zack rank hold better ranking help feel confident potential earning beat fact year backtest have reveal methodology have accurately produce positive surprise time today be give reader free look stock look ready post earning beat week check now honeywell international hon free report share honeywell climb monday signal investor have reason be excited company famous thermostat other control technology building home industry honeywell be indeed expect see revenue climb reach base current zack consensus estimate meanwhile company earning be project climb share honeywell be also currently zack rank hold sport earning esp diving little deeper hon most accurate estimate representation most recent analyst sentiment call earning share come cent current consensus estimate mean honeywell be ready top earning estimate report financial result market open friday april trade financial etfc free report volatility not be great investor online brokerage firm such trade benefit hugely have be reflect trade stock price be last year also manage come recent market downturn nearly unscathed trade be expect see first quarter revenue climb reach company bottom line be project hit share mark stellar expansion year period better still trade be currently zack rank buy rock earning esp most accurate estimate come cent current consensus estimate therefore investor consider trade stock look poise beat earning estimate report financial result market close thursday april abbott laboratory free report share abbott pop monday morning just couple day diversify healthcare company be set report first quarter earning result look abbott investor have reason be excited company quarterly revenue project surge more hit meanwhile abbott earning be expect expand reach share company be also currently zack rank hold boast earning esp mean investor see abbott top earning estimate company report financial result open bell wednesday april investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
474,ABT,stryker corporation syk free report first quarter result be schedule release apr market close company acquisition drive strategy be expect boost growth expand exist product offering business segment expect company witness steady growth orthopaedic implant sale major revenue component be project drive first quarter earning expect improvement revenue other segment especially medsurg help company generate impressive result notably last quarter stryker post earning share beat zack consensus estimate penny current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg indicate increase year year let delve other factor be likely impact skryker first quarter result orthopaedic implant focus mako implant contribute net revenue last quarter zack consensus estimate orthopaedic implant stand reflect rise year year recently stryker introduce robotic arm assist total knee arthroplasty application use mako system notably be first only robotic technology be used total knee hip partial knee replacement procedure notably mako total knee utilize stryker robotic platform triathlon total knee system guide ct base modele bone anatomy stryker system enable intra operative plan assist bone resection procedure fourth quarter mako total knee platform drive stryker earning mako robot installation totale globally unite state additionally company have first robot sale japan approval mako be expect end company exit mako robot install unite state stryker corporation price consensus stryker corporation price consensus stryker corporation quoteother factor playmedsurg unit drive growthmedsurg equipment product include surgical equipment surgical navigation system endoscopic communication digital imaging system well patient handle emergency medical equipment last quarter management announce medsurg high growth segment zack consensus estimate medsurg endoscopy revenue surge year year acquisition drive strategystryker have be follow acquisition drive strategy drive growth recently stryker acquire entellus medical inc cash transaction share equity value approximately enable physician conveniently perform broad range ent procedure late stryker acquire vexim specialize development sale vertebral compression fracture solution vexim flagship product be spinejack system mechanical expandable vcf implant fracture reduction stabilization vexim portfolio be highly complementary interventional spine business stryker stryker instrument division include extensive innovative portfolio vertebral augmentation vertebroplasty radiofrequency ablation procedure diagnostic tool decompression treatment advance contain disc herniation lower demand healthcare productsstryker persistently face challenge lower demand health care product additionally company spine business unite state be plague supply issue fourth quarter fact stryker expect face headwind be report quarter company have be face challenge economic condition particularly unite state western europe additionally lower reimbursement medical product service impose downward pressure price company product longer sale cycle slower adoption new technology ultimately impact top line model predictsour quantitative model predict earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated zack esp earning esp stryker be uncover best stock buy sell re report earning esp filter zack rank stryker carry zack rank favorable zack rank increase predictive power esp company positive esp make surprise prediction feasible other stock worth lookhere be few other medical stock worth consider also have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here cardinal heath cah free report have earning esp zack rank abbott laboratory free report have earning esp zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
475,ABT,quest diagnostic inc dgx free report be schedule report first quarter earning performance open bell apr last quarter company earning surpass zack consensus estimate penny deliver positive surprise also metric outperformed consensus mark trail quarters average beat let take look thing be shape prior announcement factor playon positive note quest diagnostic seem well align point growth agenda accelerate growth drive operational excellence new long term growth outlook revenue increase period be expect be growth project acquisition earning period be anticipate rise faster revenue mid high single digit range company estimate revenue growth period company increase number partnership other health care leader strategic acquisition be create promising opportunity top bottom line growth improve patient experience reduce overall cost care regard take note recent strategic quest diagnostic first acquisition cleveland heartlab help strengthen company position new york metropolitan marketplace second buyout mobile medical examination service medxm fortify quest diagnostic mobile provider capability population health management solution health plan transaction garner favorable result yet be report quarter quest diagnostic incorporate price ep surprise quest diagnostic incorporate price ep surprise quest diagnostic incorporate quote be also optimistic company successful execution strategy build esoteric testing business well boost profitable growth additionally quest diagnostic have recently witness significant improvement infectious disease testing prescription drug monitoring industry lead wellness business therefore expect growth driver replicate company success story upcoming quarterly result have thus remain active also performance be likely drive same primary metric precede quarter strongly believe recent development have significantly contribute company top line first quarter company expect revenue range annualize growth zack consensus estimate revenue be peg ahead company project range exclude impact special item amortization expense etb excess tax benefit associate stock base compensation adjust ep full year be project band zack consensus estimate fall guide range flip side phase continual drag several quarters company revenue requisition performance last quarters see slight rebound however still remain be see upside be here stay not company professional lab service engagement wj barnabas health healthone system hca holding inc hca also carry lower revenue requisition due nature work further take consideration persistent headwind unit price be moderately less basis point exclude impact protect access medicare act pama company expect unit price headwind remain basis point pama add extra headwind approximately basis point also get reflect first quarter result overall believe lack employment slow growth commercially insure life continuously affect company volume measure number requisition economy turn better model suggestsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp quest diagnostic have zack rank increase predictive power esp earning esp raise confidence positive surprise together combination suggest company be likely beat earning quarter conversely caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter other stock worth lookhere be few other medical stock worth consider right combination element surpass estimate time abaxis inc abax free report have earning esp zack rank see complete list today zack rank stock here abbott laboratory free report have earning esp zack rank henry schein hsic free report have earning esp be zack rank player look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
476,ABT,bid fortify heart failure business abbott free report recently announce start guide hf clinical trial largest heart failure medical device study unite state trial evaluate effectiveness cardiomem hf system improve survival quality life patient new york heart association nyha class ii iv heart failure abbott positive result trial help company expand customer base well provide additional clinical evidence expand coverage cardiomem hf system be cardiomem hf system feature small pressure sense device fda approve cardiomem hf system allow physician monitor pressure change patient condition deteriorate lower possibility hospitalization notably cardiomem device have already be proven effectiveness patient nyha class iii heart failure guide hf cinical trial guide hf clinical trial enroll patient hospital stage nyha class ii iv heart failure elevated brain type natriuretic peptide bnp level prior heart failure hospitalization past year north america patient be enrolled hospital peek heart failure business abbott have continue deliver stable top line performance recent time last report quarter sale business improve double digit notably heart failure business account total revenue broader medical device segment segment company make heartmate commercially available unite state management also inform work expand indication product include destination therapy patient be bar opt transplant market prospectsper report globaldata publish drug development delivery heart failure market be estimate reach value cagr company person suffer heart failure unite state more person get diagnosed condition year furthermore american heart association estimate more heart failure patient unite state hospitalization annually thus positive result trial help abbott cash opportunity heart failure market share price movementover past month abbott have be outperform industry stock have gain compare industry zack rank key picksabbott carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank buy hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
477,ABT,trade war cacophony have spread far wide not spare investment world conflict world biggest economy have lead dow fall more point just day last week be gradually recover market be still fraught possibility other outbreak sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector face brunt trade dispute current most economist have initially expect china be fast adopt stance square america advantage point import tariff game response trump propose imposition annual tariff chinese product beij have announce initial reciprocal tariff roughly import unite state be supposedly prepare bolder counter attack wake tariff threat nobel prize winning economist robert shiller have warn impending economic crisis meanwhile bloomberg report state unite state maintain lead trade conflict china be unite state extent be monopsony market large number buyer thus nation stop purchasing chinese product china not be able channelize surplus canada indonesia same price however china not be able adopt tit tat strategy do not import same scale unite state accordingly follow last week crash market be slowly look news nation be likely resolve issue mutually be fuel recovery however talk extinguish possibility trade war completely be yet be see meanwhile investor be catch america first make china web be medical device catch storm state earlier trade representative robert lighthizer have identify healthcare sector be subject tariff more specifically trump have consider biomedicine high performance medical device include china advanced chemical medical equipment respectively needless say have trigger decline sector follow news chance china retaliation loss be widespread medical device sector bigwig take severe blow note sector have gain significantly profit earn number medical device company bric nation go market realist report company medtronic plc mdt free report becton dickinson company bdx free report abbott other see considerable weakness mar talk china trade war start do round stock be gradually revive rise chance nation negotiating certain term investor consider still extremely vulnerable widely expose trade conflict give huge business network mainland china have shortlist stock be face brunt tumultuous market condition zimmer biomet holding inc zbh free report zack rank strong sell lose mar note company have be investing heavily cash chinese reconstructive trauma market strategic investment region past several quarters improve operational sale performance be yielding result fourth quarter company witness improvement asia pacific business solid distributor order china particularly demonstrated strong growth thus form retaliation china impact company zimmer biomet holding inc price zimmer biomet holding inc price zimmer biomet holding inc quotemedtronic last report quarter medtronic business china show strength grow double digit accord company next decade china be expect be biggest health care market needless say zack rank hold company be expending large amount cash strengthen business market company be focuse develop public private partnership well execute channel optimization strategy see complete list today zack rank strong buy stock here medtronic plc price medtronic plc price medtronic plc quoteover last few year abbott free report have be lead emerge market investment trend total sale come region zack rank stock core establish pharmaceutical division epd business operate solely emerge geography lead position chinese pharmaceutical market brand generic last report quarter well china demonstrated double digit growth epd trade war not stock be extremely vulnerable position broad network diversify business base china abbott laboratory price abbott laboratory price abbott laboratory quotebreaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
478,ABT,edward lifescience corporation ew free report have announce compute tomography imaging partner trial sapien valve sub study have recently complete enrollment notably sub study be evaluate leaflet mobility sapien surgical heart valf patient be low risk experience valve replacement treat severe aortic stenosis datum main partner study be present acc notably company expect fda approval indication late management edward lifescience be study sapien ultra system feature balloon delivery system next generation sheath technology part single arm multus center trial intermediate risk patient company now anticipate system launch late europe unite state also announce update timing european launch system do not change sale guidance peg high end project range market potentialper report market research global heart valve device market be estimate be worth end cagr very noteworthy player niche be abbott free report thv focusbasically sapien be artificial valve fall edward lifescience transcatheter heart valf thv segment thv segment include technology design treat heart valve disease used catheter base approach opposed open surgical technique fourth quarter company report thv sale growth prior year quarter tally unite state thv increase year year attributable excellent clinical performance sapien well continue strong therapy implementation region outside unite state underlie growth rate be contribution region company continue see strong tavr therapy adoption japan drive sapien buoy previous quarter strong performance edward lifescience now predict full year thv sale growth rate high end guide range also management thv boast highest margin business late edward lifescience have witness multiple development thv segment good news be company have recently receive ce mark self expand centera also management release positive patient outcome sapien valve include high survival rate low rate stroke paravalvular leak share price estimate revision trendedward have be gain investor confidence consistently positive result year time company share price have outperformed industry stock have soar compare industry rally headquarter irvine company estimate revision trend have be positive past couple month analyst moved north revision opposite direction earning estimate rise share zack rank other key picksedward lifescience carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
479,ABT,abiom inc abmd free report report second quarter fiscal earning cent share come ahead zack consensus estimate cent figure be also higher cent year quarter report quarter revenue increase roughly year year approximately outpace zack consensus estimate year year upside be support robust performance impella heart pump product line quarter revenue manufacturer developer marketer medical product surge quarter impella revenue improve drive increase patient utilization outside unite state revenue surge germany account majority international revenue grow year year basis report quarter install base impella heart pump unite state grow hospital take install customer base total site install customer base impella cp heart pump grow hospital reach total overall operate income report quarter come operate margin percentage revenue compare prior year quarter abiom gross margin quarter be compare second quarter fiscal abiom inc price consensus ep surprise abiom inc price consensus ep surprise abiom inc quotefinancial conditionabiom cash cash equivalent be sep compare mar notably management announce company currently have debt guidanceabiom forecast fiscal revenue range mark increase fiscal level operate margin be project band takefurther believe robust demand impella product line continue drive abiom top line long term company expand product portfolio improve penetration prophylactic high risk pci cardiogenic shock patient market be evident fact impella cp continue add center unite state new publication regard device lead medical journal help promote utilization effectiveness abiom significant international presence help broaden customer base other positive fluctuation currency exchange rate adversely impact company international sale fluctuation currency exchange rate adversely impact abiom international sale company international presence broaden customer base zack rank key picksabiom hold zack rank buy see complete list today zack rank strong buy stock here few other top rank stock broader medical sector include petm express inc pet free report abbott free report intuitive surgical inc isrg free report petm sport zack rank abbott intuitive surgical carry zack rank petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale totale year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
480,ABT,integra lifescience holding corporation iart free report report adjust earning share ep cent third quarter decline year figure adjust ep also miss zack consensus estimate cent include time item company report earning cent share year quarter revenue discussiontotal revenue report quarter increase year year lag zack consensus estimate exclude revenue acquisition discontinue product effect currency exchange rate organic revenue rise year year solid revenue growth third quarter be primarily drive strong contribution orthopedic tissue technology segment come product category revenue company specialty surgical solution segment increase orthopedic tissue technology revenue come third quarter year year margin trendgross margin contract basis point bps report quarter company adjust gross margin contract bps selling general administrative expense increase report quarter research development expense contract adjust operate margin see bps contraction third quarter financial positionintegra lifescience exit third quarter cash cash equivalent record end second quarter sep net cash flow operate activity be year quarter outlook have raise full year revenue guidance meanwhile full year organic revenue growth range be lower zack consensus estimate full year revenue be guide range company have revise full year adjust ep guidance previous range zack consensus estimate adjust earning be peg company guide range takeintegra lifescience exit third quarter disappointing note also contraction adjust operate margin adjust gross margin add wo moreover drop year year investment research development be discourage spite raise full year revenue guidance slash full year adjust earning range add wo however strong year year increase revenue back orthopedic tissue technology segment buoy optimism be also encourage note company segment see year year revenue growth quarter nonetheless believe company be try execute growth plan efficient management team zack rank key picksintegra lifescience have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
481,ABT,cerner corp cern free report report adjust third quarter earning cent share miss zack consensus estimate penny lackluster third quarter performance be primarily attribute year year decline booking have scale time high last quarter however earning rise year year basis company report net revenue fall short zack consensus estimate however revenue rise year year basis cerner hold zack rank buy booking disappointin third quarter cerner register booking worth year year basis fact booking be company previously issue guidance owing postponement several big contract quarter tentatively fourth quarter notably booking last quarter totale year year basis nonetheless cerner be well position strong full year performance base solid booking guidance fourth quarter next quarter booking be expect band midpoint reflect growth year year basis midpoint fourth quarter book guidance increase full year booking guidance year year basis segment detailssystem sale increase sale be buoy license software subscription partially offset decline technology resale total support maintenance service include professional manage service rise year quarter reflect solid execution company service organization revenue cycle have also be strong contributor courtesy strong sale contribution revwork service revenue management service population health service business also drive revenue third quarter solid growth flagship healtheintent solution company have be target broader shift fee service value base care long cerner also post impressive performance ambulatory small hospital market reimbursement travel revenue increase quarter slightly company full year expect growth rate geographically domestic revenue increase year quarter revenue increase margin balance sheet margin third quarter be revenue basis point bps year decline be due lower mix sublicens software lackluster performance technology resale business adjust operate margin third quarter be net sale bps year cerner end third quarter total cash investment total debt cerner include capital lease obligation be fy guidance fourth quarter cerner forecast revenue midpoint reflect growth year year basis adjust earning be expect band cent cent share midpoint be flat year year basis full year management expect revenue be low end previously issue range thank lower booking third quarter cerner currently forecast adjust earning lower previously issue range company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
482,ABT,stryker corp syk free report report adjust earning share third quarter comfortably beat zack consensus estimate cent earning improve share year quarter company base kalamazoo mi have maintain streak positive earning surprise meanwhile trail quarters company post earning beat average currently stryker carry zack rank hold upside earning be primarily drive rise revenue beat zack consensus estimate constant currency cc net sale improve year quarter segment net sale increase year year report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume be partially offset due lower price medsurg net sale increase report quarter exclude impact acquisition net sale quarter increase cc include increase unit volume neurotechnology spine net sale increase report quarter net sale quarter increase increase unit volume be partially offset due lower price fourth quarter stryker expect adjust earning range share full year company expect adjust earning band stryker expect organic sale growth full year takewe believe stryker innovative product pipeline be key catalyst term furthermore grow adoption mako drive sale orthopedic reconstructive surgery market flip side china prove be challenge market company come supply related headwind company have be grapple issue spine business long believe prove be major drawback quarters ahead nevertheless stryker effort sale force management bode well company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock hold zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy ou see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale amount year year abbott carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
483,ABT,varian medical system inc var free report report adjust earning share fourth quarter fiscal miss zack consensus estimate adjust earning also decline year year basis meanwhile revenue be year quarter revenue miss zack consensus estimate narrow margin varian medical end year backlog year year basis unfavorable performance company proton therapy unit be primary cause lackluster fourth quarter performance however solid guidance fiscal instill confidence stock palo alto base manufacturer medical device software carry zack rank hold varian medical system inc price consensus ep surprise varian medical system inc price consensus ep surprise varian medical system inc quotesegment detailsoncology system segment revenue totale year year constant currency cc oncology growth be drive double digit service growth newly issue upgrade hardware software notably varian medical register order hyperarc platform fourth quarter hyperarc be recently launch high definition radiotherapy technology gross order segment totale cc year quarter unite state gross order increase cc emea region gross order rise year year basis courtesy solid growth france germany poland india flipside gross order decline cc apac region thank weakness japan proton therapy fourth quarter revenue segment be year year basis quarter varian medical book order include concord medical proton center guangzhou china hcg india proton therapy order growth be year year basis halcyon drife growthvarian medical have be take initiative gain customer attention broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna last quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide platform have order fourth quarter order be emea order north africa apac marginsin fourth quarter gross margin contract basis point bps revenue oncology system gross margin contract nearly bps owing supply chain inefficiency percentage revenue expense research development remain flat year year basis meanwhile selling general administrative sg expense quarter be bps year year basis operate margin quarter review be net revenue bps year year notably fourth quarter last year include favorable bad debt release addition investment varian medical have spend capex buy back share company stock end fourth quarter varian medical have share remain exist repurchase authorization fy fiscal varian medical register adjust earning share revenue be cc year oncology revenue be cc full year revenue proton therapy unit totale year year company book proton therapy order fiscal fiscal be favorable varian medical term product launch well successful launch halcyon therapy system hyperarc technology deserve mention regard fy fiscal management estimate adjust earning share range cash flow operation be project fiscal revenue be estimate grow year year company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock carry zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock sport zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
484,ABT,gnc holding inc gnc free report report third quarter adjust earning share ep cent reflect massive year year deterioration adjust ep also miss zack consensus estimate penny management hurricane harvey irma marium have dent adjust ep figure tune cent year year decline be attribute dull revenue performance report quarter primarily canada manufacturing wholesale segment include time item company report earning cent share year year revenuesrevenue report quarter drop year year figure also miss zack consensus estimate lower sale canada manufacturing wholesale segment be cite major reason disappointing number same store sale increase domestic company own store include gnc com sale third quarter domestic franchise location same store sale decline gnc holding inc price consensus ep surprise gnc holding inc price consensus ep surprise gnc holding inc quote segment detailsgnc holding report operation segment canada include company own store unite state puerto rico canada franchise store unite state commerce international include franchise location approximately country health store china operation manufacturing wholesale comprise manufacture product sell other segment third party contract manufacturing sale wholesale partner report quarter gnc holding revenue canada segment drop primarily owing decrease due discontinuation gold card program unite state introduction company new loyalty program domestic franchise location well revenue decline nearly partially offset increase retail same store sale however gnc com sale be third quarter revenue international segment increase revenue international franchisee rise revenue china business increase report quarter revenue manufacturing wholesale segment exclude intersegment revenue decrease segment third party contract manufacturing sale fall owing lower demand related reduce sale customer sale wholesale partner decrease year year quarter however intersegment sale increase year company increase focus proprietary product margingross profit deteriorate report quarter consequently gross margin contract basis point bps selling general administrative expense rise accordingly adjust operate margin deteriorate bps financial positiongnc holding exit third quarter cash cash equivalent end second quarter long term debt be end quarter compare end second quarter year date net cash flow operate activity be compare year further company generate year date free cash flow compare year quarter new gnc plan updateearlier management have announce plan revamp exist business model dub new gnc company have be see change third quarter well transaction growth be third quarter oct consumer have joined company loyalty program include approximately customer enrolled pro access membership takegnc holding exit third quarter disappointing note revenue earning miss zack consensus estimate be attribute lower sale company canada manufacturing wholesale segment also decline gross adjust operate margin be matter concern positive note third quarter management witness positive response new gnc plan new consumer enrollment mygnc reward program company have also be witness improvement transaction commerce business buoy optimism zack rank key pickscurrently gnc holding have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
485,ABT,boston scientific corporation bsx free report post adjust earning share ep cent third quarter year quarter figure remain line zack consensus estimate fall exactly upper end company adjust ep guidance range cent adjustment company report earning cent share year period revenue detailrevenue third quarter be year year report basis operational basis constant exchange rate cer figure top company guidance also exceed zack consensus estimate boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoteorganic revenue growth third quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically third quarter company achieve operational growth organically europe asia middle east africa region same emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively third quarter second largest contributor boston scientific top line be rhythm management include cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm decline defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin contract basis point bps year year rise cost product sell adjust operate margin improve marginal bps report quarter quarter selling general administrative expense go research development expense increase royalty expense reduce quarter balance sheetboston scientific exit third quarter cash cash equivalent end sequential last quarter end third quarter company have total long term debt marginal decline end second quarter guidanceboston scientific have provide update full year guidance banking solid third quarter show gradually improve foreign exchange scenario company raise revenue guidance range annualize growth report basis growth operational basis include contribution approximately bps endochoice symetis earlier band annualize growth report basis growth operational basis current zack consensus estimate revenue be guide range adjust ep guidance range have be slightly narrow earlier range zack consensus estimate be guide range company also provide fourth quarter financial guidance adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be takedespite back back natural disaster boston scientific manage register solid third quarter performance earning line zack consensus estimate revenue ahead mark gradually improve foreign exchange scenario have also start contribute company overall topline performance raise guidance be more impressive indicative overall bullish trend continue rest boston scientific be leave stone unturned strengthen core business invest new technology global market account higher sale geography third quarter be also encourage company gain number approval product domestic overseas market recent development worth mention be company recent acquisition apama medical developer single shot apama radiofrequency rf balloon catheter system treatment atrial fibrillation apart company receive fda approval formri labele announce launch resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system combine heartlogic heart failure diagnostic enduralife battery technology smartcrt technology apart company receive ce mark update direction use watchman laac device europe company acurate neo transapical aortic valve system have also gain ce mark company expect begin controlled launch europe fourth quarter zack rank other key pickscurrently boston scientific carry zack rank buy other top rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
486,ABT,mckesson corporation mck free report report second quarter fiscal end sep earning share beating zack consensus estimate earning also surpass year figure mckesson post sale beating zack consensus estimate be last year quarter detailmckesson operate segment distribution solution technology solution growth rate give be year year basis distribution solution revenue be quarter report constant currency basis however revenue technology solution business decline year quarter be due bifurcation technology solution business change healthcare joint venture mar segment reflect only number enterprise information solution business mckesson corporation price consensus ep surprise mckesson corporation price consensus ep surprise mckesson corporation quotefinancial conditiona sep mckesson have cash cash equivalent mar report quarter end sep company generate cash worth operation first half year mckesson repay long term debt paid acquisition repurchase common stock invest internally paid dividend fiscal outlookmckesson expect gaap earning diluted share range fiscal year end mar adjust earning same be expect range zack rankmckesson currently carry zack rank hold company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
487,ABT,thermo fisher scientific inc tmo free report report better expect performance third quarter adjust ep come beating zack consensus estimate year quarter figure report basis second quarter ep marked year year rise revenue quarter come year year sale also exceed zack consensus estimate thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quote quarter detailorganic revenue third quarter grow year year acquisition increase revenue currency translation positively impact total revenue thermo fisher currently operate business segment life science solution analytical instrument specialty diagnostic laboratory product service revenue life science solution segment total revenue improve year year analytical instrument segment sale rise reflect acquisition fei company revenue laboratory product service segment rally specialty diagnostic segment record increase gross margin third quarter be basis point bps year year rise gross profit adjust operate margin expand approximately bps rise selling general administrative expense increase research development expense company exit third quarter cash cash equivalent compare end previous quarter year date net cash provide operate activity be compare year period guidance raisedbacked solid third quarter performance favorable foreign exchange environment forecast also consider recently close acquisition patheon thermo fisher have raise full year financial guidance revenue guidance have be raise range growth previous year earlier band growth current zack consensus estimate fall guide range company have also raise adjust ep guidance range reflect growth previous year earlier prediction be range growth zack consensus estimate share remain guide band bottom linethermo fisher end third quarter promising note adjust earning revenue beating zack consensus estimate be encourage company series product launch major progress precision medicine initiative thermo fisher acquisition fei company have already start boost analytical instrument portfolio quarter company launch new electron microscopy system structural biology material science research also have release new iq series air quality monitoring platform enabled first fda approve gene therapy apart company have open precision medicine customer experience center guangzhou china be currently look forward recently complete acquisition patheon be go significantly enhance company value proposition biopharma customer add lead contract development manufacturing outsource service raise guidance be more impressive indicative overall bullish trend continue zack rank other key pickscurrently thermo fisher have zack rank buy few other stock worth consider broader medical sector be petm express inc pet free report abbott lab free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank well see complete list today zack rank stock here petm report ep cent second quarter fiscal cent report year quarter also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
488,ABT,laboratory corporation america holding lh free report labcorp report third quarter adjust earning share ep year quarter quarter adjust ep also exceed zack consensus estimate simultaneous hurricane report quarter adversely affected adjust ep cent approximately report basis labcorp net earning come share increase year year net revenue third quarter increase year year increase net revenue be due growth acquisition organic growth net revenue growth less revenue acquisition first month close acquisition benefit foreign currency translation approximately basis point however be partially offset adverse impact multiple hurricane quarter laboratory corporation america holding price consensus ep surprise laboratory corporation america holding price consensus ep surprise laboratory corporation america holding quote quarter reviewcurrently labcorp report operate segment labcorp diagnostic covance drug development report quarter labcorp diagnostic report net revenue year year fuel price mix tuck acquisition organic volume measure requisition exclude requisition acquisition first month close acquisition benefit foreign currency translation approximately basis point company report increase total volume measure requisition increase revenue requisition quarter several quarters drag sale covance drug development report rise net revenue third quarter be primarily back acquisition chiltern organic growth benefit foreign currency translation approximately basis point gross margin expand bps quarter adjust operate income increase year year adjust operate margin contract bps year quarter rise selling general administrative expense labcorp exit quarter cash cash equivalent compare end second quarter year date operate cash flow be year period free cash flow come year period quarter company return shareholder share repurchase currently have authorization remain exist share repurchase plan outlookbased strong third quarter show consider gradually improve foreign exchange scenario company increase earlier provide outlook net revenue growth be now expect remain band year year ahead earlier range include bps impact unfavorable foreign exchange headwind current zack consensus estimate revenue be peg adjust ep guidance have be narrow range previous range current zack consensus estimate fall guide range free cash flow expectation have be raise new band previous range prior year takelabcorp third quarter earning top zack consensus estimate strong year year increase earning revenue be encourage too labcorp diagnostic business be strong improve price mix acquisition favorable foreign exchange scenario also several quarters dull performance covance drug development report strong growth be primarily back acquisition chiltern strong organic growth favorable foreign currency translation increase guidance boost investor confidence indicate chance bullish trend be maintain fourth quarter too believe integration newer acquisition labcorp be perfectly position drive long term profitable growth combination world class diagnostic drug development expertise knowledge service zack rank other key pickscurrently labcorp have zack rank buy few other top rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank see complete list today zack rank stock here petm report ep cent second quarter fiscal cent report year quarter also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
489,ABT,baxter international inc bax free report report third quarter adjust earning share cent beat zack consensus estimate cent improve year figure cent baxter currently have zack rank buy figure be also company guide range cent cent interestingly last quarters company deliver positive earning surprise average be baxter post sale beating zack consensus estimate constant currency cc revenue increase year year basis sale be year year international sale increase cc almost baxter international inc price consensus ep surprise baxter international inc price consensus ep surprise baxter international inc quote segmental detailssale hospital product segment climb cc year year basis hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also drive solid demand injectable pharmaceutical hospital pharmacy compound service meanwhile sale increase cc renal product segment renal product sale be support improve performance major product line therapy globally quarterly acquire claris third quarter baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost december baxter have initiate agreement management acquisition bolster baxter foothold generic pharmaceutical space new patient enrolled third quarter baxter register patient new clinical trial unique expand hemodialysis therapy enabled theranova dialyzer treatment chronic acute renal failure fact baxter be expect launch hemodialysis enabled theranova australia new france germany switzerland belgium end year hurricane deal blow management baxter announce possibility shortfall supply certain product next quarter be company be still grapple limit production manufacturing site puerto rico hurricane marium however company have be grant regulatory approval fda special importation product facility ireland australia canada mexico maintain product supply balance market international foothold fortify baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa quarter notably oxiris leverage company flagship prismaflex system be expect lend baxter competitive edge global market guidance full year baxter estimate sale growth approximately cc adjust earning full year be expect band diluted share previous band baxter expect fourth quarter revenue face negative impact approximately thank operational disruption result hurricane marium adjust earning fourth quarter be expect band cent cent diluted share net sale fourth quarter be expect rise cc other company solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank petm express inc pet free report adjust announce earning share cent second quarter fiscal year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
490,ABT,nuvasive inc nuva free report report third quarter adjust earning share ep cent reflect rise year quarter figure also surpass zack consensus estimate cent solid revenue growth primarily lead year year bottom line improvement include time item company report third quarter net income share cent significant improvement year figure cent share revenue report quarter increase year year constant exchange rate cer figure however miss zack consensus estimate upside revenue be drive robust performance international market strong growth geographical region unite state procedural volume be sluggish unable meet company expectation nuvasive inc price consensus ep surprise nuvasive inc price consensus ep surprise nuvasive inc quote however putt together impact hurricane harvey irma nuvasive result marium company international result less selling day revenue growth have be approximately year year report quarter company spinal hardware business register more growth backed introduction new product adjust impact hurricane offset effect less selling day spinal hardware business approximately grow year year surgical support business decline third quarter primarily continue softness biologic business new competitive product enter market company face challenge field also procedural issue be affect revenue volume however international business record growth cer continue strong demand company spine technology outside unite state particularly key market italy germany japan quarter review be increase cost good sell gross profit inched yet company report basis point bps year year contraction gross margin third quarter include bps year year impact low margin business sale marketing administrative expense go research development expense increase nuvasive post adjust operate income report quarter reflect rise year number adjust operate margin expand bps quarter review company exit third quarter cash cash equivalent short term investment end previously report quarter outlookin view continue impact marium puerto rico fourth quarter well anticipate lower procedural volume nuvasive have update full year guidance currently company expect report revenue growth lower earlier expect rate cer approximately earlier be figure also remain lower current zack consensus estimate nuvasive also lower guidance full year adjust earning share compare previous expectation share current zack consensus estimate remain significantly company guidance additionally adjust operate margin year be currently expect compare former projection exit third quarter better expect earning revenue number quarter company performance be significantly dependent stellar international growth company note report quarter marked fourth consecutive register more growth international business however overall sale quarter be grossly impact procedural volume related challenge unite state adverse impact harvey irma nuvasive result marium international front chance fourth quarter revenue be affected marium puerto rico due anticipate lower procedural volume continue same period nuvasive be pressed reduce full year guidance be disappointing zack rank key pickscurrently nuvasive have zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal cent report year quarter also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
491,ABT,baxter international inc bax free report have complete acquisition hemostat sealant product mallinckrodt plc widen exist surgical portfolio hemostat sealant especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter expect deal be modestly accretive adjust earning thereafter transaction deal increasingly add capability baxter portfolio drive bottom line turn deal be buy preveleak upfront payment approximately potential contingent payment future deal be announce earlier january baxter now gain major traction only stand alone recombinant thrombin buyout provide more option innovative hemostatic product surgeon deal severity bleed preveleak used vascular reconstruction complement company exist portfolio advanced surgical sealant baxter surgical portfoliobaxter surgical portfolio include product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other portfolio be compose hemostasis address bleed tissue sealing hard tissue regeneration well soft tissue repair microsurgery product available nearly country company consistently endeavor improve advanced surgery business company expect advanced surgery business increase constant currency basis baxter have also announce plan focus launch advanced surgery product japan come day market potentialper cision report global surgical medical device market be anticipate witness cagr forecast period reach worth consider bullish market sentiment think latest development be timely lead player niche space be abbott free report stock performance estimate revisionshare baxter have outperformed industry past year stock have rally outperform gain broader industry rise company estimate revision trend current year have be positive past couple month analyst moved north revision opposite direction earning estimate rise zack rank other key picksbaxter carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
492,ABT,transcatheter aortic valve replacement tavr market be project witness cagr report analytic publish reportsnreport have be constantly radar market expert courtesy stir cause forerunner space boston scientific corporation bsx free report last february company voluntarily recall core lotus valve device include lotus depth guard drag share pre market trading session article medical device diagnostic industry sadly again november boston scientific announce further delay re launch lotus edge aortic valve system fail meet commit timeline hurt shareholder sentiment even more article medical device diagnostic industry company have opted piper jaffray healthcare conference new york same day pull stock be follow decline market cap meanwhile rejoice situation be edward lifescience corporation ew free report lead player tavr market encouragingly company share have soar lotus valve device recall last february let take sneak peek brewing market investor be keen effectively put money healthcare space backdropboston scientific have be consistently dominate headline development lotus valve device unpleasant reason last february company have call back lotus valve device due issue related premature release pin connect lotus valve delivery system however be not first time company have face such situation earlier company have retract lotus edge valve system similar ground even have face brunt fda order withdraw unit lotus valve circulation europe due lotus valve get unlock delivery system release company have also be disappointing investor continuously delay filing premarket approval pma fda lotus edge valve system currently company expect lotus edge be back european market not also intend roll same unite state same year nevertheless major market analyst believe such numerous product misstep have always end tarnishing brand image deviate customer clinician interest edward lifescience seize boston scientific hit rough patch issue surround lotus valve device edward lifescience reap maximum benefit solid transcatheter heart valve therapy thvt platform company annual investor conference chairman ceo michael mussallem note come end performance accomplishment year significantly exceed expectation expect be strong year edward lifescience primary factor drive company global growth be prosper transcatheter aortic valve therapy business further assert regard management currently project sale transcatheter heart valve therapy moreover edward lifescience expect global tavr opportunity be more make most company have be fire cylinder lately line edward lifescience have term product pipeline track expect new sapien ultra system feature balloon delivery system next generation sheath technology be launch unite state europe later year also company anticipate begin pivotal trial ce marked centera valve system furthermore edward lifescience expect result partner trial sapien valve be present acc follow fda approval later year note market speculator believe edward lifescience solid global presence particularly high potential region europe japan delay comeback key competitive product boston scientific lotus valve help company further cement hold highly potential tavr space other major player ride gain medtronic plc mdt free report corevalve evolut tavr platform comprise corevalve corevalve evolut corevalve evolut pro system have well maintain company position formidable player tavr space article reuter share medtronic have inched boston scientific announcement withdrawal lotus valve device last february notably company record tavr growth mid unite state low international market last report quarter furthermore post acquisition st jude medical abbott laboratory free report integrate popular ce marked portico tavr former structural heart portfolio be expect gain momentum space boston scientific rebound card winston have rightly say man make mistake only wise man learn mistake unwilling let go bountiful opportunity tavr market boston scientific acquire symetis sa structural heart company focuse minimally invasive tavr device company have start selling acurate neo aortic valve europe be also work design acurate neo aortic valve system equip enhance outer sealing skirtfeature moreover boston scientific be look forward leverage exist lotus infrastructure enhance acurate neo valve system better field support geographic expansion next generation product company plan invest unite state japan trial well acurate replace lotus however several opinion have be make round tavr space late market expert believe company eventually replace lotus valve device symetis portfolio other speculate deal have be clinch cushion jitter stem lotus valve device withdrawal few analyst be also opinion boston scientific expend huge amount symetis buyout deal use contingency plan case lotus valve device issue remain unresolved nonetheless dismiss such speculation boston scientific have be consistently emphasize symetis acquisition move broaden tavr suite not replacement lotus valve device end speculation let watch find not boston scientific lotus valve find right weather bloom again zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
493,ABT,ministry health labour welfare mhlw japan grant national reimbursement abbott free report mitraclip therapy move be likely improve company structural heart business mitraclip be fda approve ce marked system also nearly country more person have be treat mitraclip mhlw approve mitraclip system japan november be mitraclip mitraclip therapy be used treat patient mitral regurgitation reimbursement be effective april japan reimbursement entitle patient access therapy country health insurance plan company mitral regurgitation be serious progressive heart disease mitral valve do not close properly allow blood flow backward heart mitraclip system be approve japan treatment severe degenerative mitral regurgitation dmr functional mitral regurgitation fmr heart disease glimpse structural heart businessabbott medical device segment presently comprise new cardiovascular neuromodulation heart failure structural heart rhythm management vascular business diabetes care business sale improvement segment be drive double digit growth heart failure structural heart neuromodulation diabetes care last quarter notably structural heart business account total revenue medical device segment upside be lead continue double digit growth mitraclip believe latest development boost company top line recently company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart business market prospectsper report ally market research tanscatheter mitral valve repair replacement market be estimate worth repair replacement valf cagr noteworthy company space be edward lifescience corporation ew free report share price estimate revision trendabbott have be gain investor confidence consistent positive result last month stock have outperformed industry stock have moved comparison broader industry gain current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank key picksabbott carry zack rank hold couple better rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
494,ABT,pass new tax bill corporate tax rate have come be likely boost profit margin moreover cash repatriation window allow bill help company bring cash stash foreign location time tax rate leave company extra spending power most big pharma company discuss plan use extra cash save new tax bill fourth quarter conference call extra cash mostly be invest capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback however majority company do not mention effort regard lower prescription drug cost last week senator tina letter big pharma company expressed concern big pharma company plan used billion dollar save tax cut offer tax bill pass december be concern fact company be favore investor instead used saving bring prescription drug cost major life save drug be protected patent be steeply price thus make drug affordable help consumer lower medical cost senator have send letter ceo pfizer inc pfe free report merck co inc mrk free report johnson johnson jnj free report abbvie inc abbv free report abbott laboratory free report provide detail intend utilize major saving tax overhaul price major prescription drug have sky-rocket past year pinch hard citizen medical bill have soar moreover government also have pay higher cost drug be cover medicare concern senator be thus justified move restrict use tax saving boost shareholder be welcome move consumer moreover large player other industry have similar plan have undercut president donald trump plan create job boost wage senator be also work make cheaper generic drug available market faster introduce new legislation report kdal large cap pharmaceutical industry yr return large cap pharmaceutical industry yr returndon even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
495,ABT,anthem inc antm free report third quarter adjust net income share surpass zack consensus estimate bottom line also jump year year operate revenue miss zack consensus estimate top line however grow year year due premium rate increase well higher enrollment medicaid medicare local group insure self funded business operational updatemedical enrollment increase year year member rise be primarily record commercial specialty business well fully insure self funded local group business medicare medicaid enrollment also contribute appreciation upside be partially offset decline membership national account individual business total expense increase nearly report quarter mainly due rise benefitexpense increase selling expense year year basis anthem benefit expense ratio deteriorate basis point bps prior year quarter be largely due year waiver health insurance tax however impact retroactive revenue adjustment medicaid business improve medical cost performance individual large group business be offset selling general administrative sg expense ratio increase bps year quarter be due year waiver health insurance tax impact fix cost leverage operate revenue growth however rise be partially offset increase spend support growth initiative quarter segment specialty businessoperate revenue be third quarter year year operate gain totale year year due increase spend support growth initiative quarter impact year waiver health insurance tax decrease be partially offset improve medical cost performance local group individual business operate margin be bps year year government businessoperate revenue be third quarter prior year quarter operate gain be year year downside reflect increase spend support growth initiative quarter impact year waiver health insurance tax however deterioration be partially offset timing impact retroactive revenue adjustment medicaid business operate margin be decline bps year year other operate revenue be third quarter prior year quarter segment report operate loss narrower operate loss prior year quarter improvement be primarily drive lower expense related terminate cigna acquisition operate margin be bps year year anthem inc price consensus ep surprise anthem inc price consensus ep surprise anthem inc quotefinancial updatea sep anthem have cash cash equivalent year end sep long term debt decline year end sep shareholder equity be year end operate cash flow be first month reflect year year growth share repurchase dividend updatedure quarter anthem repurchase share common stock first month repurchase share common stock sep have approximately share repurchase authorization remain third quarter anthem paid quarterly dividend cent share represent distribution cash totale oct audit committee declare third quarter dividend cent share payable dec shareholder record close business dec guidance anthem expect adjust net income range share previous quarter company expect same be more company have lower guidance medical enrollment medical membership be now expect range compare previous expectation fully insure membership self funded membership be likely be band previously guide range respectively operate revenue be project range unchanged previous guidance benefit expense ratio be expect be earlier projection adjustment bps sg ratio be expect be compare earlier projection adjustment expect operate cash flow be more compare previous projection more zack rank performance other presently carry zack rank hold see complete list today zack rank strong buy stock here other player medical sector have report third quarter earning so far abbott laboratory free report johnson johnson jnj free report unitedhealth group incorporate unh free report beat respective zack consensus estimate zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
496,ABT,centene inc cnc free report report third quarter adjust net income share beat zack consensus estimate earning also improve year year primarily back higher revenue operational quarter total revenue grow year year primarily drive growth health insurance marketplace business expansion new program many state be partially offset moratorium health insurer fee lower membership commercial business california revenue surpass zack consensus estimate end quarter manage care membership reflect increase third quarter health benefit ratio hbr quarter be compare prior year quarter improvement basis point bps be result new expand health plan higher hbr increase higher acuity member premium rate reduction california medicaid expansion effective jul third quarter adjust selling general administrative expense ratio be bps year year improvement reflect leverage expense higher revenue total operate expense increase prior year quarter centene corporation price consensus ep surprise centene corporation price consensus ep surprise centene corporation quotefinancial updatea sep centene have cash cash equivalent year end total asset grow year end sep centene long term debt totale year end first month cash inflow operation be compare prior year period guidancecentene expect adjust earning diluted share be range previously guide range total revenue be expect be range compare earlier guidance hbr be expect range unchanged previous guidance adjust selling general administrative expense ratio be expect range unchanged previous guidance diluted share outstanding be expect be zack rank performance other peerscentene currently sport zack rank strong buy see complete list today zack rank stock here other player medical sector have report third quarter earning so far abbott laboratory free report johnson johnson jnj free report unitedhealth group incorporate unh free report beat respective zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
497,ABT,varian medical system inc var free report be schedule report fourth quarter fiscal earning oct market close last quarter company deliver earning share beat zack consensus estimate cent however adjust earning decline year period factor playwe be upbeat varian medical oncology business account company total revenue fourth quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space fourth quarter varian expect adjust earning share range revenue be expect increase year year basis company recently launch fda approve product halcyon strengthen foothold oncology business varian medical also sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient regard note varian medical recently receive shonin approval japan market probeam system proton therapy varian medical recently enter international agreement concern proton therapy platform bangkok base king chulalongkorn memorial hospital have select probeam compact single room proton therapy system cancer treatment thailand delray medical center florida believe western europe china africa present significant top line growth opportunity term company be open office africa middle east depict be aware opportunity region moreover varian medical strong product pipeline be key catalyst nevertheless increase local competition be primary headwind unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase investment target growth acceleration geographical expansion portfolio expansion earning whispersour proven model do not conclusively show earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quotestock considerhere be company consider model show have right combination element post earning beat upcoming quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
498,ABT,abbott lab free report report third quarter adjust earning continue operation cent share ahead zack consensus estimate penny year year adjust quarterly number also remain upper end company guidance range cent cent report earning quarter come cent share compare year loss cent share third quarter worldwide sale come year year report basis quarterly figure also remain slightly ahead zack consensus estimate abbott laboratory price consensus ep surprise abbott laboratory price consensus ep surprise chart abbott laboratory quoteon comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter quarter detailabbott operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis be positive impact back currency fluctuation sale key emerge market increase drive double digit growth brazil russia india china expect sale india be positively impact purchasing pattern follow implementation new good service tax system lower second quarter sale country medical device business sale spiked report basis comparable operational basis sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis double digit growth structural heart heart failure neuromodulation vascular product sale growth however be sluggish comparable operational basis rhythm management company register loss comparable operational basis sale be impact continue competitive dynamic magnetic resonance mr conditional category product diabetes care sale improve comparable operational basis drive double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis same comparable operational basis foreign exchange favorably affected sale marginal pediatric nutrition sale increase comparable operational basis adult nutrition sale be comparable operational basis diagnostic sale rise year year report basis comparable operational basis core laboratory point care diagnostic sale grow comparable operational basis molecular diagnostic sale be strong growth infectious disease testing business be partially offset plan scale genetic business guidanceabbott have narrow full year guidance adjust certain net specify item full year adjust earning share continue operation be now expect stay band earlier guidance be current zack consensus estimate be peg midpoint project range company have also provide fourth quarter adjust earning share guidance expect report adjust earning continue operation range cent cent quarter current zack consensus estimate cent fall midpoint project range takeone more time abbott have successfully exceed zack consensus estimate earning sale front be optimistic company strong consistent epd medical device performance however strong performance be extent offset sluggish nutrition business company continue benefit recently complete acquisition st jude medical have start offer industry lead pipeline cardiovascular neuromodulation diabetes vision care company be effectively execute exist operate model focus selling portfolio core therapeutic area also emerge market performance remain extremely promising several new strategic development abbott currently carry zack rank buy stock considera few other top rank stock medical sector be integra lifescience holding corp iart free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report integra lifescience sport zack rank strong buy idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here integra lifescience have long term expect earning growth rate stock rally roughly last month idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
499,ABT,illumina inc ilmn free report be slate report third quarter fiscal result market close oct last quarter company deliver positive earning surprise average earning beat trail quarters let see thing be shape announcement key prior quarter illumina be expect gain strong performance product revenue well service other revenue segment last few quarters company product revenue increase primarily onrising sequence consumable revenue total service other revenue be demonstrate strong growth lead continue demand nextseq nipt customer partner expect factor drive yet be report quarter performance well zack consensus estimate product revenue reflect increase year quarter also zack consensus estimate service other revenue indicate rise year quarter overall third quarter total revenue be project prior year quarter illumina inc price ep surprise illumina inc price ep surprise illumina inc quote here be other factor influence illumina third quarter result illumina earlier announce fda approve next generation sequence ngs extend ra panel have meet current colorectal cancer guideline new kit fulfill most date guidance ra testing determine eligibility epidermal growth factor receptor egfr inhibitor metastatic colorectal cancer management expect shipment kit start third quarter hence expect drive top line second quarter illumina witness growth asia pacific region propel rise china emerge market china currently offer most favorable space illumina business growth recent time management have noticed considerable rise demand customer look set nipt operation china china currently be fourth largest develop nation term nominal gdp believe progress country open channel illumina thereby drive top line yet be report quarter also encourage solid second quarter performance illumina have raise full year revenue growth expectation earlier provide range flip side tough competitive landscape challenge company be also apprehensive issue pertain nih funding illumina have be face quite time now here be quantitative model predict illumina do not have right combination main ingredient positive earning esp zack rank hold better increase odd earning beat zack esp earning esp illumina be uncover best stock buy sell re report earning esp filter zack rank illumina carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
500,ABT,abbott free report have be limelight receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm notably abbott breakthrough pediatric mechanical heart valve help treat newborn infant congenital heart defect chd need valve replacement procedure moreover approval company have expand master series portfolio structural heart business interestingly master series line now offer valf diameter size vary mm furthermore approval be majorly attribute positive result clinical trial patient damage diseased malfunctioning heart valve age year apart widening portfolio approval allow abbott timely cater unmet need niche market glimpse structural heart businessabbott medical device segment presently comprise new cardiovascular neuromodulation heart failure structural heart rhythm management vascular business diabetes care business sale growth segment be drive double digit growth heart failure structural heart neuromodulation diabetes care last report quarter notably structural heart business account total revenue medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mitral regurgitation last november company announce receipt japan ministry health labour welfare mhlw approval same believe latest development help company boost top line contribution business market prospectsper report research market publish cardiovascular business global pediatric interventional cardiology market be expect see cagr company child be born chd unite state year thus addition master hp mm help abbott cash abundant opportunity pediatric interventional cardiology market share price movementover past month abbott have be outperform industry stock have gain compare industry zack rank key picksabbott carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report petm express pet free report perkinelmer pki free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate petm have long term expect earning growth rate zack rank perkinelmer have long term expect earning growth rate stock carry zack rank buy breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
501,ABT,abbott free report have recently enter agreement diagnostic technology player surmodic inc srdx free report term deal former have exclusive worldwide right surmodic surveil drug coat balloon deal remain align abbott focus expand broad line vascular care product notably surveil drug coat balloon surmodic be used treat superficial femoral artery be evaluation pivotal clinical trial significantly new generation device be likely complement extend company vascular device portfolio include stent vessel closure device address peripheral artery disease pad american heart association pad be narrowing artery cause reduce blood flow leg stomach arm head accord abbott condition be often underdiagnosed lead other serious vascular condition regard drug coat balloon have emerge important treatment option treatment pad globally person be affected pad american alone age year be suffering disease undoubtedly market therapy related indication look lucrative abbott surveil drug coat balloon hold greater promise capture market compare traditional device be include proprietary drug excipient formulation durable balloon coating be manufacture used innovative process improve coating uniformity pre clinical datum surveil have show time higher target tissue drug concentration more evenly distribute durable drug effect lower incidence downstream drug particle comparison control drug coat balloon accordingly surmodic deal seem highly strategic abbott point view monopolize huge grow market pad regulate drug coat balloon apart surveil related pact abbott have choice negotiate agreement surmodic knee arteriovenous fistula drug coat balloon product currently pre clinical development datum reportsnreport global market peripheral vascular intervention include lower extremity stent percutaneous transluminal angioplasty pta balloon pta drug eluting balloon carotid stent renal stent be estimate rise cagr major player drug coat balloon market be medtronic inc mdt free report becton dickinson company bdx free report hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
502,ABT,have be month last earning report abbott laboratory free report share have lose time frame underperform market recent negative trend continue lead next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningsabbott report fourth quarter adjust earning continue operation cent share beating zack consensus estimate penny earning improve year year meet high end company guide range cent cent however report loss quarter come cent share year earning cent notably include anticipate net expense impact tax reform full year adjust earning come share line zack consensus estimate however figure beat year number fourth quarter worldwide sale come year year report basis figure also beat zack consensus estimate comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter worldwide sale full year come year year report basis figure also surpass zack consensus estimate quarter detailabbott operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis include positive impact currency fluctuation sale key emerge market increase drive double digit growth latin america india china medical device business sale rise report basis comparable operational basis sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis double digit growth structural heart heart failure neuromodulation vascular product sale however decline comparable operational basis rhythm management company see sale drop comparable operational basis however company receive fda approval magnetic resonance mr conditional labele quadra assura quadra assura mp cardiac therapy defibrillator crt device fortify assura implantable cardioverter defibrillator icd quarter review diabetes care sale improve comparable operational basis buoy double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis comparable operational basis foreign exchange drive sale pediatric nutrition sale increase comparable operational basis adult nutrition sale be comparable operational basis diagnostic sale rise year year report basis comparable operational basis core laboratory point care diagnostic sale grow respectively comparable operational basis molecular diagnostic sale be nominal strong growth infectious disease testing business be partially offset plan scale genetic business rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing guidanceabbott issue full year guidance adjust certain net specify item full year adjust earning share continue operation be expect band current zack consensus estimate be peg low end project range company also provide first quarter adjust earning share guidance expect report adjust earning continue operation range cent cent quarter current zack consensus estimate cent be project range have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter abbott laboratory price consensus abbott laboratory price consensus abbott laboratory quotevgm scoresat time have strong growth score be lag bit momentum front stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable growth investor also be suitable look momentum lesser degree value outlookestimate have be trend upward stock magnitude revision also look promising interestingly have zack rank hold expect line return stock next few month
503,ABT,agio pharmaceutical inc agio free report announce fda accept company new drug application nda isocitrate dehydrogenase idh mutant inhibitor ivosidenib ag company be seek get ivosidenib approve treatment patient relapse refractory acute myeloid leukemia aml idh mutation fda grant priority review candidate set action date aug year date agio share price improve compare industry gain priority review designation fda be generally grant drug have potential provide significant improvement safety effectiveness treatment prevention diagnosis serious disease ivosidenib be be evaluate phase expansion cohort treatment patient idh aml datum study demonstrated durable response patient give indication enabled company submit nda fda ivosidenib december addition nda premarket approval application be also submit fda abbott laboratory free report fda review idh assay abbott realtime system assay automatically prepare sample analyze batch nucleic acid amplification detection idh mutation occur aml patient abbott assay serve companion diagnostic ivosidenib ivosidenib be also be evaluate phase study treatment advanced hematologic malignancy phase ii combination celgene celg free report vidaza treatment newly diagnosed aml patient be not eligible intensive chemotherapy potential approval candidate boost sale company agio pharmaceutical inc price agio pharmaceutical inc price agio pharmaceutical inc quote zack rank stock consideragio be zack rank hold stock better rank stock health care space be xoma corp xoma free report carry zack rank buy see complete list today zack rank strong buy stock here xoma loss share estimate have narrow cent cent last day company pull positive earning surprise last quarters average beat share price company sky-rocket year wall street next amazon zack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
504,ABT,feb issue update research report cardiovascular system inc csii free report stock carry zack rank hold medical device manufacturer developer marketer innovative solution treat patient peripheral coronary arterial disease include arterial calcium see solid second quarter fiscal company witness year year rise revenue coronary arterial disease cad coronary arterial disease pad business also expansion gross margin be impressive cardiovascular system have be expand product portfolio enhance market reach currently cardiovascular system be pursue product improvement evaluate new technology strengthen broaden portfolio powerful micro invasive tool earlier company have receive fda approval diamondback coronary oas micro crown system facilitate stent delivery patient cad company also win approval japan ministry health labor welfare mhlw diamondback coronary oas micro crown launch commercially february also company receive fda approval radial access diamondback peripheral orbital atherectomy device treat pad be upbeat cardiovascular system new partnership have broaden portfolio company be now distributor orbusneich balloon product orbusneich pci balloon include sapphire ii pro be schedule get fda approval year mm coronary balloon moreover company have sign original equipment manufacturer oem agreement integer holding corporation csi brand zilient guidewire be also optimistic favorable trend pad well cad space american heart association many american suffer pad moreover age population couple rise incidence diabetes obesity be likely increase occurrence pad offer huge scope unique pad orbital atherectomy system oas cardiovascular system past month cardiovascular system have be underperform industry stock have decline industry rise furthermore company face cutthroat competition niche space oas product compete variety other product device treatment vascular disease include stent balloon angioplasty catheter atherectomy catheter well product used vascular surgery larger competitor stent balloon angioplasty market segment include bigwig abbott laboratory free report moreover profitability front cardiovascular system have long history net loss inception immediate recovery sight key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
505,ABT,abbott free report announce availability freestyle librelink app europe use smartphone iphone android notably diabetes patient used freestylelibre system europe longer need carry freestyle libre get glucose result diabetes patient now be able check glucose result directly smartphone company freestyle librelink app allow user hold smartphone freestyle libre sensor capture view real time glucose level also show hour glucose history glucose level be change freestyle librelink app customer have access several update new feature compare freestyle libre reader company also say app replace reader also be used combination other freestyle librelink customer have option share information physician libreview librelinkup be other digital health tool be part freestyle libre platform freestyle librelink app be free cost iphone android user initially be available european country also abbott be plan mobile app solution freestyle libre user outside europe base country regulatory approval development freestyle librefreestyle libre system be flagship sensor base continuous glucose monitoring cgm system company have be witness solid growth global diabetes care business notably diabetes care sale rise comparable operational basis last report fourth quarter buoy double digit international sale growth lead continue consumer uptake freestyle libre accordingly be leave stone unturned cash grow popularity system eliminate need daily finger stick follow fda approval september freestyle libre flash glucose monitoring system abbott recently achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage meanwhile abbott have be steadily progress development diabetes care segment last september company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company announce receipt health canada license freestyle libre flash glucose monitoring system june drive diabetes care segment see revenue growth third quarter continue acceptance freestyle libre internationally market potentialaccord report mordor intelligence global market diabetes care device be expect reach value cagr consider huge potential market believe latest development help abbott gain traction space share price estimate revision trendabbott have be gain investor confidence consistently positive result last month stock have outperformed broader industry have gain comparison broader industry current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank key picksabbott carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
506,ABT,centene inc cnc free report report fourth quarter adjust net income share cent beat zack consensus estimate earning however decline year year higher expense fourth quarter total revenue grow year quarter primarily drive growth health insurance marketplace business expansion new program many state revenue surpass zack consensus estimate full year company report adjust earning year year figure also surpass zack consensus estimate centene report total revenue year year rise be primarily drive health net result year impact growth health insurance marketplace business expansion new program many state end year manage care membership totale quarterly operational updatehealth benefit ratio hbr fourth quarter be compare prior year quarter reflect year year improvement basis point bps quarter adjust selling general administrative sg ratio be bps year year deteriorationis result increase business expansion cost prior year quarter notably revenue recognize fourth quarter relate minimum mlr amendment california have reduce quarter adjust sg expense ratio hence expense ratio fourth quarter appear higher compare year quarter total operate expense end fourth quarter increase nearly prior year quarter centene corporation price consensus ep surprise centene corporation price consensus ep surprise centene corporation quotefinancial updatea dec centene have cash cash equivalent end total asset grow dec centene long term debt totale cash inflow operation be compare end guidancecentene expect adjust earning share be range previously guide range total revenue be expect be range earlier guidance hbr be expect range compare previous guidance adjust sg expense ratio be expect range previous guidance share outstanding be expect be previous guidance zack rank performance other peerscentene sport zack rank strong buy see complete list today zack rank stock here other player medical sector have report fourth quarter earning so far abbvie inc abbv free report unitedhealth group incorporate unh free report abbott laboratory free report have surpass respective zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
507,ABT,anthem inc antm free report fourth quarter adjust net income share surpass zack consensus estimate bottom line however decline year year company adjust net income come share last year operate revenue surpass zack consensus estimate top line also grow year year due premium rate increase well higher enrollment medicaid medicare local group insure self funded business upside be partially offset impact year waiver health insurance tax operate revenue come year year quarterly operational updatemedical enrollment increase year year member rise be primarily drive commercial specialty business enrollment growth government business also contribute appreciation upside be partially offset decline membership national account individual business total expense increase nearly report quarter mainly due rise benefitexpense increase selling general administrative sg expense year year basis anthem benefit expense ratio deteriorate basis point bps prior year quarter be largely due year waiver health insurance tax however deterioration be partially offset improve medical cost performance individual local group business sg expense ratio improve bps year quarter be due year waiver health insurance tax impact fix cost leverage operate revenue growth however decline be partially offset increase spend support growth initiative quarter segment specialty businessoperate revenue be fourth quarter year year operate gain totale year year due increase spend support growth initiative impact year waiver health insurance tax decrease be partially offset improve medical cost performance local group individual business operate margin be bps year year government businessoperate revenue be fourth quarter prior year quarter operate gain be year year downside reflect increase spend support growth initiative quarter impact year waiver health insurance tax however deterioration be partially offset improve medical cost performance medicaid business operate margin be decline bps year year other operate revenue be fourth quarter prior year quarter segment report operate loss narrower operate loss prior year quarter improvement be primarily drive lower expense related terminate cigna acquisition operate margin be bps year year anthem inc price consensus ep surprise anthem inc price consensus ep surprise anthem inc quotefinancial updatea dec anthem have cash cash equivalent year end dec long term debt increase year end dec shareholder equity be year end operate cash outflow be fourth quarter bring full year operate cash flow time net income also reflect year year growth fourth quarter anthem record time cash defer tax benefit corporate tax reform reduce total income tax expense share repurchase dividend updatedure quarter anthem repurchase share common stock repurchase share common stock dec have approximately share repurchase authorization remain fourth quarter anthem paid quarterly dividend cent share jan board declare dividend cent share first quarter reflect hike dividend be paid mar shareholder record mar guidance anthem expect adjust net income be greater share medical membership be now expect range operate revenue be project range benefit expense ratio be expect be adjustment bps sg ratio be expect be adjustment expect operate cash flow be more zack rank performance other sport zack rank strong buy see complete list today zack rank stock here other player medical sector have report fourth quarter earning so far abbvie inc abbv free report unitedhealth group incorporate unh free report abbott laboratory free report have surpass respective zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
508,ABT,hca healthcare inc hca free report report fourth quarter adjust earning share surpass zack consensus estimate bottom line also rise nearly year year company report net income share fourth quarter include cash increase company provision income taxe cent share stem impact tax cut job act reflect year year decline company report net income share year year hca healthcare generate revenue fourth quarter surpass zack consensus estimate report figure be year quarter upside be primarily drive increase same facility equivalent admission increase same facility revenue equivalent admission compare year quarter company report revenue year year quarterly detailsadjust ebitda totale year year same facility equivalent admission inched year year same facility admission jump same facility revenue equivalent admission increase total operate expense increase year year dec hca healthcare run hospital free standing surgery center hca holding inc price consensus ep surprise hca holding inc price consensus ep surprise hca holding inc quotefinancial updatea dec company have cash cash equivalent total long term debt total asset report quarter capital expenditure totale exclude acquisition cash flow provide operate activity totale year year share repurchase company repurchase share common stock fourth quarter company repurchase share common stock company plan increase year capital expenditure program pursue growth opportunity exist market new capital investment program be expect be roughly previous year spend nearly dividend updatehca healthcare have declare quarterly cash dividend cent share company common stock dividend be paid mar stockholder record close business mar initiation quarterly dividend reflect company financial strength company expect revenue range adjust ebidta ep capital expenditure zack rank performance other stockshca healthcare carry zack rank hold see complete list today zack rank strong buy stock here other player medical sector have report fourth quarter earning so far abbvie inc abbv free report unitedhealth group inc unh free report abbott laboratory free report have surpass respective zack consensus estimate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now be reissue article correct mistake original article issue jan longer be rely
509,ABT,oct issue update research report phibro animal health corporation pahc free report nj base company be lead global diversify animal health mineral nutrition company last month phibro have be trading broader industry currently stock have gain compare broader industry animal health be key contributor deliver positive growth last few quarters accord phibro animal health product be excellent prevent control treat disease animal well improve nutrition improve health believe diverse portfolio allow company address distinct grow condition livestock different region world outside unite state phibro have extend reach brazil other country south america china india asia pacific russia africa feel help company counter competition company continue invest far east asia poultry dairy industry be expect grow exponentially currently company be expand dairy business market australia brazil mexico believe turmoil economy russia greece brazil china phibro have perform quite well have potential maintain performance flip side phibro operate highly competitive industry respect major product face threat substantial number global regional player furthermore withdrawal approval mecadox carbadox fda be concern additionally phibro conduct operation globally entail transaction variety currency result currency fluctuation be major issue company zack rank key picksphibro carry zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
510,ABT,intuitive surgical isrg free report third quarter result schedule release oct be expect show steady growth instrument accessory revenue major revenue component majorly drive third quarter earning expect improvement revenue other segment help company generate solid result season be important note intuitive surgical deliver positive earning surprise past quarters average be similar prior quarter strong procedure growth increase sale stapling vessel sealing product be expect be main factor drive surge instrument accessory revenue zack consensus estimate instrument accessory revenue stand third quarter reflect increase year quarter continue development european market solid access company product asia new platform imaging advanced instrument be likely drive revenue segment intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quoteother factor playwe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be catalyst third quarter overall revenue be expect prior year quarter be other factor influence intuitive surgical quarterly result earning season solid procedure trend expectation outperformance mature growth procedure especially general thoracic surgery be likely boost company top line add solid growth prostatectomy procedure volume be likely lend intuitive surgical competitive edge broader prostate surgery market third quarter geographically procedure growth third quarter be expect be lead china germany japan germany procedure growth be likely be support solid install base expansion furthermore procedure trend be expect be solid globally growth lead general surgery global urology segment system service unit hold promise solid growth company product system segment be expect drive company third quarter earning fact zack consensus estimate revenue segment stand year year basis increase reflect higher system placement operate lease revenue however be partially offset lower average selling price lease buyout revenue segment come revenue service segment zack consensus estimate stand year year basis growth system install base buoy higher system placement operate lease revenue expect company total system install base be unit unit last quarter be important note intuitive surgical generate approximately revenue operate lease last quarter compare second quarter here be quantitative model predict intuitive surgical do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp intuitive surgical be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank intuitive surgical carry zack rank increase predictive power esp however also need positive esp be confident earning beat fact zack consensus estimate earning reflect decline year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
511,ABT,resm rmd free report be slate report first quarter fiscal result market close oct last quarter company deliver positive earning surprise average earning beat trail quarters let see thing be shape announcement key prior quarter resm be expect gain strong performance domestic international front company revenue domestic front be drive solid growth device well low double digit software sale growth previous quarter internationally company receipt french reimbursement approval telemonitoring buoy optimism company believe reimbursement grant drive uptake air solution ecosystem include airsense aircurve device platform well airview myair software platform be report quarter zack consensus estimate domestic revenue include contribution reflect increase year quarter also zack consensus estimate international revenue indicate rise year quarter overall fiscal first quarter total revenue be project prior year quarter resm inc price ep surprise resm inc price ep surprise resm inc quotehere be other factor influence resm first quarter result management be particularly upbeat top line contribution launch make last fiscal last report quarter introduce product include airfit airfit airtouch full face mask world smallest continuous positive airway pressure cpap resm airmini resm continue progress steadily back prong growth strategy regard company recently announce tuck acquisition product portfolio conduit technology llc allcall connect moreover last report quarter company progressed new offer outcome assessment information set oasis home health hospice market expect get reflect resm top line first quarter current zack consensus estimate revenue reflect increase year quarter flip side management expect sg expense margin band be report quarter be fourth quarter fiscal also expense margin be project first quarter fiscal compare precede quarter guidance reflect quarter gloomy operate margin scenario meanwhile company generate significant portion revenue international market expose company foreign currency fluctuation notably last report quarter foreign exchange movement hurt earning cent share reflect unfavorable impact weaker euro stronger australian dollar relative dollar be likely dent result first quarter moreover overall macroeconomic uncertainty be major obstacle company international operation also market sleep disordered breathe sdb product be highly competitive respect product price feature reliability other challenge competitive bidding reimbursement pressure continue hurt stock here be quantitative model predict resm do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp resm be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank resm carry zack rank buy increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
512,ABT,integra lifescience holding corporation iart free report develop manufacture market medical device implant biomaterial primarily used treatment burn skin defect spinal cranial disorder orthopedic other surgical application company have rally last month better gain broader industry stock have market cap company year historical growth rate be also favorable compare index solid prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable integra lifescience have positive earning surprise last quarters also have long term expect earning growth rate market be upbeat integra lifescience latest development most recent be launch collagen matrix revize revize plastic reconstructive surgery expand tissue technology portfolio also follow ce mark approval integra lifescience recently announce launch mesh acellular dermal tissue matrix adm surgimend prs mesh pre sub pectoral breast reconstruction europe moreover integra lifescience have finally complete codman neurosurgery business acquisition johnson johnson expand neurosurgery business latest development indicate company have capability sustain momentum other key picksother top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
513,ABT,transenterix inc trxc free report announce receipt fda clearance senhance surgical robotic system senhance be multiport surgical robotic system help perform minimally invasive surgery be first fda approve entrant field abdominal surgical robotic development be go fortify transenterix medical device robotic segment business accord company senhance surgical robotic system help surgeon direct small surgical instrument camera robotic precision also offer security haptic feedback eye sense camera control first time robotic surgery platform minimize procedural cost senhance enable hospital surgeon leverage technology investment operate room ecosystem system make robotic surgery cost effective procedure basis used fully reusable instrument recently transenterix sell senhance robotic surgery system japanese customer be sell saitama medical university international medical center locate saitama prefecture greater tokyo region moreover system get install imperial college london notably senhance be ce marked use general gynecology urology thoracic surgery accord report market market minimally invasive surgical instrument market be forecast reach value cagr consider substantial potential market believe latest development be strategic transenterix share have outperformed industry past month stock have sky-rocket compare industry gain same period current level be better return estimate revision trend estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate current year have narrow loss cent share loss cent zack rank key have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
514,ABT,spin activity have step lately biggy honeywell international hon free report pfizer pfe free report be most active one lately industrial giant honeywell announce plan spin home global distribution unit transportation system unit publicly trade company end read etfs buy year high manufacturing activity other hand pfizer be explore strategic alternative possibly bid good bye consumer healthcare segment sale spin consumer health unit be expect next year pfizer consumer sale have be essentially flat past year clearly explain pfizer intend concentrate more promising innovative pharmaceutical unit separate consumer healthcare move also signify likely introduction more deal make wall street journal however company also keep open chance retain business spin offssometime business form autonomous entity exist business division believe separated line add more value independent company such situation parent focus core business management new entity focus relative different goal profitable spin off be investor accord cantor fitzgerald spinoff complete outperformed first year trading average more percent article publish benzinga spun entity have be perform better parent company lately paypal pypl free report generate higher gain parent ebay ebay free report last year post spin whitewave food co gain last year decline dean food co df free report whitewave food be spun abbot laboratory free report cut ty part business form new company call abbvie abbv free report jan abbv be gain last year oct recent surge spin offa chicago base partner boston consult group recently comment bull market be witness currently equity be overvalue make materialization merger acquisition difficult instead high valuation better justify spin asset divest asset logic hold good be likely see more such action come day read bargain etfs pricey market notably unite state see complete spinoff fall dot com bubble burst number further decline number action again rise slide financial crisis kick datum provide dealogic quote cnbc momentum again gain momentum value have be subdue etfs play be always way play such corporate action highlight spin etfs detail etfs get further boost honeywell pfizer announcement guggenheim spin etf csd free report stock fund look track spin index paypal holding hewlett packard enterprise synchrony financial be top holding fund csd charge bps fee read paypal strong result put etfs focus vaneck vector global spin etf spun free report stock fund follow horizon kinetic global spin index be rule base equal weight index intend track performance list publicly hold spin off be domicile trade develop market western europe asia net expense ratio fund be unite state account fund gannett co time inc timkensteel be top stock fund want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
515,ABT,oct issue update research report abbott free report global healthcare company dedicate improve life development product technology stock carry zack rank hold last month abbott have be trading broader industry stock have gain industry decline market be upbeat several new initiative adopt abbott latest buyout company be alere oct abbott have also announce receipt fda approval freestyle libre flash glucose monitoring system unite state moreover company announce receipt fda approval magnetic resonance mr conditional labele ellipse implantable cardioverter defibrillator icd apart fda approval buyout be upbeat abbott freestyle libre flash glucose monitoring system prospect post receipt full partial reimbursement french health ministry platform company announce health canada license freestyle libre june abbott also announce freestyle libre system be now available reimbursement flip side abbott sluggish pediatric business china continue mar growth management be concern economic problem venezuela be expect remain unresolved time also foreign exchange be major headwind abbott considerable portion revenue come outside unite state key stocksa few better rank stock medical sector be qiagen qgen free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report qiagen idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here qiagen have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
516,ABT,developer robotic technology product mazor robotic ltd mzor free report recently announce expect report third quarter revenue approximately compare year quarter bullishness come strength mazor system sale increase procedure volume stock price performance israel base company have be encourage last month stock have return outperform industry gain roughly stock current return be higher return same time frame bullish price trend estimate revision stock have be quite disappointing full year see estimate move south last month compare movement opposite direction result estimate contract loss cent share loss cent aforementioned period factor mazor strengthdure third quarter company receive purchase order mazor system unite state addition mazor receive purchase order renaissance system chinese market mazor be guidance system simplify spine surgery advanced feature sophisticated integrative ability strong demand mazor system third quarter reach backlog introduction second half company be slate report financial result third quarter end sep november bottom linewe be hopeful encourage global spine surgery market research report market market suggest niche market be estimate reach cagr fact increase utilization rate mazor be quite compelling company believe cycle mazor platform be progress plan grow customer base zack rank other key pickscurrently mazor have zack rank strong buy few other top rank stock broader medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
517,ABT,oct issue update research report netherlands base molecular diagnostic provider qiagen qgen free report company offer innovative technology product pre analytical sample preparation molecular diagnostic solution be upbeat qiagen partnership co marketing agreement centogene ag boost bioinformatic portfolio also be encourage note post receipt fda approval june qiagen announce complete launch fourth generation blood test tuberculosis tb infection quantiferon tb gold qft unite state moreover company strategic focus drive growth sample insight offering buoy optimism qiagen be form collaboration personalize homecare space well qiagen currently market product more country last report second quarter company witness growth international region include top emerge market flip side last month qiagen have be trading broader industry latest share price company have gain compare gain broader industry moreover adverse currency translation continue be drag overall sale furthermore decline hpv sale unite state continue be drag competitive landscape heavy dependence collaboration continue be concern zack rank other key picksqiagen currently carry zack rank buy other top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
518,ABT,fourth quarter earning season have commence positive note most sector decent picture participant have report jan total earning company be year year higher revenue beating earning estimate surpass top line expectation notably company be report earning week latest earning preview overall earning fourth quarter be expect increase growth revenue indicate improve growth projection previous quarter drive corporate tax overhaul relatively healthy job datum factor have boost corporate earning stoke investment base pattern fourth quarter be expect register modest double digit percentage earning growth year year basis medtech earning so farmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be evident result medtech heavyweight abbott free report intuitive surgical isrg free report company exit fourth quarter solid note beating zack consensus estimate count upbeat fy guidance also instill confidence fourth quarter earning growth rate medical sector be peg revenue growth upcoming releaseslet take look major other medtech stock slate release quarterly report jan stryker corporation syk free report result be schedule release market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be year year basis stryker recently announce better expect preliminary net sale result fourth quarter full year net sale be estimate year quarter constant currency basis figure beat zack consensus estimate buoy prospect quantitative model indicate earning beat stryker quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate stryker earning esp be uncover best stock buy sell re report earning esp filter stryker carry zack rank read more core segmental growth aid stryker earning stryker corporation price consensus stryker corporation price consensus stryker corporation quotezimmer biomet holding inc zbh free report be set report result market open notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be project year year basis solid prospect company surgical sport medicine foot ankle extremity trauma arm macroeconomic uncertainty unfavorable currency fluctuation have be dent sale past few quarters company have be deal pricing pressure regard zimmer biomet witness negative pricing pressure approximately last quarter absence favorable change line headwind reflect company fourth quarter result read more arm drive zimmer biomet earning result proven model do not conclusively show earning beat zimmer biomet quarter zimmer biomet have earning esp stock carry zack rank sell see complete list today zack rank strong buy stock here zimmer biomet holding inc price consensus zimmer biomet holding inc price consensus zimmer biomet holding inc quotealign technology inc algn free report be set report result market close notably zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be cent year year basis align technology achieve milestone patient undergo treatment flagship clear aligner system invisalign november company have be adopt several strategy drive adoption core invisalign product line company receive patent align technology smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align technology collaborate digital design recent past read more invisalign drive align technology earning positive development proven model do not conclusively show align technology be likely beat earning quarter align technology have earning esp stock carry zack rank align technology inc price consensus align technology inc price consensus align technology inc quotezack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
519,ABT,boston scientific corporation bsx free report have recently announce major investment santa rosa base millipede inc augment position field mitral regurgitation mr millipede be developer iris transcatheter annuloplasty ring system treatment severe mr term agreement boston scientific have purchase portion millipede company have also keep option acquire remain share millipede point time prior completion first human clinical study meet certain parameter also millipede have option compel boston scientific purchase remain share closure clinical study full buyout millipede need additional payment boston scientific further be paid achievement commercial milestone regard management note mr occur leak mitral valve cause blood regurgitate left ventricle left atrium heart condition gradually lead heart failure heart rhythm problem patient severe mr often complain compromise heart function tolerate open heart surgery repair replacement leak valve management be optimistic large patient population space be unfortunately underserved moment hence area represent lucrative market be tap patient population benefit fully percutaneous transcatheter procedure fix dilate mitral reduce regurgitation undergo surgery encouragingly millipede iris annuloplasty ring claim be highly customizable specific patient anatomy disease state device be supply transcatheter transseptal delivery system follow standard surgical approach mend decrease size dilate mitral positive note global transcatheter mitral valve replacement market be grow stupendously cagr approximately datum provide technavio apart boston scientific other major player field be edward lifescience corporation ew free report medtronic plc mdt free report abbott free report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
520,ABT,morning pre market index look fresh time high today robust earning season hit high gear commodity oil gold be also start positive territory morning year bill be now reside good thing relatively let start report worst performer dow jone industrial average general electric ge free report zack rank strong sell company zack style score value growth momentum miss bottom line estimate cent share penny quarterly revenue fall far short expect zack consensus fiscal ge guidance be currently share recently install ceo john flannery have call reset year seek reduce corporate cost layer ge worker also don rule possibility ge be hived separate entity point future more ge earning click here former owner nbcuniversal present comcast cmcsa free report have also put earning result prior today open bell report cent share revenue better cent expect revenue grow year year growth high speed internet security automation customer somewhat offset loss voice video subscriber more cmcsa earning click here abbot lab free report beat penny cent share revenue easily top zack consensus estimate positive result be attribute higher sale pharma device diagnostic nutrition pre market share be close more earning click here fellow illinois base company illinois tool work itw free report also outperformed bottom line expectation quarterly earning share ahead expect revenue however come light have be look more itw earning click here finally unite technology utx free report general dynamic gd free report defense industry zack rank buy stock top bottom line expectation beat estimate respectively revenue utx also beat gd quarterly sale come short more utx earning click here more gd earning click here
521,ABT,thermo fisher scientific inc tmo free report have be gain investor confidence consistently positive result stock have rally last month ahead gain broader industry rise moreover massachusett base medical instrument manufacturer have market cap company year historical growth rate be favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company have impressive earning surprise history have surpass zack consensus estimate trail quarters average beat company estimate revision trend current year have be positive last day analyst revise estimate upward movement opposite direction magnitude estimate revision earning increase share same time frame let find recent positive trend be sustainable company have be steadily add capacity enhance exist one acquisition regard acquisition fei have already start generate synergy contribute largely company analytical instrument portfolio have turn boost market optimism surround stock moreover be look forward company latest patheon buyout thermo fisher forayed high potential contract development manufacturing organization cdmo space moreover company plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recent open center excellence electron microscopy saudi arabia additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor moreover believe company strong cash balance enable carry strategy inorganic expansion flip side thermo fisher derive majority revenue international market expose fluctuation foreign currency management currently estimate unfavorable foreign exchange have negative impact top line also tough competitive landscape continue challenge company other key picksother top rank stock medical sector be abbott free report idexx laboratory inc idxx free report integra lifescience holding corporation iart free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year integra lifescience have long term expect earning growth rate stock gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
522,ABT,few month line republican complete full year power unfortunately political power change healthcare community hasn have many opportunity rejoice survey report gallup analytic last month reveal adult cite healthcare second major problem face country new presidential administration fact debate repeal affordable care act aca obamacare have be rage now report peaked reach congress august consider prevailing uncertainty implementation health policy respite term seem unlikely medtech unite state blur pictureneedless say current crisis medtech industry integral part broader healthcare space show sign abate few month back company space be hopeful promise cancellation medtech tax obamacare new government unquestionably latest political development have land medtech space uncertain territory investor be mull retain exist medtech stock forego holding favor company other industry boost financial resource say spite future hold believe investor stick medtech space have show sign prosperity recent time globally yes read right even consider dull performance medical device market still hold lead position almost third world market share rise regulatory legislative uncertainty global growth have be quite encourage industry grow pace last see financial crisis emerge market hold immense uncertainty unite state worsening economic condition europe automatically shift focus emerge geography china india latin america other emerge economy be see rise uptake medical device largely due grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage make market happy hunting ground global medical device player add rise healthcare spending improve healthcare infrastructure growth continue go recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india medtech market fifth largest world be currently demonstrate annual growth continue india give good competition japan germany other emerge geography latin america even face general economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare period accord world bank datum guatemala increase spending brazil chile colombia uruguay paraguay ecuador lower domestic production latin america have make open market exporter investment emerge market player look sensiblein such scenario believe be wise investor be keen medtech stock keep eye company have turn emerge market happy hunting ground expertise network wonder stock cash enormous growth potential emerge geography have perfectly shield political turmoil unite state let look few medtech player significant emerge market presence give huge potential region long back johnson johnson jnj free report have set manufacturing center brazil china india company medical device segment emerge market be grow time faster develop market have be do business china nearly year be expand further here back synthe acquisition johnson johnson price consensus johnson johnson price consensus chart johnson johnson quote abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina abbott laboratory price consensus abbott laboratory price consensus chart abbott laboratory quote medtronic mdt free report last report first quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic remain confident long term outlook emerge market company be focuse develop new public private partnership well execute channel optimization strategy medtronic plc price consensus medtronic plc price consensus chart medtronic plc quote boston scientific bsx free report emerge market business register organic growth second quarter significant increase growth business china be once again remarkable year year company be currently look forward much better performance ahead china banking recent approval synergy china boston scientific corporation price consensus boston scientific corporation price consensus chart boston scientific corporation quote thermo fisher tmo free report too be leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus chart thermo fisher scientific inc quote wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
523,ABT,express script hold company esrx free report recently inked agreement acquire privately hold evicore healthcare investor include general atlantic ta associate ridgemont equity partner transaction be expect close fourth quarter evicore provide evidence base integrate medical benefit management service mbm solution drive cost reduction quality care outcome notably evicore operate standalone business unit express script express script pharmacy benefit management couple evicore complementary medical benefit management be likely build comprehensive patient benefit management pbm solution buyout provide express cross sell client basis financial acquisition be expect prove accretive express script adjust diluted earning share first full year operation exclude transaction related expense amortization intangible accord company deal be likely take care be spend healthcare annually industry pbm be highly competitive industry report market research project pharmacy benefit management market see cagr accord market market report global healthcare provider network management market value cagr period take account express script have be consistently try expand core pbm business company recently announce plan expand customize worker compensation pharmacy solution acquisition mymatrixx pharmacy benefit solution provider worker compensation industry furthermore company anticipate compound annual ebitda growth rate core pbm business however express script announce biggest customer lead health insurer anthem inc antm be not likely extend pharmacy benefit management agreement be slate expiration end price script stock have underperform broader industry last year specifically stock have lose period industry gain zack rank key picksexpress script currently carry zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly last year idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
524,ABT,expect abbott free report surpass expectation report third quarter result oct market open last quarter abbott deliver positive earning surprise abbott strong impressive earning track record reflect estimate beat past quarters deliver average also company share have surge so far year compare favorably industry register rally same period likely positive surprise proven model conclusively show abbott be likely beat earning quarter have right combination key ingredient stock need have positive earning esp favorable zack rank strong buy buy hold likely positive surprise zack esp abbott have earning esp indicative be confident earning surprise uncover best stock buy sell re report earning esp filter zack rank abbott currently carry bullish zack rank increase predictive power esp higher chance beating estimate conversely sell rate stock be caution go earning announcement be drive better expect earning abbott have be healthy growth trajectory establish pharmaceutical division epd business deliver encourage operational sale growth trail few quarters major part growth be stimulate series strategic action include abbott sale develop market business acquisition cfr pharmaceutical latin america veropharm russia abbott laboratory price consensus abbott laboratory price consensus abbott laboratory quote company also continue expect strong growth epd upcoming quarters particularly china russia several market latin america include brazil back abbott strong position lie competitive edge geography also be chance certain revamp epd sale india third quarter follow business loss abbott have incur due implementation good service tax gst country second quarter have be slew development medical device space well market be upbeat abbott freestyle libre flash glucose monitoring system recent reimbursement approval unite kingdom company have recently announce receipt health canada license freestyle libre flash glucose monitoring system positive place abbott freestyle libre system stand partially fully cover country include france germany japan expect uptrend further stimulate growth diabetes care sale segment medical group improve second quarter continue consumer acceptance freestyle libre international arena cardiac arrhythmia heart failure business recent fda approval abbott full maglev heartmate left ventricular assist system be expect boost company sale third quarter be also encourage ongoing synergy acquisition st jude medical jan earlier year comprehensive combine portfolio appear quite promising notably abbott project annual pre tax synergy include revenue expansion opportunity well operational sg efficiency third quarter company forecast adjust earning share cent comparable operational sale growth quarter be project mid single digit other stock considerhere be few other company worth consider same space proven model show too have right combination element come earning beat quarter qiagen qgen free report have earning esp zack rank see complete list today zack rank stock here vertex pharmaceutical incorporate vrtx free report have earning esp zack rank humana inc hum free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
525,ABT,pacific bioscience california inc pacb free report recently form alliance genomic datum drive medicine company bluebee develop advanced assembly pipeline integrate company technology combine solution be introduce american society human genetic ashg annual meeting be hold next week orlando fl announcement menlo park base pacific bioscience assembly pipeline now be integrate bluebee genomic analysis platform integration offer simplified fully automate end end datum analysis solution allow assembly genome size include human variety also include guarantee turn time enable better plan improve productivity grow demand single molecule real time smrt sequence genomic community company expect huge customer adoption new cloud base analysis option pacific bioscience end end solution integrate downstream datum analysis bluebee high security regulatory compliant compute center pacific bioscience global customer notably smrt sequence provide complete accurate picture genome courtesy superior performance sequence accuracy uniformity coverage extremely long read length ability characterize dna base modification be perfect tool investigate high sequence genetic complexity otherwise difficult resolve used short read technology industry prospect significantly prospect long read sequence market pacific bioscience be lead name be grow leap bound recent report decisive bio insight next generation sequence ngs manufacturer market size reach grow annum rate touch primarily drive adoption worldwide clinical customer believe pacific bioscience slew latest development be well time industry price performance past month stock have surge more compare favorably broader industry gain roughly zack rank key pickspacific bioscience currently carry zack rank hold few better rank stock medical sector be abbott free report thermo fisher scientific inc tmo free report idexx laboratory inc idxx free report stock carry zack rank buy see complete list today zack rank stock here abbott have long term expect earning growth rate stock have rally roughly last month thermo fisher have long term expect earning growth rate stock have gain last year idexx laboratory have long term expect earning growth rate stock have surge last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
526,ABT,share price abbott free report scale new week high sep eventually close nominally lower company have gain past month much higher gain same frame abbott have also outperformed broader industry decline respect share price movement past month stock have market cap further abbott estimate revision trend current year have be favorable past day estimate moved moved estimate be share same time frame company also have trail quarter average positive earning surprise positive long term growth hold promise abbott laboratory price consensus abbott laboratory price consensus abbott laboratory quoteabbott carry zack rank hold company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity growth market be upbeat abbott recent fda approval full maglev heartmate left ventricular assist device lvad company also announce receipt national reimbursement freestyle libre glucose monitoring system japan development have widen illinois base medical device major customer base diabetes management further company recently sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust abbott expect alliance solidify footprint rapidly grow diagnostic market meanwhile abbott second quarter performance have be promising sale adjust earning continue operation increase year year factor be expect boost company share price key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
527,ABT,emerge market investment have take backseat late thank nonstop blow economy linger geopolitical tension gulf debt policy related hazard latin america missile test north korea have lead stock investor reconsider outlay market earlier proclaim offer better growth opportunity unite state go msci emerge market index last year annualize growth rate be just other hand gdp capita growth rate last year unite state be international monetary fund world economic outlook database face such adversity goldman sachs statement bloomberg last week address emerge market stock world best bet have create quite stir investment world accord report follow selloff february other market correction investor be keen put money riskier asset emerge economy time msci index have not show significant improvement then comment sheila patel chief executive officer international gsam have force investor think again take asset market go bloomberg report goldman sachs be particularly bet indian healthcare firm consumer stock argentine debt expect india government boost spending public health prime minister narendra modi political risk be ignore investor pessimism mexico argentina be overdo report say emerge market healthcare scenario way better unite patel particularly talk grow prospect indian healthcare market datum show prospect broader emerge market be equally encourage contrary healthcare scenario unite state be muddle survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll next month state past decade marked biggest increase uninsured rate new healthcare reform bring term scenario remain pretty unclear now meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity emerge market opening medtechper recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany other emerge geographical region latin america even face economic stagnation hold enormous potential january report medtech intelligence central south american nation significantly increase capita spending healthcare give huge potential region long back johnson johnson jnj free report have set manufacturing center india china brazil company emerge market medical device segment continue grow time faster develop market abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report second quarter fiscal business china latin america southeast asia show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific bsx free report emerge market business register organic growth fourth quarter reflect significant increase growth business china be once again remarkable year year growth pace emerge market have decline pre financial crisis year however market have historically play crucial role large corporation hedge international trade risk accord bcg report go forward emerge market gdp be project grow faster develop economy market account total consumer spending more investor point view be imprudent immense growth potential emerge economy due occasional rough spot today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
528,ABT,go latest center disease control prevention report more adult be live diabetes prediabetic condition notably be gradually take shape deadly epidemic diabetes rate unite state have moved furthermore diabetes be seventh lead cause death unite state result approximately medical cost reduce productivity year article state obesity globally scenario be quite intriguing global report diabetes world health organization prevalence diabetes adult rise moreover worldwide expense related diabetes be international diabetes foundation notably projection related disease hint continuation present trend regard number patient age year diagnosed diabetes be expect rise international diabetes foundation go say rise incidence diabetes have open opportunity diabetes device maker market be expect see cagr reach worth report mordor intelligence globally market be expect value cagr transparency market research report thus investor be keen place bet healthcare space long term gain diabetes device market undoubtedly hold immense potential factor drive diabetes device marketrising healthcare expenditure unhealthy lifestyle practice expand treatment option have be drive demand center medicare medicaid service report publish advisory board healthcare spending be project rise represent gdp base assumption affordable care act continue diabetes device market be largely dependent age population census bureau report person age more be likely total almost double estimate population datum also show median age be increase most area country global scenario be pretty similar strengthen emerge market have be contribute largely rise demand diabetes care device report cision put more light report demand insulin delivery blood glucose monitoring device have be rise highly populate country china india accord international diabetes federation china record highest number diabetic patient follow india ai shape diabetes device artificial intelligence ai have be transform way diabetes be manage world tech medical device analytical predictive diagnostic tool be help create customize program support blood glucose management improve medication adherence go report statista worldwide revenue ehealth solution diabetes be expect furthermore market be expect see cagr accord report grow demand increase availability connect medical device home usage apps smartphone aid self management telemedical service service oriented apps have be stimulating growth niche market view mentioned factor number bigwig have be expending lump sum amount continuously innovate develop device improve efficacy side effect instance back medtronic plc mdt free report partner ibm watson utilize latter machine learn algorithms incorporate ai diabetes app minime company jointly launch first artificial pancreas system medtronic have utilize sugar iq cognitive compute capability ibm watson detect important pattern trend diabetes line development diabetes business february abbott laboratory free report announce availability freestyle librelink app europe use smartphone iphone android encouragingly note abbott be plan mobile app solution freestyle libre user outside europe base country regulatory approval moreover boston taipei hong kong bangalore base company have develop diabetes ai provide personalize metric analysis decision make tool physician patient improvise pre diabetes diabetes management stock bet onwe have select company believe tap promising prospect diabetes device market nordisk nvo free report company have strong presence diabetes care market global market share company boast most extensive diabetes portfolio industry encompass new generation insulin full portfolio modern insulin well once daily glp analog once weekly glp analog also company have strong presence total insulin modern new generation insulin market company have be ride high continue uptake long act insulin tresiba nordisk price nordisk price nordisk zack rank buy company have earning growth rate current year estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly earning estimate increase share sanofi sny free report company have be commit develop strengthen insulin franchise lantus toujeo soliqua suliqua insulin company have launch soliqua suliqua unite state europe receipt approval insulin lispro biosimilar same region also note company have be gain substantially availability lantus country courtesy solid sale unite state china france germany sanofi price sanofi price sanofi zack rank hold company have earning growth rate current year estimate revision trend stock have be solid estimate move upward compare downward movement past month resultantly earning estimate increase share see complete list today zack rank strong buy stock here becton dickinson company bdx free report company commonly know bd offer portfolio syringe pen needle other product related injection infusion insulin other drug diabetes care business notably company have be consistently try improve performance diabetes care unit bd medical segment bd see diabetes care revenue growth constant exchange rate first quarter fiscal becton dickinson company price becton dickinson company price becton dickinson company quote regard company recently launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction bd have widen needle length option diabetic patient interestingly most insurance plan include medicare part cover bd ultra fine micro mm pen needle zack rank company have earning growth rate current fiscal estimate revision trend stock have be solid estimate move upward compare movement opposite direction past month resultantly earning estimate increase share conclusiona say strike iron be hot be opportune time cash bountiful opportunity rapidly grow diabetes device market hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
529,ABT,abbott free report recently announce receipt fda approval freestyle libre flash glucose monitoring system unite state approval be likely widen illinois base medical device major customer base diabetes management company aim make product commercially available person diabetes unite state end flagship product be available major retail pharmacy end user prescription basis meanwhile abbott have be steadily progress development diabetic segment recently company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system drive growth diabetes care sale segment see revenue growth second quarter continue consumer acceptance freestyle libre internationally believe latest fda nod boost company performance domestic arena well expect freestyle libre contribute abbott top line japanese canadian development french health ministry have approve national reimbursement device report mordor intelligence global market diabetes care device be project reach value cagr give bullish market sentiment believe recent regulatory approval freestyle libre have come opportune moment however diabetes market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation development insulin delivery system share price have be gain investor confidence consistently positive result last month abbott share price have outperformed broader industry stock have gain contrast broader industry decline company have also outperformed gain market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock medical sector be orthofix international ofix free report owen minor inc omi free report orthofix international owen minor sport zack rank strong buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month owen minor have long term expect earning growth rate stock have gain last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
530,ABT,abbott free report ellipse implantable cardioverter defibrillator icd recently gain fda approval magnetic resonance mr conditional labele solidify company footprint rhythm management space post approval patient implanted ellipse device durata optisure lead be able undergo mri scan moreover ellipse now be available patient suffering severely high heart rhythm need icd mri scan thus believe latest regulatory approval expand company customer base drive top line moreover ellipse be embed feature know abbott tailoredtherapy be capable directly securely wirelessly forwarding therapy related datum patient physician merlin net patient care network continue effort expand mr conditional labele enabled device company receive fda approval mr conditional labele assurity mri pacemaker tendril mri pace lead also company have receive certain prior mr conditional labele approval europe meanwhile abbott have apply fda approval mri conditional labele quadra assura cardiac therapy defibrillator crt product quartet family left ventricular lead interestingly company witness softness rhythm management segment majorly due tough competition mri conditional category product market be dominate well establish player medtronic plc mdt free report boston scientific corporation bsx free report edward lifescience corporation ew free report other abbott strategy gain traction rhythm management sub segment seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
531,ABT,abiom inc abmd free report flagship impella product line shine bright receipt pre market approval fda impella rp heart pump notably impella rp be only fda clear percutaneous temporary ventricular support device available market impella rp system have be exclusively formulate provide temporary right ventricular support patient acute right heart failure decompensation important note device do not involve sort surgical procedure insertion fact impella rp provide more liter blood minute provide hemodynamic support patient management latest regulatory go ahead eradicate risk associate right ventricular failure rvf risk include increase mortality longer length stay intensive care unit end organ dysfunction believe robust demand impella product continue drive abiom top line long term notably impella line have other fda approve product impella impella cp impella business line be exclusively design treat patient cardiogenic shock undergo elective urgent percutaneous coronary intervention pci evidently impella heart pump global revenue grow strong last quarter bottom linelately management abiom have make significant investment training datum collection procedure impella platform impella line have be gain prominence international ventricular assist device market well company continue progress country germany japan leverage impella line be worth mention datum research market suggest ventricular assist device global market be set reach worth meanwhile company face stiff competition organization develop permanent heart assist product teleflex inc tfx free report abbott laboratory free report fresenius medical care fms free report stock watch massive equifax hack cybersecurity stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
532,ABT,abbott free report be healthy growth trajectory late stock have gain last month ahead gain broader industry decline stock have market cap company current year growth rate be also favorable compare increase broader industry solid prospect zack rank buy stock emerge attractive pick illinois base medical device major estimate revision trend current year have also be positive past couple month analyst moved north just movement opposite direction estimate be marginally revise upward share same time frame company also have trail quarter average positive earning surprise let find recent positive trend be sustainable market be upbeat abbott gain national reimbursement freestylelibre glucose monitoring system national health service nhs business service authority unite kingdom have be major breakthrough diabetic business reimbursement grant make freestylelibre system widely available person unite kingdom also other development include abbott srecent fda approval full maglev heartmate left ventricular assist device lvad be encourage addition company announce receipt national reimbursement freestyle libre glucose monitoring system japan breakthrough have widen medical device major customer base diabetes management company also recently sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust abbott expect alliance solidify footprint rapidly grow diagnostic market abbott second quarter performance have be promising sale adjust earning continue operation increase year year several strategic progress make expect growth stream continue day ahead other key picksother top rank medical stock be edward lifescience corporation ew free report cheme corporation che free report amedisys inc am free report edward lifescience sport zack rank strong buy cheme amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month cheme have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
533,ABT,abbott free report recently announce receipt national reimbursement freestylelibre glucose monitoring system national health service nhs business service authority notably be major breakthrough diabetic business development have widen illinois base medical device major customer base diabetes management begin nov abbott flagship glucose monitoring system be available reimbursement nhs england wale nhs scotland health social care northern ireland abbott grant reimbursement also make freestylelibre system widely available person be diagnosed diabetes also management expect be roughly person have diabetes be yet be diagnosed reimbursement approval mark milestone abbott freestyle libre system stand partially fully cover country include france germany japan notably freestyle libre system be presently review fda await approval unite state meanwhile abbott have be move steadily development diabetic segment recently company announce receipt national reimbursement freestyle libre japan moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be second quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line japanese canadian development french health ministry recently approve national reimbursement device apart july company partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market report mordor intelligence global market diabetes care device be project reach value cagr consider market potential abbott slew latest development diabetes care segment recent national reimbursement grant accelerate top line however diabetes market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system share price have be gain investor confidence consistently positive result last month abbott share price have outperformed broader industry stock have gain comparison broader industry gain company have also outperformed gain market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
534,ABT,lately medtech space have be face brunt frequent regulatory change trump administration be face socio economic upheaval investor be apprehensive impact stock historic trend suggest investor sentiment have always be partially incline fancy brand name volatile economic backdrop result company solid brand value robust fundamental generally enjoy sail even political turbulence such bigwig medtech space be abbott laboratory free report have greatly evolved recent year company have pursue slew merger divestment have also see solid growth diabetic business strategic buyout acquisition cfr pharmaceutical tendyne holding st jude medical be worth mentioningafter spin proprietary pharmaceutical product division form abbvie inc abbv free report abbott have gain traction establish pharmaceutical division then revenue have see cagr last year period company have more less report strong quarterly number indicate fundamental strength share lack lusterhowever share price performance abbott have be disappointing same time frame company represent meager return just lower broader industry gain return same time frame main issue plague abbott foreign exchange be major headwind strengthen euro other develop market currency have constantly hampered company performance international market abbott currently expect currency exchange have negative impact sale apart business environment continue be challenge globe slow growth nutrition business china economic problem venezuela be expect remain unresolved time dampening company top line growth bleak prospectswhile abbott boast solid fundamental company prospect be dull note company promise long term earning growth just lower broader industry estimate growth rate furthermore abbott revenue have decline last year compare broader industry revenue growth secondly abbott historical cash flow growth have be extremely low compare unfavorably broader industry positive growth unfavorable growth metric be indicative fact solid brand value abbott not prove be lucrative pick long haul growth stock long term growth parameter be not favor abbott hold zack rank hold now so instead opt brand value let take look follow not so fancy medtech stock be expect gain long haul apart flaunt strong zack rank strong buy buy stock promise long term expect growth rate higher compare favorably broader industry also have take growth style score consideration growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank offer best investment opportunity lonza group ltd lzagy free report lonza group sport zack rank have long term expect earning growth rate company have growth score see complete list today zack rank stock here lonza group supply product service pharmaceutical biotech specialty ingredient market worldwide outstanding first half year lonza group continue expect strong performance pharma biotech specialty ingredient segment company strategic initiative improve customer relationship management process innovation operational improvement program area automation streamline instill investor confidence stock have gain last year orasure technology inc osur free report zack rank stock promise long term expect earning growth notably orasure have growth style score company develop manufacture market sell oral fluid diagnostic product specimen collection device unite state europe internationally orasure bank solid growth infectious disease business unit higher sale company molecular product oraquick hcv product be primary growth driver company have also be banking flagship oragene product line orasure have have impressive run last year company have return significantly higher broader industry same time frame idexx laboratory inc idxx free report zack rank company continue demonstrate solid growth globally strong international expansion long term expect earning growth rate growth score idexx laboratory exit second quarter solid note beating zack consensus estimate count headquarter delaware nj idexx laboratory be developer manufacturer distributer product service primarily companion animal veterinary livestock poultry water testing dairy market major fraction idexx laboratory revenue be derive companion animal group segment drive expand premium instrument base unite state international market company be expect grow extensively long haul idexx laboratory boast stellar return last year furthermore estimate revision trend next year be promising notably analyst moved north last month zack consensus estimate next year increase share same time framee lemaitre vascular inc lmat free report lemaitre have zack rank promise long term expect earning growth rate growth score company xenosure platform be key catalyst moment stock have gain last year headquarter burlington company market sell service support medical device implant treatment peripheral vascular disease worldwide company expect sale rise almost organically next quarter strong margin expansion lemaitre estimate revision trend next year be quite encourage notably analyst moved north compare movement opposite direction result zack consensus estimate increase almost same time frame surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
535,ABT,major breakthrough diabetic business abbott free report recently announce receipt national reimbursement freestyle libre glucose monitoring system japan development have widen illinois base medical device major customer base diabetes management management population diagnosed diabetes japan be consider nation highest rate person suffering condition company state grant reimbursement also make freestyle libre system widely available more japanese person diagnosed type type diabetes insulin therapy vary age also reimbursement approval japan mark milestone abbott freestyle libre system stand partially fully cover country include france germany notably freestyle libre system be presently review fda await approval unite state abbott have be move steadily development diabetic segment july company partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be second quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line canadian development french health ministry recently approve national reimbursement device report mordor intelligence global market diabetes care device be project reach value cagr consider market potential abbott current development diabetes care segment recent national reimbursement grant japan accelerate top line believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diabetes market however market be dominate many well establish player johnson johnson jnj be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system moreover abbott have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain contrast broader industry decline company have also outperformed fall market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
536,ABT,abbott free report recently have initiate pivotal clinical study evaluate safety effectiveness modify version amplatzer device device be design correct common congenital heart defect pre term infant device be same larger size amplatzer duct occluder ii product clinical study be conduct patient center unite state accord abbott patent ductus arteriosus pda be life threaten vascular pathway duct heart remain open due failure fetal duct close birth case pda fail close spontaneously premature baby lead difficulty breathe fee pharmaceutical be used time close duct be less effective pre term infant current treatment option pre term infant be not responsive pharmaceutical be limit surgery however surgery be not always possible leave duct open lead fatal outcome infant breaking conventional treatment abbott be develop amplatzer duct occluder ii additional size ado ii device provide physician nonsurgical treatment option address pda defect newborn pre term infant ado ii be already approve use europe study be successful trial result support abbott application fda approval pediatric use country note abbott have be consistently try expand vascular business medical device segment be solid growth trajectory late last report second quarter medical device business sale spiked report basis also recent development include receipt fda approval full maglev heartmate left ventricular assist system also know lvad heartmate system enable physician manage advanced heart failure patient need short term hemodynamic support abbott also announce ce mark first use new confirm rx insertable cardiac monitor icm be world first smartphone compatible icm help physician identify difficult detect cardiac arrhythmia include atrial fibrillation af accord report market market global pediatric interventional cardiology market be estimate see cagr look bountiful opportunity niche space believe company latest development be strategical fit last month abbott have be trading broader industry stock have now gain industry decline zack rank key picksabbott carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
537,ABT,last week senator tina expressed concern big pharma company plan use large corporate tax saving reward shareholder instead bring cost expensive drug benefit consumer senator question letter ceo big pharma company pfizer pfe free report merck mrk free report johnson johnson jnj free report abbvie abbv free report abbott lab free report plan use extra cash please note conference call hold earlier year most big pharma company discuss plan do extra cash save new tax bill company plan invest extra cash capital expenditure product pipeline licensing acquisition deal reward shareholder higher dividend share buyback not many talk take step lower prescription drug cost apart key announcement week include failure dermira inc derm free report acne candidate pivotal late stage study merck oncology collaboration japan eisai expansion jardiance clinical study eli lilly lly free report fda committee back pfizer xeljanz third indication recap week most important storiesdermira share sink acne candidate fail share dermira plunge announce acne candidate olumacostat glasaretil surprisingly fail meet primary endpoint pivotal phase iii study clareo clareo company say likely stop olumacostat glasaretil development follow failure read more dermira acne candidate fail pivotal trial share sink merck jointly develop eisai cancer drug lenvima similar last year profit sharing deal astrazeneca azn free report merck announce oncology collaboration japan eisai co ltd deal company jointly develop commercialize eisai tyrosine kinase inhibitor lenvima monotherapy combination merck pd therapy keytruda several type cancer deal merck give eisai upfront payment company share global development marketing cost well gross profit lenvima equally read more merck pay upfront co develop eisai cancer drug pfizer xeljanz snda get fda committee back pfizer supplemental new drug application include ulcerative colitis uc indication label receive back fda advisory committee fda drug advisory committee gidac vote unanimously favor jak inhibitor fda decision be expect june xeljanz be already approve treat rheumatoid arthritis active psoriatic arthritis record sale represent growth year year astrazeneca look forxiga eu approval type diabetes astrazeneca application look get sglt inhibitor forxiga approve new indication oral adjunct treatment insulin type diabetes patient be accept european medicine agency forxiga be presently approve monotherapy well combination therapy treat type diabetes approve forxiga become first sglt inhibitor approve europe treatment oral treatment adjunct insulin read more astrazeneca forxiga label expansion filing accept eu glaxo present asthma hiv datum glaxo gsk free report present datum osmo study new respiratory medicine nucala american academy allergy asthma immunology aaaai world allergy organization wao joint congress orlando datum study show patient asthma be uncontrolled xolair witness improve asthma control switch glaxo new respiratory medicine nucala glaxo also present interim datum phase iiib study inspiring investigational hiv candidate dolutegravir medical conference boston read more glaxo encourage asthma hiv datum medical meeting meanwhile glaxo gain approval expand european label once daily laba ics combination treatment relvar ellipta now relvar ellipta be used eu patient asthma be already adequately controlled ics laba label update doctor prescribe asthma patient switch once daily relvar ellipta current twice daily ics laba experience comparable benefit lung function safety profile lilly boehringer expand jardiance clinical study lilly partner boehringer ingelheim announce plan initiate phase iii emperial study evaluate effect lilly sglt inhibitor jardiance exercise ability heart failure symptom person chronic heart failure irrespective have type ii diabetes presently ongoing phase iii emperor outcome study be evaluate effect jardiance long term morbidity mortality outcome person heart failure emperial study investigate treatment jardiance help improve everyday life person live chronic heart failure read more lilly boehringer expand jardiance heart failure program nyse arca pharmaceutical index be last trading session large cap pharmaceutical industry yr return large cap pharmaceutical industry yr return here be major stock perform last trading session major stock rise largest gainer be glaxo lilly last month bristol myer bmy free report gain merck decline see last pharma stock roundup here azn imfinzi get fda nod mrk buy australian firm next pharma world watch regulatory pipeline news pharma stock don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
538,ABT,henry schein medical subsidiary henry schein inc hsic free report announce exclusive distribution agreement terason distribute latter usmart nexgen development remain part henry schein medical emergency medical service em business terason division teratech corporation be manufacturer portable ultrasound machine usmart be portable ultrasound device allow emergency responder carry exam emergency medical transport vehicle aircraft reduce need speculate em professional usmart nexgen be portable light weight ultrasound tablet easy transport operate terason usmart feature many advanced feature include customize preset fast boot grab go portability wi fi capability responder recognize issue point care transportation also alert emergency room staff important vital usmart accord company access patient vital help emergency responder make more inform decision treatment also help emergency room staff prepare ahead patient arrival henry schein be consistently work boost medical segment notably worldwide medical revenue rise year year last report second quarter henry schein medical recently inked agreement cerebral assessment system cas distribute cognivue be first computerize cognitive assessment screening device clear fda detection early sign dementia moreover henry schein announce partnership simplifeye create mobile platform health care provider use practice management electronic health record software micromd accord report market market ultrasound market be expect reach value cagr consider substantial potential market believe latest development be strategic past year henry schein have underperform broader industry stock have gain compare gain broader industry estimate revision estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate current quarter earning share have increase cent cent zack rank key pickshenry schein have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
539,ABT,boston scientific bsx free report recently launch advanced resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system feature heartlogic heart failure diagnostic notably device be fda approve conditional use magnetic resonance imaging mri environment help physician improve heart failure hf management personalize care device combine company smartcrt technology enduralife battery technology allow physician customize device setting accord individual patient need drain battery have go unnecessary replacement procedure heartlogic diagnostic alarm doctor worsening hf condition combine datum sensor assess heart sound respiration rate volume thoracic impedance heart rate activity crt ds resonate family device be enabled smartcrt technology help physician modify pace lower chamber heart used multisite pace capability multus electrode pace company recently initiate enrolment patient manage hf study further assess heartlogic diagnostic boston scientific recently announce positive clinical trial datum multisensor chronic evaluation ambulatory heart failure patient multisense study study base patient be conduct examine performance heartlogic diagnostic prediction possibility study demonstrated heartlogic diagnostic increase ability classify patient high low risk experience hf event last report second quarter boston scientific cardiac rhythm management crm segment reflect year year increase sale meanwhile company have be consistently focuse product development strengthen position niche accord report globaldata heart failure market be estimate reach value cagr consider huge potential market believe latest development be strategically place however company be face tough competition global cardiac monitoring device market establish player abbott free report medtronic plc mdt free report edward lifescience corporation ew free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
540,ABT,buzz obamacare affordable care act aca remain persistent capitol hill lukewarm response replacement american health care act ahca have force republican continue seek new avenue bid save face trump administration attempt skinny repeal bill fail make headway senate go ahead believe impasse be slate continue president trump have always be outspoken critic aca apprehension come uncertainty regard outcome slew event include possibility rate hike fed stronger dollar debate fate cadillac tax excise tax high cost healthcare plan stance healthcare insurance company aca be expect spark bout volatility add factor be effect hurricane harvey bourse reason be worry investor uncertainty find investment option be not perturbed market gyration be tough decision dividend investing rescuea evident medtech story stock be volatile be risky time uncertainty ruling market be not surprising dividend investing have emerge most popular investing theme dividend stock be always investor prefer choice provide steady income cushion market risk stock be generally less volatile nature hence be dependable come long term investment plan not only offer higher income current environment rate remain low expect hike also provide relief adverse market condition dividend stock be safe bet create wealth payout generally act hedge economic uncertainty simultaneously provide downside protection offer sizable yield regular basis pick best stock benefit dividend investing be stress enough keep mind not company keep dividend pay momentum hence investor need be cautious order select best stock potential steady return have used zack stock screener narrow stock offer decent dividend yield have market cap more see complete list today zack rank strong buy stock here choicesabbott laboratory free report abbott park il base abbott laboratory discover develop manufacture sell diversify line health care product company also have large pharmaceutical business be major player nutritional diagnostic market abbott generate revenue company dividend currently yield year historical dividend growth rate be cardinal health inc cah free report headquarter dublin cardinal health inc be nation wide drug distributor provider service pharmacy healthcare provider manufacturer company have report segment pharmaceutical medical company generate revenue excess last report fiscal cardinal health dividend currently yield year historical dividend growth rate be patterson company inc pdco free report headquarter st paul mn patterson company be lead distributor dental animal health product company distribute product mainly subsidiary patterson dental patterson animal health report revenue fiscal company dividend currently yield year historical dividend growth rate be owen minor inc omi free report base mechanicsville va owen minor be global healthcare service company focuse provide supply chain service healthcare provider manufacturer healthcare product company provide logistic service spectrum medical product disposable medical supply device implant company generate revenue excess last report fiscal company dividend currently yield year historical dividend growth rate be bottom lineamid unpredictable medtech set investing high yielding dividend stock fetch promising return more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
541,ABT,wednesday january morning pre market index look fresh time high today robust earning season hit high gear commodity oil gold be also start positive territory morning year bill be now reside good thing relatively let start report worst performer dow jone industrial average general electric ge free report zack rank strong sell company zack style score value growth momentum miss bottom line estimate cent share penny quarterly revenue fall far short expect zack consensus fiscal ge guidance be currently share recently install ceo john flannery have call reset year seek reduce corporate cost layer ge worker also don rule possibility ge be hived separate entity point future more ge earning click here former owner nbcuniversal present comcast cmcsa free report have also put earning result prior today open bell report cent share revenue better cent expect revenue grow year year growth high speed internet security automation customer somewhat offset loss voice video subscriber more cmcsa earning click here abbot lab free report beat penny cent share revenue easily top zack consensus estimate positive result be attribute higher sale pharma device diagnostic nutrition pre market share be close more earning click here fellow illinois base company illinois tool work itw free report also outperformed bottom line expectation quarterly earning share ahead expect revenue however come light have be look more itw earning click here finally unite technology utx free report general dynamic gd free report defense industry zack rank buy stock top bottom line expectation beat estimate respectively revenue utx also beat gd quarterly sale come short more utx earning click here more gd earning click here mark vickerysenior editorquestion comment article author click here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
542,ABT,abbott free report report fourth quarter adjust earning continue operation cent share beating zack consensus estimate penny earning improve year year meet high end company guide range cent cent however report loss quarter come cent share year earning cent notably include anticipate net expense impact tax reform full year adjust earning come share line zack consensus estimate however figure beat year number fourth quarter worldwide sale come year year report basis figure also beat zack consensus estimate comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter worldwide sale full year come year year report basis figure also surpass zack consensus estimate abbott laboratory price consensus ep surprise abbott laboratory price consensus ep surprise abbott laboratory quote quarter detailabbott operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis include positive impact currency fluctuation sale key emerge market increase drive double digit growth latin america india china medical device business sale rise report basis comparable operational basis sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis double digit growth structural heart heart failure neuromodulation vascular product sale however decline comparable operational basis rhythm management company see sale drop comparable operational basis however company receive fda approval magnetic resonance mr conditional labele quadra assura quadra assura mp cardiac therapy defibrillator crt device fortify assura implantable cardioverter defibrillator icd quarter review diabetes care sale improve comparable operational basis buoy double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis comparable operational basis foreign exchange drive sale pediatric nutrition sale increase comparable operational basis adult nutrition sale be comparable operational basis diagnostic sale rise year year report basis comparable operational basis core laboratory point care diagnostic sale grow respectively comparable operational basis molecular diagnostic sale be nominal strong growth infectious disease testing business be partially offset plan scale genetic business rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing guidanceabbott issue full year guidance adjust certain net specify item full year adjust earning share continue operation be expect band current zack consensus estimate be peg low end project range company also provide first quarter adjust earning share guidance expect report adjust earning continue operation range cent cent quarter current zack consensus estimate cent be project range takeabbott have steer past zack consensus estimate earning sale be optimistic company strong consistent epd medical device performance be upbeat contribution company other business well company continue benefit recently complete acquisition st jude medical offer industry lead pipeline cardiovascular neuromodulation diabetes vision care be also upbeat abbott successful closure alere acquisition synergy buyout form revenue rapid diagnostic have be benefit company meanwhile company emerge market performance have be extremely promising several strategic development zack rank key picksabbott carry zack rank hold few better rank stock broader medical sector be bio rad laboratory inc bio free report intuitive surgical inc isrg free report amedisys am free report notably bio rad sport zack rank strong buy amedisys intuitive surgical carry zack rank buy see complete list today zack rank stock here bio rad be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be revenue be amedisys be expect release fourth quarter result feb zack consensus estimate fourth quarter adjust ep be cent revenue be intuitive surgical be expect release fourth quarter result jan zack consensus estimate fourth quarter adjust ep be peg revenue be hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
543,ABT,abbott free report be illinois base company focuse bring diverse line healthcare product market abbott report diversify business segment namely establish pharmaceutical division epd medical device diagnostic nutrition company have reshape portfolio strategic acquisition divestiture recent time have also be take strategic step expand footprint grow geography investing have result numerous new product launch business feb abbott complete sale brand generic pharmaceutical business develop market realignment epd division acquisition latin america russia business divestiture develop market have position company well come quarters however unfavorable movement foreign currency rate be affect top line adversely abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quote abbott have impressive track record company beat estimate last trail quarters average positive earning surprise currently abbott have zack rank hold definitely change follow company second quarter earning report be just release see complete list today zack rank strong buy stock here have highlighted key stat just reveal announcement earning zack consensus estimate remain steady cent share last day abbott fourth quarter earning share continue operation cent outpaced estimate penny revenue abbott post fourth quarter revenue beating zack consensus estimate revenue key stat worldwide nutrition sale increase report basis fourth quarter worldwide diagnostic sale increase report basis total establish pharmaceutical sale increase report basis revenue worldwide medical device increase report basis major factor abbott issue earning outlook reflect strong double digit growth company bank new product approval launch notably abbott receive fda clearance confirm rx insertable cardiac monitor october also company win fda approval magnetic resonance mr conditional labele quadra assura quadra assura mp cardiac therapy defibrillator crt device fortify assura implantable cardioverter defibrillator icd stock price follow earning release share price rise pre market trading session check back later full abbott earning report hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
544,ABT,earning season kick notch week company report include bunch dow industrial large cap not easy beating earning estimate quarter nearly quarter several year many investor underestimate management skill take consistently beat yet company have beaten miss only once quarter year impressive pressure mount keep great earning surprise record be able comply again quarter week amazing earning chart illinois tool work itw free report hasn miss yet still doesn get respect investor share have nearly double last year beat again abbott lab free report hasn miss early now impressive continue beat earning even chaos great recession share have break new year high keep momentum unite rental uri free report have miss only once year be crude price be plunge largest equipment rental company north america have oil gas business market have improve share be soar hope economy continue generate momentum honeywell hon free report be get last laugh be kick dow industrial year look now only miss once year share be new year high starbucks sbux free report have only miss once last year share have be stick narrow trading range more year finally be year join rally full disclosure author article own share uri sbux personal portfolio look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave
545,ABT,abbott free report diagnostic business have be growth trajectory late solid contribution sub segment core laboratory diagnostic molecular diagnostic point care expect strength get reflect fourth quarter result be schedule release jan core laboratory diagnosticsin june abbott announce ce mark alinity hq have become fifth diagnostic system be launch europe ongoing rollout instrument area immunoassay clinical chemistry blood screening point care have strengthen company core laboratory diagnostic business considerably late company have be headline follow receipt ce mark commercial launch alinity series integrate system hematology testing notably alinity portfolio cover clinical chemistry immunoassay blood plasma screening point care hematology molecular diagnostic abbott aliniq interestingly company also continue initial launch certain new alinity system core laboratory include alinity clinical chemistry alinity immunoassay diagnostic alinity blood plasma screening globally last report third quarter continue slew development illinois base global medical device company sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust august term collaboration abbott be authorize supplier analytical equipment consumable cover alinity ci alinity series diagnostic instrument aliniq nwlp alliance presently cover pathology market be expect carry test year thus investor be eagerly look forward outcome deal company financial zack consensus estimate core laboratory diagnostic revenue indicate rise year quarter report number abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quote point careabbott successful closure alere acquisition prolong legal battle have instilled confidence investor buyout close october amend financial term favor abbott take attractive prospect point care testing diagnostic market consideration abbott be highly optimistic alere integration accord company alere buyout significantly expand diagnostic presence create broadest point care testing portfolio strong position cardio metabolic infectious disease toxicology testing moreover abbott expect alere contribute top line thus zack consensus estimate point care revenue indicate massive rise year quarter surge sequential quarter molecular abbott have effectively focuse core area thus company have be strongly perform infectious disease testing business molecular diagnostic have be partially offset decline due plan scale other testing area company zack consensus estimate molecular diagnostic revenue indicate rise year quarter positive place abbott anticipate mid single digit increase diagnostic sale fourth quarter here be quantitative model predict abbott do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp abbott be uncover best stock buy sell re report earning esp filter zack rank abbott carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning cent reflect rise year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank buy see complete list today zack rank strong buy stock here myriad genetic inc mygn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
546,ABT,abbott laboratory free report have make encourage move respect medical device business company recently announce fda approval full maglev heartmate left ventricular assist device lvad build sophisticated full maglev fully magnetically levitated flow technology heartmate system provide advanced short term hemodynamic support advanced heart failure patient full maglev technology enable heartmate system lower trauma blood pass pump optimize blood flow interestingly heartmate be upgrade version exist heartmate ii system be used longer duration much await fda approval be award abbott post successful result momentum clinical study also encouragingly note heartmate receive ce mark management person unite state suffer heart failure roughly new patient be diagnosed condition year support datum statista report heart failure market state market be project value witness cagr moreover see encourage growth user penetration rate share ailing person thus consider datum base believe latest fda nod accelerate top line growth report culrav org global lvad market be project value witness cagr moreover transperency market research north american market ventricular assist device be expect see cagr period thus consider market potential abbott latest development help gain traction lvad space interestingly abbott medical device operate segment total revenue stand highest revenue gross business second quarter moreover company cardiovascular neuromodulation sub segment be highest contributor make total medical device revenue sale unite state alone thus company latest development help boost performance segment believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth heart failure market however market be dominate many well establish player medtronic plc mdt free report boston scientiific corporation bsx free report be most prominent one moreover abbott have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank key pickabbott carry zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
547,ABT,agilent technology inc free report have claim former employee form shanghai electronic technology co ltd have adopt not so honest way get information replicate agilent gas chromatograph lead provider application focuse solution sue shanghai number former employee allege intellectual property theft suit seek ban use agilent proprietary technology compensation loss company senior vice president general counsel michael tang state agilent be determine protect ip take appropriate legal action infringement worldwide observe agilent share have rally year date outperform industry gain ip protection property ip right protection law encourage company better production commitment additional resource enhance consumer confidence counterfeit hold key survival multibillion dollar firm give way legally fight competition be more important agilent face fierce competition like veeco instrument veco free report abbott laboratory free report thermo fisher scientific tmo free report agilent technology inc revenue ttm agilent technology inc revenue ttm agilent technology inc truth be bitterat end day employee do switch job more profitable allow liberty aren available sticking big corporate house agilent process ip also change hand illegally have be instance employee leave company form new one get sue intellectual property infringement past happen future too so agilent battle war go agilent have zack rank hold see complete list today zack rank strong buy stock here simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
548,ABT,abbott laboratory free report report second quarter adjust earning continue operation cent share higher zack consensus estimate year year adjust quarterly number also remain ahead company guidance range cent cent report earning quarter come cent share way year number cent second quarter worldwide sale come year year report basis quarterly figure also remain slightly ahead zack consensus estimate comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter abbott laboratory price consensus ep surprise abbott laboratory price consensus ep surprise abbott laboratory quotequarter detailabbott lab operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis be positive impact back currency fluctuation sale key emerge market increase drive strong growth russia china several country latin america however positive effect be partially offset impact associate implementation new good service tax gst system india medical device business sale spiked report basis however comparable operational basisexclude impact favorable resolution third party royalty agreement last year sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis growth structural heart neuromodulation vascular product sale be structural heart business grow year yearon comparable operational basis diabetes care sale improve report basis drive double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott lab nutrition sale slip year year report basis comparable operational basis unfavorable foreign exchange impact sale marginal pediatric nutrition sale increase comparable operational basis adult nutrition sale however decrease comparable operational basis diagnostic sale rise year year comparable operational basis core laboratory sale increase point care diagnostic sale grow comparable operational basis molecular diagnostic sale be strong growth infectious disease testing business be partially offset plan scale genetic business guidanceabbott lab raise full year guidance company forecast earning share continue operation remain range earlier range cent adjust certain net specify item full year adjust earning share continue operation be expect stay band earlier guidance be current zack consensus estimate be peg midpoint project range takeone more time abbott lab successfully exceed zack consensus estimate earning sale front be optimistic company strong consistent epd medical device performance however strong performance be extent offset sluggish nutrition business however company stand benefit recently complete acquisition st jude medical have already start offer industry lead pipeline cardiovascular neuromodulation diabetes vision care look forward achieve synergy benefit company have raise outlook buoy investor confidence stock company plan execute exist operate model focus selling portfolio core therapeutic area lead creation unique channel opportunity differentiate relationship physician retailer pharmacy look offer complete line solution treat prominent local health condition also abbott lab have plan beef development capability expand epd innovation center india however india transition new tax system have significantly hampered growth report quarter company transitory impact new gst be eliminate total epd sale have grow high single digit report quarter abbott lab currently carry zack rank buy stock considerbetter rank medical stock be mesa laboratory inc mlab free report insys therapeutic inc insy free report align technology inc algn free report notably insys therapeutic sport zack rank strong buy mesa laboratory align technology carry zack rank buy see complete list today zack rank stock here mesa laboratory have positive earning surprise last quarters stock have add roughly last month insys therapeutic have long term expect earning growth rate stock have rally last month align technology have expect long term adjust earning growth almost stock have surge roughly last month top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
549,ABT,abbott free report be slate report fourth quarter result market open jan last quarter company deliver positive earning surprise moreover abbott have deliver positive earning surprise trail quarters average beat let see thing be shape announcement key prior quarter abbott be expect gain strong performance establish pharmaceutical division epd business have be record operational sale growth last few quarters major part growth be stimulate series strategic action include abbott sale develop market business acquisition cfr pharmaceutical latin america veropharm russia accordingly zack consensus estimate epd revenue show rise year quarter apart russia latin america company also continue expect strong growth epd upcoming quarters particularly china back strong market position competitive advantage also expect third quarter sale india be drive purchasing pattern follow implementation new good service tax system dent second quarter sale country thus zack consensus estimate epd revenue key emerge market indicate rise year quarter be also upbeat medical device business have be healthy growth trajectory past few quarters abbott have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system historically company have be witness solid growth global diabetes care business primarily back contribution freestyle libre follow fda approval september freestyle libre flash glucose monitoring system abbott achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quote moreover last september company announce receipt national reimbursement freestyle libre mark milestone company positive abbott freestyle libre system stand partially fully cover country include france germany japan moreover zack consensus estimate diabetes care revenue indicate rise year quarter apart market be bullish abbott development other business form part medical device segment august company announce fda approval full maglev heartmate left ventricular assist device lvad be expect boost top line contribution cardiovascular neuromodulation sub segment segment have be highest contributor total medical device revenue historically zack consensus estimate cardiovascular neuromodulation revenue indicate rise sequential quarter overall fourth quarter total revenue be project prior year quarter here be quantitative model predict abbott do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp resm be uncover best stock buy sell re report earning esp filter zack rank abbott carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise zack consensus estimate earning cent reflect rise year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic inc mygn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
550,ABT,abbott free report have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system company have be witness solid growth global diabetes care business primarily back solid contribution freestyle libre accordingly be leave stone unturned cash grow popularity cgm system eliminate need daily finger stick development freestyle librefollow fda approval september freestyle libre flash glucose monitoring system abbott recently achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage post approval freestyle libre have become only user calibration cgm device medicare coverage available person diabetes unite state meanwhile abbott have be steadily progress development diabetes care segment last september company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company announce receipt health canada license freestyle libre flash glucose monitoring system june drive diabetes care segment see revenue growth third quarter continue acceptance freestyle libre internationally believe latest cms reimbursement grant boost company performance domestic arena well expect freestyle libre contribute abbott top line japanese canadian development french health ministry approve national reimbursement device last market potentialan agee population unhealthy lifestyle rise awareness expenditure healthcare be likely drive growth further diabetes market moreover report mordor intelligence global market diabetes care device be project reach value cagr give bullish market sentiment believe recent regulatory approval freestyle libre have come opportune moment however market be dominate well establish player johnson johnson jnj free report be most prominent space johnson johnson have tie base corporation successfully develop innovate insulin delivery system share price abbott have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain comparison broader industry gain zack rank key picksabbott carry zack rank hold few better rank stock broader medical sector be bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate have gain year intuitive surgical have long term expect earning growth rate stock carry zack rank have surge year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
551,ABT,abbott free report have hit headline follow announcement receipt ce mark commercial launch alinity series integrate system hematology testing management alinity series solution be faster comparison integrate hematology system presently available moreover throughput complete blood count cbcs alinity series provide cost time efficient diagnostic testing experience laboratory notably alinity portfolio cover clinical chemistry immunoassay blood plasma screening point care hematology molecular diagnostic abbott aliniq recent development illinois base global medical device company recently sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust gain traction rapidly grow diagnostic market nwlp alliance presently cover pathology market be expect carry test year continue slew development june company receive ce mark alinity hq have become fifth new diagnostic system be launch europe ongoing rollout instrument area immunoassay clinical chemistry blood screening point care interestingly abbott rake total revenue diagnostic segment last report third quarter latest development be expect help company gain further traction space market prospectswe believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive diagnostic market go report global market molecular diagnostic be project reach value cagr thus view abbott current development space expect top line contribution boost diagnostic segment however diagnostic market be dominate well establish player quest diagnostic dgx free report qiagen qgen free report share price have be gain investor confidence consistently positive result past month company share price have outperformed broader industry stock have gain higher broader industry gain company have also surpass gain market zack rank key pickabbott carry zack rank hold better rank medical stock be walgreen boot alliance inc wba free report carry zack rank buy see complete list today zack rank strong buy stock here walgreen boot have long term expect earning growth rate stock have gain year date investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
552,ABT,have be month last earning report abbott laboratory free report share have lose time frame underperform market recent negative trend continue lead stock next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important driver earningsabbott report second quarter adjust earning continue operation share higher zack consensus estimate year year adjust quarterly number also remain ahead company guidance range report earning quarter come share way year number second quarter worldwide sale come year year report basis quarterly figure also marginally line zack consensus estimate comparable operational basis adjust impact foreign exchange certain acquisition divestment sale increase year year report quarter quarter detailabbott lab operate segment establish pharmaceutical division epd medical device nutrition diagnostic epd sale be report basis comparable operational basis be positive impact back currency fluctuation sale key emerge market increase drive strong growth russia china several country latin america however positive effect be partially offset impact associate implementation new good service tax gst system india medical device business sale spiked report basis however comparable operational basisexclude impact favorable resolution third party royalty agreement last year sale increase cardiovascular neuromodulation sale soar report basis comparable operational basis growth structural heart neuromodulation vascular product sale be structural heart business grow year yearon comparable operational basis diabetes care sale improve report basis drive double digit international sale growth lead continue consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott lab nutrition sale slip year year report basis comparable operational basis unfavorable foreign exchange impact sale marginal pediatric nutrition sale increase comparable operational basis adult nutrition sale however decrease comparable operational basis diagnostic sale rise year year comparable operational basis core laboratory sale increase point care diagnostic sale grow comparable operational basis molecular diagnostic sale be strong growth infectious disease testing business be partially offset plan scale genetic business guidanceabbott lab raise full year guidance company forecast earning share continue operation remain range earlier range adjust certain net specify item full year adjust earning share continue operation be expect stay band earlier guidance be current zack consensus estimate be peg midpoint project range have estimate be move then analyst be quiet last month period none issue earning estimate revision abbott laboratory price consensus abbott laboratory price consensus abbott laboratory quotevgm scoresat time abbott laboratory stock have nice growth score be lag bit momentum front charting similar path stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable growth investor value momentum investor outlooknotably stock have zack rank hold be look inline return stock next few month
553,ABT,illinois base global medical device company abbott laboratory free report recently sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust abbott expect alliance solidify footprint rapidly grow diagnostic market term collaboration abbott be authorize supplier analytical equipment consumable cover abbott alinity ci alinity series diagnostic instrument aliniq provide professional service informatic solution also nwlp alliance presently cover pathology market be expect execute test year future abbott have be focuse gain traction diagnostic segment june company receive ce mark alinity hq have become fifth new diagnostic system be launch europe ongoing rollout instrument area immunoassay clinical chemistry blood screening point care interestingly abbott rake total revenue diagnostic segment recently report second quarter recent development be expect help company gain further traction space report global market molecular diagnostic be project reach value cagr consider market potential abbott current development diagnostic space collaboration seem be strategic believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diagnostic market however market be dominate well establish player quest diagnostic inc dgx free report qiagen qgen free report moreover abbott have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank key picksabbott currently have zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
554,ABT,trump administration failure push new healthcare law have possibly sandbagged hope policy measure boost stock future fact investor now have little confidence left president pre poll promise be start bank fundamental concern evaluate investment option needless say earning performance state economy feature top list such factor meanwhile market watcher now believe fall dollar be just tonic market need decline greenback provide equity fresh upside boost earning commodity centric multinational company volatile scenario investing stock nature be large enough be include make profitable option policy paralysis fell dollar recent set decline have provide analyst opportunity determine have positive effect corporate earning understand gravity situation need look further dollar index be year date comparison have already gain same period immediately trump surprise victory dollar soar hope president growth oriented industry friendly policy boost economy earning however repeat failure push policy proposal have left investor somewhat disenchant little headway make tax reform fiscal stimulus measure new healthcare law so call trump trade have experience reversal lead greenback decline fall dollar boost earningsinstead investor have choose focus state economy reluctance fed raise rate likely strong second quarter earning season clutch analyst now feel softer dollar be just tonic earning need earning feel heat soar dollar last year decline be extremely beneficial time additionally phenomenon illustrate expectation extent fed hike rate have undergo change fall dollar usually have positive impact price commodity be company stand gain handsomely dollar decline be business be commodity centric multinational significant overseas exposure accord analyst morgan stanley ms free report earning increase decline dollar financial major explain factor impact earning roll basis effect become apparent second half year logic decline dollar value end current year boost earning morgan stanley project dollar decline additional earning grow earning be likely receive welcome boost plunge dollar value be likely be especially beneficial company deal commodity primarily multinational operation add stock company high percentage overseas sale accord strategas research partner make look smart option juncture have narrow search follow stock base good zack rank other relevant metric micron technology inc mu free report be lead worldwide provider semiconductor memory solution micron technology have zack rank strong buy expect earning growth current year be more earning estimate current year have improve last day nvidia corporation nvda free report offer digital medium processor related software wide range visual compute platform nvidia have zack rank company have expect earning growth current year earning estimate current year have improve last day lam research corp lrcx free report supply wafer fabrication equipment service semiconductor industry lam research have expect earning growth current year earning estimate current year have improve last day stock have zack rank see complete list today zack rank strong buy stock here apply material inc amat free report be world largest supplier equipment fabrication semiconductor flat panel liquid crystal display lcds solar photovoltaic pv cell module apply material have zack rank buy expect earning growth current year be earning estimate current year have improve last day abbott laboratory free report discover develop manufacture sell diversify line health care product abbott laboratory have zack rank company have expect earning growth current year earning estimate current year have improve last day more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
555,ABT,abbott laboratory free report be illinois base company focuse bring diverse line healthcare product market abbott lab report diversify business segment namely establish pharmaceutical division epd medical device diagnostic nutrition company have reshape portfolio strategic acquisition divestiture recent time have also be take strategic step expand footprint grow geography investing have result numerous new product launch business feb abbott complete sale brand generic pharmaceutical business develop market realignment epd division acquisition latin america russia business divestiture develop market have position company well come quarters however unfavorable movement foreign currency rate be affect top line adversely abbott lab have impressive track record company beat estimate last trail quarters average positive earning surprise currently abbott lab have zack rank buy definitely change follow company second quarter earning report be just release see complete list today zack rank strong buy stock here have highlighted key stat just reveal announcement earning zack consensus estimate remain steady cent share last day abbott lab second quarter earning share continue operation cent outpaced estimate revenue abbott lab post second quarter revenue lag zack consensus estimate revenue abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quotekey stat worldwide nutrition sale decrease report basis second quarter worldwide diagnostic sale increase report basis total establish pharmaceutical sale increase report basis revenue worldwide medical device increase report basis major factor management abbott second quarter performance reflect strong start year management raise guidance range report ep continue operation range integration st jude be currently go recently launch product be contribute double digit sale growth several area abbott medical device business stock price follow earning release share price rise pre market trading session check back later full abbott lab earning report later cke_protected dtd bborder px solid ccc dbr bmso datum placement asame cell top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
556,ABT,earning season be pick steam week be key be big cross section name report earning many different sector include railroad big industrial technology regional bank get good look global economy report be good everyone have be say not easy beat estimate nearly quarter year company have be do just just have great track record doesn mean always continue beat keep earning streak alive quarter hot earning chart abbott lab free report hasn miss year share have be narrow trading range most time recently have start trickle finally be everyone have be wait ppg industry ppg free report have great track record just miss share have be stick last year be time industrial make move higher snap sna free report hasn miss year investor have grow leery share have be tread water take resume upward momentum microsoft msft free report have become important earning report again share trade year high everyone be watch cloud ebay ebay free report hasn miss spun paypal be overlooked online retailer ready head back spotlight want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today click here free day trial look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
557,ABT,share abbott free report rally new week high dec close session nominally lower represent strong year date return approximately higher stock have zack rank hold take stable stock performance consideration expect abbott scale higher quarters ahead company also have trail quarter average positive earning surprise positive long term growth hold promise well majority last month company share price have considerably outperformed broader industry stock have rally last month beating industry gain just factor drive stockalere acquisition abbott successful closure alere acquisition prolong legal battle have instilled confidence investor acquisition close october amend financial term favor abbott take attractive prospect point care testing diagnostic market consideration abbott be highly optimistic alere integration accord company alere buyout significantly expand diagnostic presence moreover abbott expect alere contribute top line recent fda approval abbott be effectively focuse core therapeutic area recently freestyle libre flash receive fda approval also receive approval mr conditional labele ellipse icd develop diabetes business have be slew development diabetic business be upbeat abbott freestyle libre flash glucose monitoring system recent reimbursement approval company recently announce receipt health canada license same company receive full partial reimbursement french health ministry product solid emerge market performance abbott emerge market performance have be promising courtesy latest strategic development notably company have be witness double digit growth brazil russia india china late key picksa few better rank medical stock be athenahealth inc athn free report align technology inc algn free report luminex corporation lmnx free report notably athenahealth align technology luminex sport zack rank strong buy see complete list today zack rank stock here athenahealth have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year luminex have long term expect earning growth rate stock have gain past month zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
558,ABT,intersect ent inc xent free report receive approval fda sinuva sinus implant company have be focuse develop innovative therapy chronic sinusitis patient sinuva be exclusive approach treat recurrent nasal polyp disease patient have undergo ethmoid sinus surgery management approximately american have go surgery be look treatment cure side effect intersect ent expect sinuva be costlier other product portfolio however higher price not dent company gross margin upcoming fourth quarter have long term expect earning growth rate notably nasal polyp be inflammation line nasal passage sinus result congestion infection low sense smell sinuva be intersect ent fourth commercial product be likely be introduce physician country follow month share shine brightyear date intersect ent have have solid run bourse trading market large company return compare favorably industry rally only also current return be higher index increase same time frame stock have zack rank hold see complete list today zack rank strong buy stock here market trend buoy new technology rapid innovation healthcare market be create opportunity company be strive make profit sinusitis treatment market report persistence market research center disease control prevention cdc have reveal person unite state get diagnosed chronic sinusitis regular basis consider solid prospect market believe intersect ent gain strong market traction upcoming day few other major market player engage manufacturing treatment product sinusitis include sanofi sny free report abbott laboratory free report eli lilly company lly free report takeintersect ent fourth quarter operate expense be likely rise thank time expense related sinuva launch production demo unit cost related market access infrastructure latest development propel contour be expect be important driver intersect ent product propel propel mini be drug eluting implant patient suffering chronic sinusitis offer product therapy ear nose throat surgeon improve treatment patient chronic disease make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
559,ABT,fda approval roche holding rhhby free report hemlibra coba cdiff nucleic acid test thermo fisher scientific tmo free report slew advancement next generation sequence latest be fda approve oncomine dx target test clearly point rapid emergence diagnostic ivd medtech space recent evaluatemedtech world preview indicate worldwide medtech sale be expect witness cagr steering ahead cardiology ivd rake annual sale cagr datum be just small indicator vast scope growth ivd market investor keen medtech most important fact be ivd benefit be not limit particular country geographic territory emergence complex transmittable disease worldwide part medtech space be currently spotlight ivd nutshellif go fda definition diagnostic be test detect disease condition infection test be used laboratory other health professional setting other test be consumer use home growth factorsrapid occurrence infectious disease worldwide increase burden killer bug cancer cardiovascular disease stroke other heart disease diabetes develop develop nation well grow cognizance early cancer screening detection prevention have make ivd indispensable healthcare space grow investment government private player form reimbursement coverage speedy patent approval be also drive demand apart report research market increase geriatric population rise capita gdp capita healthcare expenditure be act major growth catalyst report owing suitable demographical change rise disposable income couple improve basic infrastructure develop region be gradually become happy hunting ground business geographic distribution so far north america have lead diagnostic market coherent market insight datum be highest contribute region project market share cagr favorable demography regulatory policy increase healthcare spending have aid growth ivd business geography however increase instance lifestyle oriented disease improve government funding grow awareness new technology have fuel demand ivd emerge economy accord recent report research market china be fastest grow top ivd country market be likely expand more threefold other hand revenue indian ivd market have grow cagr have increase datum goldstein research segmental contribution medgadget report apart geographic distribution global diagnostic market have be segmented basis application type end user usability application wise diabetes infectious disease oncology nephrology autoimmune disease cardiology be generate huge revenue globe point view end user hospital laboratory point care testing be lead user term usability disposable ivd device re usable ivd device be widely used globe key player roche remain top player ivd market expect sale key ivd development roche include coba range test latest be coba first commercially available test detection virus rna sample human plasma other hand abbott free report recent acquisition alere establish company global leader point care testing fastest grow segment diagnostic market regard company note point care testing be segment diagnostic market be grow rapidly other bigwig becton dickinson company bdx free report deserve mention company be strive get approval innovative product fast grow infectious disease testing market bd diagnostic provide product safe collection transport diagnostic specimen well instrument reagent system detect broad range infectious disease healthcare associate infection cancer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
560,ABT,dexcom inc dxcm free report recently announce signing development agreement eli lilly company lly free report agreement dexcom flagship continuous glucose monitoring system cgm be add lilly connect diabetes ecosystem integration cgm lily smart insulin delivery device dexcom aim provide holistic approach diabetes management customer notably clinical trial be expect begin end dexcom fda clear cgm system dexcom platinum be contribute significantly top line dexcom platinum be most innovative cgm system market june dexcom have announce fda approval dexcom mobile app android device moreover dexcom have collaborative agreement several company not only bring cash form milestone payment royalty also help expand product use september dexcom announce tie lead wearable brand fitbit develop market product help person better manage diabetes get clearer picture overall health first plan initiative be bring dexcom cgm datum fitbit new smartwatch fitbit ionic company aim make smartwatch available continue explore way develop tool improve diabetes management believe glucose monitoring market represent significant commercial opportunity dexcom report mordor intelligence global market diabetes care device be project reach value cagr also international diabetes federation idf estimate worldwide incidence person suffering diabetes reach recently management dexcom confirm company be well poise congregate unmet demand global diabetic space especially come cgm dexcom increase patient convenience enhance connectivity datum analytic lower cost platform fortify company foothold global diabetic space however diabetes market be dominate many well establish player abbott free report be most prominent space abbott recently announce receipt fda approval freestyle libre flash glucose monitoring system unite state share price have be gain investor confidence consistently positive result last month company share price outperformed broader industry stock have gain compare broader industry company have also outperformed gain market zack rank key pickdexcom carry zack rank hold better rank medical stock be petm express inc pet free report zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
561,ABT,hca healthcare inc hca free report report third quarter adjust earning share come line zack consensus estimate bottom line decline nearly year year hca holding inc price consensus ep surprise hca holding inc price consensus ep surprise hca holding inc revenue be offset increase expense share be pre market trading hca healthcare post revenue almost line zack consensus estimate report figure be year quarter provision doubtful account surge year year quarterly detailsadjust ebitda totale year year same facility equivalent admission inched year year same facility admission nudge same facility revenue equivalent admission increase salary benefit supply other operate expense increase year year sep hca healthcare run hospital free standing surgery center financial updatea sep company have cash cash equivalent total debt total asset report quarter capital expenditure totale exclude acquisition cash flow provide operate activity totale year year sep company total debt adjust ebitda be compare dec quarter review company spend buy back share board director approve additional share repurchase program follow latest authorization company have remain exist repurchase authorization oct company expect revenue range adjust ebidta ep capital expenditure zack rank performance other company medical sectorhca healthcare presently carry zack rank strong sell see complete list today zack rank stock here abbvie inc abbv free report abiom inc abmd free report abbott laboratory free report have surpass respective zack consensus estimate last quarter wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
562,ABT,align technology inc algn free report report earning share ep third quarter substantially year year earning be also higher company guide range cent figure comfortably beat zack consensus estimate cent revenuesrevenue grow year year quarter surpass zack consensus estimate also remain well ahead company guide range management strong top line be drive robust invisalign case shipment year year third quarter upside be backed growth north america international region also year year surge teenage case board reflect very strong summer season contribute top line growth segment detailrevenue clear aligner segment total revenue soar year year report quarter primarily drive continue strong invisalign case volume growth customer channel geographical region third quarter invisalign case shipment amount year year aid growth region well expansion customer base quarter align technology invisalign case be ship doctor worldwide be north america be international region revenue scanner service improve significantly marginsgross margin third quarter be basis point bps year year rise cost net revenue quarter align technology witness year year increase selling general administrative expense rise research development expense operate margin however expand bps financial detailsalign technology exit third quarter cash cash equivalent short term marketable security marked rise precede quarter report quarter align technology close earlier announce accelerate stock repurchase program asr receive total share weight average share price management currently have available repurchase exist stock repurchase authorization fourth quarter company project ep cent revenue company also expect invisalign case shipment band same period year takealign technology end third quarter solid note earning revenue beating zack consensus estimate be upbeat continue strong invisalign volume extremely strong summer season drive company invisalign growth global market scanner service company witness nice uptake itero scanner gp dentist record contract come gp summit last september company expect bullish trend continue rest align be also look forward recently inked distribution agreement patterson dental align itero element intraoral scanning system additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flip side company be expose foreign exchange fluctuation seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio extension zack rank key pickscurrently align technology carry zack rank hold better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue rally year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
563,ABT,cheme corp che free report third quarter adjust earning share ep be compare year figure figure also surpass zack consensus estimate quarter detailsrevenue quarter increase year year beating zack consensus estimate cheme currently operate wholly own subsidiary namely vita healthcare corporation major provider end life care roto rooter lead commercial residential plumbing drain clean service provider third quarter net revenue vita healthcare totale reflect increase year year revenue be drive increase average net medicare reimbursement rate rise average daily census however be offset acuity mix shift impact revenue roto rooter report sale third quarter be year year accord company revenue water restoration increase year year gross margin expand basis point bps year year adjust operate margin expand bps quarter rise selling general administrative expense cheme exit third quarter total cash cash equivalent end second quarter company have total debt end third quarter compare end precede quarter sep company have approximately undrawn borrow capacity exist year credit agreement third quarter company repurchase share worth march board have authorize additional cheme exist share repurchase plan sep company have remain share repurchase authorization plan company continue project vita healthcare revenue growth range prior medicare cap also admission average daily census be expect increase earlier be medicare cap bill limitation be expect be earlier project roto rooter business be estimate grow full year compare earlier range raise guidance be backed increase job pricing water restoration service growth full year adjust ep be expect grow range previously compare report takecheme exit third quarter solid note also company witness year year growth front moreover be encourage note company subsidiary see year year revenue growth quarter expansion gross operate margin strong bottom line projection also buoy optimism further reimbursement related issue seasonality business competitive landscape dependence government mandate continue challenge cheme zack rank key pickschemedha zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
564,ABT,resm inc rmd free report announce first quarter fiscal adjust earning share ep cent prior year quarter earning also beat zack consensus estimate penny include time item resm report ep cent quarter year year revenue detailsrevenue report quarter increase year year constant exchange rate cer figure also beat zack consensus estimate geographic basis exclude revenue americas totale reflect increase prior year quarter moreover revenue report quarter totale year year revenue combine emea apac be highlight year year rise cer adjust gross margin contract basis point bps year year report quarter selling general administrative expense be year year be increase research development expense lead rise adjust operate expense amount accordingly adjust operate margin quarter contract bps financial updateresmed exit first quarter fiscal cash cash equivalent compare end fiscal year date company generate cash flow operation year figure concurrent first quarter earning release resm announce regular quarterly dividend cent share dividend be paid dec shareholder record nov previously declare resm temporarily suspend share repurchase program due recent acquisition however company still expect recommence buy back program sometime fiscal expect sg expense percentage revenue end fiscal expense percentage revenue be project fiscal reflect marketing expense associate product launch ongoing legal expense takeresm exit first quarter promising note brighter side company achieve solid double digit global revenue growth quarter lead sale software service business well new mask product device company also recently launch airfit classic nasal mask positive airway pressure pap treatment europe factor boost investor faith stock however challenge competitive bidding reimbursement issue continue plague stock company also remain expose foreign exchange fluctuation zack rank key picksresm currently carry zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
565,ABT,cardiovascular system inc csii free report report adjust loss share cent first quarter fiscal flat year quarter adjust loss cent figure be narrower earlier provide guide range loss share cent figure compare favorably zack consensus estimate loss cent result system post revenue fiscal first quarter mark year year decline also figure be lower guide range first quarter fiscal figure also miss zack consensus estimate management procedure volume first quarter fiscal be impact hurricane moreover saline infusion pump recall quarter result lower estimate usage coronary device factor play significant role result revenue miss quarter cardiovascular system inc price consensus ep surprise cardiovascular system inc price consensus ep surprise cardiovascular system inc quote date cardiovascular system have sell device lead institution unite state company add new peripheral account coronary account fiscal first quarter coronary device revenue decline year year peripheral device revenue inched margingross margin report quarter be basis point bps year year meanwhile selling administrative sg expense contract research development expense be resultantly adjust operate expense inched management operate expense be lower earlier provide guidance due lower incentive compensation result deterioration financial performance operate loss be compare loss year quarter financial company exit first quarter fiscal cash cash equivalent compare end fiscal system reaffirm fiscal revenue guidance range current zack consensus estimate fiscal revenue be peg be company guide range company expect revenue range second quarter fiscal current zack consensus estimate be peg company guide range moreover company expect gross profit account revenue operate expense be estimate second quarter fiscal company expect incur net loss loss share cent second quarter fiscal current zack consensus estimate be peg loss penny company guide range system exit first quarter fiscal mixed note decline year year revenue coronary device peripheral device be disappointing fiscal first quarter revenue decline year year basis owing impact hurricane positive note report loss quarter be narrower guide range company also expansion be gross margin be impressive company reaffirm revenue guidance fiscal buoy optimism moreover company be putt effort product innovation investment quarter company release year datum liberty clinical study late breaking presentation amputation prevention symposium amp chicago liberty show peripheral endovascular intervention help prevent amputation patient peripheral artery disease zack rank key pickscurrently cardiovascular system have zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
566,ABT,walgreen boot alliance inc wba free report report adjust earning share ep fourth quarter fiscal year year adjust ep surpass zack consensus estimate report basis net earning come reflect decrease prior year quarter report earning come cent share show decline year year basis full year adjust ep come year quarter figure also surpass zack consensus estimate total saleswalgreen boot record total sale fiscal fourth quarter year year constant exchange rate cer top line outpaced zack consensus estimate fiscal sale totale year period moreover figure beat zack consensus estimate slight margin walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc quotesegment detailwalgreen boot currently report operate segment retail pharmacy usa retail pharmacy international pharmaceutical wholesale retail pharmacy usa division record sale fourth quarter highlight increase year year basis segment total sale comparable drugstore rise prescription filled comparable store grow account medicare part growth volume growth previously announce strategic pharmacy collaboration comparable retail sale drop due lower sale consumable general merchandise category personal care category partially offset increase sale health wellness well beauty category pharmacy sale account retail pharmacy usa division sale quarter increase year quarter pharmacy sale comparable store rise higher volume revenue retail pharmacy international division decline year year basis cer owing currency fluctuation cer comparable store sale fourth quarter decrease year year comparable pharmacy sale increase lead growth pharmaceutical wholesale division record quarterly sale year year cer marginsgross profit report quarter decline year year accordingly report gross margin contract basis point bps selling general administrative sg expense be year year however adjust operate income increase rise revenue outweighed increase operate expense contrast adjust operate margin contract bps financial boot exit fiscal cash cash equivalent compare end fiscal long term debt be compare end prior fiscal company generate operate cash flow fiscal compare year resultant free cash flow be fiscal boot have issue fiscal guidance company expect adjust ep range fiscal current zack consensus estimate fiscal earning be peg lower end company guide range takewalgreen boot report impressive fourth quarter fiscal earning sale surpass zack consensus estimate however decline sale retail pharmacy international be disappointment nevertheless walgreen boot have be gain account company strategic tie up bring more patient pharmacy september walgreen boot announce receipt federal trade commission ftc approval purchase store distribution center related inventory rite aid total synergy be expect be realize year initial close transaction achieve majorly procurement cost saving other operational area walgreen boot modify merger contract be line growth strategy offer additional operational benefit also help company expand optimize retail pharmacy network key market include northeast zack rank key pickscurrently walgreen boot have zack rank sell few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
567,ABT,share price abbott free report scale new week high oct eventually close lower company have gain past month much higher gain abbott have also outperformed broader industry gain last month stock have market cap further abbott estimate revision trend current year have be favorable past day estimate moved moved estimate be share same time frame company also have trail quarter average positive earning surprise positive long term growth hold promise abbott carry zack rank hold company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity growth market be upbeat abbott acquisition alere get complete oct face several regulatory hurdle buyout help company gain access new channel geography include entry fast grow outlet such doctor office clinic pharmacy home testing major upside company be recent fda approval freestyle libre flash glucose monitoring system unite state market be also optimistic abbott gain national reimbursement freestylelibre glucose monitoring system national health service nhs business service authority have be major breakthrough company diabetic business also be worth mention abbott ellipse implantable cardioverter defibrillator icd recently gain fda approval magnetic resonance mr conditional labele factor be expect drive company share price further key picksa few better rank stock medical sector be orthofix international ofix free report luminex corporation lmnx free report idexx laboratory inc idxx free report orthofix international luminex sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month luminex have long term estimate earning growth rate stock gain last month idexx laboratoriesha long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
568,ABT,investor keen consolidation abbott lab free report alere expect much await good news arrive soon abbott latest update necessary regulatory clearance get fulfilled closure company finally plan complete hugely contentious acquisition alere inc oct notably year rollercoaster ride overcome regulatory hurdle abbott alere have progressed merger process base certain amend term original agreement amend agreement clause announce earlier april abbott have agree pay common share acquire alere reduction earlier deal common share cash transaction conclusion result expect new equity value approximately lower originally estimate equity value almost takeabbott have state successful wrap transaction total diagnostic sale be company also anticipate emerge lead player point care diagnostic space broader diagnostic market takeover combine entity be expect generate approximately point care testing sale worldwide buyout also enable company gain access new channel geography include entry fast grow outlet such doctor office clinic pharmacy home testing more alere complementary portfolio diagnostic product comprise test infection such hiv tuberculosis malaria dengue be add abbott portfolio significantly alere develop simple rapid test include alere molecular test flu strep deliver report less minute hence share business offer several option test broad array instance infectious disease molecular cardiometabolic toxicology testing also union definitely expand abbott lab platform include benchtop rapid strep test alere hitherto generate half total sale unite state alone company have grow presence key international market potential strengthen abbott footprint ahead territory price performanceover past month abbott share price have outperformed broader industry belong stock have gain versus industry loss zack rank other key picksabbott currently carry zack rank hold better rank medical stock be idexx laboratory inc idxx free report luminex corp lmnx free report masimo corp masi free report carry zack rank buy see complete list today zack rank strong buy stock here idexx laboratory have positive earning surprise last quarters stock have roughly surge last year luminex corp have long term expect earning growth rate stock have gain last month masimo have expect long term adjust earning growth almost stock have rally nearly year date today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
569,ABT,medtronic plc mdt free report recently initiate post market forward pro clinical study measure performance corevalve evolut pro transcatheter aortic valve implantation tavi system regular clinical treatment study evaluate long term performance next generation self expand tavi system patient severe symptomatic aortic stenosis be intermediate high extreme risk open heart surgery notably system have recently be approve commercial use europe unite state management multus center study enroll patient site europe moreover study involve measure safety standard corevalve evolut pro valf analyze cause mortality stroke rate day clinical performance cover valve hemodynamic paravalvular regurgitation moreover company patient be continue be follow evaluate year encouragingly note march corevalve evolut pro system have receive fda approval use symptomatic patient be high extreme risk open heart surgery moreover self expand tavi system have be grant regulatory approval europe well thus believe clinical study datum display efficiency product help company gain traction coronary structural heart csh space interestingly medtronic csh revenue be constant exchange rate back high constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform unite state continue demand corevalve evolut mm valve unite state well europe notably report medgadget global heart valve repair replacement market be expect grow cagr believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr medtronic be base highly fragmented heart valve repair replacement market however market be dominate well establish player abbott free report boston scientific corporation bsx free report edward lifescience corporation ew free report other boston scientific lotus valve platform edward lifescience sapien xt sapien offering be worth mention here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
570,ABT,accuray incorporate aray free report report loss cent share first quarter fiscal line zack consensus estimate figure be narrower loss cent incur year quarter total revenue first quarter increase approximately year year beat estimate year year upside be drive product revenue growth segment analysisproduct revenue revenue segment increase back solid performance cyberknife tomotherapy system radixact platform segment increase product revenue be drive backlog conversion order revenue eimea japan region accuray incorporate price consensus ep surprise accuray incorporate price consensus ep surprise accuray incorporate quote service revenue revenue segment see modest year year increase management growth segment be primarily drive continue install base expansion gross order update report quarter gross product order totale year year rise gross order be support company flagship radixact system tomotherapy other platform drife sale company new tomotherapy product platform also know radixact continue contribute top line radixact represent majority accuray tomotherapy order mix report quarter japan witness stellar performance radixact tomotherapy platform precision system accuray announce launch new precision treatment plan system recently system leverage company flagship radixact cyberknife system platform provide significantly improve treatment speed overall throughput cyberknife system ibms datum management system tomotherapy accuray also announce clearance new ibms datum management system tomotherapy be centralize database share make datum accessible multiple accurate system enhance flexibility improve efficiency radiation therapy department margin margin percentage net revenue expand basis point bps first quarter be primarily drive significant rise product service gross margin product gross margin improve back cyberknife system first quarter compare prior year quarter operate expense first quarter totale compare year period guidanceaccuray reaffirm guidance fiscal company maintain full year revenue projection band represent growth year year basis company also expect increase gross order fiscal adjust ebitda fiscal be anticipate range year year takeaccuray report loss first quarter fiscal however loss be narrower year figure company exit quarter solid note earning meeting consensus estimate revenue surpass same year year increase product service revenue be encourage reaffirm guidance also buoy optimism however fluctuation currency exchange rate particularly strong dollar continue affect company backlog top line zack rank key pickscurrently accuray have zack rank hold better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
571,ABT,illumina inc ilmn free report report adjust earning share ep third quarter beat zack consensus estimate cent adjust earning also surpass year number include time item company report ep compare cent year revenuesin report quarter illumina revenue grow year year moreover top line beat zack consensus estimate illumina inc price consensus ep surprise illumina inc price consensus ep surprise illumina inc quote management top line growth third quarter be attribute strong uptake sequence consumable instrument well microarray portfolio moreover novaseq platform continue drive growth close novaseq system currently customer hand launch january management be also hopeful recent launch flow cell xp nextera dna flex library preparation kit drive novaseq demand product revenue total revenue increase year year service other revenue be year year operational updateillumina adjust gross margin come reflect contraction basis point bps year year owing novaseq introduction higher array service revenue product mix sequence consumable exclude amortization acquire intangible asset include stock base compensation expense adjust gross margin be highlight contraction bps year research development expense be year year selling general administrative expense rise consequently adjust operate margin reflect decline bps year period financial updateillumina exit third quarter cash cash equivalent short term investment third quarter year date net cash provide operate activity be compare year period guidancebanking solid third quarter performance illumina have raise full year revenue growth expectation earlier provide range meanwhile zack consensus estimate full year revenue be peg company raise adjust ep band earlier zack consensus estimate illumina bottom line stand far low end guide range takeillumina exit third quarter solid note be also encourage year year increase front company have also raise full year revenue guidance adjust ep range be look forward performance novaseq flow cell reagent kit novaseq xp novaseq system flip side weak margin owing lower instrument margin associate novaseq launch higher array service mix continue act deterrent also tough competitive landscape be concern zack rank key pickscurrently illumina have zack rank hold better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
572,ABT,edward lifescience corporation ew free report report third quarter adjust earning share ep cent miss zack consensus estimate cent however adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business exclude time item net income third quarter come cent share year year respectively sale detailsedward lifescience third quarter sale improve however figure miss zack consensus estimate underlie sale increase include impact germany stocking sale customer nation choose purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance surgical heart valve therapy critical care product line too region edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quote segment third quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter unite state thvt sale quarter totale year year growth be drive excellent clinical performance sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system strong uptake core product outside unite state partially offset continue shift surgical aortic valf sapien valf unite state europe critical care sale be report quarter represent increase third quarter solid growth product category be drive strong growth company core product enhance surgical recovery program mainly unite state asia pacific marginsin third quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf well favorable comparison supply chain expenditure be however partially offset expense incur due flood hurricane marium puerto rico shutdown company manufacturing plant switzerland sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment expenditure increase year year owing continue investment company transcatheter aortic valve mitral valve program adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit third quarter cash cash equivalent short term investment compare end second quarter long term debt quarter totale compare report previous quarter cash flow operate activity be third quarter compare previous quarter exclude capital spending free cash flow be quarter average diluted share outstanding be guidance staysedward lifescience have reaffirm full year sale expectation high end previously project range zack consensus estimate full year revenue be coincide high end guide range adjust ep expectation have also be reinstate zack consensus estimate full year adjust ep stand company guide range fourth quarter company project sale adjust effect germany stocking sale zack consensus estimate revenue be company project range company estimate adjust ep cent cent meanwhile zack consensus estimate adjust ep be cent be also company forecast range takeedward lifescience exit third quarter disappointing note earning revenue lag respective zack consensus estimate company business be affected recent natural disaster caribbean unite state edward lifescience have principal manufacturing location critical care product puerto rico dominican republic puerto rico company have discontinue production due flood affected top line extent company also have postpone number procedure houston florida management natural disaster negatively impact third quarter sale tune nevertheless strong transcatheter valve sale domestic market well overseas be major positive company also perform well gross margin front raise optimism management expect gain traction ever expand tavr market base increase preference favor transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy however tough competition cardiac device market reimbursement issue continue challenge zack rank key pickscurrently edward lifescience have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
573,ABT,abaxis inc abax free report report second quarter fiscal adjust earning share cent line zack consensus estimate however adjust ep figure decline year figure cent total revenuein fiscal second quarter abaxis record revenue reflect increase year top line however miss zack consensus estimate accord company foreign currency exchange rate fluctuation have negligible impact abaxis top line segment detailon geographic basis revenue north america accounting total revenue decline report quarter revenue international market accounting rest improve abaxis operate main segment namely veterinary medical other report quarter veterinary sale account total sale medical contribute remain be generate other abaxis inc price consensus ep surprise abaxis inc price consensus ep surprise abaxis inc quote veterinary market revenue improve year year drive uptick veterinary consumable revenue veterinary instrument revenue be year year revenue medical market be same quarter last year strength piccolo instrument be offset decline medical rotor also revenue north american medical division totale year year global basis abaxis sell piccolos quarter compare year abaxis exhibit strong consumable growth year year quarter consumable product line total rotor revenue be almost line year quarter global basis abaxis sell rotor unit quarter review unit year quarter hematology reagent rapid assay drive growth consumable revenue report quarter however total instrument sale decrease due lower veterinary instrument sale operational updatesfiscal second quarter gross profit drop gross margin contract basis point bps research development expense increase year year sale marketing expense rise general administrative expense however decline however resultant operate income be quarter operate margin decline bps financial updateabaxis exit fiscal second quarter cash cash equivalent short term investment compare first quarter fiscal takeabaxis exit second quarter fiscal disappointing revenue lag zack consensus estimate also decline gross operate margin be matter concern however year year increase revenue buoy optimism be look forward improve consumable revenue boost veterinary sale performance abaxis quarter meanwhile be encourage note company be initiate new sale marketing strategy regard company recently start shipping vetscan ua hand hold urine chemistry analyzer september moreover latest launch vetscan phenobarbital profile vetscan canine pancreatic lipase rapid test buoy optimism abaxis plan additional product launch fiscal include vetscan fuse connectivity system accord company addition product drive growth long haul zack rank key pickscurrently abaxis have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year report basis intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
574,ABT,share abbott laboratory free report gain company report second quarter earning cent share higher zack consensus estimate share kinder morgan inc kmi free report soar company announce dividend hike share buyback plan share philip morris international inc pm free report decline company report second quarter earning share miss zack consensus estimate share traveler company inc trv free report drop company post second quarter earning share miss zack consensus estimate
575,ABT,petm express inc pet free report announce earning share ep cent second quarter fiscal year quarter cent also earning surpass zack consensus estimate year year rise earning be drive increase sale improve margin net sale report quarter rise year year outpace zack consensus estimate petm express inc price consensus ep surprise petm express inc price consensus ep surprise petm express inc quote lead pet pharmacy americas upside sale be result increase new order reorder quarter report quarter reorder sale increase year year basis new order sale rise average order value be approximately quarter compare year quarter note variation average order value be mainly drive shift sale higher price item company seasonality business be mainly proportion flea tick heartworm medication product mix spring summer be consider peak season fall winter represent season quarter review petm acquire new customer year roughly order be generate versus prior year quarter gross margin expand basis point bps year year report quarter general administrative expense be year year also advertising expense rise lead increase adjust operate expense depreciation expense amount nevertheless adjust operate margin quarter rise bps year quarter petm exit fiscal second quarter cash cash equivalent compare end first quarter fiscal company also announce quarterly dividend cent share payable shareholder record nov takepetm successfully deliver yet quarter solid result fiscal second quarter company once again top zack consensus estimate revenue earning be also encourage note stellar increase reorder new order sale quarter company be also strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale shift sale higher margin item also expand product offering petm currently offer wide range product cater dog cat horse work upgrading exist portfolio zack rank key pickspetm currently have zack rank hold few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock rally roughly last year idexx laboratory have long term expect earning growth rate stock surge last year thermo fisher have long term expect earning growth rate stock gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
576,ABT,baxter international inc bax free report be schedule report third quarter earning oct open bell last report quarter company deliver positive earning surprise take quarter average let see thing be shape prior release factor playwe be encourage company guidance third quarter full year third quarter baxter anticipate sale growth constant currency adjust earning share be forecast range cent versus year figure cent also full year company project earning band share continue operation special item full year earning late baxter international have accelerate pace acquisition strategic collaboration enhance product portfolio thereby open significant long term opportunity also several recent fda approval be likely drive growth yet be report third quarter company estimate revision trend be also encourage current year baxter international witness upward estimate revision movement opposite direction last month however lower sale threat company integrate pharmacy solution franchise third quarter decline sale be expect impact top line low single digit also foray group purchasing organization gpos unite state intensify competition company earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp baxter international be be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotestock considerhere be company consider model show have right combination element post earning beat upcoming quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
577,ABT,second quarter earning season be nascent stage participant have report result jul accord latest earning preview earning cycle have witness encourage start courtesy stable bank result total earning member have go increase revenue uptrend be result reduce regulatory burden tax law change improve outlook domestic economy latest earning preview report second quarter earning company be expect be year quarter higher revenue majority earning yet be release next fortnight be crucial decide quarter turn be game changer irrespective outcome investor focuse medical sector expect good news medical sector broader zack sector be expect witness higher revenue quarter decline revenue investor be adopt watch space zack categorize medical product industry have register growth last month underperform index gain market remain jittery major part month due uncertainty surround future healthcare act let take sneak peek performance major medical product company be expect report earning early next week abbott laboratory free report be schedule report second quarter result open bell jul abbott have be healthy growth trajectory establish pharmaceutical division epd business company have deliver encourage operational sale growth trail few quarters however absence substantial advancement division recent past have compel company maintain low expectation high single digit growth yet be report quarter uncover best stock buy sell re report earning esp filter proven model do not conclusively show abbott be likely beat earning quarter be abbott laboratory have earning esp zack rank buy be most accurate estimate zack consensus estimate be cent abbott zack rank increase predictive power esp however company esp make surprise prediction difficult read more abbott laboratory pull surprise earning abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quoteintuitive surgical inc isrg free report be set report second quarter result close bell believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key growth catalyst company see complete list today zack rank strong buy stock here proven model do not conclusively show intuitive surgical be likely beat earning quarter be intuitive surgical currently have earning esp zack rank hold be most accurate estimate zack consensus estimate be peg read more intuitive surgical surprise earning intuitive surgical inc price ep surprise intuitive surgical inc price ep surprise intuitive surgical inc watertown athenahealth inc athn free report cloud base network provide service manage administrative duty medical provider company software platform handle bill management quality measurement report clinical documentation datum exchange patient communication referral many other related task company be schedule report second quarter earning believe company strong product portfolio expand physician base unique business model boost prospect company however proven model do not conclusively show company be likely beat earning give combination zack rank earning esp read more store athenahealth earning athenahealth inc price ep surprise athenahealth inc price ep surprise athenahealth inc quoteabaxis inc abax free report be schedule report second quarter be california base manufacturer portable medical human veterinary animal blood analysis system provide clinician rapid blood constituent measurement medical veterinarian market worldwide abaxis currently carry zack rank hold have earning esp be most accurate estimate zack consensus estimate stand cent abaxis inc price ep surprise abaxis inc price ep surprise abaxis inc earning beat miss investor focus company fundamental make investment decision therefore don forget check full earning release stock later trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
578,ABT,abbott laboratory free report be schedule report second quarter result open bell jul last quarter company earning exceed zack consensus estimate remarkably also company post average beat trail quarters let sneak peek thing be shape prior announcement factor playabbott have be healthy growth trajectory establish pharmaceutical division epd business deliver encourage operational sale growth trail few quarters major part growth be stimulate series strategic action include sale abbott develop market business acquisition cfr pharmaceutical latin america veropharm russia however absence substantial advancement division recent past have compel company maintain low expectation high single digit growth yet be report quarter abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quoteon positive note strong market position several geography include china latin america several market southeast asia epd be well position sustain market growth largest fastest grow pharmaceutical market world abbott initiate implementation operational model epd space first quarter plan model company focus selling highly diversify line product core therapeutic area treat local health condition turn allow company widen customer base create unique relationship physician retailer pharmacy also abbott plan strengthen developmental capability expand epd innovation center india have be slew development medical device well market be upbeat abbott freestyle libre flash glucose monitoring system prospect post receipt full partial reimbursement french health ministry platform company also announce health canada license freestyle libre jun notably development be expect drive company traction diabetes care segment see sale growth last report quarter continue consumer acceptance freestyle libre internationally apart market be bullish abbott confirm rx insertable cardiac monitor receive ce mark post approval product have see strong consumer acceptance implant take place country europe company announce ce mark tacticath contact force ablation catheter be key positive continue trend extensive research new product developmet company launch science base nutrition drink better recovery surgery ensure surgery immunonutrition shake ensurepre surgery clear nutrition drink apr be also bullish ongoing synergy acquisition st jude medical jan comprehensive combine portfolio be quite promising notably abbott project annual pre tax synergy include revenue expansion opportunity well operational sg efficiency overall second quarter company forecast adjust earning share cent cent comparable operational sale growth quarter be project low mid single digit earning whispersour proven model do not conclusively show abbott be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp abbott be most accurate estimate zack consensus estimate be cent uncover best stock buy sell re report earning esp filter zack rank abbott have zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here dextera surgical inc have earning esp zack rank telefex incorporate tfx free report have earning esp zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
579,ABT,quest diagnostic inc dgx free report third quarter adjust earning share ep beat zack consensus estimate year number adjust ep report quarter exclude charge related restructure integration retirement debt gain disposition business well amortization expense report ep come slip year quarter figure report revenue third quarter inched year year quarter number however remain line zack consensus estimate accord company spite weather challenge year year improvement come back successful execution point strategy accelerate growth drive operational excellence quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate quote volume measure number requisition increase year year third quarter also revenue requisition increase diagnostic information service revenue quarter rise year year basis cost service report quarter be year year gross margin come reflect basis point bps contraction year year operate expense selling general administrative expense increase report quarter accordingly adjust operate margin show contraction bps quest diagnostic exit third quarter cash cash equivalent marked rise precede quarter year date net cash provide operate activity be compare year period third quarter company repurchase share sep quest diagnostic be left authorization previous share repurchase plan impact hurricane third quarter especially company operation florida texas puerto rico well recently close acquisition quest diagnostic have update full year guidance company now expect full year report revenue approximately annualize growth approximately compare earlier state range annualize growth current zack consensus estimate revenue be peg lower company project number addition upper end company earlier provide adjust ep range have be reduce currently quest diagnostic expect earning full year remain band earlier forecast zack consensus estimate fall lower end project band operate cash flow be expect unchanged previous guidance current estimate capital expenditure be peg unchanged takequest diagnostic third quarter earning exceed zack consensus estimate revenue remain line same positive note company be currently refocusing core diagnostic information service business work discipline capital deployment be also highly optimistic company focus point strategy company several new collaboration hospital integrate delivery network continue act major growth driver be currently look forward company recently announce strategic relationship cleveland clinic include acquisition cleveland heartlab flip side quest diagnostic face major sale disruption due hurricane florida texas company have significant presence also hurricane puerto rico earthquake mexico affected quest diagnostic overall performance report quarter company have reduce upper end earlier provide full year earning guidance range be disappointing notably company have not positively take latest center medicare medicaid service cms publication propose medicare reimbursement rate clinical laboratory test clinical lab fee schedule clf be currently request cms delay implementation pama protect access medicare act zack rank key pickscurrently quest diagnostic carry zack rank sell few better rank stock broader medical sector be integra lifescience holding corp iart free report abbott free report thermo fisher scientific inc tmo free report stock carry zack rank buy see complete list today zack rank strong buy stock here integra lifescience have long term expect earning growth rate stock rally roughly last month abbott have long term expect earning growth rate stock gain last year thermo fisher have long term expect earning growth rate stock gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
580,ABT,share fogo chao inc tank company expect adjust earning cent cent share year lower analyst expectation cent share abbott laboratory free report gain company report third quarter earning share cent ahead zack consensus estimate penny allergan plc agn free report share slump texas district court judge rule company patent lawsuit share electronic art inc ea free report decline news company be close unit be work come star war videogame
581,ABT,strengthen focus image guide volumetric intensity modulate radiotherapy cancer patient varian medical system inc var free report announce have initiate treatment latest halcyon radiotherapy treatment system europe notably treatment be provide year old male head neck cancer belgium base university hospital leuven uz leuven just month hospital have order new system halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide platform receive clearance ce mark european directive allow varian start selling system unite state europe company unveil halcyon radiotherapy treatment system astro conference vienna third quarter notably treatment used halcyon platform be cost effective short duration system have be ergonomically design provide user friendly platform clinical staff patient halcyon fortify varian global footholdvarian have long term goal treat cancer patient year highly exclusive radiotherapy treatment end third quarter management varian announce halcyon have receive order country north america varian strike strategic deal petcure deliver halcyon unit veterinary oncology network management regulatory clearance china japan follow next year furthermore varian receive order halcyon system icon group australia company book several order country india morocco romania russia turkey market prospectsvarian have be take initiative gain customer broad spectrum product especially target emerge market strong revenue opportunity oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership deal be positive varian datum market market reveal global radiotherapy market be project reach worth cagr other company eyee emerge marketsthe ongoing political uncertainty unite state deteriorate economic condition europe automatically shift focus several medtech player emerge geography china india latin america other johnson johnson jnj free report have set manufacturing center brazil china india have be do business china nearly year be expand further back synthe acquisition thermo fisher tmo free report be also leave stone unturned expand presence emerge market company garner total revenue high growth asia pacific emerge market abbott free report continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strong growth country colombia mexico peru argentina today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
582,ABT,edward lifescience corporation ew free report be schedule report third quarter earning oct market close last quarter company have post positive earning surprise be worth note edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement key catalystsimilar prior quarter edward lifescience be expect gain strength transcatheter heart valve therapy segment thvt banking continue therapy adoption geography notable strength unite state company be expect maintain bullish trend third quarter well growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region last report quarter moreover receipt expand fda approval sapien valve early june be expect further boost top line thvt segment be report quarter also zack consensus estimate thvt net sale reflect increase year quarter zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter overall third quarter revenue be project edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotehere be other factor influence edward lifescience third quarter result domestic market edward lifescience be expect continue strong performance base strength thvt other segment surgical heart valve therapy critical care company witness strength surgical heart valve therapy back strong uptake edward intuity elite valve system progress surgical heart valve therapy company receive fda approval inspiris resilium aortic valf july other hand growth critical care group be lead double digit growth enhance surgical recovery program especially unite state also zack consensus estimate net sale unite state reflect increase year quarter edward lifescience earlier raise full year sale expectation high end previously provide range moreover note company project total sale adjust earning share cent cent third quarter flip side tough competition cardiac device market reimbursement issue continue challenge company also believe unfavorable foreign currency affect company gross margin be report quarter also management expect third quarter be seasonally lowest quarter add concern here be quantitative model predict edward lifesciencesdoe not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp foredward lifescience be uncover best stock buy sell re report earning esp filter zack rank edward lifescience carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
583,ABT,abbott free report be illinois base company focuse bring diverse line healthcare product market abbott lab report diversify business segment namely establish pharmaceutical division epd medical device diagnostic nutrition company have reshape portfolio strategic acquisition divestiture recent time have also be take strategic step expand footprint grow geography investing have result numerous new product launch business feb abbott complete sale brand generic pharmaceutical business develop market realignment epd division acquisition latin america russia business divestiture develop market have position company well come quarters however unfavorable movement foreign currency rate be affect top line adversely abbott lab have impressive track record company beat estimate last trail quarters average positive earning surprise abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quotecurrently abbott lab have zack rank buy definitely change follow company third quarter earning report be just release see complete list today zack rank strong buy stock here have highlighted key stat just reveal announcement earning zack consensus estimate remain steady cent share last day abbott third quarter earning share continue operation cent outpaced estimate penny revenue abbott lab post third quarter revenue surpass zack consensus estimate revenue key stat worldwide nutrition sale increase report basis third quarter worldwide diagnostic sale increase report basis total establish pharmaceutical sale increase report basis revenue worldwide medical device increase report basis major factor management abbott third quarter result reflect strong performance company be well position achieve upper end initial full year ep guidance range management narrow full year ep guidance range now company have receive many fda approval recently stock price follow earning release share price rise pre market trading session check back later full abbott earning report later hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
584,ABT,earning season kick high gear week company report include many big cap dow name want know be happen certain industry be sure tune week earning healthcare railroad chemical restaurant advertising big financial be just few industry be represent big name be bellwether stock report set tone industry possibly even broader market big cap company have good earning beat record not stock be soar still be investor watch list week due great record see big cap earning chart ibm ibm free report have be much malign especially warren buffett decide sell have miss only twice last year be buy opportunity abbott lab free report hasn miss year share have finally bust recent narrow trading range beat push share even higher ebay ebay free report be often overlooked investor hasn miss share have be move higher beat get noticed unite airline ual free report last miss early recently announce big push hawaii add new flight chicago watch capacity expansion however unite rental uri free report be largest rental tool company unite state have miss only time year hot economy boost business share be year high go higher full disclosure author article own share uri personal portfolio want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
585,ABT,weight management product service provider nutrisystem inc ntri free report be schedule release third quarter result oct nutrisystem have impressive track beating estimate trail quarters overall company record be favorable evident quarter average positive surprise let see thing be shape prior quarter factor playnutrisystem innovative product be expect expand customer base eventually drive reactivation revenue be generate exist customer first month purchase however sluggish dieting market intense competition be primary headwind term third quarter management expect revenue range zack consensus estimate third quarter revenue be currently peg meanwhile adjust ebitda be anticipate range earning share be expect band cent share positive note company portray impressive price performance past month share nutrisystem have return industry decline however overall activity nutrisystem third quarter be inadequate analyst confidence result zack consensus estimate be report quarter fall cent cent share last day earning whispersour proven model do not conclusively show nutrisystem be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp nutrisystem have earning esp most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank nutrisystem currently carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision nutrisystem inc price ep surprise nutrisystem inc price ep surprise nutrisystem inc quote stock warrant lookhere be company want consider model show have right combination element post earning beat quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
586,ABT,medical instrument manufacturer thermo fisher scientific inc tmo free report be slate release third quarter result oct market open last quarter company post earning share surpass zack consensus estimate fact thermo fisher earning outpaced zack consensus estimate past quarters average beat let see thing be shape prior announcement key acquisition fei have already start generate synergy largely contribute waltham base company analytical instrument portfolio last quarters acquisition have enabled thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research be also vital highlight quarter be report thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotethermo fisher anticipate realize total synergy approximately end year follow deal closure cost synergy roughly adjust operate income benefit revenue related synergy get reflect third quarter performance overall company be gear yet quarter strong analytical instrument segmental growth third quarter thermo fisher expect see positive impact electron microscopy business well strong volume leverage productivity zack consensus estimate analytical instrument operate income be peg line sequentially last quarter report number total revenue estimate segment also remain impressive level here be other factor influence thermo fisher third quarter result company focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result third quarter company have spend research development same trend be continue last couple quarters major development field be novartis chimeric antigen receptor cell car therapy kymriah first fda approve cell therapy leukemia utilize thermo fisher ct dynabead technology expect innovation product launch significantly contribute company top line third quarter company aim expand capability fast grow asia pacific zone well emerge market also lead impressive result standout contributor recent time be china india south korea strategic investment support key customer application thermo fisher hope maintain bullish momentum rest growth be also likely be see apply market such environmental food safety apart life science addition company be currently bet key area focus enormous opportunity be advance precision medicine mass spectrometry target gene sequence structural biology however be apprehensive thermo fisher cite foreign exchange headwind revenue adjust ep also unfavorable macroeconomic condition continue weigh heavily stock stiff competition continue impose challenge stock value here quantitative model predict thermo fisher have right combination main ingredient positive earning esp favorable zack rank strong buy buy hold earning beat see complete list today zack rank stock here zack esp thermo fisher have earning esp uncover best stock buy sell re report earning esp filter zack rank thermo fisher carry zack rank buy increase predictive power esp other stock considerhere be few medical stock worth consider model indicate consist right combination element post earning beat quarter abbott free report have earning esp zack rank align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp aslo carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
587,ABT,express script hold company esrx free report be schedule report third quarter result oct market close result be expect show decline revenue pharmacy benefit manager pbm segment major revenue component majorly affect earning let take look thing be shape release zack consensus estimate pbm revenue stand reflect decline sequentially year quarter st loui mo base company be largest pbm north america pbm be highly competitive industry report market research project pbm market see cagr take account express script have be consistently try expand core pbm business company complete acquisition mymatrixx pharmacy benefit solution provider worker compensation industry recently furthermore company anticipate compound annual ebitda growth rate core pbm business zack consensus estimate net sale stand year year basis express script hold company price consensus express script hold company price consensus express script hold company quote factor playcome major component zack consensus estimate pbm product network stand year year zack consensus estimate pbm service revenue stand year year lackluster performance segment be likely mar express script revenue third quarter come guidance third quarter express script expect total adjust claim range notably zack consensus estimate total claim stand sequentially adjust earning diluted share third quarter be estimate range represent growth year year basis exclude contribution anthem other transition client regard express script announce biggest customer lead health insurer anthem inc antm free report be not likely extend pharmacy benefit management agreement be slate expiration end management express script lose almost revenue related anthem contract third quarter anthem sue express script overcharge drug operational failure meanwhile second quarter anthem generate revenue compare second quarter here be quantitative model predict express script have right combination main ingredient positive earning esp zack rank buy notably earning esp express script be uncover best stock buy sell re report earning esp filter fact zack consensus estimate earning reflect increase year year basis other stock considerhere be few other medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank see complete list today zack rank strong buy stock here henry schein inc hsic free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
588,ABT,illinois base global medical device company abbott laboratory free report partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market leverage abbott freestyle libre glucose sense technology collaboration result innovation marketing insulin delivery system alliance help company develop patient friendly insulin delivery system calibration glucose sensor management important trial combine technological system be project initiate clinical research site abbott have be move steadily development diabetic segment recently company announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be first quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line canadian development french health ministry recently approve national reimbursement device report mordor intelligence global market diabetes care device be project value witness cagr moreover insulin delivery device market be expect see cagr roughly thus consider market potential abbott current development diabetes care segment collaboration seem be lucrative strategically align believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diabetes market however market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system moreover abbott have be gain investor confidence consistent positive result past month company share price have outperformed zack categorize medical instrument sub industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank other key picksabbott currently have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report abiom inc abmd free report notably edward lifescience sport zack rank strong buy abiom carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month abiom have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
589,ABT,be halfway point second quarter earning season
590,ABT,result so far have be very mixed encourage median ep growth term
591,ABT,downright awful term total net income growth give mix
592,ABT,firm have report so far yet come see
593,ABT,improvement front here
594,ABT,so far firm have report be not
595,ABT,representative sample sector historically report sooner
596,ABT,other however be good news much higher percentage
597,ABT,firm bad sector financial consumer discretionary have
598,ABT,report good sector energy
599,ABT,nonetheless very limit sample be somewhat encourage positive
600,ABT,surprise be lead disappointment ratio inline recent
601,ABT,historical norm median surprise be also inline recent history
602,ABT,perhaps bit better normal expect surprise
603,ABT,ratio median surprise jump quite more report be
604,ABT,release
605,ABT,median year year ep growth rate be wonderful news
606,ABT,market look probably hold median expect
607,ABT,ep growth rate firm be yet report be give
608,ABT,propensity positive surprise outnumber disappointment median
609,ABT,ep basis second quarter earning season be far better
610,ABT,mood market seem indicate
611,ABT,base early actual return tech be winning growth derby
612,ABT,median ep growth be base result company
613,ABT,total tech firm index
614,ABT,however perhaps most impressive show have be health care
615,ABT,be currently hold silver medal spot median ep growth
616,ABT,just barely edge energy so far be however
617,ABT,health care be show positive surprise disappointment
618,ABT,median surprise be not base just handful result
619,ABT,almost third health care report be already
620,ABT,energy other hand have just third result term
621,ABT,number firm report far less base probable total
622,ABT,earning surprise metric be roughly line overall market
623,ABT,surprise ratio median surprise
624,ABT,financial have be weakest sector far median ep
625,ABT,drop year sector be responsible
626,ABT,earning disappointment point disappointment have
627,ABT,match positive surprise number
628,ABT,point be expectation have yet
629,ABT,report be just important have actually report
630,ABT,remain energy firm be expect post median ep growth
631,ABT,lift sector top spot earning growth
632,ABT,tech most likely take silver medal spot race bronze
633,ABT,currently look toss health care industrial
634,ABT,remain industrial be expect post growth
635,ABT,remain health care firm be expect post growth just
636,ABT,health care currently have big lead have be surprising
637,ABT,upside be third race
638,ABT,expect result remain financial be not bad one
639,ABT,have already report be still fairly ugly material
640,ABT,provide worst remain result expect
641,ABT,remain consumer discretionary firm be expect show decline
642,ABT,just push sector negative territory season
643,ABT,factor help median ep growth be share
644,ABT,repurchase have slow recent month still reflect
645,ABT,happened last year oddly increase share count also help boost
646,ABT,ep financial one have increase share
647,ABT,count most go hat hand sovereign wealth fund look
648,ABT,new capital be also one be likely report loss so
649,ABT,loss share be less
650,ABT,addition extent firm have large operation overseas
651,ABT,benefit currency translation effect weak dollar
652,ABT,weak dollar have also boost company export substantial
653,ABT,portion sale
654,ABT,keep mind median growth rate be inherently equally weight so
655,ABT,growth rate cabot oil gas cog free report be just significant result
656,ABT,energy sector growth rate exxon xom free report
657,ABT,second quarter scorecard report sector mediangrowth rep medianproj growth medianrep growth medianproj growth report median surprise possurprise negsurprise matchtech healthcare energy industrial utility material con stap telecom con disc financial second quarter yet report sector proj growth proj growth rep growth proj growthenergy tech industrial telecom con stap healthcare utility con disc financial material total net income growth
658,ABT,median ep growth basis thing look okay same be not
659,ABT,true total net income basis be shape be yet very
660,ABT,ugly quarter
661,ABT,blame net income decline once again go financial
662,ABT,best support actor nomination consumer discretionary overall
663,ABT,second quarter be now expect be even weaker first quarter
664,ABT,fourth quarter
665,ABT,overall total net income be expect be
666,ABT,second quarter number be deteriorate rapidly last week
667,ABT,decline be only expect be week
668,ABT,financial sector total net income be expect be lower be
669,ABT,last week week
670,ABT,thing be also fall apart discretionary firm even
671,ABT,massive force lend program know stimulus check total net
672,ABT,income sector be expect be year even
673,ABT,show year year decline post first
674,ABT,quarter
675,ABT,look report so far thing look very bleak indeed
676,ABT,financial total net income firm have actually
677,ABT,report so far year firm report total
678,ABT,profit year versus last year thing be
679,ABT,not expect get better remain report roll firm
680,ABT,yet report be expect show actual red ink aggregate not just
681,ABT,lower profit
682,ABT,total net income firm have report so far be
683,ABT,last year stay fairly stable total net
684,ABT,income yet report be expect be be
685,ABT,large part due fact bulk energy earning have yet
686,ABT,come total net income remain firm be expect fall
687,ABT,sector
688,ABT,energy be be strongest sector so far total net income
689,ABT,firm have report remain firm be not
690,ABT,expect be quite strong still keep
691,ABT,sector comfortably first place next quarter analyst be expect
692,ABT,energy really hit gusher growth expect
693,ABT,tech look strong runner otherwise weak field growth
694,ABT,so far however remain tech firm be not expect be
695,ABT,anywhere strong actually decline slightly still strong
696,ABT,result so far ensure tech hold silver total net
697,ABT,income growth health care most likely take bronze
698,ABT,growth
699,ABT,total net income growth report sector rep growth rep growth rep growth proj growth rep growth proj growth proj growthenergy technology con stap health care utility telecom industrial material con disc financial total report sector rep growth rep growth rep growth rep growthhealth care industrial technology energy con stap material financial telecom con disc utility total earning growth yet report sector rep growth rep growth proj growth proj growth rep growth proj growth proj growthenergy industrial technology utility health care con stap material telecom con disc financial total earning growth combine sector rep growth rep growth proj growth proj growth rep growth proj growth proj growthenergy technology health care industrial con stap utility telecom material con disc financial zack revision ratio
700,ABT,help gauge direction market take note analyst be
701,ABT,think tally ep change determine revision
702,ABT,ratio ratio simply divide total number positive estimate
703,ABT,revision total number estimate cut thus high ratio be
704,ABT,bullish indicator low ratio be bearish whole
705,ABT,number be generally significant individual
706,ABT,sector distance be greater number be
707,ABT,significant
708,ABT,positive surprise outnumber disappointment almost be
709,ABT,not shock revision ratio have start climb depth
710,ABT,second quarter earning be part full year earning so
711,ABT,company post positive surprise analyst don raise full
712,ABT,year earning be implicitly cut estimate third fourth
713,ABT,quarters
714,ABT,be now read be borderline neutral negative
715,ABT,last week week overall pace estimate
716,ABT,revision continue seasonal rise last week have
717,ABT,be change estimate last
718,ABT,week total number revision probably peak
719,ABT,next week ratio firm rise
720,ABT,mean estimate fall mean estimate be slightly weaker
721,ABT,revision ratio negative territory
722,ABT,back surprise ratio health care moved top slot
723,ABT,revision ratio read unseat perennial
724,ABT,leader year date energy have still strong read
725,ABT,utility staple also have respectable showing
726,ABT,health care stock post notable number estimate increase
727,ABT,include abbott lab johnson johnson jnj free report st
728,ABT,jude stj
729,ABT,notable energy stock include baker hughe bhi
730,ABT,schlumberger slb free report
731,ABT,financial be once again very weak cut increase
732,ABT,notably weak financial include allstate free report
733,ABT,comerica cma free report bank usb free report
734,ABT,avg wk epschange fy avg wk epschange fy revisionsratio firm fy increase firm fy decreasehealth care energy utility consumer staple industrial technology material consumer disc telecom financial service
735,ABT,be mechanical reason analyst raise
736,ABT,number response earning surprise revision
737,ABT,ratio do rise remain deep negative territory ratio rise
738,ABT,last week week other word
739,ABT,positive earning surprise last week analyst have
740,ABT,cut estimate have raise
741,ABT,virtually strength be energy sector revision ratio
742,ABT,utility health care also put decent showing
743,ABT,respectively energy sector account quarter
744,ABT,estimate increase last week energy firm show noteworthy
745,ABT,strength include oil service major baker hughe halliburton hal free report
746,ABT,schlumberger slb free report
747,ABT,revision picture financial sector be even
748,ABT,be come cut increase
749,ABT,revision eat away robust earning rebound see
750,ABT,get cut faster financial be exclude
751,ABT,revision index pop do not seem be get
752,ABT,wood financial sector front be weakness
753,ABT,sector major regional bank seem be worst hit particular
754,ABT,weakness bb bbt free report comerica cma free report suntrust sti free report
755,ABT,free report be
756,ABT,noteworthy
757,ABT,total number revision whole be also well
758,ABT,past seasonal low point be total revision
759,ABT,be last week
760,ABT,ratio firm rise mean estimate fall mean estimate be
761,ABT,line revision ratio
762,ABT,avg wk epschange fy avg wk epschange fy revisionsratio firm fy increase firm fy decreaseenergy utility health care material consumer staple technology industrial consumer discr telecom financial service market cap versus total earning
763,ABT,make investment decision growth always be look
764,ABT,conjunction much be pay stock thus make sense
765,ABT,look total earning expect sector relative
766,ABT,sector total market capitalization be basically variation
767,ABT,look
768,ABT,chart show share total earning
769,ABT,well share total market capitalization sector
770,ABT,final bar show be market cap weight index be
771,ABT,same index weight chart difference
772,ABT,size first bar show sector be gain lose
773,ABT,earning share difference final bar first
774,ABT,bar show sector be selling market
775,ABT,final bar be smaller other bar sector be selling
776,ABT,market however opposed just show sector es also
777,ABT,show relative importance sector overall index
778,ABT,year financial be dominate force market
779,ABT,term market cap even more so term total earning have
780,ABT,now be decisively dethrone count market cap front
781,ABT,just recapture second place energy however have now slip
782,ABT,fourth place tech health care base earning still
783,ABT,current problem financial be still very significant
784,ABT,influence market
785,ABT,even disaster sector financial
786,ABT,account total net income
787,ABT,be currently expect decline rebound
788,ABT,however recent year sector have account well
789,ABT,quarter earning
790,ABT,energy have usurp crown year earning share climb
791,ABT,energy keep earning crown
792,ABT,well gathering earning
793,ABT,market cap index weight front tech overtake financial
794,ABT,month currently stand financial have plunge
795,ABT,index recently end february financial have
796,ABT,index weighting versus tech just energy most
797,ABT,analyst be used very conservative pricing assumption forecast
798,ABT,energy sector relative imply future market so
799,ABT,earning estimate still have lot room rise
800,ABT,keep mind number be snapshot be think
801,ABT,movie end february first time have complete read
802,ABT,financial be expect gather earning
803,ABT,energy be expect only get expect
804,ABT,earning share be energy financial year
805,ABT,credit crunch hit financial be expect gather
806,ABT,earning hold weighting index energy represent
807,ABT,just total market capitalization be expect get
808,ABT,total earning general seem energy sector
809,ABT,be consistently gain share year week
810,ABT,similar decline financial trend continue then energy
811,ABT,be dominate earning front
812,ABT,financial be
813,ABT,many year financial be clearly dominate factor overall
814,ABT,market generally selling market es due implosion
815,ABT,earning have be far dismal market performance
816,ABT,sector financial now have highest es base earning
817,ABT,displacing perennial high sector technology base earning
818,ABT,financial have however give expectation
819,ABT,bleed stop next year base earning be just
820,ABT,however give pace estimate cut sector true be
821,ABT,probably higher actual earning be significantly lower
822,ABT,be first time recall happen
823,ABT,energy have just take throne cheapest base earning
824,ABT,trading base expectation be question
825,ABT,mind energy be cheapest sector market
826,ABT,portfolio be overweight tech sector be still bit
827,ABT,expensive side trading expectation health
828,ABT,care look interesting trading earning
829,ABT,keep eye revision give best clue
830,ABT,earning be achieve be real recent
831,ABT,decline oil price cause upwards revision moderate
832,ABT,energy sector most analyst be used very conservative price assumption
833,ABT,whole be trading
834,ABT,earning respectively base blend earning
835,ABT,earning translate earning yield look extremely
836,ABT,cheap relative year note even rate corporate
837,ABT,bond yield look attractive however current level
838,ABT,expectation corporate earning still imply profit stay
839,ABT,well historical average share gdp be
840,ABT,exceedingly rare occurrence recession
841,ABT,comparison earning yield year note
842,ABT,be opinion more reflection extreme long
843,ABT,term note point stock look particularly cheap
844,ABT,general however be attractive stock appear
845,ABT,flight quality have cause massive bubble price note
846,ABT,be far away opinion most significant bubble market
847,ABT,today not price oil price be hard justify give risk
848,ABT,massive injection liquidity fed ameliorate credit
849,ABT,crunch end fuel fire inflation
850,ABT,neil malkin contribute significantly report
851,ABT,datum report state otherwise be close
852,ABT,thursday
853,ABT,abbott laboratory free report recently release stellar result second quarter hike full year guidance nearly cover analyst respond increase full year estimate company offer roe industry average early june abbot declare quarterly dividend cent share dividend yield stand high yield offer peer most company industry group offer dividend
854,ABT,company description
855,ABT,abbott be global broad base health care company develop manufacture market pharmaceutical medical product include nutritional device diagnostic company employ more person market product more country company be headquarter north suburban chicago
856,ABT,healthy growth
857,ABT,mid july company post stellar result second quarter hike full year guidance earning share cent outpaced year prior cent beat consensus estimate
858,ABT,abbott achieve quarter strong performance diverse mix global business particularly strong result internationally say mile white chairman chief executive officer abbott base first half result well outlook remainder year re raise forecast sale growth earning share re also confirm expectation continue double digit earning share growth
859,ABT,company hike earning share guidance range full year exclude specify item cover analyst have full year forecast peg share compare last month analyst bump estimate past week
860,ABT,abbott laboratory offer solid return equity roe top industry average
861,ABT,continue income
862,ABT,early june company declare quarterly dividend cent share note be consecutive quarterly dividend paid abbott company add cash dividend be payable august shareholder record close business july
863,ABT,dividend translate yield stand high yield offer peer most company industry group offer dividend
864,ABT,cr bard inc be schedule report third quarter earning market close oct last quarter company report adjust earning exceed zack consensus estimate cent also company earning surpass zack consensus estimate last quarters average beat delve fundamental stock let see thing be shape prior release factor playwe believe grow adoption company flagship lutonix drug coat balloon dcb continue be key growth catalyst be report quarter regard lutonix dcb be used treat patient suffering peripheral arterial disease pad endovascular business peripheral pta line sale be solely drive accelerate demand lutonix dcb unite state expect product significantly contribute company top line quarter zack consensus estimate third quarter revenue be currently peg however management expect revenue growth report basis exclude impact foreign exchange company project revenue increase prior year furthermore company investment emerge market have strengthen position internationally be also upbeat solid contribution company vascular product line urology oncology segment be likely drive third quarter sale positive note company portray impressive price performance past month share cr bard have return compare industry decline flip side challenge med tech environment especially hernia fixation peripheral stent business raise concern company continue witness significant pricing pressure well also unfavorable foreign currency continue hurt top bottom line growth furthermore uncertainty associate possibility repeal affordable care act president trump add company concern earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp cr bard be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank cr bard currently carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision bard inc price ep surprise bard inc price ep surprise bard inc quote stock considerhere be few company want consider proven model show have right combination element post earning beat quarter abbott free report have earning esp carry zack rank see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
865,ABT,oct issue update research report new york base dentsply sirona inc xray free report global leader design development manufacture marketing dental consumable dental laboratory product dentsply recently announce renewal exist distribution agreement henry schein canada inc continue dec henry schein agreement dentsply be initiate august feel deal extension be smart move dentsply preexist agreement do not include cerec cad cam restoration system schick line imaging sensor include aforementioned line product company benefit henry schein distribution network canada recent development dentsply announce renewal partnership pacific dental service duo latest agreement extend period year be sign move be also strategic pacific dental network consist center state tenure present agreement management expect number such office utilize dentsply technology exceed dentsply dual brand strategy product innovation growth opportunity emerge market especially asia pacific middle east africa diversify product portfolio recur revenue base be key catalyst company expect solid guidance full year project adjust ep range flip side apart series macroeconomic headwind currency fluctuation continue be major dampener fact strengthen dollar euro other emerge market currency have dent company growth trajectory furthermore higher capital expenditure product development be expect keep margin pressure share price estimate revision lack lusterdentsply estimate revision trend look unfavorable moment third quarter analyst moved south compare upward revision last month notably current quarter estimate drop cent share last day dentsply share price movement have be unfavorable last month company shed much higher industry decline zack rank key picksdentsply currently carry zack rank hold few better rank stock broader medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank buy see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly year idexx laboratory have long term expect earning growth rate stock have gain year thermo fisher have long term expect earning growth rate stock have gain last year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
866,ABT,qiagen qgen free report have be hog limelight recent partnership co marketing agreement centogene ag partnership aim deliver complete sample insight research clinical testing solution end user field rare genetic condition collaboration agreement qiagen integrate bioinformatic suite centogene highly develop centomd rare disease variant database goal improvise test understand notably integration centomd phenotype genotype database be expect considerably enhance qiagen knowledge base qiagen clinical insight qci bioinformatic solution co marketing agreement qiagen now act authorize exclusive international commercial distribution partner centomd also qiagen bioinformatic solution be license centogene support latter extensive rare disease diagnostic testing service bid grow bioinformatic portfolio offer valuable observation complex biological datum qiagen announce acquisition omicsoft corporation january acquisition qiagen gain access omicsoft powerful multus omic datum management infrastructure solution well omic datum bank believe company latest partnership centogene be strategic take consideration huge prospect bioinformatic globally accord market market report global bioinformatic market be project reach worth cagr believe increase spending healthcare government private organization rise awareness trigger need nucleic acid protein sequence technological innovation development back successful partnership company research institutes continue drive growth bioinformatic market thus latest development help qiagen cash bountiful opportunity niche market share price have be gain investor confidence consistently encourage result last month company share price have outperformed broader industry stock have gain compare broader industry gain company have also surpass gain market same time frame zack rank other key picksqiagen currently carry zack rank buy other top rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report abbott idexx laboratory thermo fisher carry zack rank see complete list today zack rank strong buy stock here abbott have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
867,ABT,oct issue update research report illumina inc ilmn free report stock currently carry zack rank hold last month san diego base company provide tool integrate system analysis genetic variation function have be trading broader industry stock have gain period higher broader industry gain past few quarters company have deliver promising top line performance primarily banking strong product launch latest list include launch veriseq nipt solution europe also overall strong uptake novaseq be encourage moreover rate nipt adoption be rise outside unite state be also upbeat illumina partnership telegraph hill partner set independent company verogen inc independent company be expect boost illumina next generation sequence ngs business forensic genomic market have global commercial right product illumina be only provider miseq fgx forensic genomic system include miseq fgx sequencer forenseq dna signature prep kit forenseq universal analysis software be encourage development clinical market demand customer undergo oncology test remain robust moreover investor be await response extend ra panel be slate launch third quarter june company announce receipt fda approval extend ra companion diagnostic kit class iii pma be also look forward grail illumina own develop company focuse cancer screening market flip side weak margin due novaseq launch higher array service revenue product mix sequence consumable continue raise concern also national institutes health nih funding issue tough competitive landscape be few challenge deal key picksa few better rank stock medical sector be abbott free report idexx laboratory inc idxx free report thermo fisher scientific inc tmo free report zack rank buy see complete list today zack strong buy rank stock here abbott have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year thermo fisher have long term expect earning growth rate stock have gain last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
868,ABT,abbott laboratory free report establish pharmaceutical division epd business have be record operational sale growth last few quarters expect strength further get reflect second quarter result schedule release jul click here know company overall performance be likely pan key epd business majorly focus emerge market key area include india russia china numerous region latin america well brazil other country sale key emerge market increase organically drive double digit growth india china brazil last report quarter abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quoteper company key emerge market represent most attractive long term growth opportunity abbott brand generic product portfolio management believe market continue offer immense opportunity favorable demographic accordingly zack consensus estimate epd revenue key emerge market indicate rise year quarter tally favorable currency translation also left positive impact epd revenue first quarter moreover be encourage note management expect foreign exchange continue act tailwind be report quarter however management seem concern decelerate revenue growth rate epd russia due temporary disruption distribution channel dynamic base certain distributor consolidation company continue second quarter too also ongoing tension unite state china regard imposition tariff import have raise concern major medtech player adverse move affect sale performance china term overall be upbeat management anticipation double digit organic growth epd sale second quarter furthermore zack consensus estimate epd revenue show increase prior year period epd abbott consistent focus enhance local capability expand product portfolio core therapeutic area be aim specifically address local market need effort company also continue consolidate leadership position epd market abbott sale develop market business acquisition cfr pharmaceutical latin america veropharm russia have contribute epd business zack rank stock considerabbott carry zack rank hold here be few medical stock worth consider same space comprise right combination element beat earning time resm inc rmd free report have earning esp zack rank strong buy see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank mckesson corporation mck free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
869,ABT,abbott free report medical device business have be go strong late solid sub segmental performance expect strength get reflect second quarter result be schedule release jul market open click here know company overall performance be expect be medical device focusabbott medical device segment presently comprise new cardiovascular neuromodulation heart failure structural heart rhythm management vascular business diabetes care business abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quotemanagement expect mid high single digit growth medical device second quarter sale continue double digit growth certain sub segment consequently zack consensus estimate medical device revenue unite state indicate rise year quarter internationally consensus estimate show growth last quarter sale improvement segment be drive double digit growth neuromodulation diabetes care moreover company receive approval few product achieve clinical trial milestone let see thing be shape sub segment second quarter result account medical device revenue have be gain strongly recent launch confirm insertable cardiac heart monitor unite state europe furthermore continue uptake ensite precision cardiac mapping system be expect contribute strongly top line second quarter abbott strengthen position business successive receipt fda ce mark new advisor hd grid mapping catheter company have launch product country then currently await commercial launch unite state zack consensus estimate revenue indicate increase year company be expect keep gain strength business last report quarter company witness impressive sale growth heart failure business solid uptake recently launch heartmate system unite state zack consensus estimate heart failure business revenue indicate rise year quarter provide impetus vascular total medical device revenue business unite state abbott recently announce receipt fda approval xience sierra encouragingly note vascular business company have see slew development regard xience sierra coronary stent system company also achieve national reimbursement xience sierra company have also be get positive response xience sierra coronary stent system post launch europe zack consensus estimate vascular revenue show improvement year quarter structural heart business have maintain impressive top line performance last report quarter business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip march abbott announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart positive development be expect boost top line contribution sub segment be report quarter estimate structural heart revenue also indicate rise year quarter diabetes care international sale growth prior quarter be drive abbott freestyle libre company recently initiate launch freestylelibre unite state well proceed initiative boost arm company announce availability freestyle librelink app europe use smartphone iphone android zack consensus estimate diabetes care revenue indicate surge year quarter meanwhile be upbeat abbott kick start receipt fda approval magnetic resonance mr conditional labele quadra assura mp cardiac therapy defibrillator crt fortify assura implantable cardioverter defibrillator icd company most widely used high voltage medical device approval come heel recent mr conditional labele approval assurity mri pacemaker ellipse icd associate mri compatible lead development be expect boost rhythm management business consensus estimate rhythm management revenue show improvement year zack rank stock considerabbott carry zack rank hold better rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here align technology have project long term earning growth rate zack rank buy stryker have project long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
870,ABT,share boston scientific corporation bsx free report gain close jun follow speculation company rival stryker corporation syk free report consider bid acquire former news be wall street journal report trading stock be temporarily pause monday session nyse yesterday close boston scientific market cap be compare stryker follow reuter report state be still unclear boston scientific be open potential buyout proposal stryker prospective acquirer too decline comment report meanwhile benzinga report write bid have surpass share accord stifel nicolaus well fargo predict share be value base becton dickinson cr bard deal accord bloomberg previous bsx stryker be not first time stryker boston scientific have come strategic collaboration back orthopaedic device giant buy boston scientific neurovascular unit time rationale divestment decision boston scientific come part company aggressive restructure initiative more specifically neurovascular division company core business be struggle depress sale rationale latest rumore boston scientific position prospect possible sell rumor be still unknown analyst believe reason company contemplation probable sell lie interest gain further competitive edge medical device space be important note post colossal merger medtronic mdt free report covidien abbott free report st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space merger get materialize finally consider boston scientific stryker present market cap then consolidated entity have combine market cap more accord well fargo security be position only medtronic johnson johnson term total device revenue react widely speculate buyout bid retire twin city med tech stock analyst thom gunderson say make perfect sense go big go home be rule day analyst seem optimistic allege deal believe finally work boston scientific score vantage point fast grow competitive heart valve replacement market be currently trail edward lifescience ew free report medtronic also merger be expect reduce cost combine company time healthcare industry be already battle severe pricing pressure share price comparisonover past year share boston scientific have rally ahead stryker increase broader sector remain much rise boston scientific stryker currently carry zack rank buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
871,ABT,jun initiate research report bio rad laboratory inc bio free report be upbeat company deliver robust performance overseas tough competitive landscape be concern stock carry zack rank hold california base manufacturer global supplier clinical diagnostic life science research product have be outperform industry past year stock have gain versus industry rise bio rad kick start solid note earning revenue rise year year first quarter company have be strongly progress effort strengthen hold other geography first quarter bio rad derive net sale globally company deliver robust performance primarily north america china asia pacific region further constant currency sale life science segment be particularly strong north america china europe currency neutral sale company clinical diagnostic segment see strength china asia pacific north america be encourage company active portfolio expansion blood typing market january bio rad announce receipt clearance fda ih incubator ih centrifuge instrument be used complete range bio rad ih system gel reagent manual blood typing method meanwhile bio rad operate highly competitive environment dominate firm vary large multinational corporation start up also competitive regulatory condition market company operate limit ability switch strategy price increase other driver cost increase life science segment bio rad primarily compete like becton dickinson thermo fisher scientific tmo free report other again prominent competitor clinical diagnostic segment be abbott laboratory free report diasorin further bio rad be expose risk associate weaker global economy lower reimbursement rate key picksa better rank stock broader medical sector be intuitive surgical isrg free report sporting zack rank strong buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
872,ABT,abbott free report be slate report second quarter result market open jul last report quarter company earning share exceed zack consensus estimate moreover abbott deliver positive surprise trail quarters average beat be let see thing be shape announcement factor playover past few quarters abbott have be ride high healthy growth diabetes care business company have be hog limelight development flagship sensor base continuous glucose monitoring cgm system freestyle libre system recent datum number libre user now have reach globe represent unprecedented level patient adoption industry have firmly boost company top line number recent quarters momentum continue second quarter too produce impressive result period company expect see significant growth contribution line recently launch product portfolio zack consensus estimate diabetes care revenue indicate surge year quarter sync prior quarter abbott be anticipate gain strong performance establish pharmaceutical division epd business have be record operational sale growth last few quarters management expect sale rise high single digit second quarter furthermore zack consensus estimate epd revenue show increase year earlier period abbott laboratory price ep surprise abbott laboratory price ep surprise abbott laboratory quotewe be also upbeat consistently sturdy diagnostic business courtesy solid contribution sub segment namely core laboratory diagnostic molecular diagnostic point care moreover synergy draw alere buyout form revenue rapid diagnostic have be benefit company additionally management estimate rapid diagnostic contribute zack consensus estimate core laboratory diagnostic revenue depict gain comparable quarter last year encouragingly note nutrition be abbott fastest grow business owing age population increase rate chronic disease rise middle class emerge market furthermore abbott pediatric nutrition business continue be robust unite state thus zack consensus estimate nutrition revenue translate improvement year quarter figure favorable currency translation also have positive impact company top line first quarter be also optimistic management expectation foreign exchange appear aid result be report quarter drive revenue turn overall second quarter total revenue be project prior year period model suggestsper zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter abbott have zack rank increase predictive power esp however earning esp make surprise prediction difficult zack consensus estimate earning cent reflect growth year year stock worth lookhere be few medical stock worth consider same space comprise right combination element beat earning time resm inc rmd free report have earning esp be rank stock see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank mckesson corporation mck free report have earning esp stock be zack rank player more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
873,ABT,abbvie inc abbv free report share have outperformed large cap pharma industry past month stock have return timeframe industry decline abbvie outperformance be backed decent quarterly result optimistic outlook stronger underlie business performance rest year positive pipeline news flow regulatory update be repute name pharmaceutical sector abbvie come existence jan abbott laboratory free report divest pharmaceutical divisionhere be reason invest stock favorable rank earning surprise record abbvie have zack rank buy see complete list today zack rank strong buy stock here have be consistently beating earning expectation earning surpass expectation last quarters average positive surprise company be expect record earning sale growth respectively meanwhile estimate increase respectively past day valuation look reasonable outperformance abbvie valuation look fairly reasonable currently abbvie currently have forward month price earning ratio be lowest level past year compare highest level median level past year be apparently upside left space also look inexpensive compare industry current well median ratio industry be respectively price earning forward month chart key drug humira go strong abbvie flagship product humira be approve several inflammatory indication rheumatoid arthritis humira continue witness strong demand trend launch drug new mechanism action competition indirect biosimilar currently approve indication humira sale have increase consistently backed robust demand trend product continue see strong growth dermatology market company expect humira sale approach biosimilar version humira be already approve fda settlement amgen amgn free report samsung bioepis biosimilar entry unite state be set thus delay direct biosimilar competition country strong oncology portfolio abbvie work rigorously expand accelerate presence oncology key drug oncology portfolio be imbruvica be currently approve quite few indication have multus dollar potential abbvie be explore potential expand imbruvica label solid tumor autoimmune disease several study imbruvica be ongoing evaluate drug alone combination different patient segment abbvie expect imbruvica peak sale more revenue abbvie have develop imbruvica partnership jnj free report abbvie be also study cancer drug venclyxto venclexta expand label address broader relapse refractory chronic lymphocytic leukemia cll patient population expand earlier line therapy broaden other hematologic malignancy multiple myeloma acute myeloid leukemia june regulatory application seek approval combination venclexta roche rhhby rituxan relapse refractory cll be approve unite state label expansion include broader patient population boost venclexta commercial potential meanwhile acquisition drugmaker stemcentrx add key late stage candidate rovalpituzumab tesirine rova abbvie portfolio rova be currently registrational study first second line small cell lung cancer sclc phase arm basket study rova neuroendocrine tumor be also ongoing promising pipeline abbvie have deep pipeline consist several interesting late stage candidate promising candidate include elagolix endometriosis risankizumab inflammatory disease depatux glioblastoma multiforme abbv early alzheimer disease progressive supranuclear palsy psp upadacitinib inflammatory disease company expect move tumor candidate clinical development several pivotal datum readout regulatory milestone be expect second half year include fda decision risankizumab elagolix regulatory application mavyret perform expectation abbvie week pan genotypic ribavirin free once daily hepatitis hcv treatment mavyret gain approval unite state eu canada japan mavyret abbvie next generation hcv program be combination glecaprevir potent protease inhibitor pibrentasvir ns inhibitor mavyret have potential rejuvenate growth hcv franchise accord abbvie mavyret be used hcv patient depend stage liver disease prior treatment history mavyret perform expectation first year launch record sale almost positive sale trend continue drug record sale first quarter less year market mavyret already command share unite state conclusion abbvie face share challenge form slower sale hcv drug potential biosimilar competition humira regular pipeline setback rise competition however believe abbvie be well position overcome headwind today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
874,ABT,merck co inc mrk free report pfizer inc pfe free report report upbeat first quarter result fact pharma giant manage outpace earning estimate miss revenue front however company top bottom line rise year year merckha zack rank buy pfizer possess zack rank hold now let see stock be better position term fundamental post earning see complete list today zack rank strong buy stock here other major earning come other pharma giant abbott free report johnson johnson jnj free report earning performancein first quarter merck report adjust earning share surpass zack consensus estimate cent bottom line increase year period meanwhile company revenue fall short zack consensus estimate increase year year read more merck beat earning lag sale raise outlook pfizer post first quarter earning cent share beating zack consensus estimate only cent earning advanced year period due lower tax rate share count moreover revenue increase year year miss zack consensus estimate read more pfizer stock fall sale miss earning beat price have witness rise past month pfizer have advanced only so merck be clear winner respect better return rival merck broader industry decline same period most appropriate ratio evaluate drug maker be perhaps ev ebitda metric be usually used compare stock same industry be superior other metric such be not affected different capital structure company come pharma major pfizer ev ebitda ratio be overvalue broader industry have ev ebitda value other hand ev ebitda ratio merck be underpriced pfizer industry net marginthe pharmaceutical industry enjoy higher profit margin several other sector be possibly reason critic sector continually draw attention exorbitant drug pricing help sector maintain steep margin net margin value pfizer perform better rival merck have net margin value comparison broader industry have net margin value debt equity debt equity ratio be good indicator financial health company good proxy debt servicing capacity context capital intensive industry pharma be indicator company long term sustainability merck debt equity ratio be significantly high compare industry ratio comparatively lower ratio pfizer evidently have better leverage condition earning history estimate revisionsmerck deliver positive surprise last quarters average earning surprise comparison pfizer deliver earning beat trail quarters post average positive earning surprise consider estimate revision merck earning estimate current year have improve past day meanwhile pfizer earning estimate have decline same period conclusionin comparative analysis find pharma giant have certain positive pfizer hold better leverage position have higher net margin however term valuation merck be more underpriced pfizer further merck have comparatively higher price performance pfizer moreover merck also hold edge pfizer consider average positive earning surprise estimate revision clinch case favor merck point time be have better zack rank pfizer respect analysis clearly indicated merck be better position pfizer thus call investor attention post earning look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
875,ABT,universal health service inc uhs free report report first quarter adjust earning share miss zack consensus estimate however bottom line grow year year net revenue increase year year however top line lag zack consensus estimate total operate expense end first quarter also increase year year segment updateacute care hospital adjust admission adjust patient day increase respectively prior year quarter net revenue same facility basis climb first quarter behavioral hospital same facility basis adjust admission increase adjust patient day decline year year basis net revenue increase quarter review same facility basis universal health service inc price consensus ep surprise universal health service inc price consensus ep surprise universal health service inc quote financial updatea mar company have cash cash equivalent nearly year end total asset be mar year end company manage lower debt burden evident long term debt mar decline year end first month net cash provide operate activity totale year year buyback programin november board director authorize increase universal health stock repurchase program raise aggregate authorization previous approve concurrently first quarter company repurchase share aggregate cost zack rank performance peersuniversal health currently carry zack rank buy see complete list today zack rank strong buy stock here other player medical sector have report first quarter earning so far novartis ag nvs free report unitedhealth group incorporate unh free report abbott laboratory free report surpass respective zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
876,ABT,anthem inc antm free report first quarter adjust net income share surpass zack consensus estimate bottom line also rise year year operate revenue miss zack consensus estimate top line however remain flat year year quarterly operational updatemedical enrollment decline year year member downside be primarily cause reduce footprint individual aca affordable care act compliant marketplace anthem benefit expense ratio improve basis point bps prior year quarter drive return health insurance tax improve medical cost performance business segment sg expense ratio deteriorate bps year quarter due return health insurance tax impact increase investment spend year support growth initiative segment specialty businessoperate revenue be first quarter year year operate gain totale year year owing penn treaty assessment record first quarter improve medical cost performance operate margin be bps year year government businessoperate revenue be first quarter prior year quarter operate gain be year year upside reflect impact healthsun america st choice acquisition well organic membership growth medicare business retroactive revenue adjustment medicaid business operate margin be contract bps year year other operate revenue be first quarter prior year period segment report operate loss narrower same prior year quarter anthem inc price consensus ep surprise anthem inc price consensus ep surprise anthem inc quote financial updatea mar anthem have cash cash equivalent year end mar long term debt increase year end operate cash outflow be quarter review year year share repurchase dividend updatedure report quarter anthem repurchase share common stock mar have approximately share repurchase authorization remain first quarter anthem paid quarterly dividend cent share apr board approve dividend cent share payable jun shareholder record jun guidance anthem expect adjust net income be greater share previous projection more medical membership be now expect range previous projection operate revenue be anticipate range more earlier forecast anthem estimate operate cash flow be more zack rank performance carry zack rank buy see complete list today zack strong buy rank stock here other player medical sector have report first quarter earning so far novartis ag nvs free report unitedhealth group incorporate unh free report abbott laboratory free report surpass respective zack consensus estimate investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
877,ABT,several tailwind gradually flow opportunity be grow enormously medical device space sector be currently enjoy investment world attention investor be putt effort pick subindustry be beam prospect name pop first be cardiovascular device market world health organization cardiovascular disease be disorder heart blood vessel include coronary heart disease cerebrovascular disease rheumatic heart disease other condition go latest heart disease stroke statistic report american heart association adult be live form cardiovascular disease effect stroke further cardiovascular disease have be deem be major cause death person unite state notably be gradually take shape deadly epidemic globally scenario be quite intriguing report cardiovascular disease be major cause global death take life person notably projection related disease hint continuation present trend regard number death globally due cardiovascular disease be expect increase more moreover total direct expenditure related cardiovascular disease be expect rise go say rise incidence cardiovascular disease globally have open opportunity cardiovascular device maker market be expect witness cagr reach report visiongain accordingly investor be keen effectively put money longer term gain cardiovascular device market undoubtedly hold immense potential factor drive cardiovascular device marketrising healthcare expenditure unhealthy lifestyle practice expand treatment option have be drive demand center medicare medicaid service report publish advisory board healthcare spending be project rise represent gdp base assumption affordable care act continue cardiovascular device market be largely dependent age population census bureau report person age more be likely total almost double estimate population datum also show median age be increase most area country global scenario be pretty similar strengthen emerge market have be contribute largely rise demand cardiovascular device article lead market intelligence firm life science intelligence demand cardiovascular device have be grow solid double digit rate many emerge country include bric nation brazil russia india china turkey late ai bring new eraaccord research firm techemergence ai be be broadly used follow category better management cardiovascular disease artificial intelligence be be apply automate atrial fibrillation process fall ecg monitoring category be also be used company accurately predict risk cardiovascular disease related impact finally company be also involved actively used ai platform improve accuracy patient scan detect cardiovascular disease be certain development deserve mention here lead digital health company analytic life be actively involved design machine learn algorithm detect coronary artery disease invasively radiation accelerate heart cardiotrack india base start recently introduce technology platform used hand hold device cloud storage artificial intelligence capture analyze signal specific heart condition stock watch forwe have select company believe tap promising prospect cardiovascular device market boston scientific corporation bsx free report zack rank buy company have cardiovascular cardiac rhythm management crm reportable segment cardiovascular include interventional cardiology peripheral intervention business company be lead player interventional cardiology market coronary stent product offering see complete list today zack rank strong buy stock here company also market balloon catheter rotational atherectomy system guide wire guide catheter embolic protection device diagnostic catheter well intravascular ultrasound imaging system crm segment company deal implantable device monitor heart deliver electricity treat cardiac abnormality boston scientific project earning growth rate current year be stock deliver positive earning surprise trail quarters average beat past month boston scientific outperformed industry stock have improve compare industry gain period medtronic plc mdt free report zack rank hold company have cardiac vascular group cvg reportable segment cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv crhf division develop manufacture commercialize product diagnosis treatment management heart rhythm disorder heart failure apv division offer comprehensive portfolio product therapy treat aortic disease such aneurysm dissection transection well peripheral vascular disease critical limb ischemia further csh division offer therapy treat coronary artery disease heart valve disorder medtronic have expect earning growth rate current year stock have deliver positive earning surprise trail quarters average beat past month medtronic outperformed industry stock have improve compare industry gain period abbott laboratory free report zack rank company have cardiovascular neuromodulation business broader medical device segment company offer wide range rhythm management heart failure vascular structural heart device treatment cardiovascular disease well neuromodulation device management chronic pain movement disorder product be manufacture market distribute globally heart failure related product include heartmate left ventricular device family vascular product include xience family drug eluting coronary stent system develop multus link vision platform rhythm management product include assurity mri endurity mri pacemaker system be prominent product offer company abbott have expect earning growth rate current year stock have deliver positive earning surprise trail quarters average beat past month abbott outperformed industry stock have improve compare industry gain period conclusiona say strike iron be hot be opportune time cash bountiful opportunity rapidly grow cardiovascular device market make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
878,ABT,suspension controversial medical device tax year medical device industry be currently ride high optimism advame medical device industry lobbying group strongly advocate relief note tax repeal provide huge impetus company channelize turnover strategic consolidation research development also help create new job opportunity accord article publish daily news tax go effect january save device company much year suspension medical device market be undergo substantial transformation age population longer expectancy life grow healthcare awareness emerge economy combine powerful long term tailwind include merger acquisition product innovation have be contribute growth sector boom continue be yet be see far benefit tax repeal have be redirect now meanwhile accord mark bonifacio president bonifacio consult service private equity strategic oem original equipment manufacturer buyer be compete asset sector medical contract manufacturing broaden portfolio investing new technology strongly state start be sluggish respect be due uncertainty change global healthcare market fate obamacare medical device tax now doubt be gradually get clear industry be once again head year significant activity year biggest deal seem be card wall street journal latest rumore news related mammoth medtech space boston scientific bsx stryker corporation syk free report report say rival consider bid consolidation analyst seem be optimistic rumore deal believe colossal merger medtronic mdt free report covidien abbott st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space follow company consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company be anticipate emerge lead player point care diagnostic space mega consolidation recent time be medical device major becton dickinson co medical surgical diagnostic patient care device provider bard completion deal january becton dickinson be way expand new area vascular access segment piccs peripherally insert central catheter midline drug delivery port baxter international bax purchase thrombin topical preveleak surgical sealant specialty pharmaceutical company mallinckrodt plc mnk free report varian medical var free report also inked major deal company recently sign agreement acquire australia base global life science company sirtex medical limit total deal value investment strengthen company position interventional oncology therapy apart effort gain foothold emerge economy company recently acquire cooperative cl enterprise lead distributor radiotherapy equipment taiwan johnson johnson jnj free report subsidiary depuy synthe inked deal acquire medical enterprise distribution apart boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth divestment medical device major continue offload core business line asset be similar one acquire merger focus main segment divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market earlier month johnson johnson get offer fortive corporation sell subsidiary ethicon inc advanced sterilization product business unit fortive jnj accept proposal be step streamline business strategic roadmap better resource utilization higher shareholder return apart accord massdevice report medtronic recently divest stake lifetech scientific china everbright ltd unnamed investor bd also divest soft tissue core needle biopsy line aspira product line merit medical divestment be related acquisition bard april henry schein hsic announce decision spin company major segment global animal health business believe initiative remain part henry schein strategic plan focus more dental medical business accord company transaction enable make most opportunity dental space order deliver quality clinical care advanced wellness prevention apprehend china drug distribution reform slow company growth region accord reuter report cardinal health sell china business shanghai pharmaceutical hold follow announcement major buyout abbott divest eye care business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure sell hologic notably hologic acquire outstanding cynosure share approximately emerge market healthcare scenario bright survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll reveal past decade marked biggest increase uninsured rate meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany give huge potential region long back johnson johnson have set manufacturing center brazil china india company emerge market medical device segment continue grow time faster develop market abbott continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report fourth quarter fiscal business latin america middle east africa eastern europe china show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific emerge market business register growth first quarter reflect significant increase growth business china be once again remarkable year year key pick spacein medical instrument space be positive abiom inc abmd intuitive surgical inc isrg free report carry zack rank strong buy see complete list today zack rank stock here medical product stock baxter international surmodic inc srdx free report boston scientific orasure technology inc osur free report be also well poise zack rank buy weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring moment be nephew plc snn tg therapeutic inc tgtx free report nxstage medical inc nxtm free report insys therapeutic inc insy free report carry zack rank sell orthofix international ofix free report eagle pharmaceutical inc egrx hold zack rank strong sell zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
879,ABT,abbott free report recently announce launch latest generation afinion test system afinion analyzer unite state system deliver accurate hemoglobin hba result minute albumin creatinine ratio acr result minute therefore product enable healthcare provider adhere american diabetes association ada testing guideline efficiently promptly be afinion analyzer rapid test system afinion analyzer be rapid compact multus assay platform be capable streamline simplify delivery actionable accurate measurement hba acr result point care afinion platform also provide connectivity laboratory hospital information system li enable healthcare provider use various patient setting ada regular measure hba acr level be effective long term management patient diagnosed diabetes give host benefit offer be upbeat launch afinion analyzer system be expect boost top line contribution diagnostic division glimpse diagnostic businessabbott diagnostic division market diagnostic system well test business line core laboratory molecular point care rapid diagnostic reflect sale alere be acquire oct division account total sale first quarter last report quarter diagnostic revenue grow year year comparable operational basis drive better expect performance company rapid diagnostic business strength flu season unite state notably rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing further management project uptrend division continue back new product launch benefit alere acquisition strength alinity test platform market demographic be favor high incidence diabetes individual report mordor intelligence global market diabetes care device be expect attain value further abbott more person total population unite state be suffering diabetes thus such circumstance conclude developmental step undertake company seem be progressive be strategically align price have be gain investor optimism consistently positive result past month stock have outperformed industry share company have gain compare industry rise zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
880,ABT,abbott free report recently announce result amplatzer amulet left atrial appendage laa occlusion device bid fortify core structural heart business datum be present europcr annual meeting european association percutaneous cardiovascular intervention eapci paris further result be publish be amplatzer amulet occlusion device amplatzer amulet occluder be advanced minimally invasive laa occlusion device design seal laa person suffering valvular atrial fibrillation time efficient manner device block laa open reduce chance blood clot reach bloodstream cause stroke amplatzer amulet device come several size cater several type complex patient anatomy moreover be claim be used patient blood thinner medication be not very safe option be contraindicate notably amplatzer amulet device be currently investigational device unite state study amplatzer amulet observational post market study have valvular af patient enrolled worldwide amulet device be effectively implanted enrolled patient follow period month post device implant assessment notably result year follow demonstrate treatment amplatzer amulet have lower risk ischemic stroke also reduce chance ischemic stroke transient ischemic attack systemic embolism glimpse structural heart structural heart business have maintain impressive top line performance last report quarter sale segment rise report basis notably structural heart business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mr company recently announce encourage result global study tendyne transcatheter mitral valve replacement tmvr system march company announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip ministry health labour welfare mhlw approve mitraclip system japan last november further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart market prospectsabbott strategy gain traction structural heart segment seem be align datum provide ally market research company report global atrial fibrillation market be estimate reach worth cagr company almost person suffer atrial fibrillation globally share price have be gain investor confidence consistently positive result past month stock have outperformed industry stock have gain comparison industry zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys have expect long term earning growth rate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
881,ABT,abbott free report have be spotlight late favorable development medical device business include core structural heart division company recently announce encourage result global study tendyne transcatheter mitral valve replacement tmvr system datum be present europcr annual meeting european association percutaneous cardiovascular intervention eapci paris global study tendyne device expect register adult patient early result be base successful implantation tendyne device first patient patient enrolled study suffer symptomatic mitral regurgitation mr be not eligible open heart surgery repair replace mitral valve notably result end day demonstrated patient treat tendyne witness major reduction mitral regurgitation symptom low mortality rate further improvement symptom be assessed base new york heart association nyha grade severity kansa city cardiomyopathy questionnaire kccq tendyne device completely retrievable minimally invasive replacement option tendyne device be used treat functional degenerative mixed cause mr be treat minimally invasive valve repair open heart surgery notably tendyne device be currently clinical investigation approval europe further company plan enroll first patient pivotal trial same term glimpse structural heart businessabbott structural heart business maintain impressive top line performance last report quarter segment sale rise report basis notably structural heart business account total revenue broader medical device segment upside be lead continue double digit growth mitraclip company market lead device repair mr march company announce receipt national reimbursement japan same notably nearly country more person have be treat mitraclip ministry health labour welfare mhlw approve mitraclip system japan last november further company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart business market prospectsabbott strategy gain traction structural heart segment seem be align datum provide ally market research datum provide company report tanscatheter mitral valve repair replacement market be estimate reach worth repair replacement valf cagr company almost person age suffer moderate severe mr share price have be gain investor confidence consistently positive result past month stock have outperformed industry stock have gain comparison industry gain zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
882,ABT,abbott free report provide impetus vascular business unite state recently announce receipt fda approval xience sierra notably xience sierra be latest family xience everolimus eluting coronary stent system xience sierra sierra be equip thinner profile enhance flexibility longer length small diameter further advanced stent delivery system effectively aids treat complex case involve multiple totally block vessel provide increase flexibility precision doctor management report case involve patient suffering complex blockage believe fda approval aid drive top line contribution abbott vascular business vascular business glancerecently abbott vascular business have continue deliver stable top line performance last report quarter segment sale improve report basis notably vascular business account total revenue broader medical device segment encouragingly note vascular business abbott have be slew development regard xience sierra coronary stent system company be award national reimbursement xience sierra japan ministry health labour welfare follow receipt regulatory approval april abbott have also be get positive response xience sierra coronary stent system post launch europe late last year market potentialper grand view research safely conclude development help abbott cash opportunity coronary stent market accord report global coronary stent market be expect witness cagr roughly share price movementover past month abbott have be outperform industry stock have gain compare industry increase zack rank stock considerabbott currently carry zack rank hold few better rank stock broader medical sector be intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina have expect long term earning growth rate amedisys have expect long term earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
883,ABT,issue update research report cardiovascular system inc csii free report notably number factor continue drive optimism stock instance company firm position coronary arterial disease cad peripheral arterial disease pad market space positive study result highlight effective technology impressive portfolio expansion well strong gross margin scenario player carry zack rank hold medical device manufacturer developer marketer innovative solution treat patient peripheral coronary arterial disease include arterial calcium see solid third quarter fiscal company witness year year rise revenue cad pad business also gross margin expansion be impressive past month share cardiovascular system have outperformed industry stock have surge compare increase industry company be putt effort innovate product investment market be also look forward recently launch coronary device japan reflect company focus widening international footprint cardiovascular system inc price cardiovascular system inc price cardiovascular system inc quote cardiovascular system have be broaden product portfolio enhance market reach be currently pursue product improvement evaluate new technology strengthen develop portfolio powerful micro invasive tool be also upbeat cardiovascular system new partnership have help extend portfolio company be now distributor orbusneich balloon product orbusneich pci balloon include sapphire ii pro have recently receive fda approval mm coronary balloon moreover company have sign original equipment manufacturer agreement integer holding corporation csi brand zilient guidewire additionally be optimistic favorable trend pad cad space american heart association many american suffer pad syndrome moreover age population couple rise incidence diabetes obesity be likely aggravate frequency pad complaint thus company growth area offer huge scope unique pad orbital atherectomy system oas cardiovascular system address hitherto unmet need market flip side company face cutthroat competition niche space oas product contend variety other product device treatment vascular disease include stent balloon angioplasty catheter atherectomy catheter well product used vascular surgery larger player contest stent balloon angioplasty market segment include bigwig abbott laboratory free report moreover profitability front cardiovascular system struggle long history net loss inception immediate recovery sight key pickssome better rank stock broader medical sector be intuitive surgical isrg free report amedisys inc am free report intuitive surgical sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate amedisys have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
884,ABT,have be month last earning report abbott laboratory free report share have add time frame recent positive trend continue lead next earning release be due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent earningsabbott report first quarter adjust earning continue operation cent share beating zack consensus estimate cent bottom line also improve year year meet high end company guide range cent moreover report earning quarter come cent share compare year figure cent first quarter worldwide sale come year year report basis top line also exceed zack consensus estimate organic basis adjust impact foreign exchange certain divestment sale increase year year report quarter quarter detailabbott operate segment namely establish pharmaceutical division epd medical device nutrition diagnostic epd sale rise report basis organic basis include positive impact currency fluctuation sale key emerge market increase drive double digit growth india china brazil medical device business sale increase report basis organic basis sale grow cardiovascular neuromodulation sale reportedly organic basis rise double digit growth neuromodulation vascular product sale however decline report basis rhythm management company see sale increase report basis decline diabetes care sale improve buoy double digit international sale growth lead consistent consumer uptake freestyle libre revolutionary continuous glucose monitoring system abbott nutrition sale be year year report basis organic basis foreign exchange drive sale pediatric nutrition sale increase organic basis adult nutrition sale be organically diagnostic sale soar year year report basis comparable operational basis core laboratory point care diagnostic sale grow respectively organic basis molecular diagnostic sale be nominal strong growth infectious disease testing business be partially offset plan scale other testing area primarily unite state rapid diagnostic record sale drive solid contribution infectious disease testing include flu strep testing full year guidanceabbott have reiterate earning share guidance adjust certain net specify item full year adjust earning continue operation be still expect band zack consensus estimate remain project range company have also provide second quarter adjust earning share outlook expect report adjust earning continue operation range cent consensus mark cent fall lower end predict range have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower abbott laboratory price consensus abbott laboratory price consensus abbott laboratory quotevgm scoresat time have great growth score be lag lot momentum front stock be also allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable growth investor look value momentum outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably have zack rank hold expect line return stock next few month
885,ABT,centene inc cnc free report report first quarter adjust net income share beat zack consensus estimate also bottom line improve year year first quarter total revenue rise year period primarily drive growth health insurance marketplace business well expansion new program many state year moreover top line slightly surpass zack consensus estimate quarterly operational updatea mar manage care membership come increase march health benefit ratio hbr first quarter be compare prior year quarter reflect year year deterioration basis point bps stem membership growth health insurance marketplace business lower medical cost medicaid business reinstatement health insurer fee adjust selling general administrative sg expense ratio first quarter compare first quarter represent deterioration basis point year year arise growth health insurance marketplace business operate higher sg expense ratio centene corporation price consensus ep surprise centene corporation price consensus ep surprise centene corporation quote financial update mar centene have cash cash equivalent end total asset grow centene long term debt totale end first quarter cash inflow operation be year year guidance updatedcentene expect adjust earning share range previous projection total revenue be anticipate band earlier forecast hbr be estimate compare past view adjust sg expense ratio be predict former outlook zack rank performance peerscentene carry zack rank hold see complete list today zack rank strong buy stock here other player medical sector have report first quarter earning so far novartis ag nvs free report unitedhealth group incorporate unh free report abbott laboratory free report surpass respective zack consensus estimate make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
